<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-MedLine.d78">
    <sentence id="DDI-MedLine.d78.s0" text="The fluoroquinolones for urinary tract infections: a review.&#xd;&#xa;">
        <entity id="DDI-MedLine.d78.s0.e0" charOffset="4-19"
            type="group" text="fluoroquinolones"/>
    </sentence>
    <sentence id="DDI-MedLine.d78.s1" text="The fluoroquinolones are a rapidly growing class of antibiotics with a broad spectrum of activity against gram-negative and some gram-positive aerobic bacteria. ">
        <entity id="DDI-MedLine.d78.s1.e0" charOffset="4-19"
            type="group" text="fluoroquinolones"/>
        <entity id="DDI-MedLine.d78.s1.e1" charOffset="52-62"
            type="group" text="antibiotics"/>
        <pair id="DDI-MedLine.d78.s1.p0" e1="DDI-MedLine.d78.s1.e0"
            e2="DDI-MedLine.d78.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d78.s2" text="These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. ">
        <entity id="DDI-MedLine.d78.s2.e0" charOffset="24-34"
            type="drug" text="norfloxacin"/>
        <entity id="DDI-MedLine.d78.s2.e1" charOffset="37-49"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-MedLine.d78.s2.e2" charOffset="52-60"
            type="drug" text="ofloxacin"/>
        <entity id="DDI-MedLine.d78.s2.e3" charOffset="63-70"
            type="drug" text="enoxacin"/>
        <entity id="DDI-MedLine.d78.s2.e4" charOffset="77-88"
            type="drug" text="lomefloxacin"/>
        <pair id="DDI-MedLine.d78.s2.p0" e1="DDI-MedLine.d78.s2.e0"
            e2="DDI-MedLine.d78.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d78.s2.p1" e1="DDI-MedLine.d78.s2.e0"
            e2="DDI-MedLine.d78.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d78.s2.p2" e1="DDI-MedLine.d78.s2.e0"
            e2="DDI-MedLine.d78.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d78.s2.p3" e1="DDI-MedLine.d78.s2.e0"
            e2="DDI-MedLine.d78.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d78.s2.p4" e1="DDI-MedLine.d78.s2.e1"
            e2="DDI-MedLine.d78.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d78.s2.p5" e1="DDI-MedLine.d78.s2.e1"
            e2="DDI-MedLine.d78.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d78.s2.p6" e1="DDI-MedLine.d78.s2.e1"
            e2="DDI-MedLine.d78.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d78.s2.p7" e1="DDI-MedLine.d78.s2.e2"
            e2="DDI-MedLine.d78.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d78.s2.p8" e1="DDI-MedLine.d78.s2.e2"
            e2="DDI-MedLine.d78.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d78.s2.p9" e1="DDI-MedLine.d78.s2.e3"
            e2="DDI-MedLine.d78.s2.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d78.s3" text="Advantages offered by this class of antibiotics include optimal pharmacokinetics, effectiveness against multidrug-resistant organisms, and oral administration even when parenteral antibiotics are generally used. ">
        <entity id="DDI-MedLine.d78.s3.e0" charOffset="36-46"
            type="group" text="antibiotics"/>
        <entity id="DDI-MedLine.d78.s3.e1" charOffset="180-190"
            type="drug" text="antibiotics"/>
        <pair id="DDI-MedLine.d78.s3.p0" e1="DDI-MedLine.d78.s3.e0"
            e2="DDI-MedLine.d78.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d78.s4" text="The fluoroquinolones are also extensively used in urologic surgery.">
        <entity id="DDI-MedLine.d78.s4.e0" charOffset="4-19"
            type="group" text="fluoroquinolones"/>
    </sentence>
    <sentence id="DDI-MedLine.d80.s0" text="Progestin-only oral contraception: a comprehensive review.&#xd;&#xa;"/>
    <sentence id="DDI-MedLine.d80.s1" text="In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  ">
        <entity id="DDI-MedLine.d80.s1.e0" charOffset="79-112"
            type="group" text="progestin-only oral contraceptives"/>
        <entity id="DDI-MedLine.d80.s1.e1" charOffset="115-117"
            type="group" text="POC"/>
        <entity id="DDI-MedLine.d80.s1.e2" charOffset="166-175"
            type="drug" text="norgestrel"/>
        <entity id="DDI-MedLine.d80.s1.e3" charOffset="192-204"
            type="drug" text="norethindrone"/>
        <pair id="DDI-MedLine.d80.s1.p0" e1="DDI-MedLine.d80.s1.e0"
            e2="DDI-MedLine.d80.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d80.s1.p1" e1="DDI-MedLine.d80.s1.e0"
            e2="DDI-MedLine.d80.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d80.s1.p2" e1="DDI-MedLine.d80.s1.e0"
            e2="DDI-MedLine.d80.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d80.s1.p3" e1="DDI-MedLine.d80.s1.e1"
            e2="DDI-MedLine.d80.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d80.s1.p4" e1="DDI-MedLine.d80.s1.e1"
            e2="DDI-MedLine.d80.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d80.s1.p5" e1="DDI-MedLine.d80.s1.e2"
            e2="DDI-MedLine.d80.s1.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d80.s2" text="The goal of this review was to cite primary sources for virtually all research specific to POPs since 1975.  "/>
    <sentence id="DDI-MedLine.d80.s3" text="Conclusions and the types of studies which support these conclusions are given for each major section.  "/>
    <sentence id="DDI-MedLine.d80.s4" text="The introductory chapter discusses the advantages and disadvantages of POCs and the magnitude and prevalence of their use.  ">
        <entity id="DDI-MedLine.d80.s4.e0" charOffset="71-74"
            type="group" text="POCs"/>
    </sentence>
    <sentence id="DDI-MedLine.d80.s5" text="Future trends are also predicted.  "/>
    <sentence id="DDI-MedLine.d80.s6" text="Chapter 2 considers the mode of action, including ovulation prevention; "/>
    <sentence id="DDI-MedLine.d80.s7" text="suppression of midcycle gonadotropin peaks; "/>
    <sentence id="DDI-MedLine.d80.s8" text="changes in cervical mucus, the endometrium, and the fallopian tubes; "/>
    <sentence id="DDI-MedLine.d80.s9" text="and clinical implications.  "/>
    <sentence id="DDI-MedLine.d80.s10" text="Chapter 3 covers pharmacology (pharmacokinetics, pharmacodynamics and potency, and clinical implications).  "/>
    <sentence id="DDI-MedLine.d80.s11" text="The next chapter presents information on efficacy and pregnancy outcomes in terms of pregnancy rates, compliance and efficacy, ectopic pregnancies, the outcome of pregnancies conceived while using POCs, and fertility following discontinuation.  ">
        <entity id="DDI-MedLine.d80.s11.e0" charOffset="197-200"
            type="group" text="POCs"/>
    </sentence>
    <sentence id="DDI-MedLine.d80.s12" text="Chapter 5 focuses on metabolic effects, specifically lipid metabolism, carbohydrate metabolism and diabetes, coagulation factors, and blood pressure.  "/>
    <sentence id="DDI-MedLine.d80.s13" text="Cardiovascular disease is considered in the next chapter, and chapter 7 presents findings on endometrial, ovarian, cervical, breast, and other cancers.  "/>
    <sentence id="DDI-MedLine.d80.s14" text="A host of other medical considerations are discussed in chapter 8, including persistent ovarian follicles; "/>
    <sentence id="DDI-MedLine.d80.s15" text="reproductive tract infections; "/>
    <sentence id="DDI-MedLine.d80.s16" text="abnormal vaginal bleeding; "/>
    <sentence id="DDI-MedLine.d80.s17" text="uterine fibroids; "/>
    <sentence id="DDI-MedLine.d80.s18" text="gestational trophoblastic disease; "/>
    <sentence id="DDI-MedLine.d80.s19" text="benign breast disease; "/>
    <sentence id="DDI-MedLine.d80.s20" text="diseases of the liver, gallbladder, and bowel; "/>
    <sentence id="DDI-MedLine.d80.s21" text="endocrine dysfunction; "/>
    <sentence id="DDI-MedLine.d80.s22" text="epilepsy; "/>
    <sentence id="DDI-MedLine.d80.s23" text="bone density; "/>
    <sentence id="DDI-MedLine.d80.s24" text="sickle cell disease; "/>
    <sentence id="DDI-MedLine.d80.s25" text="ocular effects; "/>
    <sentence id="DDI-MedLine.d80.s26" text="surgery; "/>
    <sentence id="DDI-MedLine.d80.s27" text="and overdose.  "/>
    <sentence id="DDI-MedLine.d80.s28" text="The last 4 chapters cover interactions with drugs and laboratory tests, common side effects, breast feeding, and effective use of POCs.  ">
        <entity id="DDI-MedLine.d80.s28.e0" charOffset="130-133"
            type="group" text="POCs"/>
    </sentence>
    <sentence id="DDI-MedLine.d80.s29" text="Information on precautions and contraindications, indications, use instructions, and instructions for appropriate actions after missing a pill is appended."/>
    <sentence id="DDI-MedLine.d84.s0" text="Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics.&#xd;&#xa;">
        <entity id="DDI-MedLine.d84.s0.e0" charOffset="26-50"
            type="drug_n" text="Ganoderma lucidum extract"/>
        <entity id="DDI-MedLine.d84.s0.e1" charOffset="87-97"
            type="group" text="antibiotics"/>
        <pair id="DDI-MedLine.d84.s0.p0" e1="DDI-MedLine.d84.s0.e0"
            e2="DDI-MedLine.d84.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d84.s1" text="Antimicrobial activity of GL (the aqueous extract from the carpophores of Ganoderma lucidum (FR)KARST) was tested in vitro against Gram positive and Gram negative bacteria by serial broth dilution method, and the antimicrobial activity was expressed by minimal inhibitory concentration (MIC). ">
        <entity id="DDI-MedLine.d84.s1.e0" charOffset="26-27"
            type="drug_n" text="GL"/>
    </sentence>
    <sentence id="DDI-MedLine.d84.s2" text="Among fifteen species of bacteria tested, the antimicrobial activity of GL was the most potent against Micrococcus luteus (MIC, 0.75 mg/ml). ">
        <entity id="DDI-MedLine.d84.s2.e0" charOffset="72-73"
            type="drug_n" text="GL"/>
    </sentence>
    <sentence id="DDI-MedLine.d84.s3" text="To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. ">
        <entity id="DDI-MedLine.d84.s3.e0" charOffset="60-61"
            type="drug_n" text="GL"/>
        <entity id="DDI-MedLine.d84.s3.e1" charOffset="82-92"
            type="group" text="antibiotics"/>
        <entity id="DDI-MedLine.d84.s3.e2" charOffset="95-104"
            type="drug" text="ampicillin"/>
        <entity id="DDI-MedLine.d84.s3.e3" charOffset="107-115"
            type="drug" text="cefazolin"/>
        <entity id="DDI-MedLine.d84.s3.e4" charOffset="118-132"
            type="drug" text="oxytetracycline"/>
        <entity id="DDI-MedLine.d84.s3.e5" charOffset="138-152"
            type="drug" text="chloramphenicol"/>
        <pair id="DDI-MedLine.d84.s3.p0" e1="DDI-MedLine.d84.s3.e0"
            e2="DDI-MedLine.d84.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d84.s3.p1" e1="DDI-MedLine.d84.s3.e0"
            e2="DDI-MedLine.d84.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d84.s3.p2" e1="DDI-MedLine.d84.s3.e0"
            e2="DDI-MedLine.d84.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d84.s3.p3" e1="DDI-MedLine.d84.s3.e0"
            e2="DDI-MedLine.d84.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d84.s3.p4" e1="DDI-MedLine.d84.s3.e0"
            e2="DDI-MedLine.d84.s3.e5" ddi="false"/>
        <pair id="DDI-MedLine.d84.s3.p5" e1="DDI-MedLine.d84.s3.e1"
            e2="DDI-MedLine.d84.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d84.s3.p6" e1="DDI-MedLine.d84.s3.e1"
            e2="DDI-MedLine.d84.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d84.s3.p7" e1="DDI-MedLine.d84.s3.e1"
            e2="DDI-MedLine.d84.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d84.s3.p8" e1="DDI-MedLine.d84.s3.e1"
            e2="DDI-MedLine.d84.s3.e5" ddi="false"/>
        <pair id="DDI-MedLine.d84.s3.p9" e1="DDI-MedLine.d84.s3.e2"
            e2="DDI-MedLine.d84.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d84.s3.p10" e1="DDI-MedLine.d84.s3.e2"
            e2="DDI-MedLine.d84.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d84.s3.p11" e1="DDI-MedLine.d84.s3.e2"
            e2="DDI-MedLine.d84.s3.e5" ddi="false"/>
        <pair id="DDI-MedLine.d84.s3.p12" e1="DDI-MedLine.d84.s3.e3"
            e2="DDI-MedLine.d84.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d84.s3.p13" e1="DDI-MedLine.d84.s3.e3"
            e2="DDI-MedLine.d84.s3.e5" ddi="false"/>
        <pair id="DDI-MedLine.d84.s3.p14" e1="DDI-MedLine.d84.s3.e4"
            e2="DDI-MedLine.d84.s3.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d84.s4" text="The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances. ">
        <entity id="DDI-MedLine.d84.s4.e0" charOffset="34-35"
            type="drug_n" text="GL"/>
        <entity id="DDI-MedLine.d84.s4.e1" charOffset="47-57"
            type="group" text="antibiotics"/>
        <pair id="DDI-MedLine.d84.s4.p0" e1="DDI-MedLine.d84.s4.e0"
            e2="DDI-MedLine.d84.s4.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d84.s5" text="Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.">
        <entity id="DDI-MedLine.d84.s5.e0" charOffset="28-29"
            type="drug_n" text="GL"/>
        <entity id="DDI-MedLine.d84.s5.e1" charOffset="49-57"
            type="drug" text="cefazolin"/>
        <pair id="DDI-MedLine.d84.s5.p0" e1="DDI-MedLine.d84.s5.e0"
            e2="DDI-MedLine.d84.s5.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d13.s0" text="Death in amphetamine users: causes and rates.&#xd;&#xa;">
        <entity id="DDI-MedLine.d13.s0.e0" charOffset="9-19" type="drug" text="amphetamine"/>
    </sentence>
    <sentence id="DDI-MedLine.d13.s1" text="The world medical literature contains 43 reports of deaths associated with amphetamines in a 35-year period. ">
        <entity id="DDI-MedLine.d13.s1.e0" charOffset="75-86"
            type="drug" text="amphetamines"/>
    </sentence>
    <sentence id="DDI-MedLine.d13.s2" text="These included seven cerebrovascular accidents, six sudden cardiac deaths, three cases of hyperpyrexia, eight poisonings of uncertain mechanism and seven cases of medical complications of intravenous injection; "/>
    <sentence id="DDI-MedLine.d13.s3" text="the remainder were of uncertain cause. "/>
    <sentence id="DDI-MedLine.d13.s4" text="In contrast, in Ontario alone, in 1972 and 1973 there were 26 deaths in amphetamine users, of which 16 were due to accident suicide or homicide. ">
        <entity id="DDI-MedLine.d13.s4.e0" charOffset="72-82"
            type="drug" text="amphetamine"/>
    </sentence>
    <sentence id="DDI-MedLine.d13.s5" text="Of the remaining cases, two were cardiac, two hepatic and the rest were mixed drug overdose. "/>
    <sentence id="DDI-MedLine.d13.s6" text="Pulmonary granulomata, subacute hepatitis and other lesions resulting from intravenous drug use were common findings at autopsy. "/>
    <sentence id="DDI-MedLine.d13.s7" text="On the basis of the estimated number of regular users of intravenous amphetamine in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and heroin addicts. ">
        <entity id="DDI-MedLine.d13.s7.e0" charOffset="69-79"
            type="drug" text="amphetamine"/>
        <entity id="DDI-MedLine.d13.s7.e1" charOffset="247-252"
            type="drug_n" text="heroin"/>
        <pair id="DDI-MedLine.d13.s7.p0" e1="DDI-MedLine.d13.s7.e0"
            e2="DDI-MedLine.d13.s7.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d13.s8" text="However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.">
        <entity id="DDI-MedLine.d13.s8.e0" charOffset="32-38"
            type="drug" text="alcohol"/>
        <entity id="DDI-MedLine.d13.s8.e1" charOffset="99-109"
            type="drug" text="amphetamine"/>
        <entity id="DDI-MedLine.d13.s8.e2" charOffset="114-119"
            type="drug_n" text="heroin"/>
        <pair id="DDI-MedLine.d13.s8.p0" e1="DDI-MedLine.d13.s8.e0"
            e2="DDI-MedLine.d13.s8.e1" ddi="false"/>
        <pair id="DDI-MedLine.d13.s8.p1" e1="DDI-MedLine.d13.s8.e0"
            e2="DDI-MedLine.d13.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d13.s8.p2" e1="DDI-MedLine.d13.s8.e1"
            e2="DDI-MedLine.d13.s8.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d50.s0" text="Ascorbic acid and the common cold. ">
        <entity id="DDI-MedLine.d50.s0.e0" charOffset="0-12" type="drug" text="Ascorbic acid"/>
    </sentence>
    <sentence id="DDI-MedLine.d50.s1" text="Evaluation of its efficacy and toxicity.&#xa;"/>
    <sentence id="DDI-MedLine.d50.s2" text="We reviewed the clinical data relating to the efficacy and safety of pharmacologic doses of ascorbic acid in the prevention and treatment of the common cold. ">
        <entity id="DDI-MedLine.d50.s2.e0" charOffset="92-104"
            type="drug" text="ascorbic acid"/>
    </sentence>
    <sentence id="DDI-MedLine.d50.s3" text="Although one study tentatively supports the hypothesis that such doses of ascorbic acid may be efficacious, a second study by the same group did not confirm the significant findings, and no clear, reproducible pattern of efficacy has emerged from the review of all the evidence. ">
        <entity id="DDI-MedLine.d50.s3.e0" charOffset="74-86"
            type="drug" text="ascorbic acid"/>
    </sentence>
    <sentence id="DDI-MedLine.d50.s4" text="Similarly, there is currently little adequate evidence on either the presence or the absence of serious adverse reactions to such doses of ascorbic acid, although many such reactions have been hypothesized. ">
        <entity id="DDI-MedLine.d50.s4.e0" charOffset="139-151"
            type="drug" text="ascorbic acid"/>
    </sentence>
    <sentence id="DDI-MedLine.d50.s5" text="The unrestricted use of ascorbic acid for these purposes cannot be advocated on the basis of the evidence currently available.">
        <entity id="DDI-MedLine.d50.s5.e0" charOffset="24-36"
            type="drug" text="ascorbic acid"/>
    </sentence>
    <sentence id="DDI-MedLine.d26.s0" text="Optimal designs for the individual and joint exposure general logistic regression models.&#xa;"/>
    <sentence id="DDI-MedLine.d26.s1" text="Interest in administering compounds in combination lies both in enhancing efficacious effects and in limiting adverse effects. "/>
    <sentence id="DDI-MedLine.d26.s2" text="Although much statistical work has focused on developing mathematical functions to model the joint dose-response curves, relatively little work exists in regard to designing experiments for assessing joint action. "/>
    <sentence id="DDI-MedLine.d26.s3" text="A variety of parametric dose-response models based on either the normal or logistic probability distribution have been proposed in the literature. "/>
    <sentence id="DDI-MedLine.d26.s4" text="These models are typically nonlinear in the parameters, and as such, a nonlinear weighted least squares approach can be employed for the purpose of designing experiments. "/>
    <sentence id="DDI-MedLine.d26.s5" text="The approach is applicable across a wide variety of settings commonly associated with joint action data, including continuous and discrete responses, alternative error structures, and nonzero background response. "/>
    <sentence id="DDI-MedLine.d26.s6" text="Further, designs can be expressed in terms of proportionate responses associated with the individual compounds rather than dose levels, thereby providing for results that are applicable across compounds. "/>
    <sentence id="DDI-MedLine.d26.s7" text="As a precursor to this effort, optimal and minimal experimental designs for the case in which a single compound is administered have also been developed. "/>
    <sentence id="DDI-MedLine.d26.s8" text="Although the proposed methodology for deriving experimental designs can be applied to any nonlinear regression model, primary focus is given to the additive and nonadditive independent joint action (IJA) models for individual and combined exposures proposed by Barton, Braunberg, and Friedman (1)."/>
    <sentence id="DDI-MedLine.d69.s0" text="Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.">
        <entity id="DDI-MedLine.d69.s0.e0" charOffset="70-84"
            type="drug_n" text="contortrostatin"/>
        <entity id="DDI-MedLine.d69.s0.e1" charOffset="141-150"
            type="drug_n" text="echistatin"/>
        <entity id="DDI-MedLine.d69.s0.e2" charOffset="156-165"
            type="drug_n" text="flavoridin"/>
        <pair id="DDI-MedLine.d69.s0.p0" e1="DDI-MedLine.d69.s0.e0"
            e2="DDI-MedLine.d69.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d69.s0.p1" e1="DDI-MedLine.d69.s0.e0"
            e2="DDI-MedLine.d69.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d69.s0.p2" e1="DDI-MedLine.d69.s0.e1"
            e2="DDI-MedLine.d69.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d69.s1" text="The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells. ">
        <entity id="DDI-MedLine.d69.s1.e0" charOffset="28-42"
            type="drug_n" text="contortrostatin"/>
        <entity id="DDI-MedLine.d69.s1.e1" charOffset="96-105"
            type="drug_n" text="echistatin"/>
        <entity id="DDI-MedLine.d69.s1.e2" charOffset="111-120"
            type="drug_n" text="flavoridin"/>
        <pair id="DDI-MedLine.d69.s1.p0" e1="DDI-MedLine.d69.s1.e0"
            e2="DDI-MedLine.d69.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d69.s1.p1" e1="DDI-MedLine.d69.s1.e0"
            e2="DDI-MedLine.d69.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d69.s1.p2" e1="DDI-MedLine.d69.s1.e1"
            e2="DDI-MedLine.d69.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d69.s2" text="It was observed that contortrostatin had a dramatic effect on the tyrosine phosphorylation status of several proteins in T24 human bladder cancer cells, including robust induction of phosphorylation of proteins in the range of 120-140 kDa. ">
        <entity id="DDI-MedLine.d69.s2.e0" charOffset="21-35"
            type="drug_n" text="contortrostatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d69.s3" text="Echistatin alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of contortrostatin when both are added simultaneously. ">
        <entity id="DDI-MedLine.d69.s3.e0" charOffset="0-9"
            type="drug_n" text="Echistatin"/>
        <entity id="DDI-MedLine.d69.s3.e1" charOffset="118-132"
            type="drug_n" text="contortrostatin"/>
        <pair id="DDI-MedLine.d69.s3.p0" e1="DDI-MedLine.d69.s3.e0"
            e2="DDI-MedLine.d69.s3.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d69.s4" text="Among the proteins that undergo tyrosine phosphorylation in response to contortrostatin treatment is CAS, a 130 kDa adapter protein involved in integrin signaling. ">
        <entity id="DDI-MedLine.d69.s4.e0" charOffset="72-86"
            type="drug_n" text="contortrostatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d69.s5" text="Flavoridin alone was found to have no effect on CAS, but can completely block contortrostatin-induced phosphorylation of this protein in MDA-MB-435 cells. ">
        <entity id="DDI-MedLine.d69.s5.e0" charOffset="0-9"
            type="drug_n" text="Flavoridin"/>
        <entity id="DDI-MedLine.d69.s5.e1" charOffset="78-92"
            type="drug_n" text="contortrostatin"/>
        <pair id="DDI-MedLine.d69.s5.p0" e1="DDI-MedLine.d69.s5.e0"
            e2="DDI-MedLine.d69.s5.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d69.s6" text="These observations strongly suggest that the homodimeric structure of contortrostatin functionally distinguishes it from other monomeric members of the disintegrin family.">
        <entity id="DDI-MedLine.d69.s6.e0" charOffset="70-84"
            type="drug_n" text="contortrostatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d48.s0" text="Modification of surface histidine residues abolishes the cytotoxic activity of Clostridium difficile toxin A.&#xd;&#xa;">
        <entity id="DDI-MedLine.d48.s0.e0" charOffset="79-107"
            type="drug_n" text="Clostridium difficile toxin A"/>
    </sentence>
    <sentence id="DDI-MedLine.d48.s1" text="Clostridium difficile toxin A displays both cytotoxic and enterotoxic activities. ">
        <entity id="DDI-MedLine.d48.s1.e0" charOffset="0-28"
            type="drug_n" text="Clostridium difficile toxin A"/>
    </sentence>
    <sentence id="DDI-MedLine.d48.s2" text="It has recently been demonstrated that toxin A exerts its cytotoxic effect by the glucosylation of the small GTP-binding proteins of the Rho family. ">
        <entity id="DDI-MedLine.d48.s2.e0" charOffset="39-45"
            type="drug_n" text="toxin A"/>
    </sentence>
    <sentence id="DDI-MedLine.d48.s3" text="Diethyl pyrocarbonate, at pH 7.0, was used to chemically modify exposed histidine residues on toxin A. ">
        <entity id="DDI-MedLine.d48.s3.e0" charOffset="0-20"
            type="drug_n" text="Diethyl pyrocarbonate"/>
        <entity id="DDI-MedLine.d48.s3.e1" charOffset="94-100"
            type="drug_n" text="toxin A"/>
        <pair id="DDI-MedLine.d48.s3.p0" e1="DDI-MedLine.d48.s3.e0"
            e2="DDI-MedLine.d48.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d48.s4" text="Modification of toxin A with diethyl pyrocarbonate abolished both its cytotoxic activity and the ability of the toxin to bind Zn-Sepharose gel. ">
        <entity id="DDI-MedLine.d48.s4.e0" charOffset="16-22"
            type="drug_n" text="toxin A"/>
        <entity id="DDI-MedLine.d48.s4.e1" charOffset="29-49"
            type="drug_n" text="diethyl pyrocarbonate"/>
        <pair id="DDI-MedLine.d48.s4.p0" e1="DDI-MedLine.d48.s4.e0"
            e2="DDI-MedLine.d48.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d48.s5" text="Treatment of toxin A with [(14)C]-diethyl pyrocarbonate revealed concentration dependent labelling of histidine residues on the toxin molecules. ">
        <entity id="DDI-MedLine.d48.s5.e0" charOffset="13-19"
            type="drug_n" text="toxin A"/>
        <entity id="DDI-MedLine.d48.s5.e1" charOffset="34-54"
            type="drug_n" text="diethyl pyrocarbonate"/>
        <pair id="DDI-MedLine.d48.s5.p0" e1="DDI-MedLine.d48.s5.e0"
            e2="DDI-MedLine.d48.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d48.s6" text="The effects of diethyl pyrocarbonate could be reversed by hydroxylamine treatment. ">
        <entity id="DDI-MedLine.d48.s6.e0" charOffset="15-35"
            type="drug_n" text="diethyl pyrocarbonate"/>
        <entity id="DDI-MedLine.d48.s6.e1" charOffset="58-70"
            type="drug_n" text="hydroxylamine"/>
        <pair id="DDI-MedLine.d48.s6.p0" e1="DDI-MedLine.d48.s6.e0"
            e2="DDI-MedLine.d48.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d48.s7" text="These data suggest the modified histidine residues on toxin A are critical to its cytotoxic activity. ">
        <entity id="DDI-MedLine.d48.s7.e0" charOffset="54-60"
            type="drug_n" text="toxin A"/>
    </sentence>
    <sentence id="DDI-MedLine.d48.s8" text="Histidine modification had no effect on the glucosyl transferase enzyme activity of toxin A. ">
        <entity id="DDI-MedLine.d48.s8.e0" charOffset="84-90"
            type="drug_n" text="toxin A"/>
    </sentence>
    <sentence id="DDI-MedLine.d48.s9" text="However, modification abolished the 'cold' binding of toxin to bovine thyroglobulin in an ELISA and reduced ligand binding activity in a rabbit erythrocyte haemagglutination assay. "/>
    <sentence id="DDI-MedLine.d48.s10" text="The data suggest that the histidine residues may be crucial to the receptor-binding activity of toxin A. ">
        <entity id="DDI-MedLine.d48.s10.e0" charOffset="96-102"
            type="drug_n" text="toxin A"/>
    </sentence>
    <sentence id="DDI-MedLine.d48.s11" text="Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.">
        <entity id="DDI-MedLine.d48.s11.e0" charOffset="22-28"
            type="drug_n" text="toxin A"/>
        <entity id="DDI-MedLine.d48.s11.e1" charOffset="48-51"
            type="drug" text="zinc"/>
        <entity id="DDI-MedLine.d48.s11.e2" charOffset="150-156"
            type="drug_n" text="toxin A"/>
        <entity id="DDI-MedLine.d48.s11.e3" charOffset="164-167"
            type="drug" text="zinc"/>
        <pair id="DDI-MedLine.d48.s11.p0" e1="DDI-MedLine.d48.s11.e0"
            e2="DDI-MedLine.d48.s11.e1" ddi="false"/>
        <pair id="DDI-MedLine.d48.s11.p1" e1="DDI-MedLine.d48.s11.e0"
            e2="DDI-MedLine.d48.s11.e2" ddi="false"/>
        <pair id="DDI-MedLine.d48.s11.p2" e1="DDI-MedLine.d48.s11.e0"
            e2="DDI-MedLine.d48.s11.e3" ddi="false"/>
        <pair id="DDI-MedLine.d48.s11.p3" e1="DDI-MedLine.d48.s11.e1"
            e2="DDI-MedLine.d48.s11.e2" ddi="false"/>
        <pair id="DDI-MedLine.d48.s11.p4" e1="DDI-MedLine.d48.s11.e1"
            e2="DDI-MedLine.d48.s11.e3" ddi="false"/>
        <pair id="DDI-MedLine.d48.s11.p5" e1="DDI-MedLine.d48.s11.e2"
            e2="DDI-MedLine.d48.s11.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d18.s0" text="Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.&#xa;">
        <entity id="DDI-MedLine.d18.s0.e0" charOffset="42-51"
            type="drug" text="budesonide"/>
        <entity id="DDI-MedLine.d18.s0.e1" charOffset="56-63"
            type="brand" text="Survanta"/>
        <entity id="DDI-MedLine.d18.s0.e2" charOffset="74-88"
            type="group" text="lung surfactant"/>
        <pair id="DDI-MedLine.d18.s0.p0" e1="DDI-MedLine.d18.s0.e0"
            e2="DDI-MedLine.d18.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d18.s0.p1" e1="DDI-MedLine.d18.s0.e0"
            e2="DDI-MedLine.d18.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d18.s0.p2" e1="DDI-MedLine.d18.s0.e1"
            e2="DDI-MedLine.d18.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d18.s1" text="The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined. ">
        <entity id="DDI-MedLine.d18.s1.e0" charOffset="16-35"
            type="group" text="pulmonary surfactant"/>
        <entity id="DDI-MedLine.d18.s1.e1" charOffset="63-70"
            type="brand" text="Survanta"/>
        <entity id="DDI-MedLine.d18.s1.e2" charOffset="121-130"
            type="drug" text="budesonide"/>
        <pair id="DDI-MedLine.d18.s1.p0" e1="DDI-MedLine.d18.s1.e0"
            e2="DDI-MedLine.d18.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d18.s1.p1" e1="DDI-MedLine.d18.s1.e0"
            e2="DDI-MedLine.d18.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d18.s1.p2" e1="DDI-MedLine.d18.s1.e1"
            e2="DDI-MedLine.d18.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d18.s2" text="Aerosol particles of budesonide were generated from an ethanol solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments. ">
        <entity id="DDI-MedLine.d18.s2.e0" charOffset="21-30"
            type="drug" text="budesonide"/>
        <entity id="DDI-MedLine.d18.s2.e1" charOffset="55-61"
            type="drug" text="ethanol"/>
        <pair id="DDI-MedLine.d18.s2.p0" e1="DDI-MedLine.d18.s2.e0"
            e2="DDI-MedLine.d18.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d18.s3" text="Powder x-ray diffraction, differential scanning calorimetry, differential thermal analysis, and scanning electron microscopy were used to characterize the aerosol particles and starting material. "/>
    <sentence id="DDI-MedLine.d18.s4" text="No change in phase was detected, although the aerosol particles appeared to contain residual solvent. ">
        <entity id="DDI-MedLine.d18.s4.e0" charOffset="93-99"
            type="group" text="solvent"/>
    </sentence>
    <sentence id="DDI-MedLine.d18.s5" text="The dissolution rate of the aerosol particles in saline was low and variable. "/>
    <sentence id="DDI-MedLine.d18.s6" text="Survanta increased the extent of dissolution of budesonide in proportion to the added concentration, which was also verified by equilibrium solubilization studies. ">
        <entity id="DDI-MedLine.d18.s6.e0" charOffset="0-7" type="brand" text="Survanta"/>
        <entity id="DDI-MedLine.d18.s6.e1" charOffset="48-57"
            type="drug" text="budesonide"/>
        <pair id="DDI-MedLine.d18.s6.p0" e1="DDI-MedLine.d18.s6.e0"
            e2="DDI-MedLine.d18.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d18.s7" text="Survanta also increased rate of dissolution, in a manner similar to sodium dodecyl sulfate. ">
        <entity id="DDI-MedLine.d18.s7.e0" charOffset="0-7" type="brand" text="Survanta"/>
        <entity id="DDI-MedLine.d18.s7.e1" charOffset="68-89"
            type="drug_n" text="sodium dodecyl sulfate"/>
        <pair id="DDI-MedLine.d18.s7.p0" e1="DDI-MedLine.d18.s7.e0"
            e2="DDI-MedLine.d18.s7.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d18.s8" text="Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase. ">
        <entity id="DDI-MedLine.d18.s8.e0" charOffset="33-42"
            type="drug" text="budesonide"/>
        <entity id="DDI-MedLine.d18.s8.e1" charOffset="121-130"
            type="drug" text="budesonide"/>
        <entity id="DDI-MedLine.d18.s8.e2" charOffset="144-151"
            type="brand" text="Survanta"/>
        <pair id="DDI-MedLine.d18.s8.p0" e1="DDI-MedLine.d18.s8.e0"
            e2="DDI-MedLine.d18.s8.e1" ddi="false"/>
        <pair id="DDI-MedLine.d18.s8.p1" e1="DDI-MedLine.d18.s8.e0"
            e2="DDI-MedLine.d18.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d18.s8.p2" e1="DDI-MedLine.d18.s8.e1"
            e2="DDI-MedLine.d18.s8.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d18.s9" text="These results show that lung surfactant has the potential of enhancing the rate and extent of dissolution of drugs administered to the lung.">
        <entity id="DDI-MedLine.d18.s9.e0" charOffset="24-38"
            type="group" text="lung surfactant"/>
    </sentence>
    <sentence id="DDI-MedLine.d62.s0" text="Activation of an effector immediate-early gene arc by methamphetamine.&#xd;&#xa;">
        <entity id="DDI-MedLine.d62.s0.e0" charOffset="54-68"
            type="drug" text="methamphetamine"/>
    </sentence>
    <sentence id="DDI-MedLine.d62.s1" text="As immediate-early genes (IEGs) are thought to play a critical role in mediating stimulus-induced neural plasticity, IEG response induced by methamphetamine (METH) has been characterized to define the changes in gene expression that may underlie its long-lasting behavioral effects. ">
        <entity id="DDI-MedLine.d62.s1.e0" charOffset="141-155"
            type="drug" text="methamphetamine"/>
        <entity id="DDI-MedLine.d62.s1.e1" charOffset="158-161"
            type="drug" text="METH"/>
        <pair id="DDI-MedLine.d62.s1.p0" e1="DDI-MedLine.d62.s1.e0"
            e2="DDI-MedLine.d62.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d62.s2" text="Although activation of several transcription factor IEGs has been described, little is known about effector IEGs. "/>
    <sentence id="DDI-MedLine.d62.s3" text="Here, we have examined whether METH administration affects expression of an effector IEG arc (activity-regulated, cytoskeleton-associated) that encodes a protein with homology to spectrin. ">
        <entity id="DDI-MedLine.d62.s3.e0" charOffset="31-34"
            type="drug" text="METH"/>
    </sentence>
    <sentence id="DDI-MedLine.d62.s4" text="Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. ">
        <entity id="DDI-MedLine.d62.s4.e0" charOffset="46-49"
            type="drug" text="METH"/>
        <entity id="DDI-MedLine.d62.s4.e1" charOffset="234-242"
            type="drug_n" text="SCH-23390"/>
        <entity id="DDI-MedLine.d62.s4.e2" charOffset="258-277"
            type="group" text="atypical neuroleptic"/>
        <entity id="DDI-MedLine.d62.s4.e3" charOffset="279-287"
            type="drug" text="clozapine"/>
        <pair id="DDI-MedLine.d62.s4.p0" e1="DDI-MedLine.d62.s4.e0"
            e2="DDI-MedLine.d62.s4.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d62.s4.p1" e1="DDI-MedLine.d62.s4.e0"
            e2="DDI-MedLine.d62.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d62.s4.p2" e1="DDI-MedLine.d62.s4.e0"
            e2="DDI-MedLine.d62.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d62.s4.p3" e1="DDI-MedLine.d62.s4.e1"
            e2="DDI-MedLine.d62.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d62.s4.p4" e1="DDI-MedLine.d62.s4.e1"
            e2="DDI-MedLine.d62.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d62.s4.p5" e1="DDI-MedLine.d62.s4.e2"
            e2="DDI-MedLine.d62.s4.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d62.s5" text="METH induced arc mRNA in layers IV and VI of the cortex which dopamine receptor are localized to. ">
        <entity id="DDI-MedLine.d62.s5.e0" charOffset="0-3" type="drug" text="METH"/>
    </sentence>
    <sentence id="DDI-MedLine.d62.s6" text="These results suggest that D1 receptors are coupled to activation of arc gene, which may be involved in functional or structural alterations underlying neural plasticity triggered by METH.">
        <entity id="DDI-MedLine.d62.s6.e0" charOffset="183-186"
            type="drug" text="METH"/>
    </sentence>
    <sentence id="DDI-MedLine.d104.s0" text="The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.&#xd;&#xa;">
        <entity id="DDI-MedLine.d104.s0.e0" charOffset="15-20"
            type="drug_n" text="DCG-IV"/>
        <entity id="DDI-MedLine.d104.s0.e1" charOffset="26-32"
            type="drug_n" text="L-CCG-1"/>
        <entity id="DDI-MedLine.d104.s0.e2" charOffset="39-51"
            type="drug_n" text="phencyclidine"/>
        <entity id="DDI-MedLine.d104.s0.e3" charOffset="54-56"
            type="drug_n" text="PCP"/>
        <pair id="DDI-MedLine.d104.s0.p0" e1="DDI-MedLine.d104.s0.e0"
            e2="DDI-MedLine.d104.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d104.s0.p1" e1="DDI-MedLine.d104.s0.e0"
            e2="DDI-MedLine.d104.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d104.s0.p2" e1="DDI-MedLine.d104.s0.e0"
            e2="DDI-MedLine.d104.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d104.s0.p3" e1="DDI-MedLine.d104.s0.e1"
            e2="DDI-MedLine.d104.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d104.s0.p4" e1="DDI-MedLine.d104.s0.e1"
            e2="DDI-MedLine.d104.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d104.s0.p5" e1="DDI-MedLine.d104.s0.e2"
            e2="DDI-MedLine.d104.s0.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d104.s1" text="The behavioral changes of mice induced by acute and repeated i.p. "/>
    <sentence id="DDI-MedLine.d104.s2" text="injection of phencyclidine (PCP) were observed by measuring locomotor activity and stereotyped behavior. ">
        <entity id="DDI-MedLine.d104.s2.e0" charOffset="13-25"
            type="drug_n" text="phencyclidine"/>
        <entity id="DDI-MedLine.d104.s2.e1" charOffset="28-30"
            type="drug_n" text="PCP"/>
        <pair id="DDI-MedLine.d104.s2.p0" e1="DDI-MedLine.d104.s2.e0"
            e2="DDI-MedLine.d104.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d104.s3" text="Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found. ">
        <entity id="DDI-MedLine.d104.s3.e0" charOffset="71-76"
            type="drug_n" text="DCG-IV"/>
        <entity id="DDI-MedLine.d104.s3.e1" charOffset="82-88"
            type="drug_n" text="L-CCG-1"/>
        <entity id="DDI-MedLine.d104.s3.e2" charOffset="134-136"
            type="drug_n" text="PCP"/>
        <pair id="DDI-MedLine.d104.s3.p0" e1="DDI-MedLine.d104.s3.e0"
            e2="DDI-MedLine.d104.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d104.s3.p1" e1="DDI-MedLine.d104.s3.e0"
            e2="DDI-MedLine.d104.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d104.s3.p2" e1="DDI-MedLine.d104.s3.e1"
            e2="DDI-MedLine.d104.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d104.s4" text="The effects of DCG-IV were very strong and completely depressed the PCP-induced hyperlocomotion. ">
        <entity id="DDI-MedLine.d104.s4.e0" charOffset="15-20"
            type="drug_n" text="DCG-IV"/>
        <entity id="DDI-MedLine.d104.s4.e1" charOffset="68-70"
            type="drug_n" text="PCP"/>
        <pair id="DDI-MedLine.d104.s4.p0" e1="DDI-MedLine.d104.s4.e0"
            e2="DDI-MedLine.d104.s4.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d104.s5" text="The effects of L-CCG-1 were not so strong. ">
        <entity id="DDI-MedLine.d104.s5.e0" charOffset="15-21"
            type="drug_n" text="L-CCG-1"/>
    </sentence>
    <sentence id="DDI-MedLine.d104.s6" text="Repeated injection of PCP for 20 days into mice induced lower locomotor activity than that in acutely injected mice. ">
        <entity id="DDI-MedLine.d104.s6.e0" charOffset="22-24"
            type="drug_n" text="PCP"/>
    </sentence>
    <sentence id="DDI-MedLine.d104.s7" text="These behavioral changes may be related with the negative symptoms of schizophrenia. "/>
    <sentence id="DDI-MedLine.d104.s8" text="In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.">
        <entity id="DDI-MedLine.d104.s8.e0" charOffset="49-51"
            type="drug_n" text="PCP"/>
        <entity id="DDI-MedLine.d104.s8.e1" charOffset="171-173"
            type="drug_n" text="PCP"/>
        <entity id="DDI-MedLine.d104.s8.e2" charOffset="176-181"
            type="drug_n" text="DCG-IV"/>
        <entity id="DDI-MedLine.d104.s8.e3" charOffset="188-194"
            type="drug_n" text="L-CCG-1"/>
        <pair id="DDI-MedLine.d104.s8.p0" e1="DDI-MedLine.d104.s8.e0"
            e2="DDI-MedLine.d104.s8.e1" ddi="false"/>
        <pair id="DDI-MedLine.d104.s8.p1" e1="DDI-MedLine.d104.s8.e0"
            e2="DDI-MedLine.d104.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d104.s8.p2" e1="DDI-MedLine.d104.s8.e0"
            e2="DDI-MedLine.d104.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d104.s8.p3" e1="DDI-MedLine.d104.s8.e1"
            e2="DDI-MedLine.d104.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d104.s8.p4" e1="DDI-MedLine.d104.s8.e1"
            e2="DDI-MedLine.d104.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d104.s8.p5" e1="DDI-MedLine.d104.s8.e2"
            e2="DDI-MedLine.d104.s8.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d98.s0" text="Behavioral responses to repeated cocaine exposure in mice selectively bred for differential sensitivity to pentobarbital.&#xd;&#xa;">
        <entity id="DDI-MedLine.d98.s0.e0" charOffset="33-39"
            type="drug" text="cocaine"/>
        <entity id="DDI-MedLine.d98.s0.e1" charOffset="107-119"
            type="drug" text="pentobarbital"/>
        <pair id="DDI-MedLine.d98.s0.p0" e1="DDI-MedLine.d98.s0.e0"
            e2="DDI-MedLine.d98.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d98.s1" text="Mice from the 20th generation of three lines divergently selected for response to pentobarbital-induced sedation times [long-sedation time (LST), short sedation time (SST), and randomly bred control (RBC)] were used to study cocaine-induced behavioral sensitization. ">
        <entity id="DDI-MedLine.d98.s1.e0" charOffset="82-94"
            type="drug" text="pentobarbital"/>
        <entity id="DDI-MedLine.d98.s1.e1" charOffset="225-231"
            type="drug" text="cocaine"/>
        <pair id="DDI-MedLine.d98.s1.p0" e1="DDI-MedLine.d98.s1.e0"
            e2="DDI-MedLine.d98.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d98.s2" text="These lines showed variable degrees of locomotor activities in response to cocaine. ">
        <entity id="DDI-MedLine.d98.s2.e0" charOffset="75-81"
            type="drug" text="cocaine"/>
    </sentence>
    <sentence id="DDI-MedLine.d98.s3" text="At a low cocaine dose and long withdrawal period (10 mg/kg, twice a day for 5 days followed by a 14-day withdrawal), the LST mice showed tolerance development. ">
        <entity id="DDI-MedLine.d98.s3.e0" charOffset="9-15" type="drug" text="cocaine"/>
    </sentence>
    <sentence id="DDI-MedLine.d98.s4" text="In response to cocaine, the locomotor activities of the SST were not significantly different from the RBC group. ">
        <entity id="DDI-MedLine.d98.s4.e0" charOffset="15-21"
            type="drug" text="cocaine"/>
    </sentence>
    <sentence id="DDI-MedLine.d98.s5" text="At a higher dose and a shorter withdrawal period (20 mg/kg, daily for 7 days followed by a 3-day withdrawal), the SST mice showed behavioral sensitization similar to the RBC mice, but the LST mice did not develop sensitization. "/>
    <sentence id="DDI-MedLine.d98.s6" text="The different responses in locomotor activity induced by cocaine suggest that genetic factors may play a role in determining the magnitude of response to this drug. ">
        <entity id="DDI-MedLine.d98.s6.e0" charOffset="57-63"
            type="drug" text="cocaine"/>
    </sentence>
    <sentence id="DDI-MedLine.d98.s7" text="Dopamine (DA) levels did not differ significantly in either striatum (STR) or nucleus accumbens (NAC) for the cocaine-treated animals to their corresponding saline-treated controls. ">
        <entity id="DDI-MedLine.d98.s7.e0" charOffset="110-116"
            type="drug" text="cocaine"/>
    </sentence>
    <sentence id="DDI-MedLine.d98.s8" text="The affinity (Kd) of D2 in the NAC decreased significantly, without changes in density (Bmax), in the cocaine-treated SST and RBC mice. ">
        <entity id="DDI-MedLine.d98.s8.e0" charOffset="102-108"
            type="drug" text="cocaine"/>
    </sentence>
    <sentence id="DDI-MedLine.d98.s9" text="On the other hand, the density of D2 binding sites in the SST and the RBC mice in the STR was significantly increased in cocaine-treated groups without change in Kd. ">
        <entity id="DDI-MedLine.d98.s9.e0" charOffset="121-127"
            type="drug" text="cocaine"/>
    </sentence>
    <sentence id="DDI-MedLine.d98.s10" text="The LST mice did not show any changes in the Kd and Bmax in either the STR or the NAC. "/>
    <sentence id="DDI-MedLine.d98.s11" text="Taken together, these findings suggest that the changes in the Kd of D2 in the NAC and the Bmax of D2 in the STR may contribute to the differences in locomotor responses to cocaine exposure in these mouse lines.">
        <entity id="DDI-MedLine.d98.s11.e0" charOffset="173-179"
            type="drug" text="cocaine"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s0" text="18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.&#xd;&#xa;">
        <entity id="DDI-MedLine.d110.s0.e0" charOffset="0-21"
            type="drug_n" text="18-Methoxycoronaridine"/>
        <entity id="DDI-MedLine.d110.s0.e1" charOffset="24-28"
            type="drug_n" text="18-MC"/>
        <entity id="DDI-MedLine.d110.s0.e2" charOffset="35-42"
            type="drug_n" text="ibogaine"/>
        <pair id="DDI-MedLine.d110.s0.p0" e1="DDI-MedLine.d110.s0.e0"
            e2="DDI-MedLine.d110.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d110.s0.p1" e1="DDI-MedLine.d110.s0.e0"
            e2="DDI-MedLine.d110.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d110.s0.p2" e1="DDI-MedLine.d110.s0.e1"
            e2="DDI-MedLine.d110.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s1" text="18-MC, a novel iboga alkaloid congener, is being developed as a potential treatment for multiple forms of drug abuse. ">
        <entity id="DDI-MedLine.d110.s1.e0" charOffset="0-4"
            type="drug_n" text="18-MC"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s2" text="Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ">
        <entity id="DDI-MedLine.d110.s2.e0" charOffset="5-12"
            type="drug_n" text="ibogaine"/>
        <entity id="DDI-MedLine.d110.s2.e1" charOffset="26-30"
            type="drug_n" text="18-MC"/>
        <entity id="DDI-MedLine.d110.s2.e2" charOffset="92-99"
            type="drug" text="morphine"/>
        <entity id="DDI-MedLine.d110.s2.e3" charOffset="105-111"
            type="drug" text="cocaine"/>
        <entity id="DDI-MedLine.d110.s2.e4" charOffset="149-155"
            type="drug" text="ethanol"/>
        <entity id="DDI-MedLine.d110.s2.e5" charOffset="161-168"
            type="drug" text="nicotine"/>
        <pair id="DDI-MedLine.d110.s2.p0" e1="DDI-MedLine.d110.s2.e0"
            e2="DDI-MedLine.d110.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d110.s2.p1" e1="DDI-MedLine.d110.s2.e0"
            e2="DDI-MedLine.d110.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d110.s2.p2" e1="DDI-MedLine.d110.s2.e0"
            e2="DDI-MedLine.d110.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d110.s2.p3" e1="DDI-MedLine.d110.s2.e0"
            e2="DDI-MedLine.d110.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d110.s2.p4" e1="DDI-MedLine.d110.s2.e0"
            e2="DDI-MedLine.d110.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d110.s2.p5" e1="DDI-MedLine.d110.s2.e1"
            e2="DDI-MedLine.d110.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d110.s2.p6" e1="DDI-MedLine.d110.s2.e1"
            e2="DDI-MedLine.d110.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d110.s2.p7" e1="DDI-MedLine.d110.s2.e1"
            e2="DDI-MedLine.d110.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d110.s2.p8" e1="DDI-MedLine.d110.s2.e1"
            e2="DDI-MedLine.d110.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d110.s2.p9" e1="DDI-MedLine.d110.s2.e2"
            e2="DDI-MedLine.d110.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d110.s2.p10" e1="DDI-MedLine.d110.s2.e2"
            e2="DDI-MedLine.d110.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d110.s2.p11" e1="DDI-MedLine.d110.s2.e2"
            e2="DDI-MedLine.d110.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d110.s2.p12" e1="DDI-MedLine.d110.s2.e3"
            e2="DDI-MedLine.d110.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d110.s2.p13" e1="DDI-MedLine.d110.s2.e3"
            e2="DDI-MedLine.d110.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d110.s2.p14" e1="DDI-MedLine.d110.s2.e4"
            e2="DDI-MedLine.d110.s2.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s3" text="unlike ibogaine, 18-MC does not affect responding for a nondrug reinforcer (water). ">
        <entity id="DDI-MedLine.d110.s3.e0" charOffset="7-14"
            type="drug_n" text="ibogaine"/>
        <entity id="DDI-MedLine.d110.s3.e1" charOffset="17-21"
            type="drug_n" text="18-MC"/>
        <pair id="DDI-MedLine.d110.s3.p0" e1="DDI-MedLine.d110.s3.e0"
            e2="DDI-MedLine.d110.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s4" text="Both ibogaine and 18-MC ameliorate opioid withdrawal signs. ">
        <entity id="DDI-MedLine.d110.s4.e0" charOffset="5-12"
            type="drug_n" text="ibogaine"/>
        <entity id="DDI-MedLine.d110.s4.e1" charOffset="18-22"
            type="drug_n" text="18-MC"/>
        <entity id="DDI-MedLine.d110.s4.e2" charOffset="35-40"
            type="group" text="opioid"/>
        <pair id="DDI-MedLine.d110.s4.p0" e1="DDI-MedLine.d110.s4.e0"
            e2="DDI-MedLine.d110.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d110.s4.p1" e1="DDI-MedLine.d110.s4.e0"
            e2="DDI-MedLine.d110.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d110.s4.p2" e1="DDI-MedLine.d110.s4.e1"
            e2="DDI-MedLine.d110.s4.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s5" text="Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. ">
        <entity id="DDI-MedLine.d110.s5.e0" charOffset="5-12"
            type="drug_n" text="ibogaine"/>
        <entity id="DDI-MedLine.d110.s5.e1" charOffset="18-22"
            type="drug_n" text="18-MC"/>
        <entity id="DDI-MedLine.d110.s5.e2" charOffset="101-108"
            type="drug_n" text="ibogaine"/>
        <pair id="DDI-MedLine.d110.s5.p0" e1="DDI-MedLine.d110.s5.e0"
            e2="DDI-MedLine.d110.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d110.s5.p1" e1="DDI-MedLine.d110.s5.e0"
            e2="DDI-MedLine.d110.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d110.s5.p2" e1="DDI-MedLine.d110.s5.e1"
            e2="DDI-MedLine.d110.s5.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s6" text="Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ">
        <entity id="DDI-MedLine.d110.s6.e0" charOffset="5-12"
            type="drug_n" text="ibogaine"/>
        <entity id="DDI-MedLine.d110.s6.e1" charOffset="18-22"
            type="drug_n" text="18-MC"/>
        <entity id="DDI-MedLine.d110.s6.e2" charOffset="30-37"
            type="drug" text="morphine"/>
        <entity id="DDI-MedLine.d110.s6.e3" charOffset="51-58"
            type="drug" text="nicotine"/>
        <pair id="DDI-MedLine.d110.s6.p0" e1="DDI-MedLine.d110.s6.e0"
            e2="DDI-MedLine.d110.s6.e1" ddi="false"/>
        <pair id="DDI-MedLine.d110.s6.p1" e1="DDI-MedLine.d110.s6.e0"
            e2="DDI-MedLine.d110.s6.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d110.s6.p2" e1="DDI-MedLine.d110.s6.e0"
            e2="DDI-MedLine.d110.s6.e3" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d110.s6.p3" e1="DDI-MedLine.d110.s6.e1"
            e2="DDI-MedLine.d110.s6.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d110.s6.p4" e1="DDI-MedLine.d110.s6.e1"
            e2="DDI-MedLine.d110.s6.e3" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d110.s6.p5" e1="DDI-MedLine.d110.s6.e2"
            e2="DDI-MedLine.d110.s6.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s7" text="only ibogaine enhances cocaine-induced increases in accumbal dopamine. ">
        <entity id="DDI-MedLine.d110.s7.e0" charOffset="5-12"
            type="drug_n" text="ibogaine"/>
        <entity id="DDI-MedLine.d110.s7.e1" charOffset="23-29"
            type="drug" text="cocaine"/>
        <pair id="DDI-MedLine.d110.s7.p0" e1="DDI-MedLine.d110.s7.e0"
            e2="DDI-MedLine.d110.s7.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s8" text="Both ibogaine and 18-MC enhance the locomotor and/or stereotypic effects of stimulants. ">
        <entity id="DDI-MedLine.d110.s8.e0" charOffset="5-12"
            type="drug_n" text="ibogaine"/>
        <entity id="DDI-MedLine.d110.s8.e1" charOffset="18-22"
            type="drug_n" text="18-MC"/>
        <pair id="DDI-MedLine.d110.s8.p0" e1="DDI-MedLine.d110.s8.e0"
            e2="DDI-MedLine.d110.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s9" text="Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; ">
        <entity id="DDI-MedLine.d110.s9.e0" charOffset="0-7"
            type="drug_n" text="Ibogaine"/>
        <entity id="DDI-MedLine.d110.s9.e1" charOffset="25-29"
            type="drug_n" text="18-MC"/>
        <entity id="DDI-MedLine.d110.s9.e2" charOffset="75-82"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d110.s9.p0" e1="DDI-MedLine.d110.s9.e0"
            e2="DDI-MedLine.d110.s9.e1" ddi="false"/>
        <pair id="DDI-MedLine.d110.s9.p1" e1="DDI-MedLine.d110.s9.e0"
            e2="DDI-MedLine.d110.s9.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d110.s9.p2" e1="DDI-MedLine.d110.s9.e1"
            e2="DDI-MedLine.d110.s9.e2" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s10" text="both compounds attenuate morphine-induced locomotion in morphine-experienced rats. ">
        <entity id="DDI-MedLine.d110.s10.e0" charOffset="25-32"
            type="drug" text="morphine"/>
        <entity id="DDI-MedLine.d110.s10.e1" charOffset="56-63"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d110.s10.p0" e1="DDI-MedLine.d110.s10.e0"
            e2="DDI-MedLine.d110.s10.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s11" text="Ibogaine produces whole body tremors and, at high doses (> or = 100 mg/kg), cerebellar damage; ">
        <entity id="DDI-MedLine.d110.s11.e0" charOffset="0-7"
            type="drug_n" text="Ibogaine"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s12" text="18-MC does not produce these effects. ">
        <entity id="DDI-MedLine.d110.s12.e0" charOffset="0-4"
            type="drug_n" text="18-MC"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s13" text="Ibogaine, but not 18-MC, decreases heart rate at high doses. ">
        <entity id="DDI-MedLine.d110.s13.e0" charOffset="0-7"
            type="drug_n" text="Ibogaine"/>
        <entity id="DDI-MedLine.d110.s13.e1" charOffset="18-22"
            type="drug_n" text="18-MC"/>
        <pair id="DDI-MedLine.d110.s13.p0" e1="DDI-MedLine.d110.s13.e0"
            e2="DDI-MedLine.d110.s13.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s14" text="While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. ">
        <entity id="DDI-MedLine.d110.s14.e0" charOffset="6-10"
            type="drug_n" text="18-MC"/>
        <entity id="DDI-MedLine.d110.s14.e1" charOffset="16-23"
            type="drug_n" text="ibogaine"/>
        <entity id="DDI-MedLine.d110.s14.e2" charOffset="100-104"
            type="drug_n" text="18-MC"/>
        <entity id="DDI-MedLine.d110.s14.e3" charOffset="137-144"
            type="drug_n" text="ibogaine"/>
        <pair id="DDI-MedLine.d110.s14.p0" e1="DDI-MedLine.d110.s14.e0"
            e2="DDI-MedLine.d110.s14.e1" ddi="false"/>
        <pair id="DDI-MedLine.d110.s14.p1" e1="DDI-MedLine.d110.s14.e0"
            e2="DDI-MedLine.d110.s14.e2" ddi="false"/>
        <pair id="DDI-MedLine.d110.s14.p2" e1="DDI-MedLine.d110.s14.e0"
            e2="DDI-MedLine.d110.s14.e3" ddi="false"/>
        <pair id="DDI-MedLine.d110.s14.p3" e1="DDI-MedLine.d110.s14.e1"
            e2="DDI-MedLine.d110.s14.e2" ddi="false"/>
        <pair id="DDI-MedLine.d110.s14.p4" e1="DDI-MedLine.d110.s14.e1"
            e2="DDI-MedLine.d110.s14.e3" ddi="false"/>
        <pair id="DDI-MedLine.d110.s14.p5" e1="DDI-MedLine.d110.s14.e2"
            e2="DDI-MedLine.d110.s14.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s15" text="Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. ">
        <entity id="DDI-MedLine.d110.s15.e0" charOffset="5-9"
            type="drug_n" text="18-MC"/>
        <entity id="DDI-MedLine.d110.s15.e1" charOffset="15-22"
            type="drug_n" text="ibogaine"/>
        <entity id="DDI-MedLine.d110.s15.e2" charOffset="57-64"
            type="drug_n" text="ibogaine"/>
        <entity id="DDI-MedLine.d110.s15.e3" charOffset="67-71"
            type="drug_n" text="18-MC"/>
        <pair id="DDI-MedLine.d110.s15.p0" e1="DDI-MedLine.d110.s15.e0"
            e2="DDI-MedLine.d110.s15.e1" ddi="false"/>
        <pair id="DDI-MedLine.d110.s15.p1" e1="DDI-MedLine.d110.s15.e0"
            e2="DDI-MedLine.d110.s15.e2" ddi="false"/>
        <pair id="DDI-MedLine.d110.s15.p2" e1="DDI-MedLine.d110.s15.e0"
            e2="DDI-MedLine.d110.s15.e3" ddi="false"/>
        <pair id="DDI-MedLine.d110.s15.p3" e1="DDI-MedLine.d110.s15.e1"
            e2="DDI-MedLine.d110.s15.e2" ddi="false"/>
        <pair id="DDI-MedLine.d110.s15.p4" e1="DDI-MedLine.d110.s15.e1"
            e2="DDI-MedLine.d110.s15.e3" ddi="false"/>
        <pair id="DDI-MedLine.d110.s15.p5" e1="DDI-MedLine.d110.s15.e2"
            e2="DDI-MedLine.d110.s15.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d110.s16" text="The data suggest that 18-MC has a narrower spectrum of actions and will have a substantially greater therapeutic index than ibogaine.">
        <entity id="DDI-MedLine.d110.s16.e0" charOffset="22-26"
            type="drug_n" text="18-MC"/>
        <entity id="DDI-MedLine.d110.s16.e1" charOffset="124-131"
            type="drug_n" text="ibogaine"/>
        <pair id="DDI-MedLine.d110.s16.p0" e1="DDI-MedLine.d110.s16.e0"
            e2="DDI-MedLine.d110.s16.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d106.s0" text="Clinical implications of warfarin interactions with five sedatives.&#xa;">
        <entity id="DDI-MedLine.d106.s0.e0" charOffset="25-32"
            type="drug" text="warfarin"/>
        <entity id="DDI-MedLine.d106.s0.e1" charOffset="57-65"
            type="group" text="sedatives"/>
        <pair id="DDI-MedLine.d106.s0.p0" e1="DDI-MedLine.d106.s0.e0"
            e2="DDI-MedLine.d106.s0.e1" ddi="true" type="int"/>
    </sentence>
    <sentence id="DDI-MedLine.d106.s1" text="The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ">
        <entity id="DDI-MedLine.d106.s1.e0" charOffset="45-57"
            type="group" text="anticoagulant"/>
        <entity id="DDI-MedLine.d106.s1.e1" charOffset="75-87"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-MedLine.d106.s1.e2" charOffset="90-101"
            type="drug" text="secobarbital"/>
        <entity id="DDI-MedLine.d106.s1.e3" charOffset="104-115"
            type="drug" text="glutethimide"/>
        <entity id="DDI-MedLine.d106.s1.e4" charOffset="118-132"
            type="drug" text="chloral hydrate"/>
        <entity id="DDI-MedLine.d106.s1.e5" charOffset="138-149"
            type="drug" text="methaqualone"/>
        <entity id="DDI-MedLine.d106.s1.e6" charOffset="209-216"
            type="group" text="coumarin"/>
        <pair id="DDI-MedLine.d106.s1.p0" e1="DDI-MedLine.d106.s1.e0"
            e2="DDI-MedLine.d106.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p1" e1="DDI-MedLine.d106.s1.e0"
            e2="DDI-MedLine.d106.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p2" e1="DDI-MedLine.d106.s1.e0"
            e2="DDI-MedLine.d106.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p3" e1="DDI-MedLine.d106.s1.e0"
            e2="DDI-MedLine.d106.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p4" e1="DDI-MedLine.d106.s1.e0"
            e2="DDI-MedLine.d106.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p5" e1="DDI-MedLine.d106.s1.e0"
            e2="DDI-MedLine.d106.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p6" e1="DDI-MedLine.d106.s1.e1"
            e2="DDI-MedLine.d106.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p7" e1="DDI-MedLine.d106.s1.e1"
            e2="DDI-MedLine.d106.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p8" e1="DDI-MedLine.d106.s1.e1"
            e2="DDI-MedLine.d106.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p9" e1="DDI-MedLine.d106.s1.e1"
            e2="DDI-MedLine.d106.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p10" e1="DDI-MedLine.d106.s1.e1"
            e2="DDI-MedLine.d106.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p11" e1="DDI-MedLine.d106.s1.e2"
            e2="DDI-MedLine.d106.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p12" e1="DDI-MedLine.d106.s1.e2"
            e2="DDI-MedLine.d106.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p13" e1="DDI-MedLine.d106.s1.e2"
            e2="DDI-MedLine.d106.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p14" e1="DDI-MedLine.d106.s1.e2"
            e2="DDI-MedLine.d106.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p15" e1="DDI-MedLine.d106.s1.e3"
            e2="DDI-MedLine.d106.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p16" e1="DDI-MedLine.d106.s1.e3"
            e2="DDI-MedLine.d106.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p17" e1="DDI-MedLine.d106.s1.e3"
            e2="DDI-MedLine.d106.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p18" e1="DDI-MedLine.d106.s1.e4"
            e2="DDI-MedLine.d106.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p19" e1="DDI-MedLine.d106.s1.e4"
            e2="DDI-MedLine.d106.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d106.s1.p20" e1="DDI-MedLine.d106.s1.e5"
            e2="DDI-MedLine.d106.s1.e6" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d106.s2" text="Each subject received an individualized fixed daily dose of warfarin and served as his own pre- and postsedative treatment control. ">
        <entity id="DDI-MedLine.d106.s2.e0" charOffset="60-67"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-MedLine.d106.s3" text="Prothrombin times were measured four times weekly during five long-term experiments. "/>
    <sentence id="DDI-MedLine.d106.s4" text="Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide; ">
        <entity id="DDI-MedLine.d106.s4.e0" charOffset="67-79"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-MedLine.d106.s4.e1" charOffset="82-93"
            type="drug" text="secobarbital"/>
        <entity id="DDI-MedLine.d106.s4.e2" charOffset="99-110"
            type="drug" text="glutethimide"/>
        <pair id="DDI-MedLine.d106.s4.p0" e1="DDI-MedLine.d106.s4.e0"
            e2="DDI-MedLine.d106.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d106.s4.p1" e1="DDI-MedLine.d106.s4.e0"
            e2="DDI-MedLine.d106.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d106.s4.p2" e1="DDI-MedLine.d106.s4.e1"
            e2="DDI-MedLine.d106.s4.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d106.s5" text="there was no significant change in prothrombin test results during the trials of chloral hydrate and methaqualone. ">
        <entity id="DDI-MedLine.d106.s5.e0" charOffset="81-95"
            type="drug" text="chloral hydrate"/>
        <entity id="DDI-MedLine.d106.s5.e1" charOffset="101-112"
            type="drug" text="methaqualone"/>
        <pair id="DDI-MedLine.d106.s5.p0" e1="DDI-MedLine.d106.s5.e0"
            e2="DDI-MedLine.d106.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d106.s6" text="Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. ">
        <entity id="DDI-MedLine.d106.s6.e0" charOffset="0-11"
            type="group" text="Barbiturates"/>
        <entity id="DDI-MedLine.d106.s6.e1" charOffset="17-28"
            type="drug" text="glutethimide"/>
        <entity id="DDI-MedLine.d106.s6.e2" charOffset="79-92"
            type="group" text="coumarin drugs"/>
        <pair id="DDI-MedLine.d106.s6.p0" e1="DDI-MedLine.d106.s6.e0"
            e2="DDI-MedLine.d106.s6.e1" ddi="false"/>
        <pair id="DDI-MedLine.d106.s6.p1" e1="DDI-MedLine.d106.s6.e0"
            e2="DDI-MedLine.d106.s6.e2" ddi="true" type="advise"/>
        <pair id="DDI-MedLine.d106.s6.p2" e1="DDI-MedLine.d106.s6.e1"
            e2="DDI-MedLine.d106.s6.e2" ddi="true" type="advise"/>
    </sentence>
    <sentence id="DDI-MedLine.d106.s7" text="The concurrent use of drugs from these groups is decreasing according to a survey of 200 hospital medical records. "/>
    <sentence id="DDI-MedLine.d106.s8" text="Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. ">
        <entity id="DDI-MedLine.d106.s8.e0" charOffset="0-14"
            type="drug" text="Chloral hydrate"/>
        <entity id="DDI-MedLine.d106.s8.e1" charOffset="20-31"
            type="drug" text="methaqualone"/>
        <entity id="DDI-MedLine.d106.s8.e2" charOffset="85-104"
            type="group" text="anticoagulant agents"/>
        <pair id="DDI-MedLine.d106.s8.p0" e1="DDI-MedLine.d106.s8.e0"
            e2="DDI-MedLine.d106.s8.e1" ddi="false"/>
        <pair id="DDI-MedLine.d106.s8.p1" e1="DDI-MedLine.d106.s8.e0"
            e2="DDI-MedLine.d106.s8.e2" ddi="true" type="int"/>
        <pair id="DDI-MedLine.d106.s8.p2" e1="DDI-MedLine.d106.s8.e1"
            e2="DDI-MedLine.d106.s8.e2" ddi="true" type="int"/>
    </sentence>
    <sentence id="DDI-MedLine.d106.s9" text="It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.">
        <entity id="DDI-MedLine.d106.s9.e0" charOffset="21-35"
            type="drug" text="chloral hydrate"/>
        <entity id="DDI-MedLine.d106.s9.e1" charOffset="41-52"
            type="drug" text="methaqualone"/>
        <entity id="DDI-MedLine.d106.s9.e2" charOffset="151-163"
            type="group" text="anticoagulant"/>
        <pair id="DDI-MedLine.d106.s9.p0" e1="DDI-MedLine.d106.s9.e0"
            e2="DDI-MedLine.d106.s9.e1" ddi="false"/>
        <pair id="DDI-MedLine.d106.s9.p1" e1="DDI-MedLine.d106.s9.e0"
            e2="DDI-MedLine.d106.s9.e2" ddi="false"/>
        <pair id="DDI-MedLine.d106.s9.p2" e1="DDI-MedLine.d106.s9.e1"
            e2="DDI-MedLine.d106.s9.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d77.s0" text="Effects of low temperatures on microtubules in the non-myelinated axons of post-ganglionic sympathetic nerves.&#xd;&#xa;"/>
    <sentence id="DDI-MedLine.d77.s1" text="The effect of temperature changes on the number of microtubules in non-myelinated axons has been studied in cat inferior mesenteric ganglion/hypogastric nerve preparations incubated at various temperatures in Eagles minimal essential tissue culture medium in vitro. "/>
    <sentence id="DDI-MedLine.d77.s2" text="At 37 degrees C the non-myelinated axons contained 28.4 plus or minus 0.8 S.E.M. "/>
    <sentence id="DDI-MedLine.d77.s3" text="(54) microtubules per axon. "/>
    <sentence id="DDI-MedLine.d77.s4" text="After incubation at 0 degrees C for 4 h this number fell to 2.3 plus or minus 0.1 S.E.M. "/>
    <sentence id="DDI-MedLine.d77.s5" text="(41) but returned to normal levels when the nerves were rewarmed. "/>
    <sentence id="DDI-MedLine.d77.s6" text="This loss of microtubules on cooling the nerves and their reappearance on rewarming was a rapid process; "/>
    <sentence id="DDI-MedLine.d77.s7" text="it was independent of the influence of the nueronal cell body and of protein synthesis within the axon. "/>
    <sentence id="DDI-MedLine.d77.s8" text="The preservation of the microtubules was improved when D2O was present in the incubation medium. "/>
    <sentence id="DDI-MedLine.d77.s9" text="Reformed microtubules appeared to function normally with respect to their possible role in the transport of noradrenaline storage vesicles along the axons."/>
    <sentence id="DDI-MedLine.d127.s0" text="Serum digoxin levels using an 125I-labelled antigen: Validation of method and observations on cardiac patients.&#xa;">
        <entity id="DDI-MedLine.d127.s0.e0" charOffset="6-12"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-MedLine.d127.s1" text="1. "/>
    <sentence id="DDI-MedLine.d127.s2" text="Determinations of serum digoxin levels utilizing commercially available kits with an 125I-labelled antigen were precise and not materially different from results obtained with a 3H-labelled antigen. ">
        <entity id="DDI-MedLine.d127.s2.e0" charOffset="24-30"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-MedLine.d127.s3" text="2. "/>
    <sentence id="DDI-MedLine.d127.s4" text="In order to approximate the steady state level, serum digoxin levels should be drawn either before or at least six hours following the administration of an oral tablet. ">
        <entity id="DDI-MedLine.d127.s4.e0" charOffset="54-60"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-MedLine.d127.s5" text="3. "/>
    <sentence id="DDI-MedLine.d127.s6" text="Concomitantly given thiazide diuretics did not interfere with the absorption of a tablet of digoxin. ">
        <entity id="DDI-MedLine.d127.s6.e0" charOffset="20-37"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-MedLine.d127.s6.e1" charOffset="92-98"
            type="drug" text="digoxin"/>
        <pair id="DDI-MedLine.d127.s6.p0" e1="DDI-MedLine.d127.s6.e0"
            e2="DDI-MedLine.d127.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d127.s7" text="4. "/>
    <sentence id="DDI-MedLine.d127.s8" text="In the digitalized patient, slow alterations in serum levels after oral administration appeared well correlated with, at least, the negative chronotropic effects of the drug. "/>
    <sentence id="DDI-MedLine.d127.s9" text="5. "/>
    <sentence id="DDI-MedLine.d127.s10" text="Maximal exercise testing, a maneuver often applied to cardiac patients, does not significantly alter the serum digoxin level.">
        <entity id="DDI-MedLine.d127.s10.e0" charOffset="111-117"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-MedLine.d135.s0" text="Combinations of clozapine and phencyclidine: effects on drug discrimination and behavioral inhibition in rats.&#xd;&#xa;">
        <entity id="DDI-MedLine.d135.s0.e0" charOffset="16-24"
            type="drug" text="clozapine"/>
        <entity id="DDI-MedLine.d135.s0.e1" charOffset="30-42"
            type="drug_n" text="phencyclidine"/>
        <pair id="DDI-MedLine.d135.s0.p0" e1="DDI-MedLine.d135.s0.e0"
            e2="DDI-MedLine.d135.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d135.s1" text="Phencyclidine (PCP) produces psychotomimetic effects in humans that resemble schizophrenia symptoms. ">
        <entity id="DDI-MedLine.d135.s1.e0" charOffset="0-12"
            type="drug_n" text="Phencyclidine"/>
        <entity id="DDI-MedLine.d135.s1.e1" charOffset="15-17"
            type="drug_n" text="PCP"/>
        <pair id="DDI-MedLine.d135.s1.p0" e1="DDI-MedLine.d135.s1.e0"
            e2="DDI-MedLine.d135.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d135.s2" text="In an effort to screen compounds for antipsychotic activity, preclinical researchers have investigated whether these compounds block PCP-induced behaviors in animals. ">
        <entity id="DDI-MedLine.d135.s2.e0" charOffset="133-135"
            type="drug_n" text="PCP"/>
    </sentence>
    <sentence id="DDI-MedLine.d135.s3" text="In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. ">
        <entity id="DDI-MedLine.d135.s3.e0" charOffset="26-47"
            type="group" text="atypical antipsychotic"/>
        <entity id="DDI-MedLine.d135.s3.e1" charOffset="49-57"
            type="drug" text="clozapine"/>
        <entity id="DDI-MedLine.d135.s3.e2" charOffset="108-110"
            type="drug_n" text="PCP"/>
        <pair id="DDI-MedLine.d135.s3.p0" e1="DDI-MedLine.d135.s3.e0"
            e2="DDI-MedLine.d135.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d135.s3.p1" e1="DDI-MedLine.d135.s3.e0"
            e2="DDI-MedLine.d135.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d135.s3.p2" e1="DDI-MedLine.d135.s3.e1"
            e2="DDI-MedLine.d135.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d135.s4" text="PCP produced distinctive effects in each task: it substituted for the training dose in PCP discrimination and it increased the number of responses with short (&lt;3 s) interresponse times as well as increasing overall response rates in the DRL schedule. ">
        <entity id="DDI-MedLine.d135.s4.e0" charOffset="0-2"
            type="drug_n" text="PCP"/>
        <entity id="DDI-MedLine.d135.s4.e1" charOffset="87-89"
            type="drug_n" text="PCP"/>
        <pair id="DDI-MedLine.d135.s4.p0" e1="DDI-MedLine.d135.s4.e0"
            e2="DDI-MedLine.d135.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d135.s5" text="Acute dosing with clozapine failed to alter the behavioral effects of PCP in either procedure even when tested up to doses that produced pharmacological effects alone. ">
        <entity id="DDI-MedLine.d135.s5.e0" charOffset="18-26"
            type="drug" text="clozapine"/>
        <entity id="DDI-MedLine.d135.s5.e1" charOffset="70-72"
            type="drug_n" text="PCP"/>
        <pair id="DDI-MedLine.d135.s5.p0" e1="DDI-MedLine.d135.s5.e0"
            e2="DDI-MedLine.d135.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d135.s6" text="These results suggest that acute dosing with clozapine would not affect behaviors most closely associated with PCP intoxication. ">
        <entity id="DDI-MedLine.d135.s6.e0" charOffset="45-53"
            type="drug" text="clozapine"/>
        <entity id="DDI-MedLine.d135.s6.e1" charOffset="111-113"
            type="drug_n" text="PCP"/>
        <pair id="DDI-MedLine.d135.s6.p0" e1="DDI-MedLine.d135.s6.e0"
            e2="DDI-MedLine.d135.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d135.s7" text="Further, they bring into question the utility of using PCP combination procedures in animals to screen for antipsychotic potential. ">
        <entity id="DDI-MedLine.d135.s7.e0" charOffset="55-57"
            type="drug_n" text="PCP"/>
    </sentence>
    <sentence id="DDI-MedLine.d135.s8" text="Since chronic dosing is required for therapeutic efficacy of antipsychotics, future studies should focus on investigation of chronic dosing effects of these drugs in combination with PCP.">
        <entity id="DDI-MedLine.d135.s8.e0" charOffset="61-74"
            type="group" text="antipsychotics"/>
        <entity id="DDI-MedLine.d135.s8.e1" charOffset="183-185"
            type="drug_n" text="PCP"/>
        <pair id="DDI-MedLine.d135.s8.p0" e1="DDI-MedLine.d135.s8.e0"
            e2="DDI-MedLine.d135.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d95.s0" text="The mechanism of resveratrol-induced vasorelaxation differs in the mesenteric resistance arteries of lean and obese rats.&#xd;&#xa;">
        <entity id="DDI-MedLine.d95.s0.e0" charOffset="17-27"
            type="drug_n" text="resveratrol"/>
    </sentence>
    <sentence id="DDI-MedLine.d95.s1" text="Resveratrol has been shown to induce vasorelaxation. ">
        <entity id="DDI-MedLine.d95.s1.e0" charOffset="0-10"
            type="drug_n" text="Resveratrol"/>
    </sentence>
    <sentence id="DDI-MedLine.d95.s2" text="In this study, we investigated the mechanism(s) of resveratrol-induced vasorelaxation in resistance mesenteric arteries from male lean and dietary-induced obese rats. ">
        <entity id="DDI-MedLine.d95.s2.e0" charOffset="51-61"
            type="drug_n" text="resveratrol"/>
    </sentence>
    <sentence id="DDI-MedLine.d95.s3" text="Compared with lean rats, arteries from dietary-obese rats showed significant (P&lt;0.001) endothelial dysfunction, as indicated by a decrease (>20%) in maximal acetylcholine-induced vasorelaxation. "/>
    <sentence id="DDI-MedLine.d95.s4" text="Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. ">
        <entity id="DDI-MedLine.d95.s4.e0" charOffset="0-10"
            type="drug_n" text="Resveratrol"/>
        <entity id="DDI-MedLine.d95.s4.e1" charOffset="116-128"
            type="drug" text="noradrenaline"/>
        <entity id="DDI-MedLine.d95.s4.e2" charOffset="148-150"
            type="drug" text="KCl"/>
        <pair id="DDI-MedLine.d95.s4.p0" e1="DDI-MedLine.d95.s4.e0"
            e2="DDI-MedLine.d95.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d95.s4.p1" e1="DDI-MedLine.d95.s4.e0"
            e2="DDI-MedLine.d95.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d95.s4.p2" e1="DDI-MedLine.d95.s4.e1"
            e2="DDI-MedLine.d95.s4.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d95.s5" text="There were no significant differences between the two groups, achieving a maximum relaxation of >95% at a concentration of 35 micromol/l. "/>
    <sentence id="DDI-MedLine.d95.s6" text="However, L-NAME (100 and 300 micromol/l) did not alter the effects of reseveratrol on arteries from dietary-obese rats, giving superimposed concentration-responses curves. ">
        <entity id="DDI-MedLine.d95.s6.e0" charOffset="9-14"
            type="drug_n" text="L-NAME"/>
        <entity id="DDI-MedLine.d95.s6.e1" charOffset="70-81"
            type="drug_n" text="reseveratrol"/>
        <pair id="DDI-MedLine.d95.s6.p0" e1="DDI-MedLine.d95.s6.e0"
            e2="DDI-MedLine.d95.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d95.s7" text="Indomethacin was also ineffective in altering resveratrol activity in arteries from both lean and dietary-obese rats. ">
        <entity id="DDI-MedLine.d95.s7.e0" charOffset="0-11" type="drug" text="Indomethacin"/>
        <entity id="DDI-MedLine.d95.s7.e1" charOffset="46-56"
            type="drug_n" text="resveratrol"/>
        <pair id="DDI-MedLine.d95.s7.p0" e1="DDI-MedLine.d95.s7.e0"
            e2="DDI-MedLine.d95.s7.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d95.s8" text="In noradrenaline-precontracted arteries from dietary-obese rats, responses to resveratrol were not attenuated by endothelial denudation, indicating an action independent of the endothelium. ">
        <entity id="DDI-MedLine.d95.s8.e0" charOffset="3-15" type="drug" text="noradrenaline"/>
        <entity id="DDI-MedLine.d95.s8.e1" charOffset="78-88"
            type="drug_n" text="resveratrol"/>
        <pair id="DDI-MedLine.d95.s8.p0" e1="DDI-MedLine.d95.s8.e0"
            e2="DDI-MedLine.d95.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d95.s9" text="This study indicates that: (a) the maximal effects of resveratrol on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of resveratrol in lean animals (where endothelial function is not impaired), but not in dietary-obese rats, are mediated via NO.">
        <entity id="DDI-MedLine.d95.s9.e0" charOffset="54-64"
            type="drug_n" text="resveratrol"/>
        <entity id="DDI-MedLine.d95.s9.e1" charOffset="190-200"
            type="drug_n" text="resveratrol"/>
        <pair id="DDI-MedLine.d95.s9.p0" e1="DDI-MedLine.d95.s9.e0"
            e2="DDI-MedLine.d95.s9.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d79.s0" text="If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.&#xd;&#xa;">
        <entity id="DDI-MedLine.d79.s0.e0" charOffset="23-31"
            type="drug" text="indinavir"/>
        <entity id="DDI-MedLine.d79.s0.e1" charOffset="34-36"
            type="drug" text="IDV"/>
        <entity id="DDI-MedLine.d79.s0.e2" charOffset="40-49"
            type="drug" text="didanosine"/>
        <entity id="DDI-MedLine.d79.s0.e3" charOffset="67-69"
            type="drug" text="IDV"/>
        <pair id="DDI-MedLine.d79.s0.p0" e1="DDI-MedLine.d79.s0.e0"
            e2="DDI-MedLine.d79.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d79.s0.p1" e1="DDI-MedLine.d79.s0.e0"
            e2="DDI-MedLine.d79.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d79.s0.p2" e1="DDI-MedLine.d79.s0.e0"
            e2="DDI-MedLine.d79.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d79.s0.p3" e1="DDI-MedLine.d79.s0.e1"
            e2="DDI-MedLine.d79.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d79.s0.p4" e1="DDI-MedLine.d79.s0.e1"
            e2="DDI-MedLine.d79.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d79.s0.p5" e1="DDI-MedLine.d79.s0.e2"
            e2="DDI-MedLine.d79.s0.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d79.s1" text="Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ">
        <entity id="DDI-MedLine.d79.s1.e0" charOffset="29-37"
            type="drug" text="indinavir"/>
        <entity id="DDI-MedLine.d79.s1.e1" charOffset="43-52"
            type="drug" text="didanosine"/>
        <entity id="DDI-MedLine.d79.s1.e2" charOffset="101-109"
            type="drug" text="indinavir"/>
        <entity id="DDI-MedLine.d79.s1.e3" charOffset="145-154"
            type="drug" text="didanosine"/>
        <entity id="DDI-MedLine.d79.s1.e4" charOffset="171-179"
            type="drug" text="indinavir"/>
        <pair id="DDI-MedLine.d79.s1.p0" e1="DDI-MedLine.d79.s1.e0"
            e2="DDI-MedLine.d79.s1.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d79.s1.p1" e1="DDI-MedLine.d79.s1.e0"
            e2="DDI-MedLine.d79.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d79.s1.p2" e1="DDI-MedLine.d79.s1.e0"
            e2="DDI-MedLine.d79.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d79.s1.p3" e1="DDI-MedLine.d79.s1.e0"
            e2="DDI-MedLine.d79.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d79.s1.p4" e1="DDI-MedLine.d79.s1.e1"
            e2="DDI-MedLine.d79.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d79.s1.p5" e1="DDI-MedLine.d79.s1.e1"
            e2="DDI-MedLine.d79.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d79.s1.p6" e1="DDI-MedLine.d79.s1.e1"
            e2="DDI-MedLine.d79.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d79.s1.p7" e1="DDI-MedLine.d79.s1.e2"
            e2="DDI-MedLine.d79.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d79.s1.p8" e1="DDI-MedLine.d79.s1.e2"
            e2="DDI-MedLine.d79.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d79.s1.p9" e1="DDI-MedLine.d79.s1.e3"
            e2="DDI-MedLine.d79.s1.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d79.s2" text="We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. ">
        <entity id="DDI-MedLine.d79.s2.e0" charOffset="12-20"
            type="drug" text="indinavir"/>
        <entity id="DDI-MedLine.d79.s2.e1" charOffset="127-135"
            type="drug" text="indinavir"/>
        <entity id="DDI-MedLine.d79.s2.e2" charOffset="160-168"
            type="drug" text="indinavir"/>
        <entity id="DDI-MedLine.d79.s2.e3" charOffset="193-202"
            type="drug" text="didanosine"/>
        <pair id="DDI-MedLine.d79.s2.p0" e1="DDI-MedLine.d79.s2.e0"
            e2="DDI-MedLine.d79.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d79.s2.p1" e1="DDI-MedLine.d79.s2.e0"
            e2="DDI-MedLine.d79.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d79.s2.p2" e1="DDI-MedLine.d79.s2.e0"
            e2="DDI-MedLine.d79.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d79.s2.p3" e1="DDI-MedLine.d79.s2.e1"
            e2="DDI-MedLine.d79.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d79.s2.p4" e1="DDI-MedLine.d79.s2.e1"
            e2="DDI-MedLine.d79.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d79.s2.p5" e1="DDI-MedLine.d79.s2.e2"
            e2="DDI-MedLine.d79.s2.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d79.s3" text="Median gastric pH was significantly higher when indinavir was taken after didanosine administration; ">
        <entity id="DDI-MedLine.d79.s3.e0" charOffset="48-56"
            type="drug" text="indinavir"/>
        <entity id="DDI-MedLine.d79.s3.e1" charOffset="74-83"
            type="drug" text="didanosine"/>
        <pair id="DDI-MedLine.d79.s3.p0" e1="DDI-MedLine.d79.s3.e0"
            e2="DDI-MedLine.d79.s3.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d79.s4" text="however, no significant difference in the maximum concentration in plasma or the area under the concentration-time curve from time zero to 8 h was observed. "/>
    <sentence id="DDI-MedLine.d79.s5" text="Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.">
        <entity id="DDI-MedLine.d79.s5.e0" charOffset="0-8" type="drug" text="Indinavir"/>
        <entity id="DDI-MedLine.d79.s5.e1" charOffset="87-96"
            type="drug" text="didanosine"/>
        <pair id="DDI-MedLine.d79.s5.p0" e1="DDI-MedLine.d79.s5.e0"
            e2="DDI-MedLine.d79.s5.e1" ddi="true" type="advise"/>
    </sentence>
    <sentence id="DDI-MedLine.d59.s0" text="A proposed mechanism for the potentiation of cAMP-mediated acid secretion by carbachol.&#xd;&#xa;">
        <entity id="DDI-MedLine.d59.s0.e0" charOffset="77-85"
            type="drug" text="carbachol"/>
    </sentence>
    <sentence id="DDI-MedLine.d59.s1" text="Acid secretion in isolated rabbit gastric glands was monitored by the accumulation of [(14)C]aminopyrine. ">
        <entity id="DDI-MedLine.d59.s1.e0" charOffset="93-103"
            type="drug" text="aminopyrine"/>
    </sentence>
    <sentence id="DDI-MedLine.d59.s2" text="Stimulation of the glands with carbachol synergistically augmented the response to dibutyryl cAMP. ">
        <entity id="DDI-MedLine.d59.s2.e0" charOffset="31-39"
            type="drug" text="carbachol"/>
    </sentence>
    <sentence id="DDI-MedLine.d59.s3" text="The augmentation persisted even after carbachol was washed out and was resistant to chelated extracellular Ca(2+) and to inhibitors of either protein kinase C or calmodulin kinase II. ">
        <entity id="DDI-MedLine.d59.s3.e0" charOffset="38-46"
            type="drug" text="carbachol"/>
    </sentence>
    <sentence id="DDI-MedLine.d59.s4" text="Cytochalasin D at 10 microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min. ">
        <entity id="DDI-MedLine.d59.s4.e0" charOffset="0-13"
            type="drug_n" text="Cytochalasin D"/>
        <entity id="DDI-MedLine.d59.s4.e1" charOffset="75-83"
            type="drug" text="carbachol"/>
        <pair id="DDI-MedLine.d59.s4.p0" e1="DDI-MedLine.d59.s4.e0"
            e2="DDI-MedLine.d59.s4.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d59.s5" text="Cytochalasin D inhibited the carbachol-stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store. ">
        <entity id="DDI-MedLine.d59.s5.e0" charOffset="0-13"
            type="drug_n" text="Cytochalasin D"/>
        <entity id="DDI-MedLine.d59.s5.e1" charOffset="29-37"
            type="drug" text="carbachol"/>
        <pair id="DDI-MedLine.d59.s5.p0" e1="DDI-MedLine.d59.s5.e0"
            e2="DDI-MedLine.d59.s5.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d59.s6" text="Treatment of the glands with cytochalasin D redistributed type 3 inositol 1,4,5-trisphosphate receptor (the major subtype in the parietal cell) from the fraction containing membranes of large size to the microsomal fraction, suggesting a dissociation of the store from the plasma membrane. ">
        <entity id="DDI-MedLine.d59.s6.e0" charOffset="29-42"
            type="drug_n" text="cytochalasin D"/>
    </sentence>
    <sentence id="DDI-MedLine.d59.s7" text="These findings suggest that intracellular Ca(2+) release by cholinergic stimulation is critical for determining synergism with cAMP in parietal cell activation and that functional coupling between the Ca(2+) store and the receptor is maintained by actin microfilaments."/>
    <sentence id="DDI-MedLine.d75.s0" text="Interference of biocytin with opioid-evoked hyperpolarization and membrane properties of rat spinal substantia gelatinosa neurons.">
        <entity id="DDI-MedLine.d75.s0.e0" charOffset="30-35"
            type="group" text="opioid"/>
    </sentence>
    <sentence id="DDI-MedLine.d75.s1" text="In our laboratory, preliminary whole-cell, tight seal recordings of rat spinal substantia gelatinosa neurons including biocytin in the patch pipette yielded a significantly smaller proportion of neurons hyperpolarized by selective opioid agonists compared with recordings without biocytin. ">
        <entity id="DDI-MedLine.d75.s1.e0" charOffset="221-245"
            type="group" text="selective opioid agonists"/>
    </sentence>
    <sentence id="DDI-MedLine.d75.s2" text="Therefore, we investigated the effects of biocytin inclusion on opioid responses and other membrane properties during whole-cell, tight seal recordings of these neurons. ">
        <entity id="DDI-MedLine.d75.s2.e0" charOffset="64-69"
            type="group" text="opioid"/>
    </sentence>
    <sentence id="DDI-MedLine.d75.s3" text="The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not &lt; ">
        <entity id="DDI-MedLine.d75.s3.e0" charOffset="44-46;70-86"
            type="group" text="mu-selective opioids"/>
        <entity id="DDI-MedLine.d75.s3.e1" charOffset="49-57;70-86"
            type="group" text="delta(1)-selective opioids"/>
        <entity id="DDI-MedLine.d75.s3.e2" charOffset="64-86"
            type="group" text="kappa-selective opioids"/>
        <pair id="DDI-MedLine.d75.s3.p0" e1="DDI-MedLine.d75.s3.e0"
            e2="DDI-MedLine.d75.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d75.s3.p1" e1="DDI-MedLine.d75.s3.e0"
            e2="DDI-MedLine.d75.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d75.s3.p2" e1="DDI-MedLine.d75.s3.e1"
            e2="DDI-MedLine.d75.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d75.s4" text="or =0.2% biocytin was included in the recording pipette, compared with neurons recorded without biocytin. "/>
    <sentence id="DDI-MedLine.d75.s5" text="However, a significantly higher proportion of neurons fired spontaneous action potentials with either 0.05-0.2 or 1% biocytin compared to no biocytin. "/>
    <sentence id="DDI-MedLine.d75.s6" text="Resting membrane potential, input impedance and the proportion of neurons displaying transient outward rectification were each significantly altered for neurons recorded with 1% but not 0.05-0.2% biocytin. "/>
    <sentence id="DDI-MedLine.d75.s7" text="These effects may be due to a relatively specific blockade of diverse potassium channel types. "/>
    <sentence id="DDI-MedLine.d75.s8" text="Because efficient labeling can be achieved with 0.1% biocytin with whole-cell recording, higher concentrations are contraindicated."/>
    <sentence id="DDI-MedLine.d117.s0" text="Increased stability of nucleophosmin/B23 in anti-apoptotic effect of ras during serum deprivation.&#xd;&#xa;"/>
    <sentence id="DDI-MedLine.d117.s1" text="We obtained evidence that increased stability of nucleophosmin/B23 is involved in antiapoptotic effect of ras during serum deprivation. "/>
    <sentence id="DDI-MedLine.d117.s2" text="Nucleophosmin/B23 in serum-deprived (0% serum) NIH-3T3 cells was found to be highly unstable with a half-life less than 4 h. "/>
    <sentence id="DDI-MedLine.d117.s3" text="In contrast, nucleophosmin/B23 in serum-deprived ras-transformed (RAS-3T3) cells was as stable as that in serum-supplemented NIH-3T3 or RAS-3T3 cells. "/>
    <sentence id="DDI-MedLine.d117.s4" text="Treatment of RAS-3T3 cells with nucleophosmin/B23 antisense oligomer significantly potentiated the apoptosis induced by serum deprivation. "/>
    <sentence id="DDI-MedLine.d117.s5" text="Much less caspase-3 activity was noted in the lysate derived from serum-deprived RAS-3T3 cells compared with that in the lysate of serum-deprived NIH-3T3 cells. "/>
    <sentence id="DDI-MedLine.d117.s6" text="Cell permeable caspase-3 inhibitor added in the medium blocked the decrease of nucleophosmin/B23 and apoptosis induced by serum deprivation in NIH-3T3 cells. "/>
    <sentence id="DDI-MedLine.d117.s7" text="The inhibitor, on the other hand, promoted significant decrease of nucleolin/C23 in NIH-3T3 cells during serum deprivation. "/>
    <sentence id="DDI-MedLine.d117.s8" text="Unlike nucleolin/C23, down-regulation of nucleophosmin/B23 was thus not proliferation-dependent but caspase-3- and apoptosis-dependent. "/>
    <sentence id="DDI-MedLine.d117.s9" text="Our results indicate important relationships among ras, nucleophosmin/B23, activation of caspase-3, and induction of apoptosis."/>
    <sentence id="DDI-MedLine.d133.s0" text="Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.&#xd;&#xa;">
        <entity id="DDI-MedLine.d133.s0.e0" charOffset="15-23"
            type="drug" text="verapamil"/>
        <entity id="DDI-MedLine.d133.s0.e1" charOffset="28-35"
            type="drug_n" text="bombesin"/>
        <entity id="DDI-MedLine.d133.s0.e2" charOffset="109-120"
            type="drug_n" text="azoxymethane"/>
        <pair id="DDI-MedLine.d133.s0.p0" e1="DDI-MedLine.d133.s0.e0"
            e2="DDI-MedLine.d133.s0.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d133.s0.p1" e1="DDI-MedLine.d133.s0.e0"
            e2="DDI-MedLine.d133.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d133.s0.p2" e1="DDI-MedLine.d133.s0.e1"
            e2="DDI-MedLine.d133.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d133.s1" text="BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ">
        <entity id="DDI-MedLine.d133.s1.e0" charOffset="54-61"
            type="drug_n" text="bombesin"/>
        <entity id="DDI-MedLine.d133.s1.e1" charOffset="67-89"
            type="drug" text="verapamil hydrochloride"/>
        <entity id="DDI-MedLine.d133.s1.e2" charOffset="92-100"
            type="drug" text="verapamil"/>
        <entity id="DDI-MedLine.d133.s1.e3" charOffset="106-128"
            type="group" text="calcium channel blocker"/>
        <entity id="DDI-MedLine.d133.s1.e4" charOffset="214-225"
            type="drug_n" text="azoxymethane"/>
        <entity id="DDI-MedLine.d133.s1.e5" charOffset="228-230"
            type="drug_n" text="AOM"/>
        <pair id="DDI-MedLine.d133.s1.p0" e1="DDI-MedLine.d133.s1.e0"
            e2="DDI-MedLine.d133.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d133.s1.p1" e1="DDI-MedLine.d133.s1.e0"
            e2="DDI-MedLine.d133.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d133.s1.p2" e1="DDI-MedLine.d133.s1.e0"
            e2="DDI-MedLine.d133.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d133.s1.p3" e1="DDI-MedLine.d133.s1.e0"
            e2="DDI-MedLine.d133.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d133.s1.p4" e1="DDI-MedLine.d133.s1.e0"
            e2="DDI-MedLine.d133.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d133.s1.p5" e1="DDI-MedLine.d133.s1.e1"
            e2="DDI-MedLine.d133.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d133.s1.p6" e1="DDI-MedLine.d133.s1.e1"
            e2="DDI-MedLine.d133.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d133.s1.p7" e1="DDI-MedLine.d133.s1.e1"
            e2="DDI-MedLine.d133.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d133.s1.p8" e1="DDI-MedLine.d133.s1.e1"
            e2="DDI-MedLine.d133.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d133.s1.p9" e1="DDI-MedLine.d133.s1.e2"
            e2="DDI-MedLine.d133.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d133.s1.p10" e1="DDI-MedLine.d133.s1.e2"
            e2="DDI-MedLine.d133.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d133.s1.p11" e1="DDI-MedLine.d133.s1.e2"
            e2="DDI-MedLine.d133.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d133.s1.p12" e1="DDI-MedLine.d133.s1.e3"
            e2="DDI-MedLine.d133.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d133.s1.p13" e1="DDI-MedLine.d133.s1.e3"
            e2="DDI-MedLine.d133.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d133.s1.p14" e1="DDI-MedLine.d133.s1.e4"
            e2="DDI-MedLine.d133.s1.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d133.s2" text="METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. ">
        <entity id="DDI-MedLine.d133.s2.e0" charOffset="100-102"
            type="drug_n" text="AOM"/>
        <entity id="DDI-MedLine.d133.s2.e1" charOffset="159-166"
            type="drug_n" text="bombesin"/>
        <entity id="DDI-MedLine.d133.s2.e2" charOffset="260-268"
            type="drug" text="verapamil"/>
        <pair id="DDI-MedLine.d133.s2.p0" e1="DDI-MedLine.d133.s2.e0"
            e2="DDI-MedLine.d133.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d133.s2.p1" e1="DDI-MedLine.d133.s2.e0"
            e2="DDI-MedLine.d133.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d133.s2.p2" e1="DDI-MedLine.d133.s2.e1"
            e2="DDI-MedLine.d133.s2.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d133.s3" text="RESULTS: Bombesin significantly increased the incidence of intestinal tumors and cancer metastasis to the peritoneum. ">
        <entity id="DDI-MedLine.d133.s3.e0" charOffset="9-16"
            type="drug_n" text="Bombesin"/>
    </sentence>
    <sentence id="DDI-MedLine.d133.s4" text="Although verapamil administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by bombesin or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis. ">
        <entity id="DDI-MedLine.d133.s4.e0" charOffset="9-17"
            type="drug" text="verapamil"/>
        <entity id="DDI-MedLine.d133.s4.e1" charOffset="122-129"
            type="drug_n" text="bombesin"/>
        <pair id="DDI-MedLine.d133.s4.p0" e1="DDI-MedLine.d133.s4.e0"
            e2="DDI-MedLine.d133.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d133.s5" text="Verapamil also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by bombesin. ">
        <entity id="DDI-MedLine.d133.s5.e0" charOffset="0-8" type="drug" text="Verapamil"/>
        <entity id="DDI-MedLine.d133.s5.e1" charOffset="117-124"
            type="drug_n" text="bombesin"/>
        <pair id="DDI-MedLine.d133.s5.p0" e1="DDI-MedLine.d133.s5.e0"
            e2="DDI-MedLine.d133.s5.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d133.s6" text="CONCLUSION: These findings indicate that verapamil inhibits cancer metastasis through actions that do not affect the growth of intestinal cancers.">
        <entity id="DDI-MedLine.d133.s6.e0" charOffset="41-49"
            type="drug" text="verapamil"/>
    </sentence>
    <sentence id="DDI-MedLine.d17.s0" text="In vitro interaction of prostaglandin F2alpha and oxytocin in placental vessels.&#xa;">
        <entity id="DDI-MedLine.d17.s0.e0" charOffset="24-44"
            type="drug" text="prostaglandin F2alpha"/>
        <entity id="DDI-MedLine.d17.s0.e1" charOffset="50-57"
            type="drug" text="oxytocin"/>
        <pair id="DDI-MedLine.d17.s0.p0" e1="DDI-MedLine.d17.s0.e0"
            e2="DDI-MedLine.d17.s0.e1" ddi="true" type="int"/>
    </sentence>
    <sentence id="DDI-MedLine.d17.s1" text="The interaction of prostaglandin F2alpha and synthetic oxytocin on placental vessels was studied in vitro. ">
        <entity id="DDI-MedLine.d17.s1.e0" charOffset="19-39"
            type="drug" text="prostaglandin F2alpha"/>
        <entity id="DDI-MedLine.d17.s1.e1" charOffset="55-62"
            type="drug" text="oxytocin"/>
        <pair id="DDI-MedLine.d17.s1.p0" e1="DDI-MedLine.d17.s1.e0"
            e2="DDI-MedLine.d17.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d17.s2" text="Resistance was measured near the placental margin after spontaneous term delivery. "/>
    <sentence id="DDI-MedLine.d17.s3" text="In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha. ">
        <entity id="DDI-MedLine.d17.s3.e0" charOffset="34-47"
            type="drug" text="norepinephrine"/>
        <entity id="DDI-MedLine.d17.s3.e1" charOffset="53-60"
            type="drug" text="oxytocin"/>
        <entity id="DDI-MedLine.d17.s3.e2" charOffset="67-75"
            type="drug" text="PGF2alpha"/>
        <pair id="DDI-MedLine.d17.s3.p0" e1="DDI-MedLine.d17.s3.e0"
            e2="DDI-MedLine.d17.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d17.s3.p1" e1="DDI-MedLine.d17.s3.e0"
            e2="DDI-MedLine.d17.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d17.s3.p2" e1="DDI-MedLine.d17.s3.e1"
            e2="DDI-MedLine.d17.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d17.s4" text="PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin. ">
        <entity id="DDI-MedLine.d17.s4.e0" charOffset="0-8" type="drug" text="PGF2alpha"/>
        <entity id="DDI-MedLine.d17.s4.e1" charOffset="93-100"
            type="drug" text="oxytocin"/>
        <pair id="DDI-MedLine.d17.s4.p0" e1="DDI-MedLine.d17.s4.e0"
            e2="DDI-MedLine.d17.s4.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d17.s5" text="In eight experiments the perfusion medium contained oxytocin. ">
        <entity id="DDI-MedLine.d17.s5.e0" charOffset="52-59"
            type="drug" text="oxytocin"/>
    </sentence>
    <sentence id="DDI-MedLine.d17.s6" text="There was no change after a single dose of PGF2alpha. ">
        <entity id="DDI-MedLine.d17.s6.e0" charOffset="43-51"
            type="drug" text="PGF2alpha"/>
    </sentence>
    <sentence id="DDI-MedLine.d17.s7" text="The reaction after norepinephrine remained the same in both groups of experiments. ">
        <entity id="DDI-MedLine.d17.s7.e0" charOffset="19-32"
            type="drug" text="norepinephrine"/>
    </sentence>
    <sentence id="DDI-MedLine.d17.s8" text="There is thus an enhancement effect "/>
    <sentence id="DDI-MedLine.d17.s9" text="There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.">
        <entity id="DDI-MedLine.d17.s9.e0" charOffset="39-47"
            type="drug" text="PGF2alpha"/>
        <entity id="DDI-MedLine.d17.s9.e1" charOffset="91-98"
            type="drug" text="oxytocin"/>
        <pair id="DDI-MedLine.d17.s9.p0" e1="DDI-MedLine.d17.s9.e0"
            e2="DDI-MedLine.d17.s9.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d36.s0" text="Carbamazepine overdose recognized by a tricyclic antidepressant assay.&#xd;&#xa;">
        <entity id="DDI-MedLine.d36.s0.e0" charOffset="0-12" type="drug" text="Carbamazepine"/>
        <entity id="DDI-MedLine.d36.s0.e1" charOffset="39-62"
            type="group" text="tricyclic antidepressant"/>
        <pair id="DDI-MedLine.d36.s0.p0" e1="DDI-MedLine.d36.s0.e0"
            e2="DDI-MedLine.d36.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d36.s1" text="Altered mental status in an adolescent presents a diagnostic challenge, and the clinician depends on clinical evaluation and laboratory studies to determine therapy and prognosis. "/>
    <sentence id="DDI-MedLine.d36.s2" text="We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.">
        <entity id="DDI-MedLine.d36.s2.e0" charOffset="73-85"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-MedLine.d36.s2.e1" charOffset="112-135"
            type="group" text="tricyclic antidepressant"/>
        <entity id="DDI-MedLine.d36.s2.e2" charOffset="190-202"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-MedLine.d36.s2.e3" charOffset="233-257"
            type="group" text="tricyclic antidepressants"/>
        <pair id="DDI-MedLine.d36.s2.p0" e1="DDI-MedLine.d36.s2.e0"
            e2="DDI-MedLine.d36.s2.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d36.s2.p1" e1="DDI-MedLine.d36.s2.e0"
            e2="DDI-MedLine.d36.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d36.s2.p2" e1="DDI-MedLine.d36.s2.e0"
            e2="DDI-MedLine.d36.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d36.s2.p3" e1="DDI-MedLine.d36.s2.e1"
            e2="DDI-MedLine.d36.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d36.s2.p4" e1="DDI-MedLine.d36.s2.e1"
            e2="DDI-MedLine.d36.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d36.s2.p5" e1="DDI-MedLine.d36.s2.e2"
            e2="DDI-MedLine.d36.s2.e3" ddi="true" type="advise"/>
    </sentence>
    <sentence id="DDI-MedLine.d126.s0" text="Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.&#xd;&#xa;">
        <entity id="DDI-MedLine.d126.s0.e0" charOffset="0-11"
            type="drug" text="Cypermethrin"/>
        <entity id="DDI-MedLine.d126.s0.e1" charOffset="77-85"
            type="drug" text="vitamin E"/>
        <entity id="DDI-MedLine.d126.s0.e2" charOffset="90-100"
            type="drug" text="allopurinol"/>
        <pair id="DDI-MedLine.d126.s0.p0" e1="DDI-MedLine.d126.s0.e0"
            e2="DDI-MedLine.d126.s0.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d126.s0.p1" e1="DDI-MedLine.d126.s0.e0"
            e2="DDI-MedLine.d126.s0.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d126.s0.p2" e1="DDI-MedLine.d126.s0.e1"
            e2="DDI-MedLine.d126.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d126.s1" text="Considering that the involvement of reactive oxygen species (ROS) has been implicated in the toxicity of various pesticides, this study was designed to investigate the possibility of oxidative stress induction by cypermethrin, a Type II pyrethroid. ">
        <entity id="DDI-MedLine.d126.s1.e0" charOffset="213-224"
            type="drug" text="cypermethrin"/>
        <entity id="DDI-MedLine.d126.s1.e1" charOffset="229-246"
            type="drug_n" text="Type II pyrethroid"/>
        <pair id="DDI-MedLine.d126.s1.p0" e1="DDI-MedLine.d126.s1.e0"
            e2="DDI-MedLine.d126.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d126.s2" text="Either single (170 mg/kg) or repeated (75 mg/kg per day for 5 days) oral administration of cypermethrin was found to produce significant oxidative stress in cerebral and hepatic tissues of rats, as was evident by the elevation of the level of thiobarbituric acid reactive substances (TBARS) in both tissues, either 4 or 24 h after treatment. ">
        <entity id="DDI-MedLine.d126.s2.e0" charOffset="91-102"
            type="drug" text="cypermethrin"/>
    </sentence>
    <sentence id="DDI-MedLine.d126.s3" text="Much higher changes were observed in liver, increasing from a level of 60% at 4 h up to nearly 4 times the control at 24 h for single dose. "/>
    <sentence id="DDI-MedLine.d126.s4" text="Reduced levels (up to 20%) of total glutathione (total GSH), and elevation of conjugated dienes ( approximately 60% in liver by single dose at 4 h) also indicated the presence of an oxidative insult. "/>
    <sentence id="DDI-MedLine.d126.s5" text="Glutathione-S-transferase (GST) activity, however, did not differ from control values for any dose or at any time point in cerebral and hepatic tissues. "/>
    <sentence id="DDI-MedLine.d126.s6" text="Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h. ">
        <entity id="DDI-MedLine.d126.s6.e0" charOffset="26-36"
            type="drug" text="allopurinol"/>
        <entity id="DDI-MedLine.d126.s6.e1" charOffset="57-65"
            type="drug" text="Vitamin E"/>
        <entity id="DDI-MedLine.d126.s6.e2" charOffset="280-291"
            type="drug" text="cypermethrin"/>
        <pair id="DDI-MedLine.d126.s6.p0" e1="DDI-MedLine.d126.s6.e0"
            e2="DDI-MedLine.d126.s6.e1" ddi="false"/>
        <pair id="DDI-MedLine.d126.s6.p1" e1="DDI-MedLine.d126.s6.e0"
            e2="DDI-MedLine.d126.s6.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d126.s6.p2" e1="DDI-MedLine.d126.s6.e1"
            e2="DDI-MedLine.d126.s6.e2" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d126.s7" text="Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.">
        <entity id="DDI-MedLine.d126.s7.e0" charOffset="31-42"
            type="drug" text="cypermethrin"/>
        <entity id="DDI-MedLine.d126.s7.e1" charOffset="198-208"
            type="drug" text="allopurinol"/>
        <entity id="DDI-MedLine.d126.s7.e2" charOffset="214-222"
            type="drug" text="Vitamin E"/>
        <pair id="DDI-MedLine.d126.s7.p0" e1="DDI-MedLine.d126.s7.e0"
            e2="DDI-MedLine.d126.s7.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d126.s7.p1" e1="DDI-MedLine.d126.s7.e0"
            e2="DDI-MedLine.d126.s7.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d126.s7.p2" e1="DDI-MedLine.d126.s7.e1"
            e2="DDI-MedLine.d126.s7.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d58.s0" text="Effect of ginsenosides on voltage-dependent Ca(2+) channel subtypes in bovine chromaffin cells.&#xd;&#xa;">
        <entity id="DDI-MedLine.d58.s0.e0" charOffset="10-21"
            type="drug_n" text="ginsenosides"/>
    </sentence>
    <sentence id="DDI-MedLine.d58.s1" text="In previous reports we have shown that ginsenosides inhibit high threshold voltage-dependent Ca(2+) channels in neuronal cells. ">
        <entity id="DDI-MedLine.d58.s1.e0" charOffset="39-50"
            type="drug_n" text="ginsenosides"/>
    </sentence>
    <sentence id="DDI-MedLine.d58.s2" text="However, these studies did not show whether ginsenosides-induced inhibition of Ca(2+) currents discriminates among the various Ca(2+) channel subtypes, although it is known that there are at least five different Ca(2+) channel subtypes in neuronal cells. ">
        <entity id="DDI-MedLine.d58.s2.e0" charOffset="44-55"
            type="drug_n" text="ginsenosides"/>
    </sentence>
    <sentence id="DDI-MedLine.d58.s3" text="In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ">
        <entity id="DDI-MedLine.d58.s3.e0" charOffset="44-55"
            type="drug_n" text="ginsenosides"/>
        <entity id="DDI-MedLine.d58.s3.e1" charOffset="129-161"
            type="group" text="selective Ca(2+) channel blockers"/>
        <entity id="DDI-MedLine.d58.s3.e2" charOffset="163-172"
            type="drug" text="nimodipine"/>
        <entity id="DDI-MedLine.d58.s3.e3" charOffset="184-203"
            type="drug_n" text="omega-conotoxin GVIA"/>
        <entity id="DDI-MedLine.d58.s3.e4" charOffset="218-235"
            type="drug_n" text="omega-agatoxin IVA"/>
        <pair id="DDI-MedLine.d58.s3.p0" e1="DDI-MedLine.d58.s3.e0"
            e2="DDI-MedLine.d58.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d58.s3.p1" e1="DDI-MedLine.d58.s3.e0"
            e2="DDI-MedLine.d58.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d58.s3.p2" e1="DDI-MedLine.d58.s3.e0"
            e2="DDI-MedLine.d58.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d58.s3.p3" e1="DDI-MedLine.d58.s3.e0"
            e2="DDI-MedLine.d58.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d58.s3.p4" e1="DDI-MedLine.d58.s3.e1"
            e2="DDI-MedLine.d58.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d58.s3.p5" e1="DDI-MedLine.d58.s3.e1"
            e2="DDI-MedLine.d58.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d58.s3.p6" e1="DDI-MedLine.d58.s3.e1"
            e2="DDI-MedLine.d58.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d58.s3.p7" e1="DDI-MedLine.d58.s3.e2"
            e2="DDI-MedLine.d58.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d58.s3.p8" e1="DDI-MedLine.d58.s3.e2"
            e2="DDI-MedLine.d58.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d58.s3.p9" e1="DDI-MedLine.d58.s3.e3"
            e2="DDI-MedLine.d58.s3.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d58.s4" text="We could observe that ginsenosides inhibited high threshold voltage-dependent Ca(2+) currents in a dose-dependent manner. ">
        <entity id="DDI-MedLine.d58.s4.e0" charOffset="22-33"
            type="drug_n" text="ginsenosides"/>
    </sentence>
    <sentence id="DDI-MedLine.d58.s5" text="The IC(50) was about 120 microgram/ml. "/>
    <sentence id="DDI-MedLine.d58.s6" text="Nimodipine had no effect on ginsenosides response. ">
        <entity id="DDI-MedLine.d58.s6.e0" charOffset="0-9" type="drug" text="Nimodipine"/>
        <entity id="DDI-MedLine.d58.s6.e1" charOffset="28-39"
            type="drug_n" text="ginsenosides"/>
        <pair id="DDI-MedLine.d58.s6.p0" e1="DDI-MedLine.d58.s6.e0"
            e2="DDI-MedLine.d58.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d58.s7" text="These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ">
        <entity id="DDI-MedLine.d58.s7.e0" charOffset="24-35"
            type="drug_n" text="ginsenosides"/>
        <entity id="DDI-MedLine.d58.s7.e1" charOffset="135-154"
            type="drug_n" text="omega-conotoxin GVIA"/>
        <entity id="DDI-MedLine.d58.s7.e2" charOffset="187-204"
            type="drug_n" text="omega-agatoxin IVA"/>
        <entity id="DDI-MedLine.d58.s7.e3" charOffset="237-246"
            type="drug" text="nimodipine"/>
        <entity id="DDI-MedLine.d58.s7.e4" charOffset="248-267"
            type="drug_n" text="omega-conotoxin GVIA"/>
        <entity id="DDI-MedLine.d58.s7.e5" charOffset="269-286"
            type="drug_n" text="omega-agatoxin VIA"/>
        <pair id="DDI-MedLine.d58.s7.p0" e1="DDI-MedLine.d58.s7.e0"
            e2="DDI-MedLine.d58.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d58.s7.p1" e1="DDI-MedLine.d58.s7.e0"
            e2="DDI-MedLine.d58.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d58.s7.p2" e1="DDI-MedLine.d58.s7.e0"
            e2="DDI-MedLine.d58.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d58.s7.p3" e1="DDI-MedLine.d58.s7.e0"
            e2="DDI-MedLine.d58.s7.e4" ddi="false"/>
        <pair id="DDI-MedLine.d58.s7.p4" e1="DDI-MedLine.d58.s7.e0"
            e2="DDI-MedLine.d58.s7.e5" ddi="false"/>
        <pair id="DDI-MedLine.d58.s7.p5" e1="DDI-MedLine.d58.s7.e1"
            e2="DDI-MedLine.d58.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d58.s7.p6" e1="DDI-MedLine.d58.s7.e1"
            e2="DDI-MedLine.d58.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d58.s7.p7" e1="DDI-MedLine.d58.s7.e1"
            e2="DDI-MedLine.d58.s7.e4" ddi="false"/>
        <pair id="DDI-MedLine.d58.s7.p8" e1="DDI-MedLine.d58.s7.e1"
            e2="DDI-MedLine.d58.s7.e5" ddi="false"/>
        <pair id="DDI-MedLine.d58.s7.p9" e1="DDI-MedLine.d58.s7.e2"
            e2="DDI-MedLine.d58.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d58.s7.p10" e1="DDI-MedLine.d58.s7.e2"
            e2="DDI-MedLine.d58.s7.e4" ddi="false"/>
        <pair id="DDI-MedLine.d58.s7.p11" e1="DDI-MedLine.d58.s7.e2"
            e2="DDI-MedLine.d58.s7.e5" ddi="false"/>
        <pair id="DDI-MedLine.d58.s7.p12" e1="DDI-MedLine.d58.s7.e3"
            e2="DDI-MedLine.d58.s7.e4" ddi="false"/>
        <pair id="DDI-MedLine.d58.s7.p13" e1="DDI-MedLine.d58.s7.e3"
            e2="DDI-MedLine.d58.s7.e5" ddi="false"/>
        <pair id="DDI-MedLine.d58.s7.p14" e1="DDI-MedLine.d58.s7.e4"
            e2="DDI-MedLine.d58.s7.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d58.s8" text="Thus, the selective regulation of voltage-dependent Ca(2+) subtypes by ginsenosides in bovine chromaffin cell could be the cellular basis of antistress effects induced by ginseng.">
        <entity id="DDI-MedLine.d58.s8.e0" charOffset="71-82"
            type="drug_n" text="ginsenosides"/>
        <entity id="DDI-MedLine.d58.s8.e1" charOffset="171-177"
            type="drug" text="ginseng"/>
        <pair id="DDI-MedLine.d58.s8.p0" e1="DDI-MedLine.d58.s8.e0"
            e2="DDI-MedLine.d58.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d8.s0" text="In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.&#xa;">
        <entity id="DDI-MedLine.d8.s0.e0" charOffset="21-28"
            type="drug_n" text="KRM-1648"/>
        <entity id="DDI-MedLine.d8.s0.e1" charOffset="68-76" type="drug" text="ofloxacin"/>
        <pair id="DDI-MedLine.d8.s0.p0" e1="DDI-MedLine.d8.s0.e0"
            e2="DDI-MedLine.d8.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d8.s1" text="The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. ">
        <entity id="DDI-MedLine.d8.s1.e0" charOffset="30-49"
            type="drug_n" text="benzoxazinorifamycin"/>
        <entity id="DDI-MedLine.d8.s1.e1" charOffset="52-59"
            type="drug_n" text="KRM-1648"/>
        <entity id="DDI-MedLine.d8.s1.e2" charOffset="98-106"
            type="drug" text="ofloxacin"/>
        <pair id="DDI-MedLine.d8.s1.p0" e1="DDI-MedLine.d8.s1.e0"
            e2="DDI-MedLine.d8.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d8.s1.p1" e1="DDI-MedLine.d8.s1.e0"
            e2="DDI-MedLine.d8.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d8.s1.p2" e1="DDI-MedLine.d8.s1.e1"
            e2="DDI-MedLine.d8.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d8.s2" text="Growth of M. "/>
    <sentence id="DDI-MedLine.d8.s3" text="ulcerans was measured by plate counts and the BACTEC radiometric method. "/>
    <sentence id="DDI-MedLine.d8.s4" text="The minimal inhibitory concentration as well as minimal bactericidal concentration of KRM-1648 against M. ">
        <entity id="DDI-MedLine.d8.s4.e0" charOffset="86-93"
            type="drug_n" text="KRM-1648"/>
    </sentence>
    <sentence id="DDI-MedLine.d8.s5" text="ulcerans was between 0.012 and 0.025 mg/l, while corresponding values for rifampicin and rifabutin were in the range of 0.1-0.8 mg/l and 0.1-0.4 mg/l respectively. ">
        <entity id="DDI-MedLine.d8.s5.e0" charOffset="74-83" type="drug" text="rifampicin"/>
        <entity id="DDI-MedLine.d8.s5.e1" charOffset="89-97" type="drug" text="rifabutin"/>
        <pair id="DDI-MedLine.d8.s5.p0" e1="DDI-MedLine.d8.s5.e0"
            e2="DDI-MedLine.d8.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d8.s6" text="When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ">
        <entity id="DDI-MedLine.d8.s6.e0" charOffset="19-27" type="drug" text="ofloxacin"/>
        <entity id="DDI-MedLine.d8.s6.e1" charOffset="30-37"
            type="drug_n" text="KRM-1648"/>
        <entity id="DDI-MedLine.d8.s6.e2" charOffset="143-152"
            type="drug" text="rifampicin"/>
        <entity id="DDI-MedLine.d8.s6.e3" charOffset="158-166"
            type="drug" text="rifabutin"/>
        <entity id="DDI-MedLine.d8.s6.e4" charOffset="173-181"
            type="drug" text="ofloxacin"/>
        <pair id="DDI-MedLine.d8.s6.p0" e1="DDI-MedLine.d8.s6.e0"
            e2="DDI-MedLine.d8.s6.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d8.s6.p1" e1="DDI-MedLine.d8.s6.e0"
            e2="DDI-MedLine.d8.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d8.s6.p2" e1="DDI-MedLine.d8.s6.e0"
            e2="DDI-MedLine.d8.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d8.s6.p3" e1="DDI-MedLine.d8.s6.e0"
            e2="DDI-MedLine.d8.s6.e4" ddi="false"/>
        <pair id="DDI-MedLine.d8.s6.p4" e1="DDI-MedLine.d8.s6.e1"
            e2="DDI-MedLine.d8.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d8.s6.p5" e1="DDI-MedLine.d8.s6.e1"
            e2="DDI-MedLine.d8.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d8.s6.p6" e1="DDI-MedLine.d8.s6.e1"
            e2="DDI-MedLine.d8.s6.e4" ddi="false"/>
        <pair id="DDI-MedLine.d8.s6.p7" e1="DDI-MedLine.d8.s6.e2"
            e2="DDI-MedLine.d8.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d8.s6.p8" e1="DDI-MedLine.d8.s6.e2"
            e2="DDI-MedLine.d8.s6.e4" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d8.s6.p9" e1="DDI-MedLine.d8.s6.e3"
            e2="DDI-MedLine.d8.s6.e4" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d8.s7" text="These results suggest that KRM-1648 has a great potential in the treatment of M. ">
        <entity id="DDI-MedLine.d8.s7.e0" charOffset="27-34"
            type="drug_n" text="KRM-1648"/>
    </sentence>
    <sentence id="DDI-MedLine.d8.s8" text="ulcerans infection."/>
    <sentence id="DDI-MedLine.d114.s0" text="Inhibitory effects of ruthenium red on inositol 1,4, 5-trisphosphate-induced responses in rat megakaryocytes.&#xd;&#xa;">
        <entity id="DDI-MedLine.d114.s0.e0" charOffset="22-34"
            type="drug_n" text="ruthenium red"/>
    </sentence>
    <sentence id="DDI-MedLine.d114.s1" text="The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. ">
        <entity id="DDI-MedLine.d114.s1.e0" charOffset="15-27"
            type="drug_n" text="ruthenium red"/>
        <entity id="DDI-MedLine.d114.s1.e1" charOffset="30-31"
            type="drug_n" text="RR"/>
        <entity id="DDI-MedLine.d114.s1.e2" charOffset="37-64"
            type="drug_n" text="inositol 1,4,5-trisphosphate"/>
        <entity id="DDI-MedLine.d114.s1.e3" charOffset="67-73"
            type="drug_n" text="InsP(3)"/>
        <pair id="DDI-MedLine.d114.s1.p0" e1="DDI-MedLine.d114.s1.e0"
            e2="DDI-MedLine.d114.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d114.s1.p1" e1="DDI-MedLine.d114.s1.e0"
            e2="DDI-MedLine.d114.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d114.s1.p2" e1="DDI-MedLine.d114.s1.e0"
            e2="DDI-MedLine.d114.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d114.s1.p3" e1="DDI-MedLine.d114.s1.e1"
            e2="DDI-MedLine.d114.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d114.s1.p4" e1="DDI-MedLine.d114.s1.e1"
            e2="DDI-MedLine.d114.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d114.s1.p5" e1="DDI-MedLine.d114.s1.e2"
            e2="DDI-MedLine.d114.s1.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d114.s2" text="Internal application of InsP(3) (100 microM) increased intracellular Ca(2+) concentration ([Ca(2+)](i)) and activated the Ca(2+)-dependent K(+) current. ">
        <entity id="DDI-MedLine.d114.s2.e0" charOffset="24-30"
            type="drug_n" text="InsP(3)"/>
    </sentence>
    <sentence id="DDI-MedLine.d114.s3" text="Administering InsP(3) together with RR (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion. ">
        <entity id="DDI-MedLine.d114.s3.e0" charOffset="14-20"
            type="drug_n" text="InsP(3)"/>
        <entity id="DDI-MedLine.d114.s3.e1" charOffset="36-37"
            type="drug_n" text="RR"/>
        <pair id="DDI-MedLine.d114.s3.p0" e1="DDI-MedLine.d114.s3.e0"
            e2="DDI-MedLine.d114.s3.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d114.s4" text="Pretreatment of megakaryocytes with extracellular RR (50 microM) also inhibited InsP(3)-induced responses. ">
        <entity id="DDI-MedLine.d114.s4.e0" charOffset="50-51"
            type="drug_n" text="RR"/>
        <entity id="DDI-MedLine.d114.s4.e1" charOffset="80-86"
            type="drug_n" text="InsP(3)"/>
        <pair id="DDI-MedLine.d114.s4.p0" e1="DDI-MedLine.d114.s4.e0"
            e2="DDI-MedLine.d114.s4.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d114.s5" text="Intracellular and extracellular application of RR reduced ADP-induced increases in [Ca(2+)](i). ">
        <entity id="DDI-MedLine.d114.s5.e0" charOffset="47-48"
            type="drug_n" text="RR"/>
    </sentence>
    <sentence id="DDI-MedLine.d114.s6" text="In contrast, in isolated single pancreatic acinar cells, RR had no effect on InsP(3)-induced responses. ">
        <entity id="DDI-MedLine.d114.s6.e0" charOffset="57-58"
            type="drug_n" text="RR"/>
        <entity id="DDI-MedLine.d114.s6.e1" charOffset="77-83"
            type="drug_n" text="InsP(3)"/>
        <pair id="DDI-MedLine.d114.s6.p0" e1="DDI-MedLine.d114.s6.e0"
            e2="DDI-MedLine.d114.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d114.s7" text="Taken together, these results suggest that the site of the inhibitory action of RR is at the InsP(3) receptor, or its closely associated proteins. ">
        <entity id="DDI-MedLine.d114.s7.e0" charOffset="80-81"
            type="drug_n" text="RR"/>
    </sentence>
    <sentence id="DDI-MedLine.d114.s8" text="In addition, we have shown that RR is a useful pharmacological tool with which to examine the InsP(3)-mediated responses of megakaryocytes.">
        <entity id="DDI-MedLine.d114.s8.e0" charOffset="32-33"
            type="drug_n" text="RR"/>
        <entity id="DDI-MedLine.d114.s8.e1" charOffset="94-100"
            type="drug_n" text="InsP(3)"/>
        <pair id="DDI-MedLine.d114.s8.p0" e1="DDI-MedLine.d114.s8.e0"
            e2="DDI-MedLine.d114.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d109.s0" text="Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.&#xd;&#xa;">
        <entity id="DDI-MedLine.d109.s0.e0" charOffset="10-18"
            type="drug" text="rofecoxib"/>
        <entity id="DDI-MedLine.d109.s0.e1" charOffset="47-53"
            type="drug" text="digoxin"/>
        <pair id="DDI-MedLine.d109.s0.p0" e1="DDI-MedLine.d109.s0.e0"
            e2="DDI-MedLine.d109.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d109.s1" text="The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, at steady state on the pharmacokinetics of digoxin following a single dose in healthy subjects. ">
        <entity id="DDI-MedLine.d109.s1.e0" charOffset="75-83"
            type="drug" text="rofecoxib"/>
        <entity id="DDI-MedLine.d109.s1.e1" charOffset="129-135"
            type="drug" text="digoxin"/>
        <pair id="DDI-MedLine.d109.s1.p0" e1="DDI-MedLine.d109.s1.e0"
            e2="DDI-MedLine.d109.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d109.s2" text="Each healthy subject (N = 10) received rofecoxib (75 mg once daily) or placebo for 11 days in a double-blind, randomized, balanced, two-period crossover study. ">
        <entity id="DDI-MedLine.d109.s2.e0" charOffset="39-47"
            type="drug" text="rofecoxib"/>
    </sentence>
    <sentence id="DDI-MedLine.d109.s3" text="A single 0.5 mg oral dose of digoxin elixir was administered on the 7th day of each 11-day period. ">
        <entity id="DDI-MedLine.d109.s3.e0" charOffset="29-35"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-MedLine.d109.s4" text="Each treatment period was separated by 14 to 21 days. "/>
    <sentence id="DDI-MedLine.d109.s5" text="Samples for plasma and urine immunoreactive digoxin concentrations were collected through 120 hours following the digoxin dose. ">
        <entity id="DDI-MedLine.d109.s5.e0" charOffset="44-50"
            type="drug" text="digoxin"/>
        <entity id="DDI-MedLine.d109.s5.e1" charOffset="114-120"
            type="drug" text="digoxin"/>
        <pair id="DDI-MedLine.d109.s5.p0" e1="DDI-MedLine.d109.s5.e0"
            e2="DDI-MedLine.d109.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d109.s6" text="No statistically significant differences between treatment groups were observed for any of the calculated digoxin pharmacokinetic parameters. ">
        <entity id="DDI-MedLine.d109.s6.e0" charOffset="106-112"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-MedLine.d109.s7" text="For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. ">
        <entity id="DDI-MedLine.d109.s7.e0" charOffset="4-10"
            type="drug" text="digoxin"/>
        <entity id="DDI-MedLine.d109.s7.e1" charOffset="107-115"
            type="drug" text="rofecoxib"/>
        <entity id="DDI-MedLine.d109.s7.e2" charOffset="119-125"
            type="drug" text="digoxin"/>
        <entity id="DDI-MedLine.d109.s7.e3" charOffset="137-143"
            type="drug" text="digoxin"/>
        <pair id="DDI-MedLine.d109.s7.p0" e1="DDI-MedLine.d109.s7.e0"
            e2="DDI-MedLine.d109.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d109.s7.p1" e1="DDI-MedLine.d109.s7.e0"
            e2="DDI-MedLine.d109.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d109.s7.p2" e1="DDI-MedLine.d109.s7.e0"
            e2="DDI-MedLine.d109.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d109.s7.p3" e1="DDI-MedLine.d109.s7.e1"
            e2="DDI-MedLine.d109.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d109.s7.p4" e1="DDI-MedLine.d109.s7.e1"
            e2="DDI-MedLine.d109.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d109.s7.p5" e1="DDI-MedLine.d109.s7.e2"
            e2="DDI-MedLine.d109.s7.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d109.s8" text="The digoxin median tmax was 0.5 hours for both treatments. ">
        <entity id="DDI-MedLine.d109.s8.e0" charOffset="4-10"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-MedLine.d109.s9" text="The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. ">
        <entity id="DDI-MedLine.d109.s9.e0" charOffset="68-76"
            type="drug" text="rofecoxib"/>
        <entity id="DDI-MedLine.d109.s9.e1" charOffset="80-86"
            type="drug" text="digoxin"/>
        <entity id="DDI-MedLine.d109.s9.e2" charOffset="102-108"
            type="drug" text="digoxin"/>
        <pair id="DDI-MedLine.d109.s9.p0" e1="DDI-MedLine.d109.s9.e0"
            e2="DDI-MedLine.d109.s9.e1" ddi="false"/>
        <pair id="DDI-MedLine.d109.s9.p1" e1="DDI-MedLine.d109.s9.e0"
            e2="DDI-MedLine.d109.s9.e2" ddi="false"/>
        <pair id="DDI-MedLine.d109.s9.p2" e1="DDI-MedLine.d109.s9.e1"
            e2="DDI-MedLine.d109.s9.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d109.s10" text="Digoxin is eliminated renally. ">
        <entity id="DDI-MedLine.d109.s10.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
    </sentence>
    <sentence id="DDI-MedLine.d109.s11" text="The mean (SD) cumulative urinary excretion of immunoreactive digoxin after concurrent treatment with rofecoxib or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively. ">
        <entity id="DDI-MedLine.d109.s11.e0" charOffset="61-67"
            type="drug" text="digoxin"/>
        <entity id="DDI-MedLine.d109.s11.e1" charOffset="101-109"
            type="drug" text="rofecoxib"/>
        <pair id="DDI-MedLine.d109.s11.p0" e1="DDI-MedLine.d109.s11.e0"
            e2="DDI-MedLine.d109.s11.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d109.s12" text="Transient and minor adverse events occurred with similar frequency on placebo and rofecoxib treatments, and no treatment-related pattern was apparent. ">
        <entity id="DDI-MedLine.d109.s12.e0" charOffset="82-90"
            type="drug" text="rofecoxib"/>
    </sentence>
    <sentence id="DDI-MedLine.d109.s13" text="Rofecoxib did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of digoxin.">
        <entity id="DDI-MedLine.d109.s13.e0" charOffset="0-8"
            type="drug" text="Rofecoxib"/>
        <entity id="DDI-MedLine.d109.s13.e1" charOffset="102-108"
            type="drug" text="digoxin"/>
        <pair id="DDI-MedLine.d109.s13.p0" e1="DDI-MedLine.d109.s13.e0"
            e2="DDI-MedLine.d109.s13.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d115.s0" text="Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.">
        <entity id="DDI-MedLine.d115.s0.e0" charOffset="12-27"
            type="drug" text="cyclophosphamide"/>
        <entity id="DDI-MedLine.d115.s0.e1" charOffset="30-40"
            type="drug" text="doxorubicin"/>
        <entity id="DDI-MedLine.d115.s0.e2" charOffset="43-53"
            type="drug" text="vincristine"/>
        <entity id="DDI-MedLine.d115.s0.e3" charOffset="60-69"
            type="drug" text="prednisone"/>
        <entity id="DDI-MedLine.d115.s0.e4" charOffset="89-116"
            type="group" text="highly active antiretroviral"/>
        <pair id="DDI-MedLine.d115.s0.p0" e1="DDI-MedLine.d115.s0.e0"
            e2="DDI-MedLine.d115.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d115.s0.p1" e1="DDI-MedLine.d115.s0.e0"
            e2="DDI-MedLine.d115.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d115.s0.p2" e1="DDI-MedLine.d115.s0.e0"
            e2="DDI-MedLine.d115.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d115.s0.p3" e1="DDI-MedLine.d115.s0.e0"
            e2="DDI-MedLine.d115.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d115.s0.p4" e1="DDI-MedLine.d115.s0.e1"
            e2="DDI-MedLine.d115.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d115.s0.p5" e1="DDI-MedLine.d115.s0.e1"
            e2="DDI-MedLine.d115.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d115.s0.p6" e1="DDI-MedLine.d115.s0.e1"
            e2="DDI-MedLine.d115.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d115.s0.p7" e1="DDI-MedLine.d115.s0.e2"
            e2="DDI-MedLine.d115.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d115.s0.p8" e1="DDI-MedLine.d115.s0.e2"
            e2="DDI-MedLine.d115.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d115.s0.p9" e1="DDI-MedLine.d115.s0.e3"
            e2="DDI-MedLine.d115.s0.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d115.s1" text="BACKGROUND: The feasibility and efficacy of concomitant chemotherapy and highly active antiretroviral therapy (HAART) is still unknown in patients with human immunodeficiency virus (HIV)-related malignancies. ">
        <entity id="DDI-MedLine.d115.s1.e0" charOffset="73-100"
            type="group" text="highly active antiretroviral"/>
    </sentence>
    <sentence id="DDI-MedLine.d115.s2" text="To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ">
        <entity id="DDI-MedLine.d115.s2.e0" charOffset="244-259"
            type="drug" text="cyclophosphamide"/>
        <entity id="DDI-MedLine.d115.s2.e1" charOffset="262-272"
            type="drug" text="doxorubicin"/>
        <entity id="DDI-MedLine.d115.s2.e2" charOffset="275-285"
            type="drug" text="vincristine"/>
        <entity id="DDI-MedLine.d115.s2.e3" charOffset="292-301"
            type="drug" text="prednisone"/>
        <entity id="DDI-MedLine.d115.s2.e4" charOffset="440-455"
            type="drug" text="cyclophosphamide"/>
        <entity id="DDI-MedLine.d115.s2.e5" charOffset="458-468"
            type="drug" text="doxorubicin"/>
        <entity id="DDI-MedLine.d115.s2.e6" charOffset="471-480"
            type="drug" text="teniposide"/>
        <entity id="DDI-MedLine.d115.s2.e7" charOffset="487-496"
            type="drug" text="prednisone"/>
        <entity id="DDI-MedLine.d115.s2.e8" charOffset="503-513"
            type="drug" text="vincristine"/>
        <entity id="DDI-MedLine.d115.s2.e9" charOffset="520-528"
            type="drug" text="bleomycin"/>
        <entity id="DDI-MedLine.d115.s2.e10" charOffset="549-562"
            type="group" text="antiretroviral"/>
        <pair id="DDI-MedLine.d115.s2.p0" e1="DDI-MedLine.d115.s2.e0"
            e2="DDI-MedLine.d115.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p1" e1="DDI-MedLine.d115.s2.e0"
            e2="DDI-MedLine.d115.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p2" e1="DDI-MedLine.d115.s2.e0"
            e2="DDI-MedLine.d115.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p3" e1="DDI-MedLine.d115.s2.e0"
            e2="DDI-MedLine.d115.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p4" e1="DDI-MedLine.d115.s2.e0"
            e2="DDI-MedLine.d115.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p5" e1="DDI-MedLine.d115.s2.e0"
            e2="DDI-MedLine.d115.s2.e6" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p6" e1="DDI-MedLine.d115.s2.e0"
            e2="DDI-MedLine.d115.s2.e7" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p7" e1="DDI-MedLine.d115.s2.e0"
            e2="DDI-MedLine.d115.s2.e8" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p8" e1="DDI-MedLine.d115.s2.e0"
            e2="DDI-MedLine.d115.s2.e9" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p9" e1="DDI-MedLine.d115.s2.e0"
            e2="DDI-MedLine.d115.s2.e10" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p10" e1="DDI-MedLine.d115.s2.e1"
            e2="DDI-MedLine.d115.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p11" e1="DDI-MedLine.d115.s2.e1"
            e2="DDI-MedLine.d115.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p12" e1="DDI-MedLine.d115.s2.e1"
            e2="DDI-MedLine.d115.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p13" e1="DDI-MedLine.d115.s2.e1"
            e2="DDI-MedLine.d115.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p14" e1="DDI-MedLine.d115.s2.e1"
            e2="DDI-MedLine.d115.s2.e6" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p15" e1="DDI-MedLine.d115.s2.e1"
            e2="DDI-MedLine.d115.s2.e7" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p16" e1="DDI-MedLine.d115.s2.e1"
            e2="DDI-MedLine.d115.s2.e8" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p17" e1="DDI-MedLine.d115.s2.e1"
            e2="DDI-MedLine.d115.s2.e9" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p18" e1="DDI-MedLine.d115.s2.e1"
            e2="DDI-MedLine.d115.s2.e10" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p19" e1="DDI-MedLine.d115.s2.e2"
            e2="DDI-MedLine.d115.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p20" e1="DDI-MedLine.d115.s2.e2"
            e2="DDI-MedLine.d115.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p21" e1="DDI-MedLine.d115.s2.e2"
            e2="DDI-MedLine.d115.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p22" e1="DDI-MedLine.d115.s2.e2"
            e2="DDI-MedLine.d115.s2.e6" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p23" e1="DDI-MedLine.d115.s2.e2"
            e2="DDI-MedLine.d115.s2.e7" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p24" e1="DDI-MedLine.d115.s2.e2"
            e2="DDI-MedLine.d115.s2.e8" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p25" e1="DDI-MedLine.d115.s2.e2"
            e2="DDI-MedLine.d115.s2.e9" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p26" e1="DDI-MedLine.d115.s2.e2"
            e2="DDI-MedLine.d115.s2.e10" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p27" e1="DDI-MedLine.d115.s2.e3"
            e2="DDI-MedLine.d115.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p28" e1="DDI-MedLine.d115.s2.e3"
            e2="DDI-MedLine.d115.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p29" e1="DDI-MedLine.d115.s2.e3"
            e2="DDI-MedLine.d115.s2.e6" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p30" e1="DDI-MedLine.d115.s2.e3"
            e2="DDI-MedLine.d115.s2.e7" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p31" e1="DDI-MedLine.d115.s2.e3"
            e2="DDI-MedLine.d115.s2.e8" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p32" e1="DDI-MedLine.d115.s2.e3"
            e2="DDI-MedLine.d115.s2.e9" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p33" e1="DDI-MedLine.d115.s2.e3"
            e2="DDI-MedLine.d115.s2.e10" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p34" e1="DDI-MedLine.d115.s2.e4"
            e2="DDI-MedLine.d115.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p35" e1="DDI-MedLine.d115.s2.e4"
            e2="DDI-MedLine.d115.s2.e6" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p36" e1="DDI-MedLine.d115.s2.e4"
            e2="DDI-MedLine.d115.s2.e7" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p37" e1="DDI-MedLine.d115.s2.e4"
            e2="DDI-MedLine.d115.s2.e8" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p38" e1="DDI-MedLine.d115.s2.e4"
            e2="DDI-MedLine.d115.s2.e9" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p39" e1="DDI-MedLine.d115.s2.e4"
            e2="DDI-MedLine.d115.s2.e10" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p40" e1="DDI-MedLine.d115.s2.e5"
            e2="DDI-MedLine.d115.s2.e6" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p41" e1="DDI-MedLine.d115.s2.e5"
            e2="DDI-MedLine.d115.s2.e7" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p42" e1="DDI-MedLine.d115.s2.e5"
            e2="DDI-MedLine.d115.s2.e8" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p43" e1="DDI-MedLine.d115.s2.e5"
            e2="DDI-MedLine.d115.s2.e9" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p44" e1="DDI-MedLine.d115.s2.e5"
            e2="DDI-MedLine.d115.s2.e10" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p45" e1="DDI-MedLine.d115.s2.e6"
            e2="DDI-MedLine.d115.s2.e7" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p46" e1="DDI-MedLine.d115.s2.e6"
            e2="DDI-MedLine.d115.s2.e8" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p47" e1="DDI-MedLine.d115.s2.e6"
            e2="DDI-MedLine.d115.s2.e9" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p48" e1="DDI-MedLine.d115.s2.e6"
            e2="DDI-MedLine.d115.s2.e10" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p49" e1="DDI-MedLine.d115.s2.e7"
            e2="DDI-MedLine.d115.s2.e8" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p50" e1="DDI-MedLine.d115.s2.e7"
            e2="DDI-MedLine.d115.s2.e9" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p51" e1="DDI-MedLine.d115.s2.e7"
            e2="DDI-MedLine.d115.s2.e10" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p52" e1="DDI-MedLine.d115.s2.e8"
            e2="DDI-MedLine.d115.s2.e9" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p53" e1="DDI-MedLine.d115.s2.e8"
            e2="DDI-MedLine.d115.s2.e10" ddi="false"/>
        <pair id="DDI-MedLine.d115.s2.p54" e1="DDI-MedLine.d115.s2.e9"
            e2="DDI-MedLine.d115.s2.e10" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d115.s3" text="METHODS: All patients were enrolled in two sequential trials performed at the Aviano Cancer Center, Italy, from April 1988 to December 1998. "/>
    <sentence id="DDI-MedLine.d115.s4" text="HAART was included with combination therapy from January 1997. "/>
    <sentence id="DDI-MedLine.d115.s5" text="Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor. ">
        <entity id="DDI-MedLine.d115.s5.e0" charOffset="0-13"
            type="group" text="Antiretroviral"/>
        <entity id="DDI-MedLine.d115.s5.e1" charOffset="41-72"
            type="group" text="reverse transcriptase inhibitors"/>
        <entity id="DDI-MedLine.d115.s5.e2" charOffset="82-99"
            type="group" text="protease inhibitor"/>
        <pair id="DDI-MedLine.d115.s5.p0" e1="DDI-MedLine.d115.s5.e0"
            e2="DDI-MedLine.d115.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d115.s5.p1" e1="DDI-MedLine.d115.s5.e0"
            e2="DDI-MedLine.d115.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d115.s5.p2" e1="DDI-MedLine.d115.s5.e1"
            e2="DDI-MedLine.d115.s5.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d115.s6" text="RESULTS: The two treatment groups were well matched with regard to patient demographics, NHL characteristics, HIV status, and treatment, i.e., the number of cycles and chemotherapy dose. "/>
    <sentence id="DDI-MedLine.d115.s7" text="The response rates were similar between the two groups. "/>
    <sentence id="DDI-MedLine.d115.s8" text="Severe anemia (Grade 3-4 according to the World Health Organization criteria) was significantly greater in the patients who received CHOP-HAART compared with the patients who received CHOP alone (33% vs. 7%, respectively; P = 0.001). "/>
    <sentence id="DDI-MedLine.d115.s9" text="Leukopenia was similar between the two groups, but colony stimulating factor support was significantly greater in the CHOP-HAART group than in the control group (92% vs. 66%, respectively; P = 0.03). "/>
    <sentence id="DDI-MedLine.d115.s10" text="Seventeen percent of CHOP-HAART patients developed severe autonomic neurotoxicity, whereas none of the CHOP patients developed neurotoxicity (P = 0.002). "/>
    <sentence id="DDI-MedLine.d115.s11" text="At similar median follow-up, opportunistic infection (OI) rates and mortality were significantly lower in the CHOP-HAART patients than in the CHOP patients (18% vs. 52%, respectively; P = 0.05; and 38% vs. 85%, respectively; P = 0.001). "/>
    <sentence id="DDI-MedLine.d115.s12" text="The median survival for CHOP-HAART patients was not reached, whereas the medial survival of CHOP patients was 7 months (P = 0.03). "/>
    <sentence id="DDI-MedLine.d115.s13" text="CONCLUSIONS: The combination of CHOP plus HAART is feasible and may reduce the morbidity from OIs in HIV-NHL patients. "/>
    <sentence id="DDI-MedLine.d115.s14" text="However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs. ">
        <entity id="DDI-MedLine.d115.s14.e0"
            charOffset="112-125;146-150" type="group" text="antiretroviral drugs"/>
        <entity id="DDI-MedLine.d115.s14.e1" charOffset="131-150"
            type="group" text="antineoplastic drugs"/>
        <pair id="DDI-MedLine.d115.s14.p0" e1="DDI-MedLine.d115.s14.e0"
            e2="DDI-MedLine.d115.s14.e1" ddi="true" type="advise"/>
    </sentence>
    <sentence id="DDI-MedLine.d115.s15" text="The impact of the combined chemotherapy plus HAART treatment on patient survival needs urgently to be evaluated in prospective studies."/>
    <sentence id="DDI-MedLine.d21.s0" text="Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats.&#xa;">
        <entity id="DDI-MedLine.d21.s0.e0" charOffset="26-40"
            type="group" text="antidepressants"/>
    </sentence>
    <sentence id="DDI-MedLine.d21.s1" text="Diabetic patients have a 20% higher risk of depression than the general population. "/>
    <sentence id="DDI-MedLine.d21.s2" text="Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. ">
        <entity id="DDI-MedLine.d21.s2.e0" charOffset="15-34"
            type="group" text="antidepressant drugs"/>
        <entity id="DDI-MedLine.d21.s2.e1" charOffset="106-124"
            type="group" text="hypoglycemic agents"/>
        <pair id="DDI-MedLine.d21.s2.p0" e1="DDI-MedLine.d21.s2.e0"
            e2="DDI-MedLine.d21.s2.e1" ddi="true" type="int"/>
    </sentence>
    <sentence id="DDI-MedLine.d21.s3" text="The treatment of depression in diabetic patients must take into account variations of glycemic levels at different times and a comparison of the available antidepressant agents is important. ">
        <entity id="DDI-MedLine.d21.s3.e0" charOffset="155-175"
            type="group" text="antidepressant agents"/>
    </sentence>
    <sentence id="DDI-MedLine.d21.s4" text="In the present study we evaluated the interference of antidepressants with blood glucose levels of diabetic and non-diabetic rats. ">
        <entity id="DDI-MedLine.d21.s4.e0" charOffset="54-68"
            type="group" text="antidepressants"/>
    </sentence>
    <sentence id="DDI-MedLine.d21.s5" text="In a first experiment, male adult Wistar rats were fasted for 12 h. "/>
    <sentence id="DDI-MedLine.d21.s6" text="Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ">
        <entity id="DDI-MedLine.d21.s6.e0" charOffset="0-9" type="drug" text="Imipramine"/>
        <entity id="DDI-MedLine.d21.s6.e1" charOffset="22-32"
            type="drug" text="moclobemide"/>
        <entity id="DDI-MedLine.d21.s6.e2" charOffset="46-55"
            type="drug" text="clonazepam"/>
        <entity id="DDI-MedLine.d21.s6.e3" charOffset="71-80"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-MedLine.d21.s6.e4" charOffset="93-102"
            type="drug" text="sertraline"/>
        <pair id="DDI-MedLine.d21.s6.p0" e1="DDI-MedLine.d21.s6.e0"
            e2="DDI-MedLine.d21.s6.e1" ddi="false"/>
        <pair id="DDI-MedLine.d21.s6.p1" e1="DDI-MedLine.d21.s6.e0"
            e2="DDI-MedLine.d21.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d21.s6.p2" e1="DDI-MedLine.d21.s6.e0"
            e2="DDI-MedLine.d21.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d21.s6.p3" e1="DDI-MedLine.d21.s6.e0"
            e2="DDI-MedLine.d21.s6.e4" ddi="false"/>
        <pair id="DDI-MedLine.d21.s6.p4" e1="DDI-MedLine.d21.s6.e1"
            e2="DDI-MedLine.d21.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d21.s6.p5" e1="DDI-MedLine.d21.s6.e1"
            e2="DDI-MedLine.d21.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d21.s6.p6" e1="DDI-MedLine.d21.s6.e1"
            e2="DDI-MedLine.d21.s6.e4" ddi="false"/>
        <pair id="DDI-MedLine.d21.s6.p7" e1="DDI-MedLine.d21.s6.e2"
            e2="DDI-MedLine.d21.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d21.s6.p8" e1="DDI-MedLine.d21.s6.e2"
            e2="DDI-MedLine.d21.s6.e4" ddi="false"/>
        <pair id="DDI-MedLine.d21.s6.p9" e1="DDI-MedLine.d21.s6.e3"
            e2="DDI-MedLine.d21.s6.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d21.s7" text="After 30 min, fasting glycemia was measured. "/>
    <sentence id="DDI-MedLine.d21.s8" text="An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. ">
        <entity id="DDI-MedLine.d21.s8.e0" charOffset="8-14" type="drug" text="glucose"/>
        <entity id="DDI-MedLine.d21.s8.e1" charOffset="42-48"
            type="drug" text="glucose"/>
        <pair id="DDI-MedLine.d21.s8.p0" e1="DDI-MedLine.d21.s8.e0"
            e2="DDI-MedLine.d21.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d21.s9" text="Imipramine and clonazepam did not change fasting or overload glycemia. ">
        <entity id="DDI-MedLine.d21.s9.e0" charOffset="0-9" type="drug" text="Imipramine"/>
        <entity id="DDI-MedLine.d21.s9.e1" charOffset="15-24"
            type="drug" text="clonazepam"/>
        <pair id="DDI-MedLine.d21.s9.p0" e1="DDI-MedLine.d21.s9.e0"
            e2="DDI-MedLine.d21.s9.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d21.s10" text="Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. ">
        <entity id="DDI-MedLine.d21.s10.e0" charOffset="0-9" type="drug" text="Fluoxetine"/>
        <entity id="DDI-MedLine.d21.s10.e1" charOffset="15-25"
            type="drug" text="moclobemide"/>
        <entity id="DDI-MedLine.d21.s10.e2" charOffset="43-49"
            type="drug" text="glucose"/>
        <pair id="DDI-MedLine.d21.s10.p0" e1="DDI-MedLine.d21.s10.e0"
            e2="DDI-MedLine.d21.s10.e1" ddi="false"/>
        <pair id="DDI-MedLine.d21.s10.p1" e1="DDI-MedLine.d21.s10.e0"
            e2="DDI-MedLine.d21.s10.e2" ddi="false"/>
        <pair id="DDI-MedLine.d21.s10.p2" e1="DDI-MedLine.d21.s10.e1"
            e2="DDI-MedLine.d21.s10.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d21.s11" text="Sertraline neutralized the increase of glycemia induced by oral glucose overload. ">
        <entity id="DDI-MedLine.d21.s11.e0" charOffset="0-9" type="drug" text="Sertraline"/>
        <entity id="DDI-MedLine.d21.s11.e1" charOffset="64-70"
            type="drug" text="glucose"/>
        <pair id="DDI-MedLine.d21.s11.p0" e1="DDI-MedLine.d21.s11.e0"
            e2="DDI-MedLine.d21.s11.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d21.s12" text="In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. ">
        <entity id="DDI-MedLine.d21.s12.e0" charOffset="149-155"
            type="drug" text="glucose"/>
        <entity id="DDI-MedLine.d21.s12.e1" charOffset="180-186"
            type="drug" text="glucose"/>
        <pair id="DDI-MedLine.d21.s12.p0" e1="DDI-MedLine.d21.s12.e0"
            e2="DDI-MedLine.d21.s12.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d21.s13" text="Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. ">
        <entity id="DDI-MedLine.d21.s13.e0" charOffset="7-16"
            type="drug" text="sertraline"/>
        <entity id="DDI-MedLine.d21.s13.e1" charOffset="61-67"
            type="drug" text="glucose"/>
        <pair id="DDI-MedLine.d21.s13.p0" e1="DDI-MedLine.d21.s13.e0"
            e2="DDI-MedLine.d21.s13.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d21.s14" text="These data raise the question of whether sertraline is the best choice for prolonged use for diabetic individuals, because of its antihyperglycemic effects. ">
        <entity id="DDI-MedLine.d21.s14.e0" charOffset="41-50"
            type="drug" text="sertraline"/>
    </sentence>
    <sentence id="DDI-MedLine.d21.s15" text="Clonazepam would be useful in cases with potential risk of hypoglycemia.">
        <entity id="DDI-MedLine.d21.s15.e0" charOffset="0-9" type="drug" text="Clonazepam"/>
    </sentence>
    <sentence id="DDI-MedLine.d47.s0" text="Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.&#xd;&#xa;">
        <entity id="DDI-MedLine.d47.s0.e0" charOffset="12-21"
            type="drug_n" text="buforin II"/>
        <entity id="DDI-MedLine.d47.s0.e1" charOffset="53-64"
            type="drug" text="azithromycin"/>
        <entity id="DDI-MedLine.d47.s0.e2" charOffset="70-80"
            type="drug" text="minocycline"/>
        <pair id="DDI-MedLine.d47.s0.p0" e1="DDI-MedLine.d47.s0.e0"
            e2="DDI-MedLine.d47.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d47.s0.p1" e1="DDI-MedLine.d47.s0.e0"
            e2="DDI-MedLine.d47.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d47.s0.p2" e1="DDI-MedLine.d47.s0.e1"
            e2="DDI-MedLine.d47.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d47.s1" text="The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated. ">
        <entity id="DDI-MedLine.d47.s1.e0" charOffset="46-55"
            type="drug_n" text="buforin II"/>
        <entity id="DDI-MedLine.d47.s1.e1" charOffset="87-98"
            type="drug" text="azithromycin"/>
        <entity id="DDI-MedLine.d47.s1.e2" charOffset="104-114"
            type="drug" text="minocycline"/>
        <pair id="DDI-MedLine.d47.s1.p0" e1="DDI-MedLine.d47.s1.e0"
            e2="DDI-MedLine.d47.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d47.s1.p1" e1="DDI-MedLine.d47.s1.e0"
            e2="DDI-MedLine.d47.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d47.s1.p2" e1="DDI-MedLine.d47.s1.e1"
            e2="DDI-MedLine.d47.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d47.s2" text="Buforin II showed moderate activity, which increased with increasing concentration to 55.7% suppression of growth at 20 microM. ">
        <entity id="DDI-MedLine.d47.s2.e0" charOffset="0-9"
            type="drug_n" text="Buforin II"/>
    </sentence>
    <sentence id="DDI-MedLine.d47.s3" text="Moreover, its activity was enhanced when it was combined with either azithromycin or minocycline with 90% parasite reduction at the highest concentration tested. ">
        <entity id="DDI-MedLine.d47.s3.e0" charOffset="69-80"
            type="drug" text="azithromycin"/>
        <entity id="DDI-MedLine.d47.s3.e1" charOffset="85-95"
            type="drug" text="minocycline"/>
        <pair id="DDI-MedLine.d47.s3.p0" e1="DDI-MedLine.d47.s3.e0"
            e2="DDI-MedLine.d47.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d47.s4" text="Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.">
        <entity id="DDI-MedLine.d47.s4.e0" charOffset="0-9"
            type="drug_n" text="Buforin II"/>
        <entity id="DDI-MedLine.d47.s4.e1" charOffset="107-118"
            type="drug" text="azithromycin"/>
        <entity id="DDI-MedLine.d47.s4.e2" charOffset="123-133"
            type="drug" text="minocycline"/>
        <pair id="DDI-MedLine.d47.s4.p0" e1="DDI-MedLine.d47.s4.e0"
            e2="DDI-MedLine.d47.s4.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d47.s4.p1" e1="DDI-MedLine.d47.s4.e0"
            e2="DDI-MedLine.d47.s4.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d47.s4.p2" e1="DDI-MedLine.d47.s4.e1"
            e2="DDI-MedLine.d47.s4.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d112.s0" text="Effect of dofetillide on the pharmacokinetics of digoxin.&#xd;&#xa;">
        <entity id="DDI-MedLine.d112.s0.e0" charOffset="10-20"
            type="drug" text="dofetillide"/>
        <entity id="DDI-MedLine.d112.s0.e1" charOffset="49-55"
            type="drug" text="digoxin"/>
        <pair id="DDI-MedLine.d112.s0.p0" e1="DDI-MedLine.d112.s0.e0"
            e2="DDI-MedLine.d112.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d112.s1" text="The effect of dofetilide on the steady-state pharmacokinetics of digoxin was evaluated in a randomized, double-blind study. ">
        <entity id="DDI-MedLine.d112.s1.e0" charOffset="14-23"
            type="drug" text="dofetilide"/>
        <entity id="DDI-MedLine.d112.s1.e1" charOffset="65-71"
            type="drug" text="digoxin"/>
        <pair id="DDI-MedLine.d112.s1.p0" e1="DDI-MedLine.d112.s1.e0"
            e2="DDI-MedLine.d112.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d112.s2" text="Five days of dofetilide treatment did not significantly affect steady-state pharmacokinetic variables of digoxin compared with placebo; ">
        <entity id="DDI-MedLine.d112.s2.e0" charOffset="13-22"
            type="drug" text="dofetilide"/>
        <entity id="DDI-MedLine.d112.s2.e1" charOffset="105-111"
            type="drug" text="digoxin"/>
        <pair id="DDI-MedLine.d112.s2.p0" e1="DDI-MedLine.d112.s2.e0"
            e2="DDI-MedLine.d112.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d112.s3" text="therefore, the use of dofetilide does not necessitate an adjustment in digoxin dose to maintain therapeutic digoxin levels.">
        <entity id="DDI-MedLine.d112.s3.e0" charOffset="22-31"
            type="drug" text="dofetilide"/>
        <entity id="DDI-MedLine.d112.s3.e1" charOffset="71-77"
            type="drug" text="digoxin"/>
        <pair id="DDI-MedLine.d112.s3.p0" e1="DDI-MedLine.d112.s3.e0"
            e2="DDI-MedLine.d112.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d19.s0" text="Anaesthesia and the epileptic pateint. "/>
    <sentence id="DDI-MedLine.d19.s1" text="A review.&#xa;"/>
    <sentence id="DDI-MedLine.d19.s2" text="A review is presented of some of the problems that may arise in association with anaesthesia for epileptic patients. "/>
    <sentence id="DDI-MedLine.d19.s3" text="There is the possibility of precipitating anticonvulsant drug toxicity. "/>
    <sentence id="DDI-MedLine.d19.s4" text="Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems. ">
        <entity id="DDI-MedLine.d19.s4.e0" charOffset="50-70"
            type="group" text="anticonvulsant agents"/>
        <entity id="DDI-MedLine.d19.s4.e1" charOffset="81-94"
            type="drug" text="phenobarbitone"/>
        <entity id="DDI-MedLine.d19.s4.e2" charOffset="100-108"
            type="drug" text="phenytoin"/>
        <pair id="DDI-MedLine.d19.s4.p0" e1="DDI-MedLine.d19.s4.e0"
            e2="DDI-MedLine.d19.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d19.s4.p1" e1="DDI-MedLine.d19.s4.e0"
            e2="DDI-MedLine.d19.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d19.s4.p2" e1="DDI-MedLine.d19.s4.e1"
            e2="DDI-MedLine.d19.s4.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d19.s5" text="There is the risk of convulsions occurring in susceptible patients following the use of the new anaesthetic agents which are capable of inducing CNS excitability.">
        <entity id="DDI-MedLine.d19.s5.e0" charOffset="96-113"
            type="group" text="anaesthetic agents"/>
    </sentence>
    <sentence id="DDI-MedLine.d16.s0" text="Interaction of ketamine and halothane in rats.&#xa;">
        <entity id="DDI-MedLine.d16.s0.e0" charOffset="15-22"
            type="drug" text="ketamine"/>
        <entity id="DDI-MedLine.d16.s0.e1" charOffset="28-36"
            type="drug" text="halothane"/>
        <pair id="DDI-MedLine.d16.s0.p0" e1="DDI-MedLine.d16.s0.e0"
            e2="DDI-MedLine.d16.s0.e1" ddi="true" type="int"/>
    </sentence>
    <sentence id="DDI-MedLine.d16.s1" text="The interaction of intramuscularly injected ketamine and its N-demethylated metabolite (metabolite I) with halothane was evaluated in rats. ">
        <entity id="DDI-MedLine.d16.s1.e0" charOffset="44-51"
            type="drug" text="ketamine"/>
        <entity id="DDI-MedLine.d16.s1.e1" charOffset="107-115"
            type="drug" text="halothane"/>
        <pair id="DDI-MedLine.d16.s1.p0" e1="DDI-MedLine.d16.s1.e0"
            e2="DDI-MedLine.d16.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d16.s2" text="Five, 10, 20, or 50 mg/kg of ketamine alone or 20, 50, or 100 mg/kg of metabolite I alone produced less than 10 minutes of hypnosis. ">
        <entity id="DDI-MedLine.d16.s2.e0" charOffset="29-36"
            type="drug" text="ketamine"/>
    </sentence>
    <sentence id="DDI-MedLine.d16.s3" text="However, halothane anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of ketamine, 50 mg/kg, im. ">
        <entity id="DDI-MedLine.d16.s3.e0" charOffset="9-17" type="drug" text="halothane"/>
        <entity id="DDI-MedLine.d16.s3.e1" charOffset="169-176"
            type="drug" text="ketamine"/>
        <pair id="DDI-MedLine.d16.s3.p0" e1="DDI-MedLine.d16.s3.e0"
            e2="DDI-MedLine.d16.s3.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d16.s4" text="The reduction in MAC was correlated with brain levels of ketamine or metabolite I, suggesting a ketamine:metabolite I potency ration of 3:1. ">
        <entity id="DDI-MedLine.d16.s4.e0" charOffset="57-64"
            type="drug" text="ketamine"/>
        <entity id="DDI-MedLine.d16.s4.e1" charOffset="96-103"
            type="drug" text="ketamine"/>
        <pair id="DDI-MedLine.d16.s4.p0" e1="DDI-MedLine.d16.s4.e0"
            e2="DDI-MedLine.d16.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d16.s5" text="The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. ">
        <entity id="DDI-MedLine.d16.s5.e0" charOffset="17-24"
            type="drug" text="ketamine"/>
        <entity id="DDI-MedLine.d16.s5.e1" charOffset="76-84"
            type="drug" text="halothane"/>
        <entity id="DDI-MedLine.d16.s5.e2" charOffset="96-103"
            type="drug" text="ketamine"/>
        <pair id="DDI-MedLine.d16.s5.p0" e1="DDI-MedLine.d16.s5.e0"
            e2="DDI-MedLine.d16.s5.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d16.s5.p1" e1="DDI-MedLine.d16.s5.e0"
            e2="DDI-MedLine.d16.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d16.s5.p2" e1="DDI-MedLine.d16.s5.e1"
            e2="DDI-MedLine.d16.s5.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d16.s6" text="It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.">
        <entity id="DDI-MedLine.d16.s6.e0" charOffset="21-28"
            type="drug" text="ketamine"/>
        <entity id="DDI-MedLine.d16.s6.e1" charOffset="87-95"
            type="drug" text="halothane"/>
        <pair id="DDI-MedLine.d16.s6.p0" e1="DDI-MedLine.d16.s6.e0"
            e2="DDI-MedLine.d16.s6.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d116.s0" text="Rifampin and warfarin: a drug interaction.&#xd;&#xa;">
        <entity id="DDI-MedLine.d116.s0.e0" charOffset="0-7" type="drug" text="Rifampin"/>
        <entity id="DDI-MedLine.d116.s0.e1" charOffset="13-20"
            type="drug" text="warfarin"/>
        <pair id="DDI-MedLine.d116.s0.p0" e1="DDI-MedLine.d116.s0.e0"
            e2="DDI-MedLine.d116.s0.e1" ddi="true" type="int"/>
    </sentence>
    <sentence id="DDI-MedLine.d116.s1" text="The drug interaction between warfarin and rifampin is not well known. ">
        <entity id="DDI-MedLine.d116.s1.e0" charOffset="29-36"
            type="drug" text="warfarin"/>
        <entity id="DDI-MedLine.d116.s1.e1" charOffset="42-49"
            type="drug" text="rifampin"/>
        <pair id="DDI-MedLine.d116.s1.p0" e1="DDI-MedLine.d116.s1.e0"
            e2="DDI-MedLine.d116.s1.e1" ddi="true" type="int"/>
    </sentence>
    <sentence id="DDI-MedLine.d116.s2" text="Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously. ">
        <entity id="DDI-MedLine.d116.s2.e0" charOffset="0-7" type="drug" text="Rifampin"/>
        <entity id="DDI-MedLine.d116.s2.e1" charOffset="43-50"
            type="drug" text="warfarin"/>
        <pair id="DDI-MedLine.d116.s2.p0" e1="DDI-MedLine.d116.s2.e0"
            e2="DDI-MedLine.d116.s2.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d116.s3" text="The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ">
        <entity id="DDI-MedLine.d116.s3.e0" charOffset="34-41"
            type="drug" text="rifampin"/>
        <entity id="DDI-MedLine.d116.s3.e1" charOffset="47-54"
            type="drug" text="warfarin"/>
        <entity id="DDI-MedLine.d116.s3.e2" charOffset="119-126"
            type="drug" text="warfarin"/>
        <pair id="DDI-MedLine.d116.s3.p0" e1="DDI-MedLine.d116.s3.e0"
            e2="DDI-MedLine.d116.s3.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d116.s3.p1" e1="DDI-MedLine.d116.s3.e0"
            e2="DDI-MedLine.d116.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d116.s3.p2" e1="DDI-MedLine.d116.s3.e1"
            e2="DDI-MedLine.d116.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d116.s4" text="Withdrawal of rifampin decreased the warfarin requirement by 50%. ">
        <entity id="DDI-MedLine.d116.s4.e0" charOffset="14-21"
            type="drug" text="rifampin"/>
        <entity id="DDI-MedLine.d116.s4.e1" charOffset="37-44"
            type="drug" text="warfarin"/>
        <pair id="DDI-MedLine.d116.s4.p0" e1="DDI-MedLine.d116.s4.e0"
            e2="DDI-MedLine.d116.s4.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d116.s5" text="This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin. ">
        <entity id="DDI-MedLine.d116.s5.e0" charOffset="46-53"
            type="drug" text="rifampin"/>
        <entity id="DDI-MedLine.d116.s5.e1" charOffset="113-120"
            type="drug" text="warfarin"/>
        <pair id="DDI-MedLine.d116.s5.p0" e1="DDI-MedLine.d116.s5.e0"
            e2="DDI-MedLine.d116.s5.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d116.s6" text="The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ">
        <entity id="DDI-MedLine.d116.s6.e0" charOffset="14-21"
            type="drug" text="rifampin"/>
        <entity id="DDI-MedLine.d116.s6.e1" charOffset="30-37"
            type="drug" text="warfarin"/>
        <entity id="DDI-MedLine.d116.s6.e2" charOffset="125-132"
            type="drug" text="rifampin"/>
        <entity id="DDI-MedLine.d116.s6.e3" charOffset="178-185"
            type="drug" text="rifampin"/>
        <pair id="DDI-MedLine.d116.s6.p0" e1="DDI-MedLine.d116.s6.e0"
            e2="DDI-MedLine.d116.s6.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d116.s6.p1" e1="DDI-MedLine.d116.s6.e0"
            e2="DDI-MedLine.d116.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d116.s6.p2" e1="DDI-MedLine.d116.s6.e0"
            e2="DDI-MedLine.d116.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d116.s6.p3" e1="DDI-MedLine.d116.s6.e1"
            e2="DDI-MedLine.d116.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d116.s6.p4" e1="DDI-MedLine.d116.s6.e1"
            e2="DDI-MedLine.d116.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d116.s6.p5" e1="DDI-MedLine.d116.s6.e2"
            e2="DDI-MedLine.d116.s6.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d116.s7" text="This interaction appears to be clinically significant."/>
    <sentence id="DDI-MedLine.d76.s0" text="Thiolated carboxymethylcellulose: in vitro evaluation of its permeation enhancing effect on peptide drugs.&#xd;&#xa;">
        <entity id="DDI-MedLine.d76.s0.e0" charOffset="0-31"
            type="drug_n" text="Thiolated carboxymethylcellulose"/>
    </sentence>
    <sentence id="DDI-MedLine.d76.s1" text="The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ">
        <entity id="DDI-MedLine.d76.s1.e0" charOffset="56-84"
            type="drug_n" text="sodium carboxymethylcellulose"/>
        <entity id="DDI-MedLine.d76.s1.e1" charOffset="87-91"
            type="drug_n" text="NaCMC"/>
        <entity id="DDI-MedLine.d76.s1.e2" charOffset="98-128"
            type="drug_n" text="carboxymethylcellulose-cysteine"/>
        <entity id="DDI-MedLine.d76.s1.e3" charOffset="131-137"
            type="drug_n" text="CMC-Cys"/>
        <entity id="DDI-MedLine.d76.s1.e4" charOffset="183-200"
            type="drug" text="sodium fluorescein"/>
        <entity id="DDI-MedLine.d76.s1.e5" charOffset="203-207"
            type="drug" text="NaFlu"/>
        <entity id="DDI-MedLine.d76.s1.e6" charOffset="235-244"
            type="drug" text="bacitracin"/>
        <entity id="DDI-MedLine.d76.s1.e7" charOffset="250-256"
            type="drug" text="insulin"/>
        <pair id="DDI-MedLine.d76.s1.p0" e1="DDI-MedLine.d76.s1.e0"
            e2="DDI-MedLine.d76.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p1" e1="DDI-MedLine.d76.s1.e0"
            e2="DDI-MedLine.d76.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p2" e1="DDI-MedLine.d76.s1.e0"
            e2="DDI-MedLine.d76.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p3" e1="DDI-MedLine.d76.s1.e0"
            e2="DDI-MedLine.d76.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p4" e1="DDI-MedLine.d76.s1.e0"
            e2="DDI-MedLine.d76.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p5" e1="DDI-MedLine.d76.s1.e0"
            e2="DDI-MedLine.d76.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p6" e1="DDI-MedLine.d76.s1.e0"
            e2="DDI-MedLine.d76.s1.e7" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p7" e1="DDI-MedLine.d76.s1.e1"
            e2="DDI-MedLine.d76.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p8" e1="DDI-MedLine.d76.s1.e1"
            e2="DDI-MedLine.d76.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p9" e1="DDI-MedLine.d76.s1.e1"
            e2="DDI-MedLine.d76.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p10" e1="DDI-MedLine.d76.s1.e1"
            e2="DDI-MedLine.d76.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p11" e1="DDI-MedLine.d76.s1.e1"
            e2="DDI-MedLine.d76.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p12" e1="DDI-MedLine.d76.s1.e1"
            e2="DDI-MedLine.d76.s1.e7" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p13" e1="DDI-MedLine.d76.s1.e2"
            e2="DDI-MedLine.d76.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p14" e1="DDI-MedLine.d76.s1.e2"
            e2="DDI-MedLine.d76.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p15" e1="DDI-MedLine.d76.s1.e2"
            e2="DDI-MedLine.d76.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p16" e1="DDI-MedLine.d76.s1.e2"
            e2="DDI-MedLine.d76.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p17" e1="DDI-MedLine.d76.s1.e2"
            e2="DDI-MedLine.d76.s1.e7" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p18" e1="DDI-MedLine.d76.s1.e3"
            e2="DDI-MedLine.d76.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p19" e1="DDI-MedLine.d76.s1.e3"
            e2="DDI-MedLine.d76.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p20" e1="DDI-MedLine.d76.s1.e3"
            e2="DDI-MedLine.d76.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p21" e1="DDI-MedLine.d76.s1.e3"
            e2="DDI-MedLine.d76.s1.e7" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p22" e1="DDI-MedLine.d76.s1.e4"
            e2="DDI-MedLine.d76.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p23" e1="DDI-MedLine.d76.s1.e4"
            e2="DDI-MedLine.d76.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p24" e1="DDI-MedLine.d76.s1.e4"
            e2="DDI-MedLine.d76.s1.e7" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p25" e1="DDI-MedLine.d76.s1.e5"
            e2="DDI-MedLine.d76.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p26" e1="DDI-MedLine.d76.s1.e5"
            e2="DDI-MedLine.d76.s1.e7" ddi="false"/>
        <pair id="DDI-MedLine.d76.s1.p27" e1="DDI-MedLine.d76.s1.e6"
            e2="DDI-MedLine.d76.s1.e7" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d76.s2" text="Cysteine was covalently linked to carbodiimide activated NaCMC. ">
        <entity id="DDI-MedLine.d76.s2.e0" charOffset="0-7" type="drug" text="Cysteine"/>
        <entity id="DDI-MedLine.d76.s2.e1" charOffset="57-61"
            type="drug_n" text="NaCMC"/>
        <pair id="DDI-MedLine.d76.s2.p0" e1="DDI-MedLine.d76.s2.e0"
            e2="DDI-MedLine.d76.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d76.s3" text="Iodometric titration of the polymer conjugates was used to determine the extent of immobilised cysteine. ">
        <entity id="DDI-MedLine.d76.s3.e0" charOffset="95-102"
            type="drug" text="cysteine"/>
    </sentence>
    <sentence id="DDI-MedLine.d76.s4" text="Permeation studies were performed on guinea pig small intestinal mucosa mounted in Ussing-type chamber. "/>
    <sentence id="DDI-MedLine.d76.s5" text="Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. ">
        <entity id="DDI-MedLine.d76.s5.e0" charOffset="11-15"
            type="drug_n" text="NaCMC"/>
        <entity id="DDI-MedLine.d76.s5.e1" charOffset="108-112"
            type="drug" text="NaFlu"/>
        <entity id="DDI-MedLine.d76.s5.e2" charOffset="134-138"
            type="drug_n" text="NaCMC"/>
        <entity id="DDI-MedLine.d76.s5.e3" charOffset="156-163"
            type="drug" text="cysteine"/>
        <pair id="DDI-MedLine.d76.s5.p0" e1="DDI-MedLine.d76.s5.e0"
            e2="DDI-MedLine.d76.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d76.s5.p1" e1="DDI-MedLine.d76.s5.e0"
            e2="DDI-MedLine.d76.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d76.s5.p2" e1="DDI-MedLine.d76.s5.e0"
            e2="DDI-MedLine.d76.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d76.s5.p3" e1="DDI-MedLine.d76.s5.e1"
            e2="DDI-MedLine.d76.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d76.s5.p4" e1="DDI-MedLine.d76.s5.e1"
            e2="DDI-MedLine.d76.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d76.s5.p5" e1="DDI-MedLine.d76.s5.e2"
            e2="DDI-MedLine.d76.s5.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d76.s6" text="Cysteine conjugation at 3.6, 5.3 and 7.3% (m/m) resulted in R-values of 1.4, 1.7 and 1.8, respectively. ">
        <entity id="DDI-MedLine.d76.s6.e0" charOffset="0-7" type="drug" text="Cysteine"/>
    </sentence>
    <sentence id="DDI-MedLine.d76.s7" text="Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2. ">
        <entity id="DDI-MedLine.d76.s7.e0" charOffset="32-38"
            type="drug_n" text="CMC-Cys"/>
        <entity id="DDI-MedLine.d76.s7.e1" charOffset="78-85"
            type="drug" text="cysteine"/>
        <entity id="DDI-MedLine.d76.s7.e2" charOffset="153-157"
            type="drug" text="NaFlu"/>
        <pair id="DDI-MedLine.d76.s7.p0" e1="DDI-MedLine.d76.s7.e0"
            e2="DDI-MedLine.d76.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d76.s7.p1" e1="DDI-MedLine.d76.s7.e0"
            e2="DDI-MedLine.d76.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d76.s7.p2" e1="DDI-MedLine.d76.s7.e1"
            e2="DDI-MedLine.d76.s7.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d76.s8" text="NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. ">
        <entity id="DDI-MedLine.d76.s8.e0" charOffset="0-4"
            type="drug_n" text="NaCMC"/>
        <entity id="DDI-MedLine.d76.s8.e1" charOffset="42-49"
            type="drug" text="cysteine"/>
        <entity id="DDI-MedLine.d76.s8.e2" charOffset="95-99"
            type="drug" text="NaFlu"/>
        <entity id="DDI-MedLine.d76.s8.e3" charOffset="113-117"
            type="drug_n" text="NaCMC"/>
        <pair id="DDI-MedLine.d76.s8.p0" e1="DDI-MedLine.d76.s8.e0"
            e2="DDI-MedLine.d76.s8.e1" ddi="false"/>
        <pair id="DDI-MedLine.d76.s8.p1" e1="DDI-MedLine.d76.s8.e0"
            e2="DDI-MedLine.d76.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d76.s8.p2" e1="DDI-MedLine.d76.s8.e0"
            e2="DDI-MedLine.d76.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d76.s8.p3" e1="DDI-MedLine.d76.s8.e1"
            e2="DDI-MedLine.d76.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d76.s8.p4" e1="DDI-MedLine.d76.s8.e1"
            e2="DDI-MedLine.d76.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d76.s8.p5" e1="DDI-MedLine.d76.s8.e2"
            e2="DDI-MedLine.d76.s8.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d76.s9" text="Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). ">
        <entity id="DDI-MedLine.d76.s9.e0" charOffset="37-46"
            type="drug" text="bacitracin"/>
        <entity id="DDI-MedLine.d76.s9.e1" charOffset="52-58"
            type="drug" text="insulin"/>
        <entity id="DDI-MedLine.d76.s9.e2" charOffset="76-80"
            type="drug_n" text="NaCMC"/>
        <entity id="DDI-MedLine.d76.s9.e3" charOffset="173-179"
            type="drug_n" text="CMC-Cys"/>
        <pair id="DDI-MedLine.d76.s9.p0" e1="DDI-MedLine.d76.s9.e0"
            e2="DDI-MedLine.d76.s9.e1" ddi="false"/>
        <pair id="DDI-MedLine.d76.s9.p1" e1="DDI-MedLine.d76.s9.e0"
            e2="DDI-MedLine.d76.s9.e2" ddi="false"/>
        <pair id="DDI-MedLine.d76.s9.p2" e1="DDI-MedLine.d76.s9.e0"
            e2="DDI-MedLine.d76.s9.e3" ddi="false"/>
        <pair id="DDI-MedLine.d76.s9.p3" e1="DDI-MedLine.d76.s9.e1"
            e2="DDI-MedLine.d76.s9.e2" ddi="false"/>
        <pair id="DDI-MedLine.d76.s9.p4" e1="DDI-MedLine.d76.s9.e1"
            e2="DDI-MedLine.d76.s9.e3" ddi="false"/>
        <pair id="DDI-MedLine.d76.s9.p5" e1="DDI-MedLine.d76.s9.e2"
            e2="DDI-MedLine.d76.s9.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d76.s10" text="Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.">
        <entity id="DDI-MedLine.d76.s10.e0" charOffset="15-19"
            type="drug_n" text="NaCMC"/>
        <entity id="DDI-MedLine.d76.s10.e1" charOffset="26-33"
            type="drug" text="cysteine"/>
        <entity id="DDI-MedLine.d76.s10.e2" charOffset="121-125"
            type="drug" text="NaFlu"/>
        <entity id="DDI-MedLine.d76.s10.e3" charOffset="155-164"
            type="drug" text="bacitracin"/>
        <entity id="DDI-MedLine.d76.s10.e4" charOffset="170-176"
            type="drug" text="insulin"/>
        <pair id="DDI-MedLine.d76.s10.p0" e1="DDI-MedLine.d76.s10.e0"
            e2="DDI-MedLine.d76.s10.e1" ddi="false"/>
        <pair id="DDI-MedLine.d76.s10.p1" e1="DDI-MedLine.d76.s10.e0"
            e2="DDI-MedLine.d76.s10.e2" ddi="false"/>
        <pair id="DDI-MedLine.d76.s10.p2" e1="DDI-MedLine.d76.s10.e0"
            e2="DDI-MedLine.d76.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d76.s10.p3" e1="DDI-MedLine.d76.s10.e0"
            e2="DDI-MedLine.d76.s10.e4" ddi="false"/>
        <pair id="DDI-MedLine.d76.s10.p4" e1="DDI-MedLine.d76.s10.e1"
            e2="DDI-MedLine.d76.s10.e2" ddi="false"/>
        <pair id="DDI-MedLine.d76.s10.p5" e1="DDI-MedLine.d76.s10.e1"
            e2="DDI-MedLine.d76.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d76.s10.p6" e1="DDI-MedLine.d76.s10.e1"
            e2="DDI-MedLine.d76.s10.e4" ddi="false"/>
        <pair id="DDI-MedLine.d76.s10.p7" e1="DDI-MedLine.d76.s10.e2"
            e2="DDI-MedLine.d76.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d76.s10.p8" e1="DDI-MedLine.d76.s10.e2"
            e2="DDI-MedLine.d76.s10.e4" ddi="false"/>
        <pair id="DDI-MedLine.d76.s10.p9" e1="DDI-MedLine.d76.s10.e3"
            e2="DDI-MedLine.d76.s10.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d92.s0" text="Systemic antibiotic agents.">
        <entity id="DDI-MedLine.d92.s0.e0" charOffset="9-25"
            type="group" text="antibiotic agents"/>
    </sentence>
    <sentence id="DDI-MedLine.d92.s1" text="Understanding the breadth of systemic antimicrobial agents available for use by the dermatologist and their associated side-effect profiles and drug interactions allows the clinician to offer patients optimal care in the management of cutaneous infectious disease.">
        <entity id="DDI-MedLine.d92.s1.e0" charOffset="38-57"
            type="group" text="antimicrobial agents"/>
    </sentence>
    <sentence id="DDI-MedLine.d65.s0" text="Drug interactions: How to identify them.&#xd;&#xa;"/>
    <sentence id="DDI-MedLine.d65.s1" text="Interactions between theraputic agents have been recognized as increasingly important causes of drug at their usual recommended dose may, under certain conditions, produce toxicity of life-endangering proportions. "/>
    <sentence id="DDI-MedLine.d65.s2" text="While the recognition of drug toxicity resulting from interactions is of importance to all physciains, it is especially so for the clinician responsible for the welfare of those in the aerospace environment. "/>
    <sentence id="DDI-MedLine.d65.s3" text="This paper attempts to provide a basis for the understanding and identifications of important drug interactions. "/>
    <sentence id="DDI-MedLine.d65.s4" text="Guidelines are provided to assist the clinician in his logical approach to the identification of drug interactions when serious drug toxicity is encountered in a pateint. "/>
    <sentence id="DDI-MedLine.d65.s5" text="Only with knowledge of the interaction can the therapeutic regimen be altered so as to provide therapeutic levels of necessary drugs while avoiding toxicity."/>
    <sentence id="DDI-MedLine.d3.s0" text="Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.&#xa;">
        <entity id="DDI-MedLine.d3.s0.e0" charOffset="36-45" type="drug" text="amprenavir"/>
        <entity id="DDI-MedLine.d3.s0.e1" charOffset="51-59" type="drug" text="rifabutin"/>
        <entity id="DDI-MedLine.d3.s0.e2" charOffset="64-71" type="drug" text="rifampin"/>
        <pair id="DDI-MedLine.d3.s0.p0" e1="DDI-MedLine.d3.s0.e0"
            e2="DDI-MedLine.d3.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d3.s0.p1" e1="DDI-MedLine.d3.s0.e0"
            e2="DDI-MedLine.d3.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d3.s0.p2" e1="DDI-MedLine.d3.s0.e1"
            e2="DDI-MedLine.d3.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d3.s1" text="The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). ">
        <entity id="DDI-MedLine.d3.s1.e0" charOffset="92-101"
            type="drug" text="amprenavir"/>
        <entity id="DDI-MedLine.d3.s1.e1" charOffset="117-125"
            type="drug" text="rifabutin"/>
        <entity id="DDI-MedLine.d3.s1.e2" charOffset="130-137"
            type="drug" text="rifampin"/>
        <pair id="DDI-MedLine.d3.s1.p0" e1="DDI-MedLine.d3.s1.e0"
            e2="DDI-MedLine.d3.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d3.s1.p1" e1="DDI-MedLine.d3.s1.e0"
            e2="DDI-MedLine.d3.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d3.s1.p2" e1="DDI-MedLine.d3.s1.e1"
            e2="DDI-MedLine.d3.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d3.s2" text="Twenty-four healthy male subjects were randomized to one of two cohorts. "/>
    <sentence id="DDI-MedLine.d3.s3" text="All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. ">
        <entity id="DDI-MedLine.d3.s3.e0" charOffset="22-31" type="drug" text="amprenavir"/>
        <entity id="DDI-MedLine.d3.s3.e1" charOffset="123-131"
            type="drug" text="rifabutin"/>
        <entity id="DDI-MedLine.d3.s3.e2" charOffset="172-179"
            type="drug" text="rifampin"/>
        <pair id="DDI-MedLine.d3.s3.p0" e1="DDI-MedLine.d3.s3.e0"
            e2="DDI-MedLine.d3.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d3.s3.p1" e1="DDI-MedLine.d3.s3.e0"
            e2="DDI-MedLine.d3.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d3.s3.p2" e1="DDI-MedLine.d3.s3.e1"
            e2="DDI-MedLine.d3.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d3.s4" text="Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. ">
        <entity id="DDI-MedLine.d3.s4.e0" charOffset="23-32" type="drug" text="amprenavir"/>
        <entity id="DDI-MedLine.d3.s4.e1" charOffset="39-47" type="drug" text="rifabutin"/>
        <entity id="DDI-MedLine.d3.s4.e2" charOffset="84-93" type="drug" text="amprenavir"/>
        <entity id="DDI-MedLine.d3.s4.e3" charOffset="100-107"
            type="drug" text="rifampin"/>
        <pair id="DDI-MedLine.d3.s4.p0" e1="DDI-MedLine.d3.s4.e0"
            e2="DDI-MedLine.d3.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d3.s4.p1" e1="DDI-MedLine.d3.s4.e0"
            e2="DDI-MedLine.d3.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d3.s4.p2" e1="DDI-MedLine.d3.s4.e0"
            e2="DDI-MedLine.d3.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d3.s4.p3" e1="DDI-MedLine.d3.s4.e1"
            e2="DDI-MedLine.d3.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d3.s4.p4" e1="DDI-MedLine.d3.s4.e1"
            e2="DDI-MedLine.d3.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d3.s4.p5" e1="DDI-MedLine.d3.s4.e2"
            e2="DDI-MedLine.d3.s4.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d3.s5" text="Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. ">
        <entity id="DDI-MedLine.d3.s5.e0" charOffset="51-60" type="drug" text="amprenavir"/>
        <entity id="DDI-MedLine.d3.s5.e1" charOffset="63-71" type="drug" text="rifabutin"/>
        <entity id="DDI-MedLine.d3.s5.e2" charOffset="78-85" type="drug" text="rifampin"/>
        <entity id="DDI-MedLine.d3.s5.e3" charOffset="97-122"
            type="drug_n" text="25-O-desacetyl metabolites"/>
        <pair id="DDI-MedLine.d3.s5.p0" e1="DDI-MedLine.d3.s5.e0"
            e2="DDI-MedLine.d3.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d3.s5.p1" e1="DDI-MedLine.d3.s5.e0"
            e2="DDI-MedLine.d3.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d3.s5.p2" e1="DDI-MedLine.d3.s5.e0"
            e2="DDI-MedLine.d3.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d3.s5.p3" e1="DDI-MedLine.d3.s5.e1"
            e2="DDI-MedLine.d3.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d3.s5.p4" e1="DDI-MedLine.d3.s5.e1"
            e2="DDI-MedLine.d3.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d3.s5.p5" e1="DDI-MedLine.d3.s5.e2"
            e2="DDI-MedLine.d3.s5.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d3.s6" text="Rifabutin did not significantly affect amprenavir's pharmacokinetics. ">
        <entity id="DDI-MedLine.d3.s6.e0" charOffset="0-8" type="drug" text="Rifabutin"/>
        <entity id="DDI-MedLine.d3.s6.e1" charOffset="39-48" type="drug" text="amprenavir"/>
        <pair id="DDI-MedLine.d3.s6.p0" e1="DDI-MedLine.d3.s6.e0"
            e2="DDI-MedLine.d3.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d3.s7" text="Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. ">
        <entity id="DDI-MedLine.d3.s7.e0" charOffset="0-9" type="drug" text="Amprenavir"/>
        <entity id="DDI-MedLine.d3.s7.e1" charOffset="89-97" type="drug" text="rifabutin"/>
        <entity id="DDI-MedLine.d3.s7.e2" charOffset="131-153"
            type="drug_n" text="25-O-desacetylrifabutin"/>
        <pair id="DDI-MedLine.d3.s7.p0" e1="DDI-MedLine.d3.s7.e0"
            e2="DDI-MedLine.d3.s7.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d3.s7.p1" e1="DDI-MedLine.d3.s7.e0"
            e2="DDI-MedLine.d3.s7.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d3.s7.p2" e1="DDI-MedLine.d3.s7.e1"
            e2="DDI-MedLine.d3.s7.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d3.s8" text="Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. ">
        <entity id="DDI-MedLine.d3.s8.e0" charOffset="0-7" type="drug" text="Rifampin"/>
        <entity id="DDI-MedLine.d3.s8.e1" charOffset="48-57" type="drug" text="amprenavir"/>
        <entity id="DDI-MedLine.d3.s8.e2" charOffset="71-80" type="drug" text="amprenavir"/>
        <entity id="DDI-MedLine.d3.s8.e3" charOffset="99-106"
            type="drug" text="rifampin"/>
        <pair id="DDI-MedLine.d3.s8.p0" e1="DDI-MedLine.d3.s8.e0"
            e2="DDI-MedLine.d3.s8.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d3.s8.p1" e1="DDI-MedLine.d3.s8.e0"
            e2="DDI-MedLine.d3.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d3.s8.p2" e1="DDI-MedLine.d3.s8.e0"
            e2="DDI-MedLine.d3.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d3.s8.p3" e1="DDI-MedLine.d3.s8.e1"
            e2="DDI-MedLine.d3.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d3.s8.p4" e1="DDI-MedLine.d3.s8.e1"
            e2="DDI-MedLine.d3.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d3.s8.p5" e1="DDI-MedLine.d3.s8.e2"
            e2="DDI-MedLine.d3.s8.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d3.s9" text="Amprenavir decreased the results of the ERMBT by 83%. ">
        <entity id="DDI-MedLine.d3.s9.e0" charOffset="0-9" type="drug" text="Amprenavir"/>
    </sentence>
    <sentence id="DDI-MedLine.d3.s10" text="The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. ">
        <entity id="DDI-MedLine.d3.s10.e0" charOffset="42-50"
            type="drug" text="rifabutin"/>
        <entity id="DDI-MedLine.d3.s10.e1" charOffset="56-63"
            type="drug" text="rifampin"/>
        <pair id="DDI-MedLine.d3.s10.p0" e1="DDI-MedLine.d3.s10.e0"
            e2="DDI-MedLine.d3.s10.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d3.s11" text="Amprenavir plus rifampin was well tolerated. ">
        <entity id="DDI-MedLine.d3.s11.e0" charOffset="0-9" type="drug" text="Amprenavir"/>
        <entity id="DDI-MedLine.d3.s11.e1" charOffset="16-23"
            type="drug" text="rifampin"/>
        <pair id="DDI-MedLine.d3.s11.p0" e1="DDI-MedLine.d3.s11.e0"
            e2="DDI-MedLine.d3.s11.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d3.s12" text="Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. ">
        <entity id="DDI-MedLine.d3.s12.e0" charOffset="0-9" type="drug" text="Amprenavir"/>
        <entity id="DDI-MedLine.d3.s12.e1" charOffset="16-24"
            type="drug" text="rifabutin"/>
        <pair id="DDI-MedLine.d3.s12.p0" e1="DDI-MedLine.d3.s12.e0"
            e2="DDI-MedLine.d3.s12.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d3.s13" text="Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. ">
        <entity id="DDI-MedLine.d3.s13.e0" charOffset="0-7" type="drug" text="Rifampin"/>
        <entity id="DDI-MedLine.d3.s13.e1" charOffset="55-64"
            type="drug" text="amprenavir"/>
        <pair id="DDI-MedLine.d3.s13.p0" e1="DDI-MedLine.d3.s13.e0"
            e2="DDI-MedLine.d3.s13.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d3.s14" text="Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. ">
        <entity id="DDI-MedLine.d3.s14.e0" charOffset="0-9" type="drug" text="Amprenavir"/>
        <entity id="DDI-MedLine.d3.s14.e1" charOffset="48-56"
            type="drug" text="rifabutin"/>
        <entity id="DDI-MedLine.d3.s14.e2" charOffset="62-84"
            type="drug_n" text="25-O-desacetylrifabutin"/>
        <pair id="DDI-MedLine.d3.s14.p0" e1="DDI-MedLine.d3.s14.e0"
            e2="DDI-MedLine.d3.s14.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d3.s14.p1" e1="DDI-MedLine.d3.s14.e0"
            e2="DDI-MedLine.d3.s14.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d3.s14.p2" e1="DDI-MedLine.d3.s14.e1"
            e2="DDI-MedLine.d3.s14.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d3.s15" text="Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.">
        <entity id="DDI-MedLine.d3.s15.e0" charOffset="0-9" type="drug" text="Amprenavir"/>
        <entity id="DDI-MedLine.d3.s15.e1" charOffset="35-42"
            type="drug" text="rifampin"/>
        <entity id="DDI-MedLine.d3.s15.e2" charOffset="48-56"
            type="drug" text="rifabutin"/>
        <pair id="DDI-MedLine.d3.s15.p0" e1="DDI-MedLine.d3.s15.e0"
            e2="DDI-MedLine.d3.s15.e1" ddi="false"/>
        <pair id="DDI-MedLine.d3.s15.p1" e1="DDI-MedLine.d3.s15.e0"
            e2="DDI-MedLine.d3.s15.e2" ddi="false"/>
        <pair id="DDI-MedLine.d3.s15.p2" e1="DDI-MedLine.d3.s15.e1"
            e2="DDI-MedLine.d3.s15.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d28.s0" text="New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.&#xa;">
        <entity id="DDI-MedLine.d28.s0.e0" charOffset="53-62"
            type="group" text="glitazones"/>
    </sentence>
    <sentence id="DDI-MedLine.d28.s1" text="Type 2 diabetes mellitus is a growing problem not only in the United States but also across the world. "/>
    <sentence id="DDI-MedLine.d28.s2" text="There is now strong evidence that intensive control of blood glucose can significantly reduce and retard the microvascular complications of retinopathy, nephropathy, and neuropathy. "/>
    <sentence id="DDI-MedLine.d28.s3" text="Ultimately however, up to 80% of type 2 diabetics die from macrovascular cardiovascular disease. "/>
    <sentence id="DDI-MedLine.d28.s4" text="This increased incidence of atherosclerotic disease is intricately associated with insulin resistance, which is a major pathophysiologic abnormality in type 2 diabetes. "/>
    <sentence id="DDI-MedLine.d28.s5" text="There is strong evidence that insulin resistance is involved in the development of not only hyperglycemia, but also dyslipidemia, hypertension, hypercoagulation, vasculopathy, and ultimately atherosclerotic cardiovascular disease. "/>
    <sentence id="DDI-MedLine.d28.s6" text="This cluster of metabolic abnormalities has been termed the insulin resistance or cardiovascular dysmetabolic syndrome. "/>
    <sentence id="DDI-MedLine.d28.s7" text="The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are &quot;insulin sensitizers&quot; ">
        <entity id="DDI-MedLine.d28.s7.e0" charOffset="4-21"
            type="group" text="thiazolidinediones"/>
        <entity id="DDI-MedLine.d28.s7.e1" charOffset="24-36"
            type="drug" text="rosiglitazone"/>
        <entity id="DDI-MedLine.d28.s7.e2" charOffset="42-53"
            type="drug" text="pioglitazone"/>
        <entity id="DDI-MedLine.d28.s7.e3" charOffset="77-95"
            type="group" text="antidiabetic agents"/>
        <pair id="DDI-MedLine.d28.s7.p0" e1="DDI-MedLine.d28.s7.e0"
            e2="DDI-MedLine.d28.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d28.s7.p1" e1="DDI-MedLine.d28.s7.e0"
            e2="DDI-MedLine.d28.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d28.s7.p2" e1="DDI-MedLine.d28.s7.e0"
            e2="DDI-MedLine.d28.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d28.s7.p3" e1="DDI-MedLine.d28.s7.e1"
            e2="DDI-MedLine.d28.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d28.s7.p4" e1="DDI-MedLine.d28.s7.e1"
            e2="DDI-MedLine.d28.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d28.s7.p5" e1="DDI-MedLine.d28.s7.e2"
            e2="DDI-MedLine.d28.s7.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d28.s8" text="and exert direct effects on the mechanisms of insulin resistance. "/>
    <sentence id="DDI-MedLine.d28.s9" text="These effects not only improve insulin sensitivity and glycemic control with reduced insulin requirements, but also have potentially favorable effects on other components of the cardiovascular dysmetabolic syndrome. "/>
    <sentence id="DDI-MedLine.d28.s10" text="Long-term studies are needed to determine whether the insulin-sensitizing effects of the glitazones can prevent or delay premature atherosclerotic cardiovascular disease, morbidity, and death.">
        <entity id="DDI-MedLine.d28.s10.e0" charOffset="89-98"
            type="group" text="glitazones"/>
    </sentence>
    <sentence id="DDI-MedLine.d74.s0" text="Responses to arginine of the perfused pancreas of the genetically diabetic Chinese hamster.&#xa;">
        <entity id="DDI-MedLine.d74.s0.e0" charOffset="13-20"
            type="drug" text="arginine"/>
    </sentence>
    <sentence id="DDI-MedLine.d74.s1" text="Nonketotic, genetically diabetic Cinese hamsters show subnormal pancreatic insulin release and impaired suppression of glucagon in response to glucose. "/>
    <sentence id="DDI-MedLine.d74.s2" text="To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). ">
        <entity id="DDI-MedLine.d74.s2.e0" charOffset="216-223"
            type="drug" text="arginine"/>
        <entity id="DDI-MedLine.d74.s2.e1" charOffset="233-239"
            type="drug" text="glucose"/>
        <entity id="DDI-MedLine.d74.s2.e2" charOffset="275-286"
            type="drug" text="theophylline"/>
        <pair id="DDI-MedLine.d74.s2.p0" e1="DDI-MedLine.d74.s2.e0"
            e2="DDI-MedLine.d74.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d74.s2.p1" e1="DDI-MedLine.d74.s2.e0"
            e2="DDI-MedLine.d74.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d74.s2.p2" e1="DDI-MedLine.d74.s2.e1"
            e2="DDI-MedLine.d74.s2.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d74.s3" text="Theophylline alone caused identical insulin and glucagon release in diabetics and normals. ">
        <entity id="DDI-MedLine.d74.s3.e0" charOffset="0-11" type="drug" text="Theophylline"/>
    </sentence>
    <sentence id="DDI-MedLine.d74.s4" text="Glucose, alone and in the presence of theophylline, caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals. ">
        <entity id="DDI-MedLine.d74.s4.e0" charOffset="0-6" type="drug" text="Glucose"/>
        <entity id="DDI-MedLine.d74.s4.e1" charOffset="38-49"
            type="drug" text="theophylline"/>
        <pair id="DDI-MedLine.d74.s4.p0" e1="DDI-MedLine.d74.s4.e0"
            e2="DDI-MedLine.d74.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d74.s5" text="Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics. ">
        <entity id="DDI-MedLine.d74.s5.e0" charOffset="0-7" type="drug" text="Arginine"/>
        <entity id="DDI-MedLine.d74.s5.e1" charOffset="29-35"
            type="drug" text="glucose"/>
        <entity id="DDI-MedLine.d74.s5.e2" charOffset="41-52"
            type="drug" text="theophylline"/>
        <pair id="DDI-MedLine.d74.s5.p0" e1="DDI-MedLine.d74.s5.e0"
            e2="DDI-MedLine.d74.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d74.s5.p1" e1="DDI-MedLine.d74.s5.e0"
            e2="DDI-MedLine.d74.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d74.s5.p2" e1="DDI-MedLine.d74.s5.e1"
            e2="DDI-MedLine.d74.s5.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d74.s6" text="Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. ">
        <entity id="DDI-MedLine.d74.s6.e0" charOffset="0-7" type="drug" text="Arginine"/>
        <entity id="DDI-MedLine.d74.s6.e1" charOffset="28-34"
            type="drug" text="glucose"/>
        <entity id="DDI-MedLine.d74.s6.e2" charOffset="39-50"
            type="drug" text="theophylline"/>
        <pair id="DDI-MedLine.d74.s6.p0" e1="DDI-MedLine.d74.s6.e0"
            e2="DDI-MedLine.d74.s6.e1" ddi="false"/>
        <pair id="DDI-MedLine.d74.s6.p1" e1="DDI-MedLine.d74.s6.e0"
            e2="DDI-MedLine.d74.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d74.s6.p2" e1="DDI-MedLine.d74.s6.e1"
            e2="DDI-MedLine.d74.s6.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d74.s7" text="Pancreatic content after perfusion did not correlate with release during perfusion. "/>
    <sentence id="DDI-MedLine.d74.s8" text="Infusion of arginine alone markedly decreased the amount of extractable pancreatic insulin and glucagon. ">
        <entity id="DDI-MedLine.d74.s8.e0" charOffset="12-19"
            type="drug" text="arginine"/>
    </sentence>
    <sentence id="DDI-MedLine.d74.s9" text="These results indicate that the pancreatic alpha cell of the diabetic Chinese hamster responds excessively to arginine, as is seen in the human diabetic. ">
        <entity id="DDI-MedLine.d74.s9.e0" charOffset="110-117"
            type="drug" text="arginine"/>
    </sentence>
    <sentence id="DDI-MedLine.d74.s10" text="This defect is not related to acute insulin release or the presence of glucose. ">
        <entity id="DDI-MedLine.d74.s10.e0" charOffset="71-77"
            type="drug" text="glucose"/>
    </sentence>
    <sentence id="DDI-MedLine.d74.s11" text="Further, these results confirm that the diabetic Chinese hamster's alpha and beta cells respond normally to theophylline, but are relatively insensitive to glucose.">
        <entity id="DDI-MedLine.d74.s11.e0" charOffset="108-119"
            type="drug" text="theophylline"/>
        <entity id="DDI-MedLine.d74.s11.e1" charOffset="156-162"
            type="drug" text="glucose"/>
        <pair id="DDI-MedLine.d74.s11.p0" e1="DDI-MedLine.d74.s11.e0"
            e2="DDI-MedLine.d74.s11.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d44.s0" text="Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease.&#xd;&#xa;">
        <entity id="DDI-MedLine.d44.s0.e0" charOffset="11-20"
            type="drug" text="etofibrate"/>
    </sentence>
    <sentence id="DDI-MedLine.d44.s1" text="Slow chylomicron intravascular catabolism has been associated with coronary artery disease and screening for drugs that can speed-up this process can be important. "/>
    <sentence id="DDI-MedLine.d44.s2" text="In this study, the effects of etofibrate upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day etofibrate or placebo for 1-month. ">
        <entity id="DDI-MedLine.d44.s2.e0" charOffset="30-39"
            type="drug" text="etofibrate"/>
        <entity id="DDI-MedLine.d44.s2.e1" charOffset="401-410"
            type="drug" text="etofibrate"/>
        <pair id="DDI-MedLine.d44.s2.p0" e1="DDI-MedLine.d44.s2.e0"
            e2="DDI-MedLine.d44.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d44.s3" text="A 1-month washout period was inserted between the treatment periods. "/>
    <sentence id="DDI-MedLine.d44.s4" text="Patients were intravenously injected a chylomicron-like emulsion doubly labeled with 14C-cholesteryl oleate and 3H-triolein at baseline and after treatments. "/>
    <sentence id="DDI-MedLine.d44.s5" text="After etofibrate treatment, there was decrease of total cholesterol and triglyceride plasma levels and a trend to increase high-density lipoprotein cholesterol plasma levels. ">
        <entity id="DDI-MedLine.d44.s5.e0" charOffset="6-15" type="drug" text="etofibrate"/>
    </sentence>
    <sentence id="DDI-MedLine.d44.s6" text="Etofibrate elicited 62% enhancement of post-heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment. ">
        <entity id="DDI-MedLine.d44.s6.e0" charOffset="0-9" type="drug" text="Etofibrate"/>
        <entity id="DDI-MedLine.d44.s6.e1" charOffset="44-50"
            type="drug" text="heparin"/>
        <pair id="DDI-MedLine.d44.s6.p0" e1="DDI-MedLine.d44.s6.e0"
            e2="DDI-MedLine.d44.s6.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d44.s7" text="14C-cholesterol ester fractional clearance rate was 260% greater after etofibrate than after placebo. ">
        <entity id="DDI-MedLine.d44.s7.e0" charOffset="71-80"
            type="drug" text="etofibrate"/>
    </sentence>
    <sentence id="DDI-MedLine.d44.s8" text="Therefore, a potent effect of etofibrate on both chylomicron lipolysis and remnant removal was achieved, indicating that this drug can be used to improve this metabolism in future prospective studies.">
        <entity id="DDI-MedLine.d44.s8.e0" charOffset="30-39"
            type="drug" text="etofibrate"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s0" text="The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.&#xd;&#xa;">
        <entity id="DDI-MedLine.d125.s0.e0" charOffset="42-48"
            type="drug_n" text="gliftor"/>
        <entity id="DDI-MedLine.d125.s0.e1" charOffset="69-87"
            type="drug_n" text="1,3-difluoroacetone"/>
        <entity id="DDI-MedLine.d125.s0.e2" charOffset="92-116"
            type="drug_n" text="(-)-erythro-fluorocitrate"/>
        <pair id="DDI-MedLine.d125.s0.p0" e1="DDI-MedLine.d125.s0.e0"
            e2="DDI-MedLine.d125.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d125.s0.p1" e1="DDI-MedLine.d125.s0.e0"
            e2="DDI-MedLine.d125.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s0.p2" e1="DDI-MedLine.d125.s0.e1"
            e2="DDI-MedLine.d125.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s1" text="The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide Gliftor (1,3-difluoro-2-propanol), was investigated in vivo and in vitro. ">
        <entity id="DDI-MedLine.d125.s1.e0" charOffset="30-48"
            type="drug_n" text="1,3-difluoroacetone"/>
        <entity id="DDI-MedLine.d125.s1.e1" charOffset="111-117"
            type="drug_n" text="Gliftor"/>
        <entity id="DDI-MedLine.d125.s1.e2" charOffset="120-142"
            type="drug_n" text="1,3-difluoro-2-propanol"/>
        <pair id="DDI-MedLine.d125.s1.p0" e1="DDI-MedLine.d125.s1.e0"
            e2="DDI-MedLine.d125.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d125.s1.p1" e1="DDI-MedLine.d125.s1.e0"
            e2="DDI-MedLine.d125.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s1.p2" e1="DDI-MedLine.d125.s1.e1"
            e2="DDI-MedLine.d125.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s2" text="Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted 1,3-difluoroacetone to (-)-erythro-fluorocitrate in vitro. ">
        <entity id="DDI-MedLine.d125.s2.e0" charOffset="91-109"
            type="drug_n" text="1,3-difluoroacetone"/>
        <entity id="DDI-MedLine.d125.s2.e1" charOffset="114-138"
            type="drug_n" text="(-)-erythro-fluorocitrate"/>
        <pair id="DDI-MedLine.d125.s2.p0" e1="DDI-MedLine.d125.s2.e0"
            e2="DDI-MedLine.d125.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s3" text="Administration of 1,3-difluoroacetone (100 mg kg(-1) body weight) to rats in vivo resulted in (-)-erythro-fluorocitrate synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation. ">
        <entity id="DDI-MedLine.d125.s3.e0" charOffset="18-36"
            type="drug_n" text="1,3-difluoroacetone"/>
        <entity id="DDI-MedLine.d125.s3.e1" charOffset="94-118"
            type="drug_n" text="(-)-erythro-fluorocitrate"/>
        <pair id="DDI-MedLine.d125.s3.p0" e1="DDI-MedLine.d125.s3.e0"
            e2="DDI-MedLine.d125.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s4" text="Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol. ">
        <entity id="DDI-MedLine.d125.s4.e0" charOffset="19-37"
            type="drug_n" text="1,3-difluoroacetone"/>
        <entity id="DDI-MedLine.d125.s4.e1" charOffset="88-112"
            type="drug_n" text="(-)-erythro-fluorocitrate"/>
        <entity id="DDI-MedLine.d125.s4.e2" charOffset="201-223"
            type="drug_n" text="1,3-difluoro-2-propanol"/>
        <pair id="DDI-MedLine.d125.s4.p0" e1="DDI-MedLine.d125.s4.e0"
            e2="DDI-MedLine.d125.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d125.s4.p1" e1="DDI-MedLine.d125.s4.e0"
            e2="DDI-MedLine.d125.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s4.p2" e1="DDI-MedLine.d125.s4.e1"
            e2="DDI-MedLine.d125.s4.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s5" text="We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. ">
        <entity id="DDI-MedLine.d125.s5.e0" charOffset="38-60"
            type="drug_n" text="1,3-difluoro-2-propanol"/>
        <entity id="DDI-MedLine.d125.s5.e1" charOffset="65-83"
            type="drug_n" text="1,3-difluoroacetone"/>
        <entity id="DDI-MedLine.d125.s5.e2" charOffset="181-205"
            type="drug_n" text="(-)-erythro-fluorocitrate"/>
        <entity id="DDI-MedLine.d125.s5.e3" charOffset="212-234"
            type="drug_n" text="1,3-difluoro-2-propanol"/>
        <pair id="DDI-MedLine.d125.s5.p0" e1="DDI-MedLine.d125.s5.e0"
            e2="DDI-MedLine.d125.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d125.s5.p1" e1="DDI-MedLine.d125.s5.e0"
            e2="DDI-MedLine.d125.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s5.p2" e1="DDI-MedLine.d125.s5.e0"
            e2="DDI-MedLine.d125.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d125.s5.p3" e1="DDI-MedLine.d125.s5.e1"
            e2="DDI-MedLine.d125.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s5.p4" e1="DDI-MedLine.d125.s5.e1"
            e2="DDI-MedLine.d125.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d125.s5.p5" e1="DDI-MedLine.d125.s5.e2"
            e2="DDI-MedLine.d125.s5.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s6" text="Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. ">
        <entity id="DDI-MedLine.d125.s6.e0" charOffset="24-39"
            type="drug" text="4-methylpyrazole"/>
        <entity id="DDI-MedLine.d125.s6.e1" charOffset="107-129"
            type="drug_n" text="1,3-difluoro-2-propanol"/>
        <entity id="DDI-MedLine.d125.s6.e2" charOffset="162-186"
            type="drug_n" text="(-)-erythro-fluorocitrate"/>
        <entity id="DDI-MedLine.d125.s6.e3" charOffset="257-279"
            type="drug_n" text="1,3-difluoro-2-propanol"/>
        <pair id="DDI-MedLine.d125.s6.p0" e1="DDI-MedLine.d125.s6.e0"
            e2="DDI-MedLine.d125.s6.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d125.s6.p1" e1="DDI-MedLine.d125.s6.e0"
            e2="DDI-MedLine.d125.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s6.p2" e1="DDI-MedLine.d125.s6.e0"
            e2="DDI-MedLine.d125.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d125.s6.p3" e1="DDI-MedLine.d125.s6.e1"
            e2="DDI-MedLine.d125.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s6.p4" e1="DDI-MedLine.d125.s6.e1"
            e2="DDI-MedLine.d125.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d125.s6.p5" e1="DDI-MedLine.d125.s6.e2"
            e2="DDI-MedLine.d125.s6.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s7" text="However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. ">
        <entity id="DDI-MedLine.d125.s7.e0" charOffset="27-42"
            type="drug" text="4-methylpyrazole"/>
        <entity id="DDI-MedLine.d125.s7.e1" charOffset="96-114"
            type="drug_n" text="1,3-difluoroacetone"/>
        <entity id="DDI-MedLine.d125.s7.e2" charOffset="174-198"
            type="drug_n" text="(-)-erythro-fluorocitrate"/>
        <pair id="DDI-MedLine.d125.s7.p0" e1="DDI-MedLine.d125.s7.e0"
            e2="DDI-MedLine.d125.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d125.s7.p1" e1="DDI-MedLine.d125.s7.e0"
            e2="DDI-MedLine.d125.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s7.p2" e1="DDI-MedLine.d125.s7.e1"
            e2="DDI-MedLine.d125.s7.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s8" text="We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.">
        <entity id="DDI-MedLine.d125.s8.e0" charOffset="62-77"
            type="drug" text="4-methylpyrazole"/>
        <entity id="DDI-MedLine.d125.s8.e1" charOffset="108-130"
            type="drug_n" text="1,3-difluoro-2-propanol"/>
        <entity id="DDI-MedLine.d125.s8.e2" charOffset="224-246"
            type="drug_n" text="1,3-difluoro-2-propanol"/>
        <entity id="DDI-MedLine.d125.s8.e3" charOffset="251-269"
            type="drug_n" text="1,3-difluoroacetone"/>
        <pair id="DDI-MedLine.d125.s8.p0" e1="DDI-MedLine.d125.s8.e0"
            e2="DDI-MedLine.d125.s8.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d125.s8.p1" e1="DDI-MedLine.d125.s8.e0"
            e2="DDI-MedLine.d125.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s8.p2" e1="DDI-MedLine.d125.s8.e0"
            e2="DDI-MedLine.d125.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d125.s8.p3" e1="DDI-MedLine.d125.s8.e1"
            e2="DDI-MedLine.d125.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s8.p4" e1="DDI-MedLine.d125.s8.e1"
            e2="DDI-MedLine.d125.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d125.s8.p5" e1="DDI-MedLine.d125.s8.e2"
            e2="DDI-MedLine.d125.s8.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d101.s0" text="Pharmacology and pharmacotherapy of cardiovascular drugs in patients with chronic renal disease.&#xa;"/>
    <sentence id="DDI-MedLine.d101.s1" text="Cardiovascular disease is a common comorbidity and a major cause of mortality in patients with chronic renal disease. "/>
    <sentence id="DDI-MedLine.d101.s2" text="Drug regimens in patients with cardiovascular disease are frequently complex and can be significantly affected by alterations in renal function. "/>
    <sentence id="DDI-MedLine.d101.s3" text="In addition, several cardiovascular drugs directly affect renal function and the management of patients with renal disease. "/>
    <sentence id="DDI-MedLine.d101.s4" text="This article reviews the impact of renal disease on the pharmacokinetics of cardiovascular drugs and identifies clinically important interactions between these and other drugs commonly used in the management of chronic renal disease. "/>
    <sentence id="DDI-MedLine.d101.s5" text="Several classes of cardiovascular drugs are also discussed in relationship to their differential effects on the management and progression of renal disease."/>
    <sentence id="DDI-MedLine.d129.s0" text="Green tea polyphenols as potent enhancers of glucocorticoid-induced mouse mammary tumor virus gene expression.&#xa;">
        <entity id="DDI-MedLine.d129.s0.e0" charOffset="0-20"
            type="drug" text="Green tea polyphenols"/>
        <entity id="DDI-MedLine.d129.s0.e1" charOffset="32-40"
            type="drug" text="enhancers"/>
        <pair id="DDI-MedLine.d129.s0.p0" e1="DDI-MedLine.d129.s0.e0"
            e2="DDI-MedLine.d129.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d129.s1" text="The effect of natural and synthetic galloyl esters on glucocorticoid-induced gene expression was evaluated by using rat fibroblast 3Y1 cells stably transfected with a luciferase reporter gene under the transcriptional regulation of the mouse mammary tumor virus promoter. ">
        <entity id="DDI-MedLine.d129.s1.e0" charOffset="262-269"
            type="drug" text="promoter"/>
    </sentence>
    <sentence id="DDI-MedLine.d129.s2" text="The glucocorticoid-induced gene transcription was strongly suppressed by synthetic alkyl esters; "/>
    <sentence id="DDI-MedLine.d129.s3" text="n-dodecyl gallate showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude tannic acid. ">
        <entity id="DDI-MedLine.d129.s3.e0" charOffset="0-16"
            type="drug" text="n-dodecyl gallate"/>
        <entity id="DDI-MedLine.d129.s3.e1" charOffset="128-138"
            type="drug" text="tannic acid"/>
        <pair id="DDI-MedLine.d129.s3.p0" e1="DDI-MedLine.d129.s3.e0"
            e2="DDI-MedLine.d129.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d129.s4" text="n-Octyl and n-cetyl gallate also showed good inhibition, while gallic acid itself was not so active, suggesting that the presence of hydrophobic side chain is important for the suppressive effect. "/>
    <sentence id="DDI-MedLine.d129.s5" text="On the other hand, surprisingly, green tea gallocatechins, (-)-epigallocatechin-3-O-gallate and theasinensin A, potently enhanced the promoter activity (182 and 247% activity at 1 microM, respectively). ">
        <entity id="DDI-MedLine.d129.s5.e0" charOffset="33-56"
            type="drug" text="green tea gallocatechins"/>
    </sentence>
    <sentence id="DDI-MedLine.d129.s6" text="The regulation of the level of the glucocorticoid-induced gene expression by the antioxidative gallates is of great interest from a therapeutic point of view."/>
    <sentence id="DDI-MedLine.d86.s0" text="Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.&#xd;&#xa;">
        <entity id="DDI-MedLine.d86.s0.e0" charOffset="57-65"
            type="drug" text="diltiazem"/>
        <entity id="DDI-MedLine.d86.s0.e1" charOffset="71-79"
            type="drug" text="sirolimus"/>
        <pair id="DDI-MedLine.d86.s0.p0" e1="DDI-MedLine.d86.s0.e0"
            e2="DDI-MedLine.d86.s0.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d86.s1" text="AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. ">
        <entity id="DDI-MedLine.d86.s1.e0" charOffset="60-68"
            type="drug" text="sirolimus"/>
        <entity id="DDI-MedLine.d86.s1.e1" charOffset="73-99"
            type="group" text="macrolide immunosuppressant"/>
        <entity id="DDI-MedLine.d86.s1.e2" charOffset="132-154"
            type="group" text="calcium channel blocker"/>
        <entity id="DDI-MedLine.d86.s1.e3" charOffset="156-164"
            type="drug" text="diltiazem"/>
        <pair id="DDI-MedLine.d86.s1.p0" e1="DDI-MedLine.d86.s1.e0"
            e2="DDI-MedLine.d86.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d86.s1.p1" e1="DDI-MedLine.d86.s1.e0"
            e2="DDI-MedLine.d86.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d86.s1.p2" e1="DDI-MedLine.d86.s1.e0"
            e2="DDI-MedLine.d86.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d86.s1.p3" e1="DDI-MedLine.d86.s1.e1"
            e2="DDI-MedLine.d86.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d86.s1.p4" e1="DDI-MedLine.d86.s1.e1"
            e2="DDI-MedLine.d86.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d86.s1.p5" e1="DDI-MedLine.d86.s1.e2"
            e2="DDI-MedLine.d86.s1.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d86.s2" text="Several clinically important interactions have previously been reported for other immunosuppressive drugs that are metabolized by the same enzyme and for calcium antagonists. ">
        <entity id="DDI-MedLine.d86.s2.e0" charOffset="82-104"
            type="group" text="immunosuppressive drugs"/>
        <entity id="DDI-MedLine.d86.s2.e1" charOffset="154-172"
            type="group" text="calcium antagonists"/>
        <pair id="DDI-MedLine.d86.s2.p0" e1="DDI-MedLine.d86.s2.e0"
            e2="DDI-MedLine.d86.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d86.s3" text="METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of sirolimus, a single oral 120-mg dose of diltiazem, and the two drugs given together. ">
        <entity id="DDI-MedLine.d86.s3.e0" charOffset="176-184"
            type="drug" text="sirolimus"/>
        <entity id="DDI-MedLine.d86.s3.e1" charOffset="216-224"
            type="drug" text="diltiazem"/>
        <pair id="DDI-MedLine.d86.s3.p0" e1="DDI-MedLine.d86.s3.e0"
            e2="DDI-MedLine.d86.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d86.s4" text="The three study periods were separated by a 21-day washout phase. "/>
    <sentence id="DDI-MedLine.d86.s5" text="RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. ">
        <entity id="DDI-MedLine.d86.s5.e0" charOffset="66-74"
            type="drug" text="sirolimus"/>
        <entity id="DDI-MedLine.d86.s5.e1" charOffset="253-261"
            type="drug" text="diltiazem"/>
        <entity id="DDI-MedLine.d86.s5.e2" charOffset="323-331"
            type="drug" text="sirolimus"/>
        <pair id="DDI-MedLine.d86.s5.p0" e1="DDI-MedLine.d86.s5.e0"
            e2="DDI-MedLine.d86.s5.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d86.s5.p1" e1="DDI-MedLine.d86.s5.e0"
            e2="DDI-MedLine.d86.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d86.s5.p2" e1="DDI-MedLine.d86.s5.e1"
            e2="DDI-MedLine.d86.s5.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d86.s6" text="Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. ">
        <entity id="DDI-MedLine.d86.s6.e0" charOffset="54-62"
            type="drug" text="sirolimus"/>
        <entity id="DDI-MedLine.d86.s6.e1" charOffset="111-119"
            type="drug" text="sirolimus"/>
        <entity id="DDI-MedLine.d86.s6.e2" charOffset="136-144"
            type="drug" text="diltiazem"/>
        <pair id="DDI-MedLine.d86.s6.p0" e1="DDI-MedLine.d86.s6.e0"
            e2="DDI-MedLine.d86.s6.e1" ddi="false"/>
        <pair id="DDI-MedLine.d86.s6.p1" e1="DDI-MedLine.d86.s6.e0"
            e2="DDI-MedLine.d86.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d86.s6.p2" e1="DDI-MedLine.d86.s6.e1"
            e2="DDI-MedLine.d86.s6.e2" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d86.s7" text="The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. ">
        <entity id="DDI-MedLine.d86.s7.e0" charOffset="87-95"
            type="drug" text="diltiazem"/>
        <entity id="DDI-MedLine.d86.s7.e1" charOffset="98-115"
            type="drug_n" text="desacetyldiltiazem"/>
        <entity id="DDI-MedLine.d86.s7.e2" charOffset="122-139"
            type="drug_n" text="desmethyldiltiazem"/>
        <entity id="DDI-MedLine.d86.s7.e3" charOffset="182-190"
            type="drug" text="sirolimus"/>
        <entity id="DDI-MedLine.d86.s7.e4" charOffset="231-239"
            type="drug" text="diltiazem"/>
        <pair id="DDI-MedLine.d86.s7.p0" e1="DDI-MedLine.d86.s7.e0"
            e2="DDI-MedLine.d86.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d86.s7.p1" e1="DDI-MedLine.d86.s7.e0"
            e2="DDI-MedLine.d86.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d86.s7.p2" e1="DDI-MedLine.d86.s7.e0"
            e2="DDI-MedLine.d86.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d86.s7.p3" e1="DDI-MedLine.d86.s7.e0"
            e2="DDI-MedLine.d86.s7.e4" ddi="false"/>
        <pair id="DDI-MedLine.d86.s7.p4" e1="DDI-MedLine.d86.s7.e1"
            e2="DDI-MedLine.d86.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d86.s7.p5" e1="DDI-MedLine.d86.s7.e1"
            e2="DDI-MedLine.d86.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d86.s7.p6" e1="DDI-MedLine.d86.s7.e1"
            e2="DDI-MedLine.d86.s7.e4" ddi="false"/>
        <pair id="DDI-MedLine.d86.s7.p7" e1="DDI-MedLine.d86.s7.e2"
            e2="DDI-MedLine.d86.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d86.s7.p8" e1="DDI-MedLine.d86.s7.e2"
            e2="DDI-MedLine.d86.s7.e4" ddi="false"/>
        <pair id="DDI-MedLine.d86.s7.p9" e1="DDI-MedLine.d86.s7.e3"
            e2="DDI-MedLine.d86.s7.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d86.s8" text="CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. ">
        <entity id="DDI-MedLine.d86.s8.e0" charOffset="25-33"
            type="drug" text="diltiazem"/>
        <entity id="DDI-MedLine.d86.s8.e1" charOffset="68-76"
            type="drug" text="sirolimus"/>
        <entity id="DDI-MedLine.d86.s8.e2" charOffset="145-153"
            type="drug" text="sirolimus"/>
        <pair id="DDI-MedLine.d86.s8.p0" e1="DDI-MedLine.d86.s8.e0"
            e2="DDI-MedLine.d86.s8.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d86.s8.p1" e1="DDI-MedLine.d86.s8.e0"
            e2="DDI-MedLine.d86.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d86.s8.p2" e1="DDI-MedLine.d86.s8.e1"
            e2="DDI-MedLine.d86.s8.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d86.s9" text="Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.">
        <entity id="DDI-MedLine.d86.s9.e0" charOffset="72-80"
            type="drug" text="sirolimus"/>
        <entity id="DDI-MedLine.d86.s9.e1" charOffset="82-90"
            type="drug" text="diltiazem"/>
        <entity id="DDI-MedLine.d86.s9.e2" charOffset="117-125"
            type="drug" text="sirolimus"/>
        <pair id="DDI-MedLine.d86.s9.p0" e1="DDI-MedLine.d86.s9.e0"
            e2="DDI-MedLine.d86.s9.e1" ddi="true" type="advise"/>
        <pair id="DDI-MedLine.d86.s9.p1" e1="DDI-MedLine.d86.s9.e0"
            e2="DDI-MedLine.d86.s9.e2" ddi="false"/>
        <pair id="DDI-MedLine.d86.s9.p2" e1="DDI-MedLine.d86.s9.e1"
            e2="DDI-MedLine.d86.s9.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d99.s0" text="Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.&#xa;">
        <entity id="DDI-MedLine.d99.s0.e0" charOffset="0-10" type="drug" text="Fluvoxamine"/>
        <entity id="DDI-MedLine.d99.s0.e1" charOffset="63-73"
            type="drug" text="tolbutamide"/>
        <pair id="DDI-MedLine.d99.s0.p0" e1="DDI-MedLine.d99.s0.e0"
            e2="DDI-MedLine.d99.s0.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d99.s1" text="OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. ">
        <entity id="DDI-MedLine.d99.s1.e0" charOffset="64-74"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-MedLine.d99.s1.e1" charOffset="80-90"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-MedLine.d99.s1.e2" charOffset="108-118"
            type="drug" text="fluvoxamine"/>
        <pair id="DDI-MedLine.d99.s1.p0" e1="DDI-MedLine.d99.s1.e0"
            e2="DDI-MedLine.d99.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d99.s1.p1" e1="DDI-MedLine.d99.s1.e0"
            e2="DDI-MedLine.d99.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d99.s1.p2" e1="DDI-MedLine.d99.s1.e1"
            e2="DDI-MedLine.d99.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d99.s2" text="METHODS: The study was carried out as an open, randomized, crossover design with 14 healthy participants. "/>
    <sentence id="DDI-MedLine.d99.s3" text="In period A, all volunteers took 500 mg of tolbutamide orally. ">
        <entity id="DDI-MedLine.d99.s3.e0" charOffset="43-53"
            type="drug" text="tolbutamide"/>
    </sentence>
    <sentence id="DDI-MedLine.d99.s4" text="In period B, the volunteers were randomly assigned to one of two groups. "/>
    <sentence id="DDI-MedLine.d99.s5" text="Each group took either 150 mg or 75 mg of fluvoxamine a day for 5 days (day -3 to day 2). ">
        <entity id="DDI-MedLine.d99.s5.e0" charOffset="42-52"
            type="drug" text="fluvoxamine"/>
    </sentence>
    <sentence id="DDI-MedLine.d99.s6" text="The groups then took 500 mg of tolbutamide as a single dose (day 0). ">
        <entity id="DDI-MedLine.d99.s6.e0" charOffset="31-41"
            type="drug" text="tolbutamide"/>
    </sentence>
    <sentence id="DDI-MedLine.d99.s7" text="In both periods, blood and urine were sampled at regular intervals. "/>
    <sentence id="DDI-MedLine.d99.s8" text="Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. ">
        <entity id="DDI-MedLine.d99.s8.e0" charOffset="24-34"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-MedLine.d99.s8.e1" charOffset="64-74"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-MedLine.d99.s8.e2" charOffset="101-120"
            type="drug_n" text="4-hydroxytolbutamide"/>
        <entity id="DDI-MedLine.d99.s8.e3" charOffset="126-143"
            type="drug_n" text="carboxytolbutamide"/>
        <pair id="DDI-MedLine.d99.s8.p0" e1="DDI-MedLine.d99.s8.e0"
            e2="DDI-MedLine.d99.s8.e1" ddi="false"/>
        <pair id="DDI-MedLine.d99.s8.p1" e1="DDI-MedLine.d99.s8.e0"
            e2="DDI-MedLine.d99.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d99.s8.p2" e1="DDI-MedLine.d99.s8.e0"
            e2="DDI-MedLine.d99.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d99.s8.p3" e1="DDI-MedLine.d99.s8.e1"
            e2="DDI-MedLine.d99.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d99.s8.p4" e1="DDI-MedLine.d99.s8.e1"
            e2="DDI-MedLine.d99.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d99.s8.p5" e1="DDI-MedLine.d99.s8.e2"
            e2="DDI-MedLine.d99.s8.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d99.s9" text="RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. ">
        <entity id="DDI-MedLine.d99.s9.e0" charOffset="31-41"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-MedLine.d99.s9.e1" charOffset="131-141"
            type="drug" text="tolbutamide"/>
        <pair id="DDI-MedLine.d99.s9.p0" e1="DDI-MedLine.d99.s9.e0"
            e2="DDI-MedLine.d99.s9.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d99.s10" text="There was a reduction that reached borderline statistical significance in the group that received 150 mg/d of tolbutamide. ">
        <entity id="DDI-MedLine.d99.s10.e0" charOffset="110-120"
            type="drug" text="tolbutamide"/>
    </sentence>
    <sentence id="DDI-MedLine.d99.s11" text="The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). ">
        <entity id="DDI-MedLine.d99.s11.e0" charOffset="26-45"
            type="drug_n" text="4-hydroxytolbutamide"/>
        <entity id="DDI-MedLine.d99.s11.e1" charOffset="51-68"
            type="drug_n" text="carboxytolbutamide"/>
        <entity id="DDI-MedLine.d99.s11.e2" charOffset="179-189"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-MedLine.d99.s11.e3" charOffset="265-275"
            type="drug" text="tolbutamide"/>
        <pair id="DDI-MedLine.d99.s11.p0" e1="DDI-MedLine.d99.s11.e0"
            e2="DDI-MedLine.d99.s11.e1" ddi="false"/>
        <pair id="DDI-MedLine.d99.s11.p1" e1="DDI-MedLine.d99.s11.e0"
            e2="DDI-MedLine.d99.s11.e2" ddi="false"/>
        <pair id="DDI-MedLine.d99.s11.p2" e1="DDI-MedLine.d99.s11.e0"
            e2="DDI-MedLine.d99.s11.e3" ddi="false"/>
        <pair id="DDI-MedLine.d99.s11.p3" e1="DDI-MedLine.d99.s11.e1"
            e2="DDI-MedLine.d99.s11.e2" ddi="false"/>
        <pair id="DDI-MedLine.d99.s11.p4" e1="DDI-MedLine.d99.s11.e1"
            e2="DDI-MedLine.d99.s11.e3" ddi="false"/>
        <pair id="DDI-MedLine.d99.s11.p5" e1="DDI-MedLine.d99.s11.e2"
            e2="DDI-MedLine.d99.s11.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d99.s12" text="Thus there was a tendency toward a more pronounced inhibition of the 4-hydroxylation during treatment with 150 mg/d of fluvoxamine compared with 75 mg/d, but the difference was not statistically significant. ">
        <entity id="DDI-MedLine.d99.s12.e0" charOffset="119-129"
            type="drug" text="fluvoxamine"/>
    </sentence>
    <sentence id="DDI-MedLine.d99.s13" text="CONCLUSION: Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo.">
        <entity id="DDI-MedLine.d99.s13.e0" charOffset="12-22"
            type="drug" text="Fluvoxamine"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s0" text="Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.&#xd;&#xa;">
        <entity id="DDI-MedLine.d140.s0.e0" charOffset="27-36"
            type="drug" text="everolimus"/>
        <entity id="DDI-MedLine.d140.s0.e1" charOffset="182-193"
            type="drug" text="cyclosporine"/>
        <pair id="DDI-MedLine.d140.s0.p0" e1="DDI-MedLine.d140.s0.e0"
            e2="DDI-MedLine.d140.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s1" text="OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. ">
        <entity id="DDI-MedLine.d140.s1.e0" charOffset="82-91"
            type="drug" text="everolimus"/>
        <entity id="DDI-MedLine.d140.s1.e1" charOffset="97-108"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-MedLine.d140.s1.e2" charOffset="116-126"
            type="drug" text="ciclosporin"/>
        <pair id="DDI-MedLine.d140.s1.p0" e1="DDI-MedLine.d140.s1.e0"
            e2="DDI-MedLine.d140.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d140.s1.p1" e1="DDI-MedLine.d140.s1.e0"
            e2="DDI-MedLine.d140.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d140.s1.p2" e1="DDI-MedLine.d140.s1.e1"
            e2="DDI-MedLine.d140.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s2" text="METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. ">
        <entity id="DDI-MedLine.d140.s2.e0" charOffset="127-136"
            type="drug" text="everolimus"/>
        <entity id="DDI-MedLine.d140.s2.e1" charOffset="197-208"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-MedLine.d140.s2.e2" charOffset="214-223"
            type="drug" text="prednisone"/>
        <pair id="DDI-MedLine.d140.s2.p0" e1="DDI-MedLine.d140.s2.e0"
            e2="DDI-MedLine.d140.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d140.s2.p1" e1="DDI-MedLine.d140.s2.e0"
            e2="DDI-MedLine.d140.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d140.s2.p2" e1="DDI-MedLine.d140.s2.e1"
            e2="DDI-MedLine.d140.s2.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s3" text="Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12. ">
        <entity id="DDI-MedLine.d140.s3.e0" charOffset="43-52"
            type="drug" text="everolimus"/>
        <entity id="DDI-MedLine.d140.s3.e1" charOffset="58-69"
            type="drug" text="cyclosporine"/>
        <pair id="DDI-MedLine.d140.s3.p0" e1="DDI-MedLine.d140.s3.e0"
            e2="DDI-MedLine.d140.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s4" text="Everolimus dose-proportionality and stability over time were assessed in the context of linear regression and ANOVA models. ">
        <entity id="DDI-MedLine.d140.s4.e0" charOffset="0-9" type="drug" text="Everolimus"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s5" text="Everolimus exposure-response relationships between area under the blood concentration-time curve (AUC) and changes in platelets, leukocytes, and lipids were explored with the median-effect model. ">
        <entity id="DDI-MedLine.d140.s5.e0" charOffset="0-9" type="drug" text="Everolimus"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s6" text="Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA. ">
        <entity id="DDI-MedLine.d140.s6.e0" charOffset="25-36"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-MedLine.d140.s6.e1" charOffset="89-98"
            type="drug" text="everolimus"/>
        <pair id="DDI-MedLine.d140.s6.p0" e1="DDI-MedLine.d140.s6.e0"
            e2="DDI-MedLine.d140.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s7" text="RESULTS: Everolimus steady state was reached on or before day 7, with a median 3-fold accumulation of drug exposure compared with that after the first postoperative dose. ">
        <entity id="DDI-MedLine.d140.s7.e0" charOffset="9-18"
            type="drug" text="Everolimus"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s8" text="Both steady-state maximum concentration and AUC were dose proportional over the full dose range when assessed on day 1, as well as for the full duration of the study at steady state. "/>
    <sentence id="DDI-MedLine.d140.s9" text="There was evidence for longitudinal stability in AUC of everolimus during the course of the study. ">
        <entity id="DDI-MedLine.d140.s9.e0" charOffset="56-65"
            type="drug" text="everolimus"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s10" text="The interindividual pharmacokinetic variability for AUC was 85.4% and intraindividual, interoccasion variability was 40.8%. "/>
    <sentence id="DDI-MedLine.d140.s11" text="Age (range, 17-69 years), weight (range, 49-106 kg), and sex (65 men and 36 women) were not significant contributors to variability. "/>
    <sentence id="DDI-MedLine.d140.s12" text="There was an increasing incidence of transient thrombocytopenia (or =100 x 10(9)/L) with increasing everolimus AUC (P = .03). ">
        <entity id="DDI-MedLine.d140.s12.e0" charOffset="100-109"
            type="drug" text="everolimus"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s13" text="Cyclosporine doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level (P = .13, .82, and .76, respectively). ">
        <entity id="DDI-MedLine.d140.s13.e0" charOffset="0-11"
            type="drug" text="Cyclosporine"/>
        <entity id="DDI-MedLine.d140.s13.e1" charOffset="152-161"
            type="drug" text="everolimus"/>
        <pair id="DDI-MedLine.d140.s13.p0" e1="DDI-MedLine.d140.s13.e0"
            e2="DDI-MedLine.d140.s13.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s14" text="CONCLUSIONS: Everolimus exhibited dose-proportional, stable exposure during the first post-transplant year. ">
        <entity id="DDI-MedLine.d140.s14.e0" charOffset="13-22"
            type="drug" text="Everolimus"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s15" text="For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics.">
        <entity id="DDI-MedLine.d140.s15.e0" charOffset="22-31"
            type="drug" text="everolimus"/>
        <entity id="DDI-MedLine.d140.s15.e1" charOffset="77-88"
            type="drug" text="cyclosporine"/>
        <pair id="DDI-MedLine.d140.s15.p0" e1="DDI-MedLine.d140.s15.e0"
            e2="DDI-MedLine.d140.s15.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d87.s0" text="ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.&#xd;&#xa;">
        <entity id="DDI-MedLine.d87.s0.e0" charOffset="0-9" type="drug" text="ADL 8-2698"/>
        <entity id="DDI-MedLine.d87.s0.e1" charOffset="114-121"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d87.s0.p0" e1="DDI-MedLine.d87.s0.e0"
            e2="DDI-MedLine.d87.s0.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d87.s1" text="ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. ">
        <entity id="DDI-MedLine.d87.s1.e0" charOffset="0-9" type="drug" text="ADL-8-2698"/>
        <entity id="DDI-MedLine.d87.s1.e1" charOffset="22-62"
            type="group" text="peripherally restricted opioid antagonist"/>
        <entity id="DDI-MedLine.d87.s1.e2" charOffset="93-98"
            type="group" text="opioid"/>
        <pair id="DDI-MedLine.d87.s1.p0" e1="DDI-MedLine.d87.s1.e0"
            e2="DDI-MedLine.d87.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d87.s1.p1" e1="DDI-MedLine.d87.s1.e0"
            e2="DDI-MedLine.d87.s1.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d87.s1.p2" e1="DDI-MedLine.d87.s1.e1"
            e2="DDI-MedLine.d87.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d87.s2" text="Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. ">
        <entity id="DDI-MedLine.d87.s2.e0" charOffset="157-164"
            type="drug" text="morphine"/>
        <entity id="DDI-MedLine.d87.s2.e1" charOffset="195-204"
            type="drug" text="ADL 8-2698"/>
        <entity id="DDI-MedLine.d87.s2.e2" charOffset="229-236"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d87.s2.p0" e1="DDI-MedLine.d87.s2.e0"
            e2="DDI-MedLine.d87.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d87.s2.p1" e1="DDI-MedLine.d87.s2.e0"
            e2="DDI-MedLine.d87.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d87.s2.p2" e1="DDI-MedLine.d87.s2.e1"
            e2="DDI-MedLine.d87.s2.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d87.s3" text="Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); ">
        <entity id="DDI-MedLine.d87.s3.e0" charOffset="0-7" type="drug" text="Morphine"/>
    </sentence>
    <sentence id="DDI-MedLine.d87.s4" text="Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004). ">
        <entity id="DDI-MedLine.d87.s4.e0" charOffset="0-7" type="drug" text="Morphine"/>
        <entity id="DDI-MedLine.d87.s4.e1" charOffset="106-115"
            type="drug" text="ADL 8-2698"/>
        <pair id="DDI-MedLine.d87.s4.p0" e1="DDI-MedLine.d87.s4.e0"
            e2="DDI-MedLine.d87.s4.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d87.s5" text="Postoperatively, 45 patients were randomly assigned in a double-blind fashion to receive ADL 8-2698 (4 mg) or placebo and intravenous morphine (0.15 mg/kg) or to receive oral and intravenous placebo. ">
        <entity id="DDI-MedLine.d87.s5.e0" charOffset="89-98"
            type="drug" text="ADL 8-2698"/>
        <entity id="DDI-MedLine.d87.s5.e1" charOffset="134-141"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d87.s5.p0" e1="DDI-MedLine.d87.s5.e0"
            e2="DDI-MedLine.d87.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d87.s6" text="Analgesia and pupil constriction were measured. "/>
    <sentence id="DDI-MedLine.d87.s7" text="Morphine analgesia and pupil constriction were unaffected by ADL 8-2698 and differed from placebo (P &lt; .002). ">
        <entity id="DDI-MedLine.d87.s7.e0" charOffset="0-7" type="drug" text="Morphine"/>
        <entity id="DDI-MedLine.d87.s7.e1" charOffset="61-70"
            type="drug" text="ADL 8-2698"/>
        <pair id="DDI-MedLine.d87.s7.p0" e1="DDI-MedLine.d87.s7.e0"
            e2="DDI-MedLine.d87.s7.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d87.s8" text="We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.">
        <entity id="DDI-MedLine.d87.s8.e0" charOffset="17-26"
            type="drug" text="ADL 8-2698"/>
        <entity id="DDI-MedLine.d87.s8.e1" charOffset="37-44"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d87.s8.p0" e1="DDI-MedLine.d87.s8.e0"
            e2="DDI-MedLine.d87.s8.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d52.s0" text="Restoration of vancomycin susceptibility in Enterococcus faecalis by antiresistance determinant gene transfer.&#xd;&#xa;">
        <entity id="DDI-MedLine.d52.s0.e0" charOffset="15-24"
            type="drug" text="vancomycin"/>
    </sentence>
    <sentence id="DDI-MedLine.d52.s1" text="We assessed the ability of gene transfer to reverse vancomycin resistance in class A (VanA) glycopeptide-resistant Enterococcus faecalis. ">
        <entity id="DDI-MedLine.d52.s1.e0" charOffset="52-61"
            type="drug" text="vancomycin"/>
    </sentence>
    <sentence id="DDI-MedLine.d52.s2" text="Recombinant shuttle vectors containing a vanH promoter-vanA antisense gene cassette fully restored vancomycin susceptibility through a combined transcriptional activator binding domain decoy and inducible vanA antisense RNA effect.">
        <entity id="DDI-MedLine.d52.s2.e0" charOffset="99-108"
            type="drug" text="vancomycin"/>
    </sentence>
    <sentence id="DDI-MedLine.d25.s0" text="Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.&#xd;&#xa;">
        <entity id="DDI-MedLine.d25.s0.e0" charOffset="55-65"
            type="drug" text="simvastatin"/>
        <entity id="DDI-MedLine.d25.s0.e1" charOffset="71-84"
            type="drug" text="clarithromycin"/>
        <pair id="DDI-MedLine.d25.s0.p0" e1="DDI-MedLine.d25.s0.e0"
            e2="DDI-MedLine.d25.s0.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d25.s1" text="OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of clarithromycin and simvastatin. ">
        <entity id="DDI-MedLine.d25.s1.e0" charOffset="80-93"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-MedLine.d25.s1.e1" charOffset="99-109"
            type="drug" text="simvastatin"/>
        <pair id="DDI-MedLine.d25.s1.p0" e1="DDI-MedLine.d25.s1.e0"
            e2="DDI-MedLine.d25.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d25.s2" text="CASE SUMMARY: A 64-year-old African-American man was admitted to the hospital for worsening renal failure, elevated creatine phosphokinase, diffuse muscle pain, and severe muscle weakness. "/>
    <sentence id="DDI-MedLine.d25.s3" text="About three weeks prior to admission, the patient was started on clarithromycin for sinusitis. ">
        <entity id="DDI-MedLine.d25.s3.e0" charOffset="65-78"
            type="drug" text="clarithromycin"/>
    </sentence>
    <sentence id="DDI-MedLine.d25.s4" text="The patient had been receiving simvastatin for approximately six months. ">
        <entity id="DDI-MedLine.d25.s4.e0" charOffset="31-41"
            type="drug" text="simvastatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d25.s5" text="He was treated aggressively with intravenous hydration, sodium bicarbonate, and hemodialysis. ">
        <entity id="DDI-MedLine.d25.s5.e0" charOffset="56-73"
            type="drug" text="sodium bicarbonate"/>
    </sentence>
    <sentence id="DDI-MedLine.d25.s6" text="A muscle biopsy revealed necrotizing myopathy secondary to a toxin. "/>
    <sentence id="DDI-MedLine.d25.s7" text="The patient continued to receive intermittent hemodialysis until his death from infectious complications that occurred three months after admission. "/>
    <sentence id="DDI-MedLine.d25.s8" text="There were several factors that could have increased his risk for developing rhabdomyolysis, including chronic renal failure. "/>
    <sentence id="DDI-MedLine.d25.s9" text="DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism. ">
        <entity id="DDI-MedLine.d25.s9.e0" charOffset="12-25"
            type="drug" text="Clarithromycin"/>
        <entity id="DDI-MedLine.d25.s9.e1" charOffset="93-103"
            type="drug" text="simvastatin"/>
        <pair id="DDI-MedLine.d25.s9.p0" e1="DDI-MedLine.d25.s9.e0"
            e2="DDI-MedLine.d25.s9.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d25.s10" text="The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis. ">
        <entity id="DDI-MedLine.d25.s10.e0" charOffset="34-54"
            type="group" text="macrolide antibiotics"/>
        <entity id="DDI-MedLine.d25.s10.e1" charOffset="66-128"
            type="group" text="hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors"/>
        <pair id="DDI-MedLine.d25.s10.p0" e1="DDI-MedLine.d25.s10.e0"
            e2="DDI-MedLine.d25.s10.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d25.s11" text="Other factors may increase the risk of this drug interaction, including the administration of other medications that are associated with myopathy, underlying renal insufficiency, and administration of high doses of HMG-CoA reductase inhibitors. ">
        <entity id="DDI-MedLine.d25.s11.e0" charOffset="215-242"
            type="group" text="HMG-CoA reductase inhibitors"/>
    </sentence>
    <sentence id="DDI-MedLine.d25.s12" text="CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ">
        <entity id="DDI-MedLine.d25.s12.e0" charOffset="13-33"
            type="group" text="Macrolide antibiotics"/>
        <entity id="DDI-MedLine.d25.s12.e1" charOffset="61-88"
            type="group" text="HMG-CoA reductase inhibitors"/>
        <entity id="DDI-MedLine.d25.s12.e2" charOffset="128-139"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-MedLine.d25.s12.e3" charOffset="142-153"
            type="drug" text="cerivastatin"/>
        <entity id="DDI-MedLine.d25.s12.e4" charOffset="156-165"
            type="drug" text="lovastatin"/>
        <entity id="DDI-MedLine.d25.s12.e5" charOffset="168-178"
            type="drug" text="simvastatin"/>
        <pair id="DDI-MedLine.d25.s12.p0" e1="DDI-MedLine.d25.s12.e0"
            e2="DDI-MedLine.d25.s12.e1" ddi="false"/>
        <pair id="DDI-MedLine.d25.s12.p1" e1="DDI-MedLine.d25.s12.e0"
            e2="DDI-MedLine.d25.s12.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d25.s12.p2" e1="DDI-MedLine.d25.s12.e0"
            e2="DDI-MedLine.d25.s12.e3" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d25.s12.p3" e1="DDI-MedLine.d25.s12.e0"
            e2="DDI-MedLine.d25.s12.e4" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d25.s12.p4" e1="DDI-MedLine.d25.s12.e0"
            e2="DDI-MedLine.d25.s12.e5" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d25.s12.p5" e1="DDI-MedLine.d25.s12.e1"
            e2="DDI-MedLine.d25.s12.e2" ddi="false"/>
        <pair id="DDI-MedLine.d25.s12.p6" e1="DDI-MedLine.d25.s12.e1"
            e2="DDI-MedLine.d25.s12.e3" ddi="false"/>
        <pair id="DDI-MedLine.d25.s12.p7" e1="DDI-MedLine.d25.s12.e1"
            e2="DDI-MedLine.d25.s12.e4" ddi="false"/>
        <pair id="DDI-MedLine.d25.s12.p8" e1="DDI-MedLine.d25.s12.e1"
            e2="DDI-MedLine.d25.s12.e5" ddi="false"/>
        <pair id="DDI-MedLine.d25.s12.p9" e1="DDI-MedLine.d25.s12.e2"
            e2="DDI-MedLine.d25.s12.e3" ddi="false"/>
        <pair id="DDI-MedLine.d25.s12.p10" e1="DDI-MedLine.d25.s12.e2"
            e2="DDI-MedLine.d25.s12.e4" ddi="false"/>
        <pair id="DDI-MedLine.d25.s12.p11" e1="DDI-MedLine.d25.s12.e2"
            e2="DDI-MedLine.d25.s12.e5" ddi="false"/>
        <pair id="DDI-MedLine.d25.s12.p12" e1="DDI-MedLine.d25.s12.e3"
            e2="DDI-MedLine.d25.s12.e4" ddi="false"/>
        <pair id="DDI-MedLine.d25.s12.p13" e1="DDI-MedLine.d25.s12.e3"
            e2="DDI-MedLine.d25.s12.e5" ddi="false"/>
        <pair id="DDI-MedLine.d25.s12.p14" e1="DDI-MedLine.d25.s12.e4"
            e2="DDI-MedLine.d25.s12.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d25.s13" text="This interaction may result in myopathy and rhabdomyolysis, particularly in patients with renal insufficiency or those who are concurrently taking medications associated with myopathy."/>
    <sentence id="DDI-MedLine.d141.s0" text="Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).&#xa;">
        <entity id="DDI-MedLine.d141.s0.e0" charOffset="24-27"
            type="drug" text="zinc"/>
    </sentence>
    <sentence id="DDI-MedLine.d141.s1" text="The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus. ">
        <entity id="DDI-MedLine.d141.s1.e0" charOffset="25-28"
            type="drug" text="zinc"/>
    </sentence>
    <sentence id="DDI-MedLine.d141.s2" text="Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; "/>
    <sentence id="DDI-MedLine.d141.s3" text="however, at lower concentrations only zinc demonstrated toxicity. ">
        <entity id="DDI-MedLine.d141.s3.e0" charOffset="38-41"
            type="drug" text="zinc"/>
    </sentence>
    <sentence id="DDI-MedLine.d141.s4" text="Mixtures of cadmium and zinc had a synergistic effect compared with single metal toxicity but only at 50000 microg/l. ">
        <entity id="DDI-MedLine.d141.s4.e0" charOffset="24-27"
            type="drug" text="zinc"/>
    </sentence>
    <sentence id="DDI-MedLine.d141.s5" text="Excystment in vitro was only significantly affected by cercariae exposed to cadmium/zinc mixtures whilst encysting. "/>
    <sentence id="DDI-MedLine.d141.s6" text="Twenty-four h exposures of fully formed cysts had no effect on excystment in vitro. "/>
    <sentence id="DDI-MedLine.d141.s7" text="Effects on in vitro excystment rates over a 2 h period demonstrated widespread effects for cercariae-exposed P. "/>
    <sentence id="DDI-MedLine.d141.s8" text="acanthus. "/>
    <sentence id="DDI-MedLine.d141.s9" text="No effects were evident on excystment rates of cyst-exposed parasites."/>
    <sentence id="DDI-MedLine.d70.s0" text="Toxicity of cadmium and zinc to miracidia of Schistosoma mansoni.&#xa;">
        <entity id="DDI-MedLine.d70.s0.e0" charOffset="24-27"
            type="drug" text="zinc"/>
    </sentence>
    <sentence id="DDI-MedLine.d70.s1" text="The specific objectives of this study were to elucidate metal toxicity to hatching, survival and avoidance behaviour of Schistosoma mansoni miracidia. "/>
    <sentence id="DDI-MedLine.d70.s2" text="The toxicity of cadmium, zinc, and cadmium/zinc mixtures at concentrations ranging from 10000 to 10 microg/l was investigated. ">
        <entity id="DDI-MedLine.d70.s2.e0" charOffset="25-28"
            type="drug" text="zinc"/>
    </sentence>
    <sentence id="DDI-MedLine.d70.s3" text="Metal mixture toxicity investigation was undertaken with equal concentrations of the metals. "/>
    <sentence id="DDI-MedLine.d70.s4" text="The hatching of miracidia from eggs was inhibited by concentrations of 1000-10000 microg/l of single metals. "/>
    <sentence id="DDI-MedLine.d70.s5" text="Metal mixtures had no effect on egg hatching. ">
        <entity id="DDI-MedLine.d70.s5.e0" charOffset="32-34"
            type="drug" text="egg"/>
    </sentence>
    <sentence id="DDI-MedLine.d70.s6" text="Survival of miracidia was reduced by increasing metal concentration except at concentrations of 10 microg/l for single metal toxicity where survival was increased above the control. "/>
    <sentence id="DDI-MedLine.d70.s7" text="Miracidia demonstrated a rapid avoidance behaviour when briefly exposed to heavy metals. "/>
    <sentence id="DDI-MedLine.d70.s8" text="The mechanisms of metal toxicity to miracidia are briefly discussed."/>
    <sentence id="DDI-MedLine.d35.s0" text="[Importance of pharmacogenetics];Pharmacogenetics deals with the differences in effect of drugs caused by genetic variation. "/>
    <sentence id="DDI-MedLine.d35.s1" text="Differences can occur in therapeutic effect and in adverse events. "/>
    <sentence id="DDI-MedLine.d35.s2" text="Genetic variation in metabolism may result in high concentrations of drugs and an increased risk of adverse effects in slow metabolizers, which is important when using for example antidepressants or chemotherapy. ">
        <entity id="DDI-MedLine.d35.s2.e0" charOffset="180-194"
            type="group" text="antidepressants"/>
    </sentence>
    <sentence id="DDI-MedLine.d35.s3" text="Genetic variation also occurs in proteins interacting with drugs, which may change the effect of e.g. "/>
    <sentence id="DDI-MedLine.d35.s4" text="asthma drugs and antipsychotics. ">
        <entity id="DDI-MedLine.d35.s4.e0" charOffset="17-30"
            type="group" text="antipsychotics"/>
    </sentence>
    <sentence id="DDI-MedLine.d35.s5" text="The selection of drugs and their dosages may be improved, and the number of adverse effects reduced by pharmacogenetic investigations. "/>
    <sentence id="DDI-MedLine.d35.s6" text="However, it may be important also in case of medical examinations for insurances and job appointments, since some patients may turn out to need expensive drugs or to be susceptible to a certain disease. "/>
    <sentence id="DDI-MedLine.d35.s7" text="Therefore, the use of genetic data in these instances has to be regulated."/>
    <sentence id="DDI-MedLine.d0.s0" text="The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.&#xd;&#xa;">
        <entity id="DDI-MedLine.d0.s0.e0" charOffset="27-35" type="drug" text="phenytoin"/>
        <entity id="DDI-MedLine.d0.s0.e1" charOffset="92-101"
            type="drug" text="quetiapine"/>
        <pair id="DDI-MedLine.d0.s0.p0" e1="DDI-MedLine.d0.s0.e0"
            e2="DDI-MedLine.d0.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d0.s1" text="Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. ">
        <entity id="DDI-MedLine.d0.s1.e0" charOffset="0-18" type="drug" text="Quetiapine fumarate"/>
        <entity id="DDI-MedLine.d0.s1.e1" charOffset="22-29"
            type="brand" text="Seroquel"/>
        <entity id="DDI-MedLine.d0.s1.e2" charOffset="55-76"
            type="group" text="atypical antipsychotic"/>
        <pair id="DDI-MedLine.d0.s1.p0" e1="DDI-MedLine.d0.s1.e0"
            e2="DDI-MedLine.d0.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d0.s1.p1" e1="DDI-MedLine.d0.s1.e0"
            e2="DDI-MedLine.d0.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d0.s1.p2" e1="DDI-MedLine.d0.s1.e1"
            e2="DDI-MedLine.d0.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d0.s2" text="It is extensively metabolized, predominantly by cytochrome P450 3A4. "/>
    <sentence id="DDI-MedLine.d0.s3" text="Therefore, concurrent administration of drugs that induce or inhibit this enzyme may affect quetiapine pharmacokinetics. ">
        <entity id="DDI-MedLine.d0.s3.e0" charOffset="92-101"
            type="drug" text="quetiapine"/>
    </sentence>
    <sentence id="DDI-MedLine.d0.s4" text="This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. ">
        <entity id="DDI-MedLine.d0.s4.e0" charOffset="71-79" type="drug" text="phenytoin"/>
        <entity id="DDI-MedLine.d0.s4.e1" charOffset="134-143"
            type="drug" text="quetiapine"/>
        <pair id="DDI-MedLine.d0.s4.p0" e1="DDI-MedLine.d0.s4.e0"
            e2="DDI-MedLine.d0.s4.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d0.s5" text="These results indicate that dosage adjustment of quetiapine may be necessary when the two drugs are given concurrently and that caution may be required when administering other drugs that inhibit or induce cytochromes, particularly P450 3A4.">
        <entity id="DDI-MedLine.d0.s5.e0" charOffset="49-58" type="drug" text="quetiapine"/>
    </sentence>
    <sentence id="DDI-MedLine.d111.s0" text="Effect of coadministered drugs and ethanol on the binding of therapeutic drugs to human serum in vitro.&#xd;&#xa;">
        <entity id="DDI-MedLine.d111.s0.e0" charOffset="35-41"
            type="drug" text="ethanol"/>
    </sentence>
    <sentence id="DDI-MedLine.d111.s1" text="The effects of coadministered drugs and ethanol on the binding of therapeutic drugs to human serum in vitro was investigated. ">
        <entity id="DDI-MedLine.d111.s1.e0" charOffset="40-46"
            type="drug" text="ethanol"/>
    </sentence>
    <sentence id="DDI-MedLine.d111.s2" text="Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ">
        <entity id="DDI-MedLine.d111.s2.e0" charOffset="0-12"
            type="drug" text="Acetaminophen"/>
        <entity id="DDI-MedLine.d111.s2.e1" charOffset="15-23"
            type="drug" text="lidocaine"/>
        <entity id="DDI-MedLine.d111.s2.e2" charOffset="26-38"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-MedLine.d111.s2.e3" charOffset="41-49"
            type="drug" text="quinidine"/>
        <entity id="DDI-MedLine.d111.s2.e4" charOffset="52-63"
            type="drug" text="theophylline"/>
        <entity id="DDI-MedLine.d111.s2.e5" charOffset="70-82"
            type="drug" text="valproic acid"/>
        <pair id="DDI-MedLine.d111.s2.p0" e1="DDI-MedLine.d111.s2.e0"
            e2="DDI-MedLine.d111.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d111.s2.p1" e1="DDI-MedLine.d111.s2.e0"
            e2="DDI-MedLine.d111.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d111.s2.p2" e1="DDI-MedLine.d111.s2.e0"
            e2="DDI-MedLine.d111.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d111.s2.p3" e1="DDI-MedLine.d111.s2.e0"
            e2="DDI-MedLine.d111.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d111.s2.p4" e1="DDI-MedLine.d111.s2.e0"
            e2="DDI-MedLine.d111.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d111.s2.p5" e1="DDI-MedLine.d111.s2.e1"
            e2="DDI-MedLine.d111.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d111.s2.p6" e1="DDI-MedLine.d111.s2.e1"
            e2="DDI-MedLine.d111.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d111.s2.p7" e1="DDI-MedLine.d111.s2.e1"
            e2="DDI-MedLine.d111.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d111.s2.p8" e1="DDI-MedLine.d111.s2.e1"
            e2="DDI-MedLine.d111.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d111.s2.p9" e1="DDI-MedLine.d111.s2.e2"
            e2="DDI-MedLine.d111.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d111.s2.p10" e1="DDI-MedLine.d111.s2.e2"
            e2="DDI-MedLine.d111.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d111.s2.p11" e1="DDI-MedLine.d111.s2.e2"
            e2="DDI-MedLine.d111.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d111.s2.p12" e1="DDI-MedLine.d111.s2.e3"
            e2="DDI-MedLine.d111.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d111.s2.p13" e1="DDI-MedLine.d111.s2.e3"
            e2="DDI-MedLine.d111.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d111.s2.p14" e1="DDI-MedLine.d111.s2.e4"
            e2="DDI-MedLine.d111.s2.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d111.s3" text="To each preparation was added one additional drug at three concentrations ranging from therapeutic to toxic. "/>
    <sentence id="DDI-MedLine.d111.s4" text="The following eight target drug/added drug combinations were studied: acetaminophen/phenobarbital. ">
        <entity id="DDI-MedLine.d111.s4.e0" charOffset="70-82"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-MedLine.d111.s4.e1" charOffset="84-96"
            type="drug" text="phenobarbital"/>
        <pair id="DDI-MedLine.d111.s4.p0" e1="DDI-MedLine.d111.s4.e0"
            e2="DDI-MedLine.d111.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d111.s5" text="acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ">
        <entity id="DDI-MedLine.d111.s5.e0" charOffset="0-12"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-MedLine.d111.s5.e1" charOffset="14-25"
            type="drug" text="theophylline"/>
        <entity id="DDI-MedLine.d111.s5.e2" charOffset="28-36"
            type="drug" text="lidocaine"/>
        <entity id="DDI-MedLine.d111.s5.e3" charOffset="38-46"
            type="drug" text="quinidine"/>
        <entity id="DDI-MedLine.d111.s5.e4" charOffset="49-61"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-MedLine.d111.s5.e5" charOffset="63-75"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-MedLine.d111.s5.e6" charOffset="78-90"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-MedLine.d111.s5.e7" charOffset="92-104"
            type="drug" text="valproic acid"/>
        <entity id="DDI-MedLine.d111.s5.e8" charOffset="107-115"
            type="drug" text="quinidine"/>
        <entity id="DDI-MedLine.d111.s5.e9" charOffset="117-125"
            type="drug" text="lidocaine"/>
        <entity id="DDI-MedLine.d111.s5.e10" charOffset="128-139"
            type="drug" text="theophylline"/>
        <entity id="DDI-MedLine.d111.s5.e11" charOffset="141-153"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-MedLine.d111.s5.e12" charOffset="160-172"
            type="drug" text="valproic acid"/>
        <entity id="DDI-MedLine.d111.s5.e13" charOffset="174-186"
            type="drug" text="phenobarbital"/>
        <pair id="DDI-MedLine.d111.s5.p0" e1="DDI-MedLine.d111.s5.e0"
            e2="DDI-MedLine.d111.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p1" e1="DDI-MedLine.d111.s5.e0"
            e2="DDI-MedLine.d111.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p2" e1="DDI-MedLine.d111.s5.e0"
            e2="DDI-MedLine.d111.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p3" e1="DDI-MedLine.d111.s5.e0"
            e2="DDI-MedLine.d111.s5.e4" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p4" e1="DDI-MedLine.d111.s5.e0"
            e2="DDI-MedLine.d111.s5.e5" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p5" e1="DDI-MedLine.d111.s5.e0"
            e2="DDI-MedLine.d111.s5.e6" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p6" e1="DDI-MedLine.d111.s5.e0"
            e2="DDI-MedLine.d111.s5.e7" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p7" e1="DDI-MedLine.d111.s5.e0"
            e2="DDI-MedLine.d111.s5.e8" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p8" e1="DDI-MedLine.d111.s5.e0"
            e2="DDI-MedLine.d111.s5.e9" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p9" e1="DDI-MedLine.d111.s5.e0"
            e2="DDI-MedLine.d111.s5.e10" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p10" e1="DDI-MedLine.d111.s5.e0"
            e2="DDI-MedLine.d111.s5.e11" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p11" e1="DDI-MedLine.d111.s5.e0"
            e2="DDI-MedLine.d111.s5.e12" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p12" e1="DDI-MedLine.d111.s5.e0"
            e2="DDI-MedLine.d111.s5.e13" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p13" e1="DDI-MedLine.d111.s5.e1"
            e2="DDI-MedLine.d111.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p14" e1="DDI-MedLine.d111.s5.e1"
            e2="DDI-MedLine.d111.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p15" e1="DDI-MedLine.d111.s5.e1"
            e2="DDI-MedLine.d111.s5.e4" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p16" e1="DDI-MedLine.d111.s5.e1"
            e2="DDI-MedLine.d111.s5.e5" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p17" e1="DDI-MedLine.d111.s5.e1"
            e2="DDI-MedLine.d111.s5.e6" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p18" e1="DDI-MedLine.d111.s5.e1"
            e2="DDI-MedLine.d111.s5.e7" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p19" e1="DDI-MedLine.d111.s5.e1"
            e2="DDI-MedLine.d111.s5.e8" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p20" e1="DDI-MedLine.d111.s5.e1"
            e2="DDI-MedLine.d111.s5.e9" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p21" e1="DDI-MedLine.d111.s5.e1"
            e2="DDI-MedLine.d111.s5.e10" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p22" e1="DDI-MedLine.d111.s5.e1"
            e2="DDI-MedLine.d111.s5.e11" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p23" e1="DDI-MedLine.d111.s5.e1"
            e2="DDI-MedLine.d111.s5.e12" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p24" e1="DDI-MedLine.d111.s5.e1"
            e2="DDI-MedLine.d111.s5.e13" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p25" e1="DDI-MedLine.d111.s5.e2"
            e2="DDI-MedLine.d111.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p26" e1="DDI-MedLine.d111.s5.e2"
            e2="DDI-MedLine.d111.s5.e4" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p27" e1="DDI-MedLine.d111.s5.e2"
            e2="DDI-MedLine.d111.s5.e5" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p28" e1="DDI-MedLine.d111.s5.e2"
            e2="DDI-MedLine.d111.s5.e6" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p29" e1="DDI-MedLine.d111.s5.e2"
            e2="DDI-MedLine.d111.s5.e7" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p30" e1="DDI-MedLine.d111.s5.e2"
            e2="DDI-MedLine.d111.s5.e8" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p31" e1="DDI-MedLine.d111.s5.e2"
            e2="DDI-MedLine.d111.s5.e9" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p32" e1="DDI-MedLine.d111.s5.e2"
            e2="DDI-MedLine.d111.s5.e10" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p33" e1="DDI-MedLine.d111.s5.e2"
            e2="DDI-MedLine.d111.s5.e11" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p34" e1="DDI-MedLine.d111.s5.e2"
            e2="DDI-MedLine.d111.s5.e12" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p35" e1="DDI-MedLine.d111.s5.e2"
            e2="DDI-MedLine.d111.s5.e13" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p36" e1="DDI-MedLine.d111.s5.e3"
            e2="DDI-MedLine.d111.s5.e4" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p37" e1="DDI-MedLine.d111.s5.e3"
            e2="DDI-MedLine.d111.s5.e5" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p38" e1="DDI-MedLine.d111.s5.e3"
            e2="DDI-MedLine.d111.s5.e6" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p39" e1="DDI-MedLine.d111.s5.e3"
            e2="DDI-MedLine.d111.s5.e7" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p40" e1="DDI-MedLine.d111.s5.e3"
            e2="DDI-MedLine.d111.s5.e8" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p41" e1="DDI-MedLine.d111.s5.e3"
            e2="DDI-MedLine.d111.s5.e9" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p42" e1="DDI-MedLine.d111.s5.e3"
            e2="DDI-MedLine.d111.s5.e10" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p43" e1="DDI-MedLine.d111.s5.e3"
            e2="DDI-MedLine.d111.s5.e11" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p44" e1="DDI-MedLine.d111.s5.e3"
            e2="DDI-MedLine.d111.s5.e12" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p45" e1="DDI-MedLine.d111.s5.e3"
            e2="DDI-MedLine.d111.s5.e13" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p46" e1="DDI-MedLine.d111.s5.e4"
            e2="DDI-MedLine.d111.s5.e5" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p47" e1="DDI-MedLine.d111.s5.e4"
            e2="DDI-MedLine.d111.s5.e6" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p48" e1="DDI-MedLine.d111.s5.e4"
            e2="DDI-MedLine.d111.s5.e7" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p49" e1="DDI-MedLine.d111.s5.e4"
            e2="DDI-MedLine.d111.s5.e8" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p50" e1="DDI-MedLine.d111.s5.e4"
            e2="DDI-MedLine.d111.s5.e9" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p51" e1="DDI-MedLine.d111.s5.e4"
            e2="DDI-MedLine.d111.s5.e10" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p52" e1="DDI-MedLine.d111.s5.e4"
            e2="DDI-MedLine.d111.s5.e11" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p53" e1="DDI-MedLine.d111.s5.e4"
            e2="DDI-MedLine.d111.s5.e12" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p54" e1="DDI-MedLine.d111.s5.e4"
            e2="DDI-MedLine.d111.s5.e13" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p55" e1="DDI-MedLine.d111.s5.e5"
            e2="DDI-MedLine.d111.s5.e6" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p56" e1="DDI-MedLine.d111.s5.e5"
            e2="DDI-MedLine.d111.s5.e7" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p57" e1="DDI-MedLine.d111.s5.e5"
            e2="DDI-MedLine.d111.s5.e8" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p58" e1="DDI-MedLine.d111.s5.e5"
            e2="DDI-MedLine.d111.s5.e9" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p59" e1="DDI-MedLine.d111.s5.e5"
            e2="DDI-MedLine.d111.s5.e10" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p60" e1="DDI-MedLine.d111.s5.e5"
            e2="DDI-MedLine.d111.s5.e11" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p61" e1="DDI-MedLine.d111.s5.e5"
            e2="DDI-MedLine.d111.s5.e12" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p62" e1="DDI-MedLine.d111.s5.e5"
            e2="DDI-MedLine.d111.s5.e13" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p63" e1="DDI-MedLine.d111.s5.e6"
            e2="DDI-MedLine.d111.s5.e7" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p64" e1="DDI-MedLine.d111.s5.e6"
            e2="DDI-MedLine.d111.s5.e8" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p65" e1="DDI-MedLine.d111.s5.e6"
            e2="DDI-MedLine.d111.s5.e9" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p66" e1="DDI-MedLine.d111.s5.e6"
            e2="DDI-MedLine.d111.s5.e10" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p67" e1="DDI-MedLine.d111.s5.e6"
            e2="DDI-MedLine.d111.s5.e11" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p68" e1="DDI-MedLine.d111.s5.e6"
            e2="DDI-MedLine.d111.s5.e12" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p69" e1="DDI-MedLine.d111.s5.e6"
            e2="DDI-MedLine.d111.s5.e13" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p70" e1="DDI-MedLine.d111.s5.e7"
            e2="DDI-MedLine.d111.s5.e8" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p71" e1="DDI-MedLine.d111.s5.e7"
            e2="DDI-MedLine.d111.s5.e9" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p72" e1="DDI-MedLine.d111.s5.e7"
            e2="DDI-MedLine.d111.s5.e10" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p73" e1="DDI-MedLine.d111.s5.e7"
            e2="DDI-MedLine.d111.s5.e11" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p74" e1="DDI-MedLine.d111.s5.e7"
            e2="DDI-MedLine.d111.s5.e12" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p75" e1="DDI-MedLine.d111.s5.e7"
            e2="DDI-MedLine.d111.s5.e13" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p76" e1="DDI-MedLine.d111.s5.e8"
            e2="DDI-MedLine.d111.s5.e9" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p77" e1="DDI-MedLine.d111.s5.e8"
            e2="DDI-MedLine.d111.s5.e10" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p78" e1="DDI-MedLine.d111.s5.e8"
            e2="DDI-MedLine.d111.s5.e11" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p79" e1="DDI-MedLine.d111.s5.e8"
            e2="DDI-MedLine.d111.s5.e12" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p80" e1="DDI-MedLine.d111.s5.e8"
            e2="DDI-MedLine.d111.s5.e13" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p81" e1="DDI-MedLine.d111.s5.e9"
            e2="DDI-MedLine.d111.s5.e10" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p82" e1="DDI-MedLine.d111.s5.e9"
            e2="DDI-MedLine.d111.s5.e11" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p83" e1="DDI-MedLine.d111.s5.e9"
            e2="DDI-MedLine.d111.s5.e12" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p84" e1="DDI-MedLine.d111.s5.e9"
            e2="DDI-MedLine.d111.s5.e13" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p85" e1="DDI-MedLine.d111.s5.e10"
            e2="DDI-MedLine.d111.s5.e11" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p86" e1="DDI-MedLine.d111.s5.e10"
            e2="DDI-MedLine.d111.s5.e12" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p87" e1="DDI-MedLine.d111.s5.e10"
            e2="DDI-MedLine.d111.s5.e13" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p88" e1="DDI-MedLine.d111.s5.e11"
            e2="DDI-MedLine.d111.s5.e12" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p89" e1="DDI-MedLine.d111.s5.e11"
            e2="DDI-MedLine.d111.s5.e13" ddi="false"/>
        <pair id="DDI-MedLine.d111.s5.p90" e1="DDI-MedLine.d111.s5.e12"
            e2="DDI-MedLine.d111.s5.e13" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d111.s6" text="Each serum without the other added drug as well as the serum supplemented with the other drug at the three concentrations was dialyzed against phosphate buffer. "/>
    <sentence id="DDI-MedLine.d111.s7" text="Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. ">
        <entity id="DDI-MedLine.d111.s7.e0" charOffset="24-36"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-MedLine.d111.s7.e1" charOffset="39-47"
            type="drug" text="quinidine"/>
        <entity id="DDI-MedLine.d111.s7.e2" charOffset="54-65"
            type="drug" text="theophylline"/>
        <entity id="DDI-MedLine.d111.s7.e3" charOffset="127-133"
            type="drug" text="ethanol"/>
        <pair id="DDI-MedLine.d111.s7.p0" e1="DDI-MedLine.d111.s7.e0"
            e2="DDI-MedLine.d111.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d111.s7.p1" e1="DDI-MedLine.d111.s7.e0"
            e2="DDI-MedLine.d111.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d111.s7.p2" e1="DDI-MedLine.d111.s7.e0"
            e2="DDI-MedLine.d111.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d111.s7.p3" e1="DDI-MedLine.d111.s7.e1"
            e2="DDI-MedLine.d111.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d111.s7.p4" e1="DDI-MedLine.d111.s7.e1"
            e2="DDI-MedLine.d111.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d111.s7.p5" e1="DDI-MedLine.d111.s7.e2"
            e2="DDI-MedLine.d111.s7.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d111.s8" text="The percentage of drug binding in each preparation was calculated. "/>
    <sentence id="DDI-MedLine.d111.s9" text="Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. ">
        <entity id="DDI-MedLine.d111.s9.e0" charOffset="0-12"
            type="drug" text="Acetaminophen"/>
        <entity id="DDI-MedLine.d111.s9.e1" charOffset="40-51"
            type="drug" text="theophylline"/>
        <pair id="DDI-MedLine.d111.s9.p0" e1="DDI-MedLine.d111.s9.e0"
            e2="DDI-MedLine.d111.s9.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d111.s10" text="Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L; ">
        <entity id="DDI-MedLine.d111.s10.e0" charOffset="0-11"
            type="drug" text="Theophylline"/>
        <entity id="DDI-MedLine.d111.s10.e1" charOffset="38-50"
            type="drug" text="acetaminophen"/>
        <pair id="DDI-MedLine.d111.s10.p0" e1="DDI-MedLine.d111.s10.e0"
            e2="DDI-MedLine.d111.s10.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d111.s11" text="phenobarbital reduced it by a net change of 6.6% (percentage increase in FDF, 8.5%) at 431 micromol/L. ">
        <entity id="DDI-MedLine.d111.s11.e0" charOffset="0-12"
            type="drug" text="phenobarbital"/>
    </sentence>
    <sentence id="DDI-MedLine.d111.s12" text="Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. ">
        <entity id="DDI-MedLine.d111.s12.e0" charOffset="0-12"
            type="drug" text="Valproic acid"/>
        <entity id="DDI-MedLine.d111.s12.e1" charOffset="36-48"
            type="drug" text="phenobarbital"/>
        <pair id="DDI-MedLine.d111.s12.p0" e1="DDI-MedLine.d111.s12.e0"
            e2="DDI-MedLine.d111.s12.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d111.s13" text="No significant effects were noted with other drug combinations or with the addition of ethanol. ">
        <entity id="DDI-MedLine.d111.s13.e0" charOffset="87-93"
            type="drug" text="ethanol"/>
    </sentence>
    <sentence id="DDI-MedLine.d111.s14" text="Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ">
        <entity id="DDI-MedLine.d111.s14.e0" charOffset="15-27"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-MedLine.d111.s14.e1" charOffset="34-45"
            type="drug" text="theophylline"/>
        <entity id="DDI-MedLine.d111.s14.e2" charOffset="48-60"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-MedLine.d111.s14.e3" charOffset="67-79"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-MedLine.d111.s14.e4" charOffset="86-98"
            type="drug" text="valproic acid"/>
        <entity id="DDI-MedLine.d111.s14.e5" charOffset="105-117"
            type="drug" text="phenobarbital"/>
        <pair id="DDI-MedLine.d111.s14.p0" e1="DDI-MedLine.d111.s14.e0"
            e2="DDI-MedLine.d111.s14.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d111.s14.p1" e1="DDI-MedLine.d111.s14.e0"
            e2="DDI-MedLine.d111.s14.e2" ddi="false"/>
        <pair id="DDI-MedLine.d111.s14.p2" e1="DDI-MedLine.d111.s14.e0"
            e2="DDI-MedLine.d111.s14.e3" ddi="false"/>
        <pair id="DDI-MedLine.d111.s14.p3" e1="DDI-MedLine.d111.s14.e0"
            e2="DDI-MedLine.d111.s14.e4" ddi="false"/>
        <pair id="DDI-MedLine.d111.s14.p4" e1="DDI-MedLine.d111.s14.e0"
            e2="DDI-MedLine.d111.s14.e5" ddi="false"/>
        <pair id="DDI-MedLine.d111.s14.p5" e1="DDI-MedLine.d111.s14.e1"
            e2="DDI-MedLine.d111.s14.e2" ddi="false"/>
        <pair id="DDI-MedLine.d111.s14.p6" e1="DDI-MedLine.d111.s14.e1"
            e2="DDI-MedLine.d111.s14.e3" ddi="false"/>
        <pair id="DDI-MedLine.d111.s14.p7" e1="DDI-MedLine.d111.s14.e1"
            e2="DDI-MedLine.d111.s14.e4" ddi="false"/>
        <pair id="DDI-MedLine.d111.s14.p8" e1="DDI-MedLine.d111.s14.e1"
            e2="DDI-MedLine.d111.s14.e5" ddi="false"/>
        <pair id="DDI-MedLine.d111.s14.p9" e1="DDI-MedLine.d111.s14.e2"
            e2="DDI-MedLine.d111.s14.e3" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d111.s14.p10" e1="DDI-MedLine.d111.s14.e2"
            e2="DDI-MedLine.d111.s14.e4" ddi="false"/>
        <pair id="DDI-MedLine.d111.s14.p11" e1="DDI-MedLine.d111.s14.e2"
            e2="DDI-MedLine.d111.s14.e5" ddi="false"/>
        <pair id="DDI-MedLine.d111.s14.p12" e1="DDI-MedLine.d111.s14.e3"
            e2="DDI-MedLine.d111.s14.e4" ddi="false"/>
        <pair id="DDI-MedLine.d111.s14.p13" e1="DDI-MedLine.d111.s14.e3"
            e2="DDI-MedLine.d111.s14.e5" ddi="false"/>
        <pair id="DDI-MedLine.d111.s14.p14" e1="DDI-MedLine.d111.s14.e4"
            e2="DDI-MedLine.d111.s14.e5" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d111.s15" text="The resulting increase in free drug concentration may lead to enhanced drug effect in vivo."/>
    <sentence id="DDI-MedLine.d60.s0" text="Phenytoin intoxication induced by fluvoxamine.&#xa;">
        <entity id="DDI-MedLine.d60.s0.e0" charOffset="34-44"
            type="drug" text="fluvoxamine"/>
    </sentence>
    <sentence id="DDI-MedLine.d60.s1" text="A patient had phenytoin intoxication after administration of fluvoxamine, a selective serotonin reuptake inhibitor. ">
        <entity id="DDI-MedLine.d60.s1.e0" charOffset="61-71"
            type="drug" text="fluvoxamine"/>
    </sentence>
    <sentence id="DDI-MedLine.d60.s2" text="The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. ">
        <entity id="DDI-MedLine.d60.s2.e0" charOffset="27-35"
            type="drug" text="phenytoin"/>
        <entity id="DDI-MedLine.d60.s2.e1" charOffset="93-103"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-MedLine.d60.s2.e2" charOffset="154-162"
            type="drug" text="phenytoin"/>
        <entity id="DDI-MedLine.d60.s2.e3" charOffset="174-178"
            type="drug" text="drugs"/>
        <pair id="DDI-MedLine.d60.s2.p0" e1="DDI-MedLine.d60.s2.e0"
            e2="DDI-MedLine.d60.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d60.s2.p1" e1="DDI-MedLine.d60.s2.e0"
            e2="DDI-MedLine.d60.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d60.s2.p2" e1="DDI-MedLine.d60.s2.e0"
            e2="DDI-MedLine.d60.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d60.s2.p3" e1="DDI-MedLine.d60.s2.e1"
            e2="DDI-MedLine.d60.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d60.s2.p4" e1="DDI-MedLine.d60.s2.e1"
            e2="DDI-MedLine.d60.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d60.s2.p5" e1="DDI-MedLine.d60.s2.e2"
            e2="DDI-MedLine.d60.s2.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d60.s3" text="During phenytoin and fluvoxamine treatment, ataxia, a typical side effect of phenytoin, was observed. ">
        <entity id="DDI-MedLine.d60.s3.e0" charOffset="7-15" type="drug" text="phenytoin"/>
        <entity id="DDI-MedLine.d60.s3.e1" charOffset="77-85"
            type="drug" text="phenytoin"/>
        <pair id="DDI-MedLine.d60.s3.p0" e1="DDI-MedLine.d60.s3.e0"
            e2="DDI-MedLine.d60.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d60.s4" text="The genotypes of CYP2C9 and 2C19, the enzymes responsible for phenytoin metabolism, were homozygous for the wild-type alleles (CYP2C9*1/*1 and 2C19*1/ *1). ">
        <entity id="DDI-MedLine.d60.s4.e0" charOffset="17-22"
            type="drug" text="CYP2C9"/>
        <entity id="DDI-MedLine.d60.s4.e1" charOffset="127-132"
            type="drug" text="CYP2C9"/>
        <pair id="DDI-MedLine.d60.s4.p0" e1="DDI-MedLine.d60.s4.e0"
            e2="DDI-MedLine.d60.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d60.s5" text="The interaction may be a result of inhibition of both CYP2C9 and 2C19 by fluvoxamine.">
        <entity id="DDI-MedLine.d60.s5.e0" charOffset="54-59"
            type="drug" text="CYP2C9"/>
        <entity id="DDI-MedLine.d60.s5.e1" charOffset="73-83"
            type="drug" text="fluvoxamine"/>
        <pair id="DDI-MedLine.d60.s5.p0" e1="DDI-MedLine.d60.s5.e0"
            e2="DDI-MedLine.d60.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d123.s0" text="Vancomycin resistance reversal in enterococci by flavonoids.&#xa;"/>
    <sentence id="DDI-MedLine.d123.s1" text="The development of clinical vancomycin-resistant strains of enterococci (VRE) is a major cause for concern. "/>
    <sentence id="DDI-MedLine.d123.s2" text="Here we show that a combination of galangin or 3,7-dihydroxyflavone with vancomycin may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains. ">
        <entity id="DDI-MedLine.d123.s2.e0" charOffset="35-42"
            type="drug" text="galangin"/>
        <entity id="DDI-MedLine.d123.s2.e1" charOffset="73-82"
            type="drug" text="vancomycin"/>
        <pair id="DDI-MedLine.d123.s2.p0" e1="DDI-MedLine.d123.s2.e0"
            e2="DDI-MedLine.d123.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d123.s3" text="Minimum inhibitory concentrations (MICs) and viable counts were determined in Iso-sensitest broth using a microtitre method. "/>
    <sentence id="DDI-MedLine.d123.s4" text="MICs of vancomycin against 67% of resistant clinical isolates and a type strain of enterococci were lowered from > 250 microg mL(-1) to 1">
        <entity id="DDI-MedLine.d123.s4.e0" charOffset="8-17"
            type="drug" text="vancomycin"/>
    </sentence>
    <sentence id="DDI-MedLine.d123.s5" text="4 microg mL(-1) in the presence of galangin (12.5 microg mL(-1)) or 3,7-dihydroxyflavone (6.25 microg mL(-1)). ">
        <entity id="DDI-MedLine.d123.s5.e0" charOffset="35-42"
            type="drug" text="galangin"/>
    </sentence>
    <sentence id="DDI-MedLine.d123.s6" text="Viable counts for type culture E. "/>
    <sentence id="DDI-MedLine.d123.s7" text="faecalis ATCC 51299 showed the flavonoids alone significantly lowered numbers of colony forming units (CFUs). "/>
    <sentence id="DDI-MedLine.d123.s8" text="CFUs were maintained at low levels (10(3) CFU mL(-1)) for 24 h by vancomycin/flavone combinations. ">
        <entity id="DDI-MedLine.d123.s8.e0" charOffset="66-75"
            type="drug" text="vancomycin"/>
    </sentence>
    <sentence id="DDI-MedLine.d123.s9" text="This combinational action in reversing vancomycin resistance of enterococci highlights novel drug targets and has importance in the design of new therapeutic regimes against resistant pathogens."/>
    <sentence id="DDI-MedLine.d137.s0" text="Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans.&#xa;">
        <entity id="DDI-MedLine.d137.s0.e0" charOffset="0-6" type="drug" text="Glucose"/>
        <entity id="DDI-MedLine.d137.s0.e1" charOffset="12-18"
            type="drug" text="insulin"/>
        <pair id="DDI-MedLine.d137.s0.p0" e1="DDI-MedLine.d137.s0.e0"
            e2="DDI-MedLine.d137.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d137.s1" text="AIMS/HYPOTHESIS: There is evidence that insulin and glucose cause renal and ocular vasodilation. ">
        <entity id="DDI-MedLine.d137.s1.e0" charOffset="40-46"
            type="drug" text="insulin"/>
        <entity id="DDI-MedLine.d137.s1.e1" charOffset="52-58"
            type="drug" text="glucose"/>
        <pair id="DDI-MedLine.d137.s1.p0" e1="DDI-MedLine.d137.s1.e0"
            e2="DDI-MedLine.d137.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d137.s2" text="There is, however, currently no data on the effect of combined hyperglycaemia and hyperinsulinaemia on the renal and ocular blood flow seen in diabetic patients on insulin therapy. ">
        <entity id="DDI-MedLine.d137.s2.e0" charOffset="87-93"
            type="drug" text="insulin"/>
    </sentence>
    <sentence id="DDI-MedLine.d137.s3" text="METHODS: We carried out two different 3-way crossover studies in healthy subjects (each, n = 9). "/>
    <sentence id="DDI-MedLine.d137.s4" text="In study one, hyperglycaemic clamps (5.6 mmol/l, 11.1 mmol/ 1, 16.7 mmol/l) were carried out during placebo or insulin (dose 1: 1 mU/kg/min; dose 2: 2 mU/kg/min) infusion. ">
        <entity id="DDI-MedLine.d137.s4.e0" charOffset="111-117"
            type="drug" text="insulin"/>
    </sentence>
    <sentence id="DDI-MedLine.d137.s5" text="The second study was identical but endogenous insulin secretion was blocked with somatostatin. ">
        <entity id="DDI-MedLine.d137.s5.e0" charOffset="81-92"
            type="drug" text="somatostatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d137.s6" text="The renal plasma flow, glomerular filtration rate and pulsatile choroidal blood flow were measured using the paraaminohippurate method, the inulin method and a laser interferometric measurement of fundus pulsation amplitude, respectively. "/>
    <sentence id="DDI-MedLine.d137.s7" text="RESULTS: Insulin increased renal plasma flow and fundus pulsation amplitude but not the glomerular filtration rate. ">
        <entity id="DDI-MedLine.d137.s7.e0" charOffset="9-15"
            type="drug" text="Insulin"/>
    </sentence>
    <sentence id="DDI-MedLine.d137.s8" text="Hyperglycaemia increased all the renal and ocular parameters studied. "/>
    <sentence id="DDI-MedLine.d137.s9" text="Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions. ">
        <entity id="DDI-MedLine.d137.s9.e0" charOffset="24-30"
            type="drug" text="glucose"/>
        <entity id="DDI-MedLine.d137.s9.e1" charOffset="36-42"
            type="drug" text="insulin"/>
        <entity id="DDI-MedLine.d137.s9.e2" charOffset="63-74"
            type="drug" text="somatostatin"/>
        <pair id="DDI-MedLine.d137.s9.p0" e1="DDI-MedLine.d137.s9.e0"
            e2="DDI-MedLine.d137.s9.e1" ddi="false"/>
        <pair id="DDI-MedLine.d137.s9.p1" e1="DDI-MedLine.d137.s9.e0"
            e2="DDI-MedLine.d137.s9.e2" ddi="false"/>
        <pair id="DDI-MedLine.d137.s9.p2" e1="DDI-MedLine.d137.s9.e1"
            e2="DDI-MedLine.d137.s9.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d137.s10" text="CONCLUSIONS/INTERPRETATION: Glucose and insulin can exert additive vasodilator properties on renal and ocular circulation. ">
        <entity id="DDI-MedLine.d137.s10.e0" charOffset="28-34"
            type="drug" text="Glucose"/>
        <entity id="DDI-MedLine.d137.s10.e1" charOffset="40-46"
            type="drug" text="insulin"/>
        <pair id="DDI-MedLine.d137.s10.p0" e1="DDI-MedLine.d137.s10.e0"
            e2="DDI-MedLine.d137.s10.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d137.s11" text="To find out whether this observation is related to the increased regional perfusion in diabetes longitudinal studies on patients with Type I (insulin-dependent) diabetes mellitus are needed."/>
    <sentence id="DDI-MedLine.d124.s0" text="Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.&#xd;&#xa;">
        <entity id="DDI-MedLine.d124.s0.e0" charOffset="28-39"
            type="drug" text="levofloxacin"/>
        <entity id="DDI-MedLine.d124.s0.e1" charOffset="45-53"
            type="drug" text="oxycodone"/>
        <pair id="DDI-MedLine.d124.s0.p0" e1="DDI-MedLine.d124.s0.e0"
            e2="DDI-MedLine.d124.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d124.s1" text="Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. ">
        <entity id="DDI-MedLine.d124.s1.e0" charOffset="90-102"
            type="drug" text="trovafloxacin"/>
        <entity id="DDI-MedLine.d124.s1.e1" charOffset="108-120"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-MedLine.d124.s1.e2" charOffset="174-179"
            type="group" text="opiate"/>
        <entity id="DDI-MedLine.d124.s1.e3" charOffset="189-196"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d124.s1.p0" e1="DDI-MedLine.d124.s1.e0"
            e2="DDI-MedLine.d124.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d124.s1.p1" e1="DDI-MedLine.d124.s1.e0"
            e2="DDI-MedLine.d124.s1.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d124.s1.p2" e1="DDI-MedLine.d124.s1.e0"
            e2="DDI-MedLine.d124.s1.e3" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d124.s1.p3" e1="DDI-MedLine.d124.s1.e1"
            e2="DDI-MedLine.d124.s1.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d124.s1.p4" e1="DDI-MedLine.d124.s1.e1"
            e2="DDI-MedLine.d124.s1.e3" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d124.s1.p5" e1="DDI-MedLine.d124.s1.e2"
            e2="DDI-MedLine.d124.s1.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d124.s2" text="This decrease in absorption results in a 36% and 50% lower AUC for trovafloxacin and ciprofloxacin, respectively, which could cause clinical failures. ">
        <entity id="DDI-MedLine.d124.s2.e0" charOffset="67-79"
            type="drug" text="trovafloxacin"/>
        <entity id="DDI-MedLine.d124.s2.e1" charOffset="85-97"
            type="drug" text="ciprofloxacin"/>
        <pair id="DDI-MedLine.d124.s2.p0" e1="DDI-MedLine.d124.s2.e0"
            e2="DDI-MedLine.d124.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d124.s3" text="The authors investigated the possibility of a similar interaction between oxycodone and levofloxacin. ">
        <entity id="DDI-MedLine.d124.s3.e0" charOffset="74-82"
            type="drug" text="oxycodone"/>
        <entity id="DDI-MedLine.d124.s3.e1" charOffset="88-99"
            type="drug" text="levofloxacin"/>
        <pair id="DDI-MedLine.d124.s3.p0" e1="DDI-MedLine.d124.s3.e0"
            e2="DDI-MedLine.d124.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d124.s4" text="Eight healthy volunteers were randomized in an open-label, two-way crossover study to receive oxycodone, 5 mg p.o. ">
        <entity id="DDI-MedLine.d124.s4.e0" charOffset="94-102"
            type="drug" text="oxycodone"/>
    </sentence>
    <sentence id="DDI-MedLine.d124.s5" text="Q4H, and levofloxacin, 500 mg p.o. ">
        <entity id="DDI-MedLine.d124.s5.e0" charOffset="9-20"
            type="drug" text="levofloxacin"/>
    </sentence>
    <sentence id="DDI-MedLine.d124.s6" text="1 hour after starting the oxycodone or levofloxacin 500 mg p.o. ">
        <entity id="DDI-MedLine.d124.s6.e0" charOffset="26-34"
            type="drug" text="oxycodone"/>
        <entity id="DDI-MedLine.d124.s6.e1" charOffset="39-50"
            type="drug" text="levofloxacin"/>
        <pair id="DDI-MedLine.d124.s6.p0" e1="DDI-MedLine.d124.s6.e0"
            e2="DDI-MedLine.d124.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d124.s7" text="alone. "/>
    <sentence id="DDI-MedLine.d124.s8" text="Blood samples were drawn at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours for Cmax, tmax, and AUC determinations. "/>
    <sentence id="DDI-MedLine.d124.s9" text="There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens. ">
        <entity id="DDI-MedLine.d124.s9.e0" charOffset="173-184"
            type="drug" text="levofloxacin"/>
        <entity id="DDI-MedLine.d124.s9.e1" charOffset="193-204"
            type="drug" text="levofloxacin"/>
        <entity id="DDI-MedLine.d124.s9.e2" charOffset="206-214"
            type="drug" text="oxycodone"/>
        <pair id="DDI-MedLine.d124.s9.p0" e1="DDI-MedLine.d124.s9.e0"
            e2="DDI-MedLine.d124.s9.e1" ddi="false"/>
        <pair id="DDI-MedLine.d124.s9.p1" e1="DDI-MedLine.d124.s9.e0"
            e2="DDI-MedLine.d124.s9.e2" ddi="false"/>
        <pair id="DDI-MedLine.d124.s9.p2" e1="DDI-MedLine.d124.s9.e1"
            e2="DDI-MedLine.d124.s9.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d124.s10" text="It was concluded that oral oxycodone and levofloxacin can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax.">
        <entity id="DDI-MedLine.d124.s10.e0" charOffset="27-35"
            type="drug" text="oxycodone"/>
        <entity id="DDI-MedLine.d124.s10.e1" charOffset="41-52"
            type="drug" text="levofloxacin"/>
        <pair id="DDI-MedLine.d124.s10.p0" e1="DDI-MedLine.d124.s10.e0"
            e2="DDI-MedLine.d124.s10.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d105.s0" text="Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.">
        <entity id="DDI-MedLine.d105.s0.e0" charOffset="21-32"
            type="drug" text="azithromycin"/>
        <entity id="DDI-MedLine.d105.s0.e1" charOffset="56-65"
            type="drug" text="zidovudine"/>
        <entity id="DDI-MedLine.d105.s0.e2" charOffset="71-84"
            type="drug" text="dideoxyinosine"/>
        <pair id="DDI-MedLine.d105.s0.p0" e1="DDI-MedLine.d105.s0.e0"
            e2="DDI-MedLine.d105.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d105.s0.p1" e1="DDI-MedLine.d105.s0.e0"
            e2="DDI-MedLine.d105.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d105.s0.p2" e1="DDI-MedLine.d105.s0.e1"
            e2="DDI-MedLine.d105.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d105.s1" text="Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine. ">
        <entity id="DDI-MedLine.d105.s1.e0" charOffset="80-91"
            type="drug" text="azithromycin"/>
        <entity id="DDI-MedLine.d105.s1.e1" charOffset="110-119"
            type="drug" text="zidovudine"/>
        <entity id="DDI-MedLine.d105.s1.e2" charOffset="125-138"
            type="drug" text="dideoxyinosine"/>
        <pair id="DDI-MedLine.d105.s1.p0" e1="DDI-MedLine.d105.s1.e0"
            e2="DDI-MedLine.d105.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d105.s1.p1" e1="DDI-MedLine.d105.s1.e0"
            e2="DDI-MedLine.d105.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d105.s1.p2" e1="DDI-MedLine.d105.s1.e1"
            e2="DDI-MedLine.d105.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d105.s2" text="Both studies used 12 subjects. "/>
    <sentence id="DDI-MedLine.d105.s3" text="The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine. ">
        <entity id="DDI-MedLine.d105.s3.e0" charOffset="4-13"
            type="drug" text="zidovudine"/>
        <entity id="DDI-MedLine.d105.s3.e1" charOffset="56-67"
            type="drug" text="azithromycin"/>
        <entity id="DDI-MedLine.d105.s3.e2" charOffset="180-189"
            type="drug" text="zidovudine"/>
        <pair id="DDI-MedLine.d105.s3.p0" e1="DDI-MedLine.d105.s3.e0"
            e2="DDI-MedLine.d105.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d105.s3.p1" e1="DDI-MedLine.d105.s3.e0"
            e2="DDI-MedLine.d105.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d105.s3.p2" e1="DDI-MedLine.d105.s3.e1"
            e2="DDI-MedLine.d105.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d105.s4" text="Subjects treated with 200 mg of dideoxyinosine twice daily for 21 days received 1200 mg of azithromycin or an equivalent amount of placebo/day for Days 8 to 21. ">
        <entity id="DDI-MedLine.d105.s4.e0" charOffset="32-45"
            type="drug" text="dideoxyinosine"/>
        <entity id="DDI-MedLine.d105.s4.e1" charOffset="91-102"
            type="drug" text="azithromycin"/>
        <pair id="DDI-MedLine.d105.s4.p0" e1="DDI-MedLine.d105.s4.e0"
            e2="DDI-MedLine.d105.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d105.s5" text="Antiretroviral plasma and urine sampling were conducted on Days 1, 7, and 21 for zidovudine and on Days 7 and 21 for dideoxyinosine. ">
        <entity id="DDI-MedLine.d105.s5.e0" charOffset="0-13"
            type="group" text="Antiretroviral"/>
        <entity id="DDI-MedLine.d105.s5.e1" charOffset="81-90"
            type="drug" text="zidovudine"/>
        <entity id="DDI-MedLine.d105.s5.e2" charOffset="117-130"
            type="drug" text="dideoxyinosine"/>
        <pair id="DDI-MedLine.d105.s5.p0" e1="DDI-MedLine.d105.s5.e0"
            e2="DDI-MedLine.d105.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d105.s5.p1" e1="DDI-MedLine.d105.s5.e0"
            e2="DDI-MedLine.d105.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d105.s5.p2" e1="DDI-MedLine.d105.s5.e1"
            e2="DDI-MedLine.d105.s5.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d105.s6" text="Peripheral mononuclear cells were also collected for quantitation of phosphorylated zidovudine. ">
        <entity id="DDI-MedLine.d105.s6.e0" charOffset="84-93"
            type="drug" text="zidovudine"/>
    </sentence>
    <sentence id="DDI-MedLine.d105.s7" text="Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. ">
        <entity id="DDI-MedLine.d105.s7.e0" charOffset="0-11"
            type="drug" text="Azithromycin"/>
        <entity id="DDI-MedLine.d105.s7.e1" charOffset="62-71"
            type="drug" text="zidovudine"/>
        <entity id="DDI-MedLine.d105.s7.e2" charOffset="114-123"
            type="drug" text="zidovudine"/>
        <entity id="DDI-MedLine.d105.s7.e3" charOffset="196-205"
            type="drug" text="zidovudine"/>
        <pair id="DDI-MedLine.d105.s7.p0" e1="DDI-MedLine.d105.s7.e0"
            e2="DDI-MedLine.d105.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d105.s7.p1" e1="DDI-MedLine.d105.s7.e0"
            e2="DDI-MedLine.d105.s7.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d105.s7.p2" e1="DDI-MedLine.d105.s7.e0"
            e2="DDI-MedLine.d105.s7.e3" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d105.s7.p3" e1="DDI-MedLine.d105.s7.e1"
            e2="DDI-MedLine.d105.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d105.s7.p4" e1="DDI-MedLine.d105.s7.e1"
            e2="DDI-MedLine.d105.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d105.s7.p5" e1="DDI-MedLine.d105.s7.e2"
            e2="DDI-MedLine.d105.s7.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d105.s8" text="Azithromycin had no significant effect on dideoxyinosine pharmacokinetics. ">
        <entity id="DDI-MedLine.d105.s8.e0" charOffset="0-11"
            type="drug" text="Azithromycin"/>
        <entity id="DDI-MedLine.d105.s8.e1" charOffset="42-55"
            type="drug" text="dideoxyinosine"/>
        <pair id="DDI-MedLine.d105.s8.p0" e1="DDI-MedLine.d105.s8.e0"
            e2="DDI-MedLine.d105.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d105.s9" text="Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine.">
        <entity id="DDI-MedLine.d105.s9.e0" charOffset="60-71"
            type="drug" text="azithromycin"/>
        <entity id="DDI-MedLine.d105.s9.e1" charOffset="112-121"
            type="drug" text="zidovudine"/>
        <entity id="DDI-MedLine.d105.s9.e2" charOffset="127-140"
            type="drug" text="dideoxyinosine"/>
        <pair id="DDI-MedLine.d105.s9.p0" e1="DDI-MedLine.d105.s9.e0"
            e2="DDI-MedLine.d105.s9.e1" ddi="false"/>
        <pair id="DDI-MedLine.d105.s9.p1" e1="DDI-MedLine.d105.s9.e0"
            e2="DDI-MedLine.d105.s9.e2" ddi="false"/>
        <pair id="DDI-MedLine.d105.s9.p2" e1="DDI-MedLine.d105.s9.e1"
            e2="DDI-MedLine.d105.s9.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d67.s0" text="Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.">
        <entity id="DDI-MedLine.d67.s0.e0" charOffset="10-17"
            type="drug" text="diazepam"/>
        <entity id="DDI-MedLine.d67.s0.e1" charOffset="23-31"
            type="drug" text="midazolam"/>
        <entity id="DDI-MedLine.d67.s0.e2" charOffset="66-73"
            type="drug" text="morphine"/>
        <entity id="DDI-MedLine.d67.s0.e3" charOffset="76-84"
            type="drug" text="metamizol"/>
        <entity id="DDI-MedLine.d67.s0.e4" charOffset="90-101"
            type="drug" text="indomethacin"/>
        <pair id="DDI-MedLine.d67.s0.p0" e1="DDI-MedLine.d67.s0.e0"
            e2="DDI-MedLine.d67.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d67.s0.p1" e1="DDI-MedLine.d67.s0.e0"
            e2="DDI-MedLine.d67.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d67.s0.p2" e1="DDI-MedLine.d67.s0.e0"
            e2="DDI-MedLine.d67.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d67.s0.p3" e1="DDI-MedLine.d67.s0.e0"
            e2="DDI-MedLine.d67.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d67.s0.p4" e1="DDI-MedLine.d67.s0.e1"
            e2="DDI-MedLine.d67.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d67.s0.p5" e1="DDI-MedLine.d67.s0.e1"
            e2="DDI-MedLine.d67.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d67.s0.p6" e1="DDI-MedLine.d67.s0.e1"
            e2="DDI-MedLine.d67.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d67.s0.p7" e1="DDI-MedLine.d67.s0.e2"
            e2="DDI-MedLine.d67.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d67.s0.p8" e1="DDI-MedLine.d67.s0.e2"
            e2="DDI-MedLine.d67.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d67.s0.p9" e1="DDI-MedLine.d67.s0.e3"
            e2="DDI-MedLine.d67.s0.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d67.s1" text="The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. ">
        <entity id="DDI-MedLine.d67.s1.e0" charOffset="17-25"
            type="drug" text="midazolam"/>
        <entity id="DDI-MedLine.d67.s1.e1" charOffset="31-38"
            type="drug" text="diazepam"/>
        <entity id="DDI-MedLine.d67.s1.e2" charOffset="69-76"
            type="drug" text="morphine"/>
        <entity id="DDI-MedLine.d67.s1.e3" charOffset="90-98"
            type="drug" text="metamizol"/>
        <entity id="DDI-MedLine.d67.s1.e4" charOffset="116-127"
            type="drug" text="indomethacin"/>
        <pair id="DDI-MedLine.d67.s1.p0" e1="DDI-MedLine.d67.s1.e0"
            e2="DDI-MedLine.d67.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d67.s1.p1" e1="DDI-MedLine.d67.s1.e0"
            e2="DDI-MedLine.d67.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d67.s1.p2" e1="DDI-MedLine.d67.s1.e0"
            e2="DDI-MedLine.d67.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d67.s1.p3" e1="DDI-MedLine.d67.s1.e0"
            e2="DDI-MedLine.d67.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d67.s1.p4" e1="DDI-MedLine.d67.s1.e1"
            e2="DDI-MedLine.d67.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d67.s1.p5" e1="DDI-MedLine.d67.s1.e1"
            e2="DDI-MedLine.d67.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d67.s1.p6" e1="DDI-MedLine.d67.s1.e1"
            e2="DDI-MedLine.d67.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d67.s1.p7" e1="DDI-MedLine.d67.s1.e2"
            e2="DDI-MedLine.d67.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d67.s1.p8" e1="DDI-MedLine.d67.s1.e2"
            e2="DDI-MedLine.d67.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d67.s1.p9" e1="DDI-MedLine.d67.s1.e3"
            e2="DDI-MedLine.d67.s1.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d67.s2" text="All drugs were injected intraperitoneally. "/>
    <sentence id="DDI-MedLine.d67.s3" text="Benzodiazepines were administered to mice 30 min before applying the analgesic drugs. ">
        <entity id="DDI-MedLine.d67.s3.e0" charOffset="0-14"
            type="group" text="Benzodiazepines"/>
        <entity id="DDI-MedLine.d67.s3.e1" charOffset="69-83"
            type="group" text="analgesic drugs"/>
        <pair id="DDI-MedLine.d67.s3.p0" e1="DDI-MedLine.d67.s3.e0"
            e2="DDI-MedLine.d67.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d67.s4" text="Measurement of nociception was performed within 2 h after benzodiazepine administration. ">
        <entity id="DDI-MedLine.d67.s4.e0" charOffset="58-71"
            type="group" text="benzodiazepine"/>
    </sentence>
    <sentence id="DDI-MedLine.d67.s5" text="Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. ">
        <entity id="DDI-MedLine.d67.s5.e0" charOffset="0-7" type="drug" text="Diazepam"/>
        <entity id="DDI-MedLine.d67.s5.e1" charOffset="60-67"
            type="drug" text="morphine"/>
        <entity id="DDI-MedLine.d67.s5.e2" charOffset="121-128"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d67.s5.p0" e1="DDI-MedLine.d67.s5.e0"
            e2="DDI-MedLine.d67.s5.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d67.s5.p1" e1="DDI-MedLine.d67.s5.e0"
            e2="DDI-MedLine.d67.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d67.s5.p2" e1="DDI-MedLine.d67.s5.e1"
            e2="DDI-MedLine.d67.s5.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d67.s6" text="Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. ">
        <entity id="DDI-MedLine.d67.s6.e0" charOffset="11-18"
            type="drug" text="diazepam"/>
        <entity id="DDI-MedLine.d67.s6.e1" charOffset="60-68"
            type="drug" text="metamizol"/>
        <entity id="DDI-MedLine.d67.s6.e2" charOffset="104-115"
            type="drug" text="indomethacin"/>
        <pair id="DDI-MedLine.d67.s6.p0" e1="DDI-MedLine.d67.s6.e0"
            e2="DDI-MedLine.d67.s6.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d67.s6.p1" e1="DDI-MedLine.d67.s6.e0"
            e2="DDI-MedLine.d67.s6.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d67.s6.p2" e1="DDI-MedLine.d67.s6.e1"
            e2="DDI-MedLine.d67.s6.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d67.s7" text="Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.">
        <entity id="DDI-MedLine.d67.s7.e0" charOffset="0-8" type="drug" text="Midazolam"/>
        <entity id="DDI-MedLine.d67.s7.e1" charOffset="92-99"
            type="drug" text="morphine"/>
        <entity id="DDI-MedLine.d67.s7.e2" charOffset="102-110"
            type="drug" text="metamizol"/>
        <entity id="DDI-MedLine.d67.s7.e3" charOffset="146-157"
            type="drug" text="indomethacin"/>
        <pair id="DDI-MedLine.d67.s7.p0" e1="DDI-MedLine.d67.s7.e0"
            e2="DDI-MedLine.d67.s7.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d67.s7.p1" e1="DDI-MedLine.d67.s7.e0"
            e2="DDI-MedLine.d67.s7.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d67.s7.p2" e1="DDI-MedLine.d67.s7.e0"
            e2="DDI-MedLine.d67.s7.e3" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d67.s7.p3" e1="DDI-MedLine.d67.s7.e1"
            e2="DDI-MedLine.d67.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d67.s7.p4" e1="DDI-MedLine.d67.s7.e1"
            e2="DDI-MedLine.d67.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d67.s7.p5" e1="DDI-MedLine.d67.s7.e2"
            e2="DDI-MedLine.d67.s7.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d64.s0" text="Pharmacological treatment of depression: the role of paroxetine.&#xd;&#xa;">
        <entity id="DDI-MedLine.d64.s0.e0" charOffset="53-62"
            type="drug" text="paroxetine"/>
    </sentence>
    <sentence id="DDI-MedLine.d64.s1" text="Depression is reaching epidemic proportions in the western world. "/>
    <sentence id="DDI-MedLine.d64.s2" text="With each successive generation more people are becoming more severely depressed at a younger age."/>
    <sentence id="DDI-MedLine.d102.s0" text="Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.&#xd;&#xa;">
        <entity id="DDI-MedLine.d102.s0.e0" charOffset="13-21"
            type="drug" text="estradiol"/>
        <entity id="DDI-MedLine.d102.s0.e1" charOffset="27-38"
            type="drug" text="progesterone"/>
        <entity id="DDI-MedLine.d102.s0.e2" charOffset="84-96"
            type="drug" text="noradrenaline"/>
        <pair id="DDI-MedLine.d102.s0.p0" e1="DDI-MedLine.d102.s0.e0"
            e2="DDI-MedLine.d102.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d102.s0.p1" e1="DDI-MedLine.d102.s0.e0"
            e2="DDI-MedLine.d102.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d102.s0.p2" e1="DDI-MedLine.d102.s0.e1"
            e2="DDI-MedLine.d102.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d102.s1" text="The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. ">
        <entity id="DDI-MedLine.d102.s1.e0" charOffset="78-86"
            type="drug" text="estradiol"/>
        <entity id="DDI-MedLine.d102.s1.e1" charOffset="96-107"
            type="drug" text="progesterone"/>
        <entity id="DDI-MedLine.d102.s1.e2" charOffset="128-140"
            type="drug" text="noradrenaline"/>
        <pair id="DDI-MedLine.d102.s1.p0" e1="DDI-MedLine.d102.s1.e0"
            e2="DDI-MedLine.d102.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d102.s1.p1" e1="DDI-MedLine.d102.s1.e0"
            e2="DDI-MedLine.d102.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d102.s1.p2" e1="DDI-MedLine.d102.s1.e1"
            e2="DDI-MedLine.d102.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d102.s2" text="Two weeks after bilateral ovariectomy, female rats received a s.c. "/>
    <sentence id="DDI-MedLine.d102.s3" text="injection of vehicle (corn oil, 0.1 mL/day), estradiol (10 microg/kg/day or 4 mg/kg/day) and/or progesterone (20 mg/kg/day), for eight days. ">
        <entity id="DDI-MedLine.d102.s3.e0" charOffset="45-53"
            type="drug" text="estradiol"/>
        <entity id="DDI-MedLine.d102.s3.e1" charOffset="96-107"
            type="drug" text="progesterone"/>
        <pair id="DDI-MedLine.d102.s3.p0" e1="DDI-MedLine.d102.s3.e0"
            e2="DDI-MedLine.d102.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d102.s4" text="On the ninth day, the rats were sacrificed and aortic rings, with or without endothelium, were used to generate concentration-response curves to noradrenaline. ">
        <entity id="DDI-MedLine.d102.s4.e0" charOffset="145-157"
            type="drug" text="noradrenaline"/>
    </sentence>
    <sentence id="DDI-MedLine.d102.s5" text="Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). ">
        <entity id="DDI-MedLine.d102.s5.e0" charOffset="70-78"
            type="drug" text="estradiol"/>
        <entity id="DDI-MedLine.d102.s5.e1" charOffset="109-121"
            type="drug" text="noradrenaline"/>
        <pair id="DDI-MedLine.d102.s5.p0" e1="DDI-MedLine.d102.s5.e0"
            e2="DDI-MedLine.d102.s5.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d102.s6" text="Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ">
        <entity id="DDI-MedLine.d102.s6.e0" charOffset="42-50"
            type="drug" text="estradiol"/>
        <entity id="DDI-MedLine.d102.s6.e1" charOffset="80-92"
            type="drug" text="noradrenaline"/>
        <entity id="DDI-MedLine.d102.s6.e2" charOffset="121-132"
            type="drug" text="progesterone"/>
        <entity id="DDI-MedLine.d102.s6.e3" charOffset="139-150"
            type="drug" text="progesterone"/>
        <entity id="DDI-MedLine.d102.s6.e4" charOffset="159-167"
            type="drug" text="estradiol"/>
        <pair id="DDI-MedLine.d102.s6.p0" e1="DDI-MedLine.d102.s6.e0"
            e2="DDI-MedLine.d102.s6.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d102.s6.p1" e1="DDI-MedLine.d102.s6.e0"
            e2="DDI-MedLine.d102.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d102.s6.p2" e1="DDI-MedLine.d102.s6.e0"
            e2="DDI-MedLine.d102.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d102.s6.p3" e1="DDI-MedLine.d102.s6.e0"
            e2="DDI-MedLine.d102.s6.e4" ddi="false"/>
        <pair id="DDI-MedLine.d102.s6.p4" e1="DDI-MedLine.d102.s6.e1"
            e2="DDI-MedLine.d102.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d102.s6.p5" e1="DDI-MedLine.d102.s6.e1"
            e2="DDI-MedLine.d102.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d102.s6.p6" e1="DDI-MedLine.d102.s6.e1"
            e2="DDI-MedLine.d102.s6.e4" ddi="false"/>
        <pair id="DDI-MedLine.d102.s6.p7" e1="DDI-MedLine.d102.s6.e2"
            e2="DDI-MedLine.d102.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d102.s6.p8" e1="DDI-MedLine.d102.s6.e2"
            e2="DDI-MedLine.d102.s6.e4" ddi="false"/>
        <pair id="DDI-MedLine.d102.s6.p9" e1="DDI-MedLine.d102.s6.e3"
            e2="DDI-MedLine.d102.s6.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d102.s7" text="There were no significant differences among the pD2 values for noradrenaline in aortic rings without endothelium. ">
        <entity id="DDI-MedLine.d102.s7.e0" charOffset="63-75"
            type="drug" text="noradrenaline"/>
    </sentence>
    <sentence id="DDI-MedLine.d102.s8" text="Both of these effects were endothelium-dependent."/>
    <sentence id="DDI-MedLine.d1.s0" text="[Drug treatment of erection disorders in patients with cardiovascular disease]&#xa;Erectile dysfunction is a frequent condition in cardiovascular patients. "/>
    <sentence id="DDI-MedLine.d1.s1" text="Since the arrival of oral erection-supporting medication, patients want to know how safe sexual activity is in cardiovascular disease in general and during use of erection-supporting medication in particular. ">
        <entity id="DDI-MedLine.d1.s1.e0" charOffset="26-55"
            type="group" text="erection-supporting medication"/>
        <entity id="DDI-MedLine.d1.s1.e1" charOffset="163-192"
            type="group" text="erection-supporting medication"/>
        <pair id="DDI-MedLine.d1.s1.p0" e1="DDI-MedLine.d1.s1.e0"
            e2="DDI-MedLine.d1.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d1.s2" text="Sexual intercourse with a steady partner causes no more cardiovascular risk than normal daily activities such as ironing, 2 kilometers of walking without climbing, paperhanging, playing golf or gardening. "/>
    <sentence id="DDI-MedLine.d1.s3" text="The relative risk of myocardial infarction during sexual activity is not significantly higher than for healthy persons. "/>
    <sentence id="DDI-MedLine.d1.s4" text="The incidence of cardiovascular morbidity and mortality is not higher among users of sildenafil. ">
        <entity id="DDI-MedLine.d1.s4.e0" charOffset="85-94" type="drug" text="sildenafil"/>
    </sentence>
    <sentence id="DDI-MedLine.d1.s5" text="Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. ">
        <entity id="DDI-MedLine.d1.s5.e0" charOffset="0-9" type="drug" text="Sildenafil"/>
        <entity id="DDI-MedLine.d1.s5.e1" charOffset="48-67"
            type="group" text="long-acting nitrates"/>
        <entity id="DDI-MedLine.d1.s5.e2" charOffset="92-112"
            type="group" text="short-acting nitrates"/>
        <pair id="DDI-MedLine.d1.s5.p0" e1="DDI-MedLine.d1.s5.e0"
            e2="DDI-MedLine.d1.s5.e1" ddi="true" type="advise"/>
        <pair id="DDI-MedLine.d1.s5.p1" e1="DDI-MedLine.d1.s5.e0"
            e2="DDI-MedLine.d1.s5.e2" ddi="true" type="advise"/>
        <pair id="DDI-MedLine.d1.s5.p2" e1="DDI-MedLine.d1.s5.e1"
            e2="DDI-MedLine.d1.s5.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d1.s6" text="No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. ">
        <entity id="DDI-MedLine.d1.s6.e0" charOffset="40-61"
            type="group" text="beta-receptor blockers"/>
        <entity id="DDI-MedLine.d1.s6.e1" charOffset="64-82"
            type="group" text="calcium antagonists"/>
        <entity id="DDI-MedLine.d1.s6.e2" charOffset="85-92;103-111"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-MedLine.d1.s6.e3" charOffset="98-111"
            type="group" text="loop diuretics"/>
        <entity id="DDI-MedLine.d1.s6.e4" charOffset="117-130"
            type="group" text="ACE inhibitors"/>
        <pair id="DDI-MedLine.d1.s6.p0" e1="DDI-MedLine.d1.s6.e0"
            e2="DDI-MedLine.d1.s6.e1" ddi="false"/>
        <pair id="DDI-MedLine.d1.s6.p1" e1="DDI-MedLine.d1.s6.e0"
            e2="DDI-MedLine.d1.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d1.s6.p2" e1="DDI-MedLine.d1.s6.e0"
            e2="DDI-MedLine.d1.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d1.s6.p3" e1="DDI-MedLine.d1.s6.e0"
            e2="DDI-MedLine.d1.s6.e4" ddi="false"/>
        <pair id="DDI-MedLine.d1.s6.p4" e1="DDI-MedLine.d1.s6.e1"
            e2="DDI-MedLine.d1.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d1.s6.p5" e1="DDI-MedLine.d1.s6.e1"
            e2="DDI-MedLine.d1.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d1.s6.p6" e1="DDI-MedLine.d1.s6.e1"
            e2="DDI-MedLine.d1.s6.e4" ddi="false"/>
        <pair id="DDI-MedLine.d1.s6.p7" e1="DDI-MedLine.d1.s6.e2"
            e2="DDI-MedLine.d1.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d1.s6.p8" e1="DDI-MedLine.d1.s6.e2"
            e2="DDI-MedLine.d1.s6.e4" ddi="false"/>
        <pair id="DDI-MedLine.d1.s6.p9" e1="DDI-MedLine.d1.s6.e3"
            e2="DDI-MedLine.d1.s6.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d1.s7" text="Before prescribing a symptomatic (pharmaceutical) treatment for patients with an erection disorder, attention should be given tot the sexological, psychological and medical backgrounds of the disorder. "/>
    <sentence id="DDI-MedLine.d1.s8" text="Secondary prevention of atherosclerotic risk factors is also important: regulation of blood pressure and blood sugar level, hyperlipidaemia and obesity, as well as a change of lifestyle (giving up smoking, adapting of diet and more physical exertion). "/>
    <sentence id="DDI-MedLine.d1.s9" text="Patients with a very low cardiac capacity should be advised to refrain from treatment of the erection disorder."/>
    <sentence id="DDI-MedLine.d46.s0" text="Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.&#xd;&#xa;">
        <entity id="DDI-MedLine.d46.s0.e0" charOffset="33-42"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-MedLine.d46.s0.e1" charOffset="47-55"
            type="drug" text="cisapride"/>
        <pair id="DDI-MedLine.d46.s0.p0" e1="DDI-MedLine.d46.s0.e0"
            e2="DDI-MedLine.d46.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d46.s1" text="STUDY OBJECTIVE: To evaluate the effect of fluoxetine on the pharmacokinetics and cardiovascular safety of cisapride at steady state in healthy men. ">
        <entity id="DDI-MedLine.d46.s1.e0" charOffset="43-52"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-MedLine.d46.s1.e1" charOffset="107-115"
            type="drug" text="cisapride"/>
        <pair id="DDI-MedLine.d46.s1.p0" e1="DDI-MedLine.d46.s1.e0"
            e2="DDI-MedLine.d46.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d46.s2" text="DESIGN: Open-label, three-phase, sequential study. "/>
    <sentence id="DDI-MedLine.d46.s3" text="SETTING: Clinical research center. "/>
    <sentence id="DDI-MedLine.d46.s4" text="SUBJECTS:Twelve healthy male volunteers. "/>
    <sentence id="DDI-MedLine.d46.s5" text="INTERVENTIONS: Each subject was treated according to the following sequence: baseline; "/>
    <sentence id="DDI-MedLine.d46.s6" text="phase 1 (days 1-6): cisapride 10 mg 4 times/day; ">
        <entity id="DDI-MedLine.d46.s6.e0" charOffset="20-28"
            type="drug" text="cisapride"/>
    </sentence>
    <sentence id="DDI-MedLine.d46.s7" text="washout (days 7-13); "/>
    <sentence id="DDI-MedLine.d46.s8" text="phase 2 (days 14-44): fluoxetine 20 mg/day; ">
        <entity id="DDI-MedLine.d46.s8.e0" charOffset="22-31"
            type="drug" text="fluoxetine"/>
    </sentence>
    <sentence id="DDI-MedLine.d46.s9" text="and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52). ">
        <entity id="DDI-MedLine.d46.s9.e0" charOffset="26-34"
            type="drug" text="cisapride"/>
        <entity id="DDI-MedLine.d46.s9.e1" charOffset="72-81"
            type="drug" text="fluoxetine"/>
        <pair id="DDI-MedLine.d46.s9.p0" e1="DDI-MedLine.d46.s9.e0"
            e2="DDI-MedLine.d46.s9.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d46.s10" text="MEASUREMENTS and MAIN RESULTS: Blood samples were drawn and 12-lead electrocardiograms performed at specified time points after the last morning dose of cisapride in phases 1 and 3. ">
        <entity id="DDI-MedLine.d46.s10.e0" charOffset="153-161"
            type="drug" text="cisapride"/>
    </sentence>
    <sentence id="DDI-MedLine.d46.s11" text="Blood samples also were taken before morning doses on the 3rd, 4th, and 5th days of phases 1 and 3. "/>
    <sentence id="DDI-MedLine.d46.s12" text="Electrocardiograms were done at baseline and on the last day of the washout period and phase 2. "/>
    <sentence id="DDI-MedLine.d46.s13" text="Coadministration of fluoxetine significantly decreased cisapride plasma concentrations. ">
        <entity id="DDI-MedLine.d46.s13.e0" charOffset="20-29"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-MedLine.d46.s13.e1" charOffset="55-63"
            type="drug" text="cisapride"/>
        <pair id="DDI-MedLine.d46.s13.p0" e1="DDI-MedLine.d46.s13.e0"
            e2="DDI-MedLine.d46.s13.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d46.s14" text="There were no clinically significant changes in corrected QT intervals during administration of cisapride alone or with fluoxetine. ">
        <entity id="DDI-MedLine.d46.s14.e0" charOffset="96-104"
            type="drug" text="cisapride"/>
        <entity id="DDI-MedLine.d46.s14.e1" charOffset="120-129"
            type="drug" text="fluoxetine"/>
        <pair id="DDI-MedLine.d46.s14.p0" e1="DDI-MedLine.d46.s14.e0"
            e2="DDI-MedLine.d46.s14.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d46.s15" text="Cisapride was well tolerated when administered alone or with fluoxetine. ">
        <entity id="DDI-MedLine.d46.s15.e0" charOffset="0-8" type="drug" text="Cisapride"/>
        <entity id="DDI-MedLine.d46.s15.e1" charOffset="61-70"
            type="drug" text="fluoxetine"/>
        <pair id="DDI-MedLine.d46.s15.p0" e1="DDI-MedLine.d46.s15.e0"
            e2="DDI-MedLine.d46.s15.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d46.s16" text="CONCLUSION: Cisapride can be administered safely to patients receiving low therapeutic dosages of fluoxetine.">
        <entity id="DDI-MedLine.d46.s16.e0" charOffset="12-20"
            type="drug" text="Cisapride"/>
        <entity id="DDI-MedLine.d46.s16.e1" charOffset="98-107"
            type="drug" text="fluoxetine"/>
        <pair id="DDI-MedLine.d46.s16.p0" e1="DDI-MedLine.d46.s16.e0"
            e2="DDI-MedLine.d46.s16.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s0" text="Olanzapine: an updated review of its use in the management of schizophrenia.&#xa;">
        <entity id="DDI-MedLine.d83.s0.e0" charOffset="0-9" type="drug" text="Olanzapine"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s1" text="Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. ">
        <entity id="DDI-MedLine.d83.s1.e0" charOffset="0-9" type="drug" text="Olanzapine"/>
        <entity id="DDI-MedLine.d83.s1.e1" charOffset="14-44"
            type="group" text="thienobenzodiazepine derivative"/>
        <entity id="DDI-MedLine.d83.s1.e2" charOffset="52-99"
            type="group" text="second generation (atypical) antipsychotic agent"/>
        <pair id="DDI-MedLine.d83.s1.p0" e1="DDI-MedLine.d83.s1.e0"
            e2="DDI-MedLine.d83.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d83.s1.p1" e1="DDI-MedLine.d83.s1.e0"
            e2="DDI-MedLine.d83.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d83.s1.p2" e1="DDI-MedLine.d83.s1.e1"
            e2="DDI-MedLine.d83.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s2" text="Compared with conventional antipsychotics, it has greater affinity for serotonin 5-HT2A than for dopamine D2 receptors. ">
        <entity id="DDI-MedLine.d83.s2.e0" charOffset="14-40"
            type="group" text="conventional antipsychotics"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s3" text="In large, well controlled trials in patients with schizophrenia or related psychoses, olanzapine 5 to 20 mg/day was significantly superior to haloperidol 5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms. ">
        <entity id="DDI-MedLine.d83.s3.e0" charOffset="86-95"
            type="drug" text="olanzapine"/>
        <entity id="DDI-MedLine.d83.s3.e1" charOffset="142-152"
            type="drug" text="haloperidol"/>
        <pair id="DDI-MedLine.d83.s3.p0" e1="DDI-MedLine.d83.s3.e0"
            e2="DDI-MedLine.d83.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s4" text="The 1-year risk of relapse (rehospitalisation) was significantly lower with olanzapine than with haloperidol treatment. ">
        <entity id="DDI-MedLine.d83.s4.e0" charOffset="76-85"
            type="drug" text="olanzapine"/>
        <entity id="DDI-MedLine.d83.s4.e1" charOffset="97-107"
            type="drug" text="haloperidol"/>
        <pair id="DDI-MedLine.d83.s4.p0" e1="DDI-MedLine.d83.s4.e0"
            e2="DDI-MedLine.d83.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s5" text="In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. ">
        <entity id="DDI-MedLine.d83.s5.e0" charOffset="57-66"
            type="drug" text="olanzapine"/>
        <entity id="DDI-MedLine.d83.s5.e1" charOffset="72-82"
            type="drug" text="risperidone"/>
        <entity id="DDI-MedLine.d83.s5.e2" charOffset="85-94"
            type="drug" text="olanzapine"/>
        <entity id="DDI-MedLine.d83.s5.e3" charOffset="159-169"
            type="drug" text="risperidone"/>
        <pair id="DDI-MedLine.d83.s5.p0" e1="DDI-MedLine.d83.s5.e0"
            e2="DDI-MedLine.d83.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d83.s5.p1" e1="DDI-MedLine.d83.s5.e0"
            e2="DDI-MedLine.d83.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d83.s5.p2" e1="DDI-MedLine.d83.s5.e0"
            e2="DDI-MedLine.d83.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d83.s5.p3" e1="DDI-MedLine.d83.s5.e1"
            e2="DDI-MedLine.d83.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d83.s5.p4" e1="DDI-MedLine.d83.s5.e1"
            e2="DDI-MedLine.d83.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d83.s5.p5" e1="DDI-MedLine.d83.s5.e2"
            e2="DDI-MedLine.d83.s5.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s6" text="In contrast, preliminary results from an 8-week controlled study suggested risperidone 2 to 6 mg/day was superior to olanzapine 5 to 20 mg/day against positive and anxiety/depressive symptoms (p &lt; 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology. ">
        <entity id="DDI-MedLine.d83.s6.e0" charOffset="75-85"
            type="drug" text="risperidone"/>
        <entity id="DDI-MedLine.d83.s6.e1" charOffset="117-126"
            type="drug" text="olanzapine"/>
        <pair id="DDI-MedLine.d83.s6.p0" e1="DDI-MedLine.d83.s6.e0"
            e2="DDI-MedLine.d83.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s7" text="Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. ">
        <entity id="DDI-MedLine.d83.s7.e0" charOffset="53-62"
            type="drug" text="olanzapine"/>
        <entity id="DDI-MedLine.d83.s7.e1" charOffset="204-214"
            type="drug" text="risperidone"/>
        <entity id="DDI-MedLine.d83.s7.e2" charOffset="219-229"
            type="drug" text="haloperidol"/>
        <pair id="DDI-MedLine.d83.s7.p0" e1="DDI-MedLine.d83.s7.e0"
            e2="DDI-MedLine.d83.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d83.s7.p1" e1="DDI-MedLine.d83.s7.e0"
            e2="DDI-MedLine.d83.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d83.s7.p2" e1="DDI-MedLine.d83.s7.e1"
            e2="DDI-MedLine.d83.s7.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s8" text="However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of olanzapine and risperidone treatment in patients with schizophrenia or schizoaffective disorder. ">
        <entity id="DDI-MedLine.d83.s8.e0" charOffset="99-108"
            type="drug" text="olanzapine"/>
        <entity id="DDI-MedLine.d83.s8.e1" charOffset="114-124"
            type="drug" text="risperidone"/>
        <pair id="DDI-MedLine.d83.s8.p0" e1="DDI-MedLine.d83.s8.e0"
            e2="DDI-MedLine.d83.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s9" text="Several studies indicate that olanzapine has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of olanzapine in the treatment of depressive symptomatology. ">
        <entity id="DDI-MedLine.d83.s9.e0" charOffset="30-39"
            type="drug" text="olanzapine"/>
        <entity id="DDI-MedLine.d83.s9.e1" charOffset="158-167"
            type="drug" text="olanzapine"/>
        <pair id="DDI-MedLine.d83.s9.p0" e1="DDI-MedLine.d83.s9.e0"
            e2="DDI-MedLine.d83.s9.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s10" text="Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. ">
        <entity id="DDI-MedLine.d83.s10.e0" charOffset="0-9" type="drug" text="Olanzapine"/>
        <entity id="DDI-MedLine.d83.s10.e1" charOffset="79-89"
            type="drug" text="haloperidol"/>
        <entity id="DDI-MedLine.d83.s10.e2" charOffset="95-105"
            type="drug" text="risperidone"/>
        <pair id="DDI-MedLine.d83.s10.p0" e1="DDI-MedLine.d83.s10.e0"
            e2="DDI-MedLine.d83.s10.e1" ddi="false"/>
        <pair id="DDI-MedLine.d83.s10.p1" e1="DDI-MedLine.d83.s10.e0"
            e2="DDI-MedLine.d83.s10.e2" ddi="false"/>
        <pair id="DDI-MedLine.d83.s10.p2" e1="DDI-MedLine.d83.s10.e1"
            e2="DDI-MedLine.d83.s10.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s11" text="In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. ">
        <entity id="DDI-MedLine.d83.s11.e0" charOffset="13-22"
            type="drug" text="olanzapine"/>
        <entity id="DDI-MedLine.d83.s11.e1" charOffset="86-94"
            type="drug" text="clozapine"/>
        <entity id="DDI-MedLine.d83.s11.e2" charOffset="155-165"
            type="drug" text="risperidone"/>
        <pair id="DDI-MedLine.d83.s11.p0" e1="DDI-MedLine.d83.s11.e0"
            e2="DDI-MedLine.d83.s11.e1" ddi="false"/>
        <pair id="DDI-MedLine.d83.s11.p1" e1="DDI-MedLine.d83.s11.e0"
            e2="DDI-MedLine.d83.s11.e2" ddi="false"/>
        <pair id="DDI-MedLine.d83.s11.p2" e1="DDI-MedLine.d83.s11.e1"
            e2="DDI-MedLine.d83.s11.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s12" text="The most common adverse effects reported with olanzapine are bodyweight gain, somnolence, dizziness, anticholinergic effects (constipation and dry mouth) and transient asymptomatic liver enzyme elevations. ">
        <entity id="DDI-MedLine.d83.s12.e0" charOffset="46-55"
            type="drug" text="olanzapine"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s13" text="In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. ">
        <entity id="DDI-MedLine.d83.s13.e0" charOffset="19-29"
            type="drug" text="haloperidol"/>
        <entity id="DDI-MedLine.d83.s13.e1" charOffset="95-104"
            type="drug" text="olanzapine"/>
        <entity id="DDI-MedLine.d83.s13.e2" charOffset="206-216"
            type="drug" text="risperidone"/>
        <entity id="DDI-MedLine.d83.s13.e3" charOffset="284-293"
            type="drug" text="olanzapine"/>
        <pair id="DDI-MedLine.d83.s13.p0" e1="DDI-MedLine.d83.s13.e0"
            e2="DDI-MedLine.d83.s13.e1" ddi="false"/>
        <pair id="DDI-MedLine.d83.s13.p1" e1="DDI-MedLine.d83.s13.e0"
            e2="DDI-MedLine.d83.s13.e2" ddi="false"/>
        <pair id="DDI-MedLine.d83.s13.p2" e1="DDI-MedLine.d83.s13.e0"
            e2="DDI-MedLine.d83.s13.e3" ddi="false"/>
        <pair id="DDI-MedLine.d83.s13.p3" e1="DDI-MedLine.d83.s13.e1"
            e2="DDI-MedLine.d83.s13.e2" ddi="false"/>
        <pair id="DDI-MedLine.d83.s13.p4" e1="DDI-MedLine.d83.s13.e1"
            e2="DDI-MedLine.d83.s13.e3" ddi="false"/>
        <pair id="DDI-MedLine.d83.s13.p5" e1="DDI-MedLine.d83.s13.e2"
            e2="DDI-MedLine.d83.s13.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s14" text="The high acquisition cost of olanzapine is offset by reductions in other treatment costs (inpatient and/or outpatient services) of schizophrenia. ">
        <entity id="DDI-MedLine.d83.s14.e0" charOffset="29-38"
            type="drug" text="olanzapine"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s15" text="Pharmacoeconomic analyses indicate that olanzapine does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with haloperidol. ">
        <entity id="DDI-MedLine.d83.s15.e0" charOffset="40-49"
            type="drug" text="olanzapine"/>
        <entity id="DDI-MedLine.d83.s15.e1" charOffset="174-184"
            type="drug" text="haloperidol"/>
        <pair id="DDI-MedLine.d83.s15.p0" e1="DDI-MedLine.d83.s15.e0"
            e2="DDI-MedLine.d83.s15.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s16" text="Compared with risperidone, olanzapine has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug. ">
        <entity id="DDI-MedLine.d83.s16.e0" charOffset="14-24"
            type="drug" text="risperidone"/>
        <entity id="DDI-MedLine.d83.s16.e1" charOffset="27-36"
            type="drug" text="olanzapine"/>
        <pair id="DDI-MedLine.d83.s16.p0" e1="DDI-MedLine.d83.s16.e0"
            e2="DDI-MedLine.d83.s16.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s17" text="Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. ">
        <entity id="DDI-MedLine.d83.s17.e0" charOffset="0-9" type="drug" text="Olanzapine"/>
        <entity id="DDI-MedLine.d83.s17.e1" charOffset="124-134"
            type="drug" text="haloperidol"/>
        <entity id="DDI-MedLine.d83.s17.e2" charOffset="171-181"
            type="drug" text="risperidone"/>
        <pair id="DDI-MedLine.d83.s17.p0" e1="DDI-MedLine.d83.s17.e0"
            e2="DDI-MedLine.d83.s17.e1" ddi="false"/>
        <pair id="DDI-MedLine.d83.s17.p1" e1="DDI-MedLine.d83.s17.e0"
            e2="DDI-MedLine.d83.s17.e2" ddi="false"/>
        <pair id="DDI-MedLine.d83.s17.p2" e1="DDI-MedLine.d83.s17.e1"
            e2="DDI-MedLine.d83.s17.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s18" text="CONCLUSIONS: Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia. ">
        <entity id="DDI-MedLine.d83.s18.e0" charOffset="13-22"
            type="drug" text="Olanzapine"/>
        <entity id="DDI-MedLine.d83.s18.e1" charOffset="83-93"
            type="drug" text="haloperidol"/>
        <pair id="DDI-MedLine.d83.s18.p0" e1="DDI-MedLine.d83.s18.e0"
            e2="DDI-MedLine.d83.s18.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d83.s19" text="The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.">
        <entity id="DDI-MedLine.d83.s19.e0" charOffset="77-87"
            type="drug" text="haloperidol"/>
        <entity id="DDI-MedLine.d83.s19.e1" charOffset="93-103"
            type="drug" text="risperidone"/>
        <entity id="DDI-MedLine.d83.s19.e2" charOffset="180-189"
            type="drug" text="olanzapine"/>
        <pair id="DDI-MedLine.d83.s19.p0" e1="DDI-MedLine.d83.s19.e0"
            e2="DDI-MedLine.d83.s19.e1" ddi="false"/>
        <pair id="DDI-MedLine.d83.s19.p1" e1="DDI-MedLine.d83.s19.e0"
            e2="DDI-MedLine.d83.s19.e2" ddi="false"/>
        <pair id="DDI-MedLine.d83.s19.p2" e1="DDI-MedLine.d83.s19.e1"
            e2="DDI-MedLine.d83.s19.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d132.s0" text="The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.">
        <entity id="DDI-MedLine.d132.s0.e0" charOffset="22-68"
            type="group" text="non-nucleoside reverse transcriptase inhibitors"/>
        <entity id="DDI-MedLine.d132.s0.e1" charOffset="73-86"
            type="group" text="antiretroviral"/>
        <pair id="DDI-MedLine.d132.s0.p0" e1="DDI-MedLine.d132.s0.e0"
            e2="DDI-MedLine.d132.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d132.s1" text="The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. ">
        <entity id="DDI-MedLine.d132.s1.e0" charOffset="27-72"
            type="group" text="non-nucleoside reverse transcriptase inhibitor"/>
        <entity id="DDI-MedLine.d132.s1.e1" charOffset="75-79"
            type="group" text="NNRTI"/>
        <entity id="DDI-MedLine.d132.s1.e2" charOffset="101-114"
            type="group" text="antiretroviral"/>
        <entity id="DDI-MedLine.d132.s1.e3" charOffset="147-164"
            type="group" text="protease inhibitor"/>
        <entity id="DDI-MedLine.d132.s1.e4" charOffset="167-168"
            type="group" text="PI"/>
        <pair id="DDI-MedLine.d132.s1.p0" e1="DDI-MedLine.d132.s1.e0"
            e2="DDI-MedLine.d132.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d132.s1.p1" e1="DDI-MedLine.d132.s1.e0"
            e2="DDI-MedLine.d132.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d132.s1.p2" e1="DDI-MedLine.d132.s1.e0"
            e2="DDI-MedLine.d132.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d132.s1.p3" e1="DDI-MedLine.d132.s1.e0"
            e2="DDI-MedLine.d132.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d132.s1.p4" e1="DDI-MedLine.d132.s1.e1"
            e2="DDI-MedLine.d132.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d132.s1.p5" e1="DDI-MedLine.d132.s1.e1"
            e2="DDI-MedLine.d132.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d132.s1.p6" e1="DDI-MedLine.d132.s1.e1"
            e2="DDI-MedLine.d132.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d132.s1.p7" e1="DDI-MedLine.d132.s1.e2"
            e2="DDI-MedLine.d132.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d132.s1.p8" e1="DDI-MedLine.d132.s1.e2"
            e2="DDI-MedLine.d132.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d132.s1.p9" e1="DDI-MedLine.d132.s1.e3"
            e2="DDI-MedLine.d132.s1.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d132.s2" text="NNRTI-based regimens may have several advantages over PI-based therapy for initial or prolonged therapy, including more convenient administration regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration. ">
        <entity id="DDI-MedLine.d132.s2.e0" charOffset="0-4"
            type="group" text="NNRTI"/>
        <entity id="DDI-MedLine.d132.s2.e1" charOffset="54-55"
            type="group" text="PI"/>
        <pair id="DDI-MedLine.d132.s2.p0" e1="DDI-MedLine.d132.s2.e0"
            e2="DDI-MedLine.d132.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d132.s3" text="No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, nevirapine or delavirdine). ">
        <entity id="DDI-MedLine.d132.s3.e0" charOffset="90-98"
            type="drug" text="efavirenz"/>
        <entity id="DDI-MedLine.d132.s3.e1" charOffset="101-110"
            type="drug" text="nevirapine"/>
        <entity id="DDI-MedLine.d132.s3.e2" charOffset="115-125"
            type="drug" text="delavirdine"/>
        <pair id="DDI-MedLine.d132.s3.p0" e1="DDI-MedLine.d132.s3.e0"
            e2="DDI-MedLine.d132.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d132.s3.p1" e1="DDI-MedLine.d132.s3.e0"
            e2="DDI-MedLine.d132.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d132.s3.p2" e1="DDI-MedLine.d132.s3.e1"
            e2="DDI-MedLine.d132.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d132.s4" text="Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ">
        <entity id="DDI-MedLine.d132.s4.e0" charOffset="5-13"
            type="drug" text="efavirenz"/>
        <entity id="DDI-MedLine.d132.s4.e1" charOffset="19-28"
            type="drug" text="nevirapine"/>
        <entity id="DDI-MedLine.d132.s4.e2" charOffset="76-77"
            type="group" text="PI"/>
        <entity id="DDI-MedLine.d132.s4.e3" charOffset="79-87"
            type="drug" text="indinavir"/>
        <entity id="DDI-MedLine.d132.s4.e4" charOffset="166-175"
            type="drug" text="nevirapine"/>
        <entity id="DDI-MedLine.d132.s4.e5" charOffset="216-224"
            type="drug" text="efavirenz"/>
        <pair id="DDI-MedLine.d132.s4.p0" e1="DDI-MedLine.d132.s4.e0"
            e2="DDI-MedLine.d132.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d132.s4.p1" e1="DDI-MedLine.d132.s4.e0"
            e2="DDI-MedLine.d132.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d132.s4.p2" e1="DDI-MedLine.d132.s4.e0"
            e2="DDI-MedLine.d132.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d132.s4.p3" e1="DDI-MedLine.d132.s4.e0"
            e2="DDI-MedLine.d132.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d132.s4.p4" e1="DDI-MedLine.d132.s4.e0"
            e2="DDI-MedLine.d132.s4.e5" ddi="false"/>
        <pair id="DDI-MedLine.d132.s4.p5" e1="DDI-MedLine.d132.s4.e1"
            e2="DDI-MedLine.d132.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d132.s4.p6" e1="DDI-MedLine.d132.s4.e1"
            e2="DDI-MedLine.d132.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d132.s4.p7" e1="DDI-MedLine.d132.s4.e1"
            e2="DDI-MedLine.d132.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d132.s4.p8" e1="DDI-MedLine.d132.s4.e1"
            e2="DDI-MedLine.d132.s4.e5" ddi="false"/>
        <pair id="DDI-MedLine.d132.s4.p9" e1="DDI-MedLine.d132.s4.e2"
            e2="DDI-MedLine.d132.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d132.s4.p10" e1="DDI-MedLine.d132.s4.e2"
            e2="DDI-MedLine.d132.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d132.s4.p11" e1="DDI-MedLine.d132.s4.e2"
            e2="DDI-MedLine.d132.s4.e5" ddi="false"/>
        <pair id="DDI-MedLine.d132.s4.p12" e1="DDI-MedLine.d132.s4.e3"
            e2="DDI-MedLine.d132.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d132.s4.p13" e1="DDI-MedLine.d132.s4.e3"
            e2="DDI-MedLine.d132.s4.e5" ddi="false"/>
        <pair id="DDI-MedLine.d132.s4.p14" e1="DDI-MedLine.d132.s4.e4"
            e2="DDI-MedLine.d132.s4.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d132.s5" text="A smaller 24-week study has suggested nevirapine may be superior to the PI nelfinavir. ">
        <entity id="DDI-MedLine.d132.s5.e0" charOffset="38-47"
            type="drug" text="nevirapine"/>
        <entity id="DDI-MedLine.d132.s5.e1" charOffset="72-73"
            type="group" text="PI"/>
        <entity id="DDI-MedLine.d132.s5.e2" charOffset="75-84"
            type="drug" text="nelfinavir"/>
        <pair id="DDI-MedLine.d132.s5.p0" e1="DDI-MedLine.d132.s5.e0"
            e2="DDI-MedLine.d132.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d132.s5.p1" e1="DDI-MedLine.d132.s5.e0"
            e2="DDI-MedLine.d132.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d132.s5.p2" e1="DDI-MedLine.d132.s5.e1"
            e2="DDI-MedLine.d132.s5.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d132.s6" text="Limited comparative data in patients with high viral loads treated with nevirapine- or delavirdine-based regimens currently exist. ">
        <entity id="DDI-MedLine.d132.s6.e0" charOffset="72-81"
            type="drug" text="nevirapine"/>
        <entity id="DDI-MedLine.d132.s6.e1" charOffset="87-97"
            type="drug" text="delavirdine"/>
        <pair id="DDI-MedLine.d132.s6.p0" e1="DDI-MedLine.d132.s6.e0"
            e2="DDI-MedLine.d132.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d132.s7" text="However, cohort data and selected patient data from clinical trials suggest comparable activity to PI-based regimens in these patients. ">
        <entity id="DDI-MedLine.d132.s7.e0" charOffset="99-100"
            type="group" text="PI"/>
    </sentence>
    <sentence id="DDI-MedLine.d132.s8" text="The superiority of efavirenz over indinavir-based regimens has been observed in comparative data in a subset of patients with high viral loads. ">
        <entity id="DDI-MedLine.d132.s8.e0" charOffset="19-27"
            type="drug" text="efavirenz"/>
        <entity id="DDI-MedLine.d132.s8.e1" charOffset="34-42"
            type="drug" text="indinavir"/>
        <pair id="DDI-MedLine.d132.s8.p0" e1="DDI-MedLine.d132.s8.e0"
            e2="DDI-MedLine.d132.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d132.s9" text="In treatment-experienced patients, available uncontrolled data suggest these agents contribute to regimen efficacy in NNRTI-na  ve, treatment-experienced patients. ">
        <entity id="DDI-MedLine.d132.s9.e0" charOffset="118-122"
            type="group" text="NNRTI"/>
    </sentence>
    <sentence id="DDI-MedLine.d132.s10" text="Efavirenz has demonstrated superiority over nelfinavir in nucleoside-experienced patients, although combining these 2 agents may represent the best approach in these circumstances. ">
        <entity id="DDI-MedLine.d132.s10.e0" charOffset="0-8"
            type="drug" text="Efavirenz"/>
        <entity id="DDI-MedLine.d132.s10.e1" charOffset="44-53"
            type="drug" text="nelfinavir"/>
        <pair id="DDI-MedLine.d132.s10.p0" e1="DDI-MedLine.d132.s10.e0"
            e2="DDI-MedLine.d132.s10.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d132.s11" text="The tolerability of NNRTIs appears generally good with few individuals discontinuing in clinical studies as a result of adverse drug events. ">
        <entity id="DDI-MedLine.d132.s11.e0" charOffset="20-25"
            type="group" text="NNRTIs"/>
    </sentence>
    <sentence id="DDI-MedLine.d132.s12" text="The majority of adverse events with NNRTIs occur within the first month, and are predictable and manageable without therapy interruption.">
        <entity id="DDI-MedLine.d132.s12.e0" charOffset="36-41"
            type="group" text="NNRTIs"/>
    </sentence>
    <sentence id="DDI-MedLine.d72.s0" text="[Pharmacologic interactions in chronic treatments: corrective measures for its prevention in a basic area of rural health]&#xd;&#xa;OBJECTIVES: To identify the pharmacological interactions of clinical relevance (PICR) in the medication authorization cards (MAC) of the chronically ill and to establish strategies to minimise their appearance. "/>
    <sentence id="DDI-MedLine.d72.s1" text="DESIGN: Cross-sectional descriptive study. "/>
    <sentence id="DDI-MedLine.d72.s2" text="SETTING: Rural primary care centre. "/>
    <sentence id="DDI-MedLine.d72.s3" text="PATIENTS: Random sample of 626 MAC out of a total of 1306. "/>
    <sentence id="DDI-MedLine.d72.s4" text="MEASUREMENTS AND MAIN RESULTS: In December 1998, the following was gathered for every MAC with more than one drug treatment: age, sex, number of drugs, intrinsic value, drugs prescribed, daily dose and pharmacological interactions (PI), classified (using the scale of Hansten 1996) into light and clinically relevant. "/>
    <sentence id="DDI-MedLine.d72.s5" text="Statistical analysis: Mantel-Haenszel (alpha = 0.05). "/>
    <sentence id="DDI-MedLine.d72.s6" text="Patients' mean age was 69.1 (95% CI, +/- 1.2). "/>
    <sentence id="DDI-MedLine.d72.s7" text="Mean number of drugs per MAC was 4 (95% CI, +/- 0.2). "/>
    <sentence id="DDI-MedLine.d72.s8" text="341 PI affecting 197 patients (31.5%, 95% CI, +/- 3.6) were identified. "/>
    <sentence id="DDI-MedLine.d72.s9" text="24.9% (95% CI, +/- 4.5) were PICR, detected in 11.7% (95% CI, +/- 2.5) of the MAC. "/>
    <sentence id="DDI-MedLine.d72.s10" text="The existence of PI was related to the number of drugs prescribed to each patient (p &lt; 0.01). "/>
    <sentence id="DDI-MedLine.d72.s11" text="There were 26 PI with drugs of low intrinsic value (7.6%; 95% CI, +/- 2.8). "/>
    <sentence id="DDI-MedLine.d72.s12" text="74.1% (95% CI, +/- 9.3) of the total PICR could be avoided by simple recommendations; "/>
    <sentence id="DDI-MedLine.d72.s13" text="and the remaining 25.9% (95% CI, +/- 9.3) by monitoring and follow-up of patients. "/>
    <sentence id="DDI-MedLine.d72.s14" text="CONCLUSIONS: It is important to identify the medications most commonly involved in the PICR so as to establish corrective measures to minimise the risks arising from multiple medication. "/>
    <sentence id="DDI-MedLine.d72.s15" text="Four educational messages advise on over 60% of the PICR detected."/>
    <sentence id="DDI-MedLine.d32.s0" text="Prescribing. "/>
    <sentence id="DDI-MedLine.d32.s1" text="Keys to maximizing benefit while avoiding adverse drug effects.&#xa;"/>
    <sentence id="DDI-MedLine.d32.s2" text="When prescribing for older patients, some physicians are overly cautious, and this strategy can result in a less than optimal treatment outcome. "/>
    <sentence id="DDI-MedLine.d32.s3" text="The reluctance to treat aggressively is understandable because the geriatric population is susceptible to adverse drug reactions. "/>
    <sentence id="DDI-MedLine.d32.s4" text="The key to maximizing therapy lies in individualizing it as much as possible. "/>
    <sentence id="DDI-MedLine.d32.s5" text="There are a number of steps physicians can take to ensure that their patients are not being undertreated. "/>
    <sentence id="DDI-MedLine.d32.s6" text="These steps include regular reevaluations of dosages and plasma drug concentrations, recognition and understanding of drug side effects, and avoidance of certain agents. "/>
    <sentence id="DDI-MedLine.d32.s7" text="Close monitoring allows physicians to minimize risks, maximize benefits, and get the most out of what modern medications can do to help older patients."/>
    <sentence id="DDI-MedLine.d42.s0" text="Sildenafil citrate: a therapeutic update.&#xa;">
        <entity id="DDI-MedLine.d42.s0.e0" charOffset="0-17" type="drug" text="Sildenafil citrate"/>
    </sentence>
    <sentence id="DDI-MedLine.d42.s1" text="BACKGROUND: Since its approval by the US Food and Drug Administration in March 1998, sildenafil citrate has been used by millions of men for the treatment of erectile dysfunction. ">
        <entity id="DDI-MedLine.d42.s1.e0" charOffset="85-102"
            type="drug" text="sildenafil citrate"/>
    </sentence>
    <sentence id="DDI-MedLine.d42.s2" text="Recent studies and consensus reports have expanded our understanding of its efficacy, safety, contraindications, and drug interactions. "/>
    <sentence id="DDI-MedLine.d42.s3" text="OBJECTIVE: This paper reviews recent studies of the efficacy of sildenafil, its adverse effects and drug interactions, and socioeconomic factors involved in its use, with a focus on specific patient populations (prostate cancer, diabetes mellitus, ischemic heart disease, spinal cord injuries, neurologic disorders). ">
        <entity id="DDI-MedLine.d42.s3.e0" charOffset="64-73"
            type="drug" text="sildenafil"/>
    </sentence>
    <sentence id="DDI-MedLine.d42.s4" text="METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, Viagra, and erectile dysfunction. ">
        <entity id="DDI-MedLine.d42.s4.e0" charOffset="84-93"
            type="drug" text="sildenafil"/>
        <entity id="DDI-MedLine.d42.s4.e1" charOffset="291-300"
            type="drug" text="sildenafil"/>
        <entity id="DDI-MedLine.d42.s4.e2" charOffset="303-308"
            type="brand" text="Viagra"/>
        <pair id="DDI-MedLine.d42.s4.p0" e1="DDI-MedLine.d42.s4.e0"
            e2="DDI-MedLine.d42.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d42.s4.p1" e1="DDI-MedLine.d42.s4.e0"
            e2="DDI-MedLine.d42.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d42.s4.p2" e1="DDI-MedLine.d42.s4.e1"
            e2="DDI-MedLine.d42.s4.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d42.s5" text="RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]). ">
        <entity id="DDI-MedLine.d42.s5.e0" charOffset="9-18" type="drug" text="Sildenafil"/>
        <entity id="DDI-MedLine.d42.s5.e1" charOffset="205-243"
            type="group" text="selective serotonin reuptake inhibitors"/>
        <entity id="DDI-MedLine.d42.s5.e2" charOffset="246-250"
            type="group" text="SSRIs"/>
        <pair id="DDI-MedLine.d42.s5.p0" e1="DDI-MedLine.d42.s5.e0"
            e2="DDI-MedLine.d42.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d42.s5.p1" e1="DDI-MedLine.d42.s5.e0"
            e2="DDI-MedLine.d42.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d42.s5.p2" e1="DDI-MedLine.d42.s5.e1"
            e2="DDI-MedLine.d42.s5.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d42.s6" text="It has not been as effective in women with sexual dysfunction, with the exception of SSRI-associated sexual dysfunction. ">
        <entity id="DDI-MedLine.d42.s6.e0" charOffset="85-88"
            type="group" text="SSRI"/>
    </sentence>
    <sentence id="DDI-MedLine.d42.s7" text="Some disorders unrelated to sexual dysfunction (eg, esophageal motility dysfunction) may also respond to sildenafil. ">
        <entity id="DDI-MedLine.d42.s7.e0" charOffset="105-114"
            type="drug" text="sildenafil"/>
    </sentence>
    <sentence id="DDI-MedLine.d42.s8" text="In the general population, sildenafil is considered to have an acceptable tolerability profile; ">
        <entity id="DDI-MedLine.d42.s8.e0" charOffset="27-36"
            type="drug" text="sildenafil"/>
    </sentence>
    <sentence id="DDI-MedLine.d42.s9" text="however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy. ">
        <entity id="DDI-MedLine.d42.s9.e0" charOffset="81-87"
            type="group" text="nitrate"/>
        <entity id="DDI-MedLine.d42.s9.e1" charOffset="179-188"
            type="drug" text="sildenafil"/>
        <pair id="DDI-MedLine.d42.s9.p0" e1="DDI-MedLine.d42.s9.e0"
            e2="DDI-MedLine.d42.s9.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d42.s10" text="In addition, patients taking drugs that inhibit the cytochrome P450 3A4 isozyme, which metabolizes sildenafil, may experience increased drug concentrations and possible toxicity from normal doses of sildenafil. ">
        <entity id="DDI-MedLine.d42.s10.e0" charOffset="99-108"
            type="drug" text="sildenafil"/>
        <entity id="DDI-MedLine.d42.s10.e1" charOffset="199-208"
            type="drug" text="sildenafil"/>
        <pair id="DDI-MedLine.d42.s10.p0" e1="DDI-MedLine.d42.s10.e0"
            e2="DDI-MedLine.d42.s10.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d42.s11" text="CONCLUSIONS: Sildenafil is an effective first-line therapy for erectile dysfunction in men. ">
        <entity id="DDI-MedLine.d42.s11.e0" charOffset="13-22"
            type="drug" text="Sildenafil"/>
    </sentence>
    <sentence id="DDI-MedLine.d42.s12" text="The decision to prescribe this agent should include such considerations as the cost-risk-benefit balance, patient access, drug distribution pathways, and prescription drug coverage."/>
    <sentence id="DDI-MedLine.d38.s0" text="Acute hydrocortisone administration does not affect subjective responses to d-amphetamine in humans.&#xd;&#xa;">
        <entity id="DDI-MedLine.d38.s0.e0" charOffset="6-19" type="drug" text="hydrocortisone"/>
        <entity id="DDI-MedLine.d38.s0.e1" charOffset="76-88"
            type="drug" text="d-amphetamine"/>
        <pair id="DDI-MedLine.d38.s0.p0" e1="DDI-MedLine.d38.s0.e0"
            e2="DDI-MedLine.d38.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d38.s1" text="RATIONALE: Stress and glucocorticoids facilitate and reinstate psychostimulant self-administration in rodents. ">
        <entity id="DDI-MedLine.d38.s1.e0" charOffset="22-36"
            type="group" text="glucocorticoids"/>
    </sentence>
    <sentence id="DDI-MedLine.d38.s2" text="However, the effects of stress and glucocorticoids on the subjective and behavioral effects of psychostimulants have not been well studied in humans. ">
        <entity id="DDI-MedLine.d38.s2.e0" charOffset="35-49"
            type="group" text="glucocorticoids"/>
        <entity id="DDI-MedLine.d38.s2.e1" charOffset="95-110"
            type="group" text="psychostimulants"/>
        <pair id="DDI-MedLine.d38.s2.p0" e1="DDI-MedLine.d38.s2.e0"
            e2="DDI-MedLine.d38.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d38.s3" text="OBJECTIVES: To examine the effects of acute hydrocortisone pretreatment on the subjective and behavioral effects of d-amphetamine. ">
        <entity id="DDI-MedLine.d38.s3.e0" charOffset="44-57"
            type="drug" text="hydrocortisone"/>
        <entity id="DDI-MedLine.d38.s3.e1" charOffset="116-128"
            type="drug" text="d-amphetamine"/>
        <pair id="DDI-MedLine.d38.s3.p0" e1="DDI-MedLine.d38.s3.e0"
            e2="DDI-MedLine.d38.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d38.s4" text="METHODS: Hydrocortisone (100 mg) and d-amphetamine (20 mg) were administered orally to 16 healthy male and female volunteers in a four-session, placebo-controlled, within-subject, crossover design. ">
        <entity id="DDI-MedLine.d38.s4.e0" charOffset="9-22" type="drug" text="Hydrocortisone"/>
        <entity id="DDI-MedLine.d38.s4.e1" charOffset="37-49"
            type="drug" text="d-amphetamine"/>
        <pair id="DDI-MedLine.d38.s4.p0" e1="DDI-MedLine.d38.s4.e0"
            e2="DDI-MedLine.d38.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d38.s5" text="To prevent stomach irritation, subjects received rantidine hydrochloride before each experimental session. ">
        <entity id="DDI-MedLine.d38.s5.e0" charOffset="49-71"
            type="drug" text="rantidine hydrochloride"/>
    </sentence>
    <sentence id="DDI-MedLine.d38.s6" text="Dependent measures included self-reported mood and subjective effects (Addiction Research Center inventory, the profile of mood states, and a series of visual analogue scales), vital signs, salivary cortisol, and psychomotor performance. "/>
    <sentence id="DDI-MedLine.d38.s7" text="RESULTS: Hydrocortisone elevated salivary cortisol levels, produced modest dysphoria, and reduced subjects' reports of wanting more drug. ">
        <entity id="DDI-MedLine.d38.s7.e0" charOffset="9-22" type="drug" text="Hydrocortisone"/>
    </sentence>
    <sentence id="DDI-MedLine.d38.s8" text="However, hydrocortisone pretreatment did not affect any of the physiological, behavioral, or subjective effects of d-amphetamine. ">
        <entity id="DDI-MedLine.d38.s8.e0" charOffset="9-22" type="drug" text="hydrocortisone"/>
        <entity id="DDI-MedLine.d38.s8.e1" charOffset="115-127"
            type="drug" text="d-amphetamine"/>
        <pair id="DDI-MedLine.d38.s8.p0" e1="DDI-MedLine.d38.s8.e0"
            e2="DDI-MedLine.d38.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d38.s9" text="CONCLUSIONS: In contrast to the effects of glucocorticoids in rodent studies, these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of d-amphetamine in humans.">
        <entity id="DDI-MedLine.d38.s9.e0" charOffset="43-57"
            type="group" text="glucocorticoids"/>
        <entity id="DDI-MedLine.d38.s9.e1" charOffset="184-196"
            type="drug" text="d-amphetamine"/>
        <pair id="DDI-MedLine.d38.s9.p0" e1="DDI-MedLine.d38.s9.e0"
            e2="DDI-MedLine.d38.s9.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d23.s0" text="The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.&#xd;&#xa;">
        <entity id="DDI-MedLine.d23.s0.e0" charOffset="15-22"
            type="drug" text="ketamine"/>
        <entity id="DDI-MedLine.d23.s0.e1" charOffset="31-37"
            type="brand" text="Innovar"/>
        <entity id="DDI-MedLine.d23.s0.e2" charOffset="53-61"
            type="group" text="digitalis"/>
        <pair id="DDI-MedLine.d23.s0.p0" e1="DDI-MedLine.d23.s0.e0"
            e2="DDI-MedLine.d23.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d23.s0.p1" e1="DDI-MedLine.d23.s0.e0"
            e2="DDI-MedLine.d23.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d23.s0.p2" e1="DDI-MedLine.d23.s0.e1"
            e2="DDI-MedLine.d23.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d23.s1" text="In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ">
        <entity id="DDI-MedLine.d23.s1.e0" charOffset="19-27"
            type="group" text="digitalis"/>
        <entity id="DDI-MedLine.d23.s1.e1" charOffset="65-72"
            type="drug" text="ketamine"/>
        <entity id="DDI-MedLine.d23.s1.e2" charOffset="75-85"
            type="brand" text="Innovar Vet"/>
        <entity id="DDI-MedLine.d23.s1.e3" charOffset="91-103"
            type="drug" text="pentobarbital"/>
        <entity id="DDI-MedLine.d23.s1.e4" charOffset="120-126"
            type="drug" text="ouabain"/>
        <entity id="DDI-MedLine.d23.s1.e5" charOffset="213-219"
            type="drug" text="ouabain"/>
        <entity id="DDI-MedLine.d23.s1.e6" charOffset="227-234"
            type="drug" text="ketamine"/>
        <entity id="DDI-MedLine.d23.s1.e7" charOffset="239-245"
            type="brand" text="Innovar"/>
        <entity id="DDI-MedLine.d23.s1.e8" charOffset="257-269"
            type="drug" text="pentobarbital"/>
        <pair id="DDI-MedLine.d23.s1.p0" e1="DDI-MedLine.d23.s1.e0"
            e2="DDI-MedLine.d23.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p1" e1="DDI-MedLine.d23.s1.e0"
            e2="DDI-MedLine.d23.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p2" e1="DDI-MedLine.d23.s1.e0"
            e2="DDI-MedLine.d23.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p3" e1="DDI-MedLine.d23.s1.e0"
            e2="DDI-MedLine.d23.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p4" e1="DDI-MedLine.d23.s1.e0"
            e2="DDI-MedLine.d23.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p5" e1="DDI-MedLine.d23.s1.e0"
            e2="DDI-MedLine.d23.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p6" e1="DDI-MedLine.d23.s1.e0"
            e2="DDI-MedLine.d23.s1.e7" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p7" e1="DDI-MedLine.d23.s1.e0"
            e2="DDI-MedLine.d23.s1.e8" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p8" e1="DDI-MedLine.d23.s1.e1"
            e2="DDI-MedLine.d23.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p9" e1="DDI-MedLine.d23.s1.e1"
            e2="DDI-MedLine.d23.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p10" e1="DDI-MedLine.d23.s1.e1"
            e2="DDI-MedLine.d23.s1.e4" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d23.s1.p11" e1="DDI-MedLine.d23.s1.e1"
            e2="DDI-MedLine.d23.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p12" e1="DDI-MedLine.d23.s1.e1"
            e2="DDI-MedLine.d23.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p13" e1="DDI-MedLine.d23.s1.e1"
            e2="DDI-MedLine.d23.s1.e7" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p14" e1="DDI-MedLine.d23.s1.e1"
            e2="DDI-MedLine.d23.s1.e8" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p15" e1="DDI-MedLine.d23.s1.e2"
            e2="DDI-MedLine.d23.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p16" e1="DDI-MedLine.d23.s1.e2"
            e2="DDI-MedLine.d23.s1.e4" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d23.s1.p17" e1="DDI-MedLine.d23.s1.e2"
            e2="DDI-MedLine.d23.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p18" e1="DDI-MedLine.d23.s1.e2"
            e2="DDI-MedLine.d23.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p19" e1="DDI-MedLine.d23.s1.e2"
            e2="DDI-MedLine.d23.s1.e7" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p20" e1="DDI-MedLine.d23.s1.e2"
            e2="DDI-MedLine.d23.s1.e8" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p21" e1="DDI-MedLine.d23.s1.e3"
            e2="DDI-MedLine.d23.s1.e4" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d23.s1.p22" e1="DDI-MedLine.d23.s1.e3"
            e2="DDI-MedLine.d23.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p23" e1="DDI-MedLine.d23.s1.e3"
            e2="DDI-MedLine.d23.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p24" e1="DDI-MedLine.d23.s1.e3"
            e2="DDI-MedLine.d23.s1.e7" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p25" e1="DDI-MedLine.d23.s1.e3"
            e2="DDI-MedLine.d23.s1.e8" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p26" e1="DDI-MedLine.d23.s1.e4"
            e2="DDI-MedLine.d23.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p27" e1="DDI-MedLine.d23.s1.e4"
            e2="DDI-MedLine.d23.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p28" e1="DDI-MedLine.d23.s1.e4"
            e2="DDI-MedLine.d23.s1.e7" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p29" e1="DDI-MedLine.d23.s1.e4"
            e2="DDI-MedLine.d23.s1.e8" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p30" e1="DDI-MedLine.d23.s1.e5"
            e2="DDI-MedLine.d23.s1.e6" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p31" e1="DDI-MedLine.d23.s1.e5"
            e2="DDI-MedLine.d23.s1.e7" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p32" e1="DDI-MedLine.d23.s1.e5"
            e2="DDI-MedLine.d23.s1.e8" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p33" e1="DDI-MedLine.d23.s1.e6"
            e2="DDI-MedLine.d23.s1.e7" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p34" e1="DDI-MedLine.d23.s1.e6"
            e2="DDI-MedLine.d23.s1.e8" ddi="false"/>
        <pair id="DDI-MedLine.d23.s1.p35" e1="DDI-MedLine.d23.s1.e7"
            e2="DDI-MedLine.d23.s1.e8" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d23.s2" text="Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.">
        <entity id="DDI-MedLine.d23.s2.e0" charOffset="35-41"
            type="drug" text="ouabain"/>
        <entity id="DDI-MedLine.d23.s2.e1" charOffset="111-117"
            type="brand" text="Innovar"/>
        <entity id="DDI-MedLine.d23.s2.e2" charOffset="120-127"
            type="drug" text="ketamine"/>
        <entity id="DDI-MedLine.d23.s2.e3" charOffset="133-142"
            type="drug" text="droperidol"/>
        <entity id="DDI-MedLine.d23.s2.e4" charOffset="176-182"
            type="drug" text="fentayl"/>
        <entity id="DDI-MedLine.d23.s2.e5" charOffset="199-211"
            type="drug" text="pentobarbital"/>
        <pair id="DDI-MedLine.d23.s2.p0" e1="DDI-MedLine.d23.s2.e0"
            e2="DDI-MedLine.d23.s2.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d23.s2.p1" e1="DDI-MedLine.d23.s2.e0"
            e2="DDI-MedLine.d23.s2.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d23.s2.p2" e1="DDI-MedLine.d23.s2.e0"
            e2="DDI-MedLine.d23.s2.e3" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d23.s2.p3" e1="DDI-MedLine.d23.s2.e0"
            e2="DDI-MedLine.d23.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d23.s2.p4" e1="DDI-MedLine.d23.s2.e0"
            e2="DDI-MedLine.d23.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d23.s2.p5" e1="DDI-MedLine.d23.s2.e1"
            e2="DDI-MedLine.d23.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d23.s2.p6" e1="DDI-MedLine.d23.s2.e1"
            e2="DDI-MedLine.d23.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d23.s2.p7" e1="DDI-MedLine.d23.s2.e1"
            e2="DDI-MedLine.d23.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d23.s2.p8" e1="DDI-MedLine.d23.s2.e1"
            e2="DDI-MedLine.d23.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d23.s2.p9" e1="DDI-MedLine.d23.s2.e2"
            e2="DDI-MedLine.d23.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d23.s2.p10" e1="DDI-MedLine.d23.s2.e2"
            e2="DDI-MedLine.d23.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d23.s2.p11" e1="DDI-MedLine.d23.s2.e2"
            e2="DDI-MedLine.d23.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d23.s2.p12" e1="DDI-MedLine.d23.s2.e3"
            e2="DDI-MedLine.d23.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d23.s2.p13" e1="DDI-MedLine.d23.s2.e3"
            e2="DDI-MedLine.d23.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d23.s2.p14" e1="DDI-MedLine.d23.s2.e4"
            e2="DDI-MedLine.d23.s2.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d138.s0" text="Interaction between oxytocin and antidiuretic hormone and its effect on the milk secretion by alveoli of the mammary gland of lactating rats.&#xd;&#xa;">
        <entity id="DDI-MedLine.d138.s0.e0" charOffset="20-27"
            type="drug" text="oxytocin"/>
    </sentence>
    <sentence id="DDI-MedLine.d138.s1" text="Interaction between exogenous and endogenous oxytocin and vasopressin was found to affect the mechanism of milk ejection by the alveoli of the mammary gland in lactating rats. ">
        <entity id="DDI-MedLine.d138.s1.e0" charOffset="45-52"
            type="drug" text="oxytocin"/>
    </sentence>
    <sentence id="DDI-MedLine.d138.s2" text="Inhibition and stimulation of the effect of oxytocin on milk ejection by vasopressin was demonstrated. ">
        <entity id="DDI-MedLine.d138.s2.e0" charOffset="44-51"
            type="drug" text="oxytocin"/>
    </sentence>
    <sentence id="DDI-MedLine.d138.s3" text="On the basis of the principles observed the concentrations fo these hormones were investigated in the plasma of dogs deprived of water for 3 days and then allowed to drink."/>
    <sentence id="DDI-MedLine.d49.s0" text="Interaction of clindamycin and gentamicin in vitro.&#xa;">
        <entity id="DDI-MedLine.d49.s0.e0" charOffset="15-25"
            type="drug" text="clindamycin"/>
        <entity id="DDI-MedLine.d49.s0.e1" charOffset="31-40"
            type="drug" text="gentamicin"/>
        <pair id="DDI-MedLine.d49.s0.p0" e1="DDI-MedLine.d49.s0.e0"
            e2="DDI-MedLine.d49.s0.e1" ddi="true" type="int"/>
    </sentence>
    <sentence id="DDI-MedLine.d49.s1" text="The minimal inhibitory concentrations of clindamycin and gentamicin alone and in combinations were determined by a microdilution method for 163 aerobic, facultative, and anaerobic clinical isolates. ">
        <entity id="DDI-MedLine.d49.s1.e0" charOffset="41-51"
            type="drug" text="clindamycin"/>
        <entity id="DDI-MedLine.d49.s1.e1" charOffset="57-66"
            type="drug" text="gentamicin"/>
        <pair id="DDI-MedLine.d49.s1.p0" e1="DDI-MedLine.d49.s1.e0"
            e2="DDI-MedLine.d49.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d49.s2" text="All 77 strains of Staphylococcus aureus, Diplococcus pneumoniae, Streptococcus pyogenes, and anaerobic bacteria (except for three strains of Clostridium) were inhibited by 1.6 mug or less of clindamycin per ml. ">
        <entity id="DDI-MedLine.d49.s2.e0" charOffset="191-201"
            type="drug" text="clindamycin"/>
    </sentence>
    <sentence id="DDI-MedLine.d49.s3" text="Gentamicin did not interfere with the activity of clindamycin within the range of concentrations tested (0.1 to 100 mug/ml); ">
        <entity id="DDI-MedLine.d49.s3.e0" charOffset="0-9" type="drug" text="Gentamicin"/>
        <entity id="DDI-MedLine.d49.s3.e1" charOffset="50-60"
            type="drug" text="clindamycin"/>
        <pair id="DDI-MedLine.d49.s3.p0" e1="DDI-MedLine.d49.s3.e0"
            e2="DDI-MedLine.d49.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d49.s4" text="for some strains combinations were synergistic. "/>
    <sentence id="DDI-MedLine.d49.s5" text="Sixty-two (94%) of 66 strains of Enterobacteriaceae and Pseudomonas aeruginosa were inhibited by 6.2 mug or less of gentamicin per ml. ">
        <entity id="DDI-MedLine.d49.s5.e0" charOffset="116-125"
            type="drug" text="gentamicin"/>
    </sentence>
    <sentence id="DDI-MedLine.d49.s6" text="Combinations of clindamycin and gentamicin were indifferent for 29 strains and synergistic for 33 strains. ">
        <entity id="DDI-MedLine.d49.s6.e0" charOffset="16-26"
            type="drug" text="clindamycin"/>
        <entity id="DDI-MedLine.d49.s6.e1" charOffset="32-41"
            type="drug" text="gentamicin"/>
        <pair id="DDI-MedLine.d49.s6.p0" e1="DDI-MedLine.d49.s6.e0"
            e2="DDI-MedLine.d49.s6.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d49.s7" text="All 20 strains of enterococcus, three strains of Clostridium, three strains of Escherichia coli, and one strain of Proteus rettgeri were resistant to both clindamycin (minimal inhibitory concentration greater than 3.1 mug/ml) and gentamicin (minimal inhibitory concentration greater than 6.2 mug/ml). ">
        <entity id="DDI-MedLine.d49.s7.e0" charOffset="155-165"
            type="drug" text="clindamycin"/>
        <entity id="DDI-MedLine.d49.s7.e1" charOffset="230-239"
            type="drug" text="gentamicin"/>
        <pair id="DDI-MedLine.d49.s7.p0" e1="DDI-MedLine.d49.s7.e0"
            e2="DDI-MedLine.d49.s7.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d49.s8" text="Combinations of clindamycin and gentamicin were indifferent for 16 and synergistic for 11 of the resistant strains. ">
        <entity id="DDI-MedLine.d49.s8.e0" charOffset="16-26"
            type="drug" text="clindamycin"/>
        <entity id="DDI-MedLine.d49.s8.e1" charOffset="32-41"
            type="drug" text="gentamicin"/>
        <pair id="DDI-MedLine.d49.s8.p0" e1="DDI-MedLine.d49.s8.e0"
            e2="DDI-MedLine.d49.s8.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d49.s9" text="Except for clindamycin-sensitive isolates, synergy was usually observed only at concentrations of one or both drugs which are not readily obtainable in vivo. ">
        <entity id="DDI-MedLine.d49.s9.e0" charOffset="11-21"
            type="drug" text="clindamycin"/>
    </sentence>
    <sentence id="DDI-MedLine.d49.s10" text="Antagonism was never observed."/>
    <sentence id="DDI-MedLine.d120.s0" text="Molecular basis for the selective toxicity of amphotericin B for yeast and filipin for animal cells.">
        <entity id="DDI-MedLine.d120.s0.e0" charOffset="46-59"
            type="drug" text="amphotericin B"/>
        <entity id="DDI-MedLine.d120.s0.e1" charOffset="75-81"
            type="drug_n" text="filipin"/>
        <pair id="DDI-MedLine.d120.s0.p0" e1="DDI-MedLine.d120.s0.e0"
            e2="DDI-MedLine.d120.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d120.s1" text="Among the polyene antibiotics, many, like filipin, cannot be used clinically because they are toxic; ">
        <entity id="DDI-MedLine.d120.s1.e0" charOffset="10-28"
            type="group" text="polyene antibiotics"/>
        <entity id="DDI-MedLine.d120.s1.e1" charOffset="42-48"
            type="drug_n" text="filipin"/>
        <pair id="DDI-MedLine.d120.s1.p0" e1="DDI-MedLine.d120.s1.e0"
            e2="DDI-MedLine.d120.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d120.s2" text="amphotericin B, however, is useful in therapy of human fungal infections because it is less toxic. ">
        <entity id="DDI-MedLine.d120.s2.e0" charOffset="0-13"
            type="drug" text="amphotericin B"/>
    </sentence>
    <sentence id="DDI-MedLine.d120.s3" text="Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; ">
        <entity id="DDI-MedLine.d120.s3.e0" charOffset="21-27"
            type="drug_n" text="filipin"/>
        <entity id="DDI-MedLine.d120.s3.e1" charOffset="58-71"
            type="drug" text="amphotericin B"/>
        <entity id="DDI-MedLine.d120.s3.e2" charOffset="170-188"
            type="group" text="polyene antibiotics"/>
        <pair id="DDI-MedLine.d120.s3.p0" e1="DDI-MedLine.d120.s3.e0"
            e2="DDI-MedLine.d120.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d120.s3.p1" e1="DDI-MedLine.d120.s3.e0"
            e2="DDI-MedLine.d120.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d120.s3.p2" e1="DDI-MedLine.d120.s3.e1"
            e2="DDI-MedLine.d120.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d120.s4" text="filipin was more potent in lysing human red blood cells, whereas amphotericin B was more potent in inhibiting yeast cell growth; ">
        <entity id="DDI-MedLine.d120.s4.e0" charOffset="0-6"
            type="drug_n" text="filipin"/>
        <entity id="DDI-MedLine.d120.s4.e1" charOffset="65-78"
            type="drug" text="amphotericin B"/>
        <pair id="DDI-MedLine.d120.s4.p0" e1="DDI-MedLine.d120.s4.e0"
            e2="DDI-MedLine.d120.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d120.s5" text="and (ii) the effects of filipin were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of amphotericin B were more efficiently inhibited by ergosterol, the major membrane sterol in yeast. ">
        <entity id="DDI-MedLine.d120.s5.e0" charOffset="24-30"
            type="drug_n" text="filipin"/>
        <entity id="DDI-MedLine.d120.s5.e1" charOffset="151-164"
            type="drug" text="amphotericin B"/>
        <pair id="DDI-MedLine.d120.s5.p0" e1="DDI-MedLine.d120.s5.e0"
            e2="DDI-MedLine.d120.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d120.s6" text="The simplest inference is that the toxicity and effectiveness of polyenes are determined by their relative avidities for the predominant sterol in cell membranes."/>
    <sentence id="DDI-MedLine.d40.s0" text="Studies on the mechanism of action of miconazole: effect of miconazole on respiration and cell permeability of Candida albicans.&#xd;&#xa;">
        <entity id="DDI-MedLine.d40.s0.e0" charOffset="38-47"
            type="drug" text="miconazole"/>
        <entity id="DDI-MedLine.d40.s0.e1" charOffset="60-69"
            type="drug" text="miconazole"/>
        <pair id="DDI-MedLine.d40.s0.p0" e1="DDI-MedLine.d40.s0.e0"
            e2="DDI-MedLine.d40.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d40.s1" text="The antifungal drug, miconazole nitrate, inhibits the growth of several species of Candida. ">
        <entity id="DDI-MedLine.d40.s1.e0" charOffset="4-18"
            type="group" text="antifungal drug"/>
        <entity id="DDI-MedLine.d40.s1.e1" charOffset="21-38"
            type="drug" text="miconazole nitrate"/>
        <pair id="DDI-MedLine.d40.s1.p0" e1="DDI-MedLine.d40.s1.e0"
            e2="DDI-MedLine.d40.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d40.s2" text="Candida albicans, one of the pathogenic species, was totally inhibited at a concentration of approximately 10 mug/ml. "/>
    <sentence id="DDI-MedLine.d40.s3" text="Endogenous respiration was unaffected by the drug at a concentration as high as 100 mug/ml, whereas exogenous respiration was markedly sensitive and inhibited to an extent of 85%. "/>
    <sentence id="DDI-MedLine.d40.s4" text="The permeability of the cell membrane was changed as evidenced by the leakage of 260-nm absorbing materials, amino acids, proteins, and inorganic cations. "/>
    <sentence id="DDI-MedLine.d40.s5" text="The results we present clearly show that the drug alters the cellular permeability, and thus the exogenous respiration becomes sensitive to the drug."/>
    <sentence id="DDI-MedLine.d29.s0" text="Effect of probenecid on the apparent volume of distribution and elimination of cloxacillin.&#xd;&#xa;">
        <entity id="DDI-MedLine.d29.s0.e0" charOffset="10-19"
            type="drug" text="probenecid"/>
        <entity id="DDI-MedLine.d29.s0.e1" charOffset="79-89"
            type="drug" text="cloxacillin"/>
        <pair id="DDI-MedLine.d29.s0.p0" e1="DDI-MedLine.d29.s0.e0"
            e2="DDI-MedLine.d29.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d29.s1" text="According to Gibaldi et al. "/>
    <sentence id="DDI-MedLine.d29.s2" text="(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body. ">
        <entity id="DDI-MedLine.d29.s2.e0" charOffset="49-59"
            type="group" text="penicillins"/>
        <entity id="DDI-MedLine.d29.s2.e1" charOffset="65-77"
            type="drug" text="cephaloridine"/>
        <entity id="DDI-MedLine.d29.s2.e2" charOffset="111-120"
            type="drug" text="probenecid"/>
        <pair id="DDI-MedLine.d29.s2.p0" e1="DDI-MedLine.d29.s2.e0"
            e2="DDI-MedLine.d29.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d29.s2.p1" e1="DDI-MedLine.d29.s2.e0"
            e2="DDI-MedLine.d29.s2.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d29.s2.p2" e1="DDI-MedLine.d29.s2.e1"
            e2="DDI-MedLine.d29.s2.e2" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d29.s3" text="To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. ">
        <entity id="DDI-MedLine.d29.s3.e0" charOffset="21-30"
            type="drug" text="probenecid"/>
        <entity id="DDI-MedLine.d29.s3.e1" charOffset="75-85"
            type="drug" text="cloxacillin"/>
        <entity id="DDI-MedLine.d29.s3.e2" charOffset="124-134"
            type="drug" text="cloxacillin"/>
        <entity id="DDI-MedLine.d29.s3.e3" charOffset="274-283"
            type="drug" text="probenecid"/>
        <pair id="DDI-MedLine.d29.s3.p0" e1="DDI-MedLine.d29.s3.e0"
            e2="DDI-MedLine.d29.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d29.s3.p1" e1="DDI-MedLine.d29.s3.e0"
            e2="DDI-MedLine.d29.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d29.s3.p2" e1="DDI-MedLine.d29.s3.e0"
            e2="DDI-MedLine.d29.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d29.s3.p3" e1="DDI-MedLine.d29.s3.e1"
            e2="DDI-MedLine.d29.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d29.s3.p4" e1="DDI-MedLine.d29.s3.e1"
            e2="DDI-MedLine.d29.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d29.s3.p5" e1="DDI-MedLine.d29.s3.e2"
            e2="DDI-MedLine.d29.s3.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d29.s4" text="No significant difference was found between the mean values of the volume of distribution of cloxacillin with and without probenecid (13.0 and 12.6 liters, respectively). ">
        <entity id="DDI-MedLine.d29.s4.e0" charOffset="93-103"
            type="drug" text="cloxacillin"/>
        <entity id="DDI-MedLine.d29.s4.e1" charOffset="122-131"
            type="drug" text="probenecid"/>
        <pair id="DDI-MedLine.d29.s4.p0" e1="DDI-MedLine.d29.s4.e0"
            e2="DDI-MedLine.d29.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d29.s5" text="Thus, the hypothesis of Gibaldi et al. "/>
    <sentence id="DDI-MedLine.d29.s6" text="could not be confirmed for cloxacillin in patients lacking kidney function. ">
        <entity id="DDI-MedLine.d29.s6.e0" charOffset="27-37"
            type="drug" text="cloxacillin"/>
    </sentence>
    <sentence id="DDI-MedLine.d29.s7" text="In spite of the absence of kidney function, the value of the elimination rate constant was significantly decreased in the presence of probenecid (from 0.326 to 0.263/h). ">
        <entity id="DDI-MedLine.d29.s7.e0" charOffset="134-143"
            type="drug" text="probenecid"/>
    </sentence>
    <sentence id="DDI-MedLine.d29.s8" text="This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.">
        <entity id="DDI-MedLine.d29.s8.e0" charOffset="41-50"
            type="drug" text="probenecid"/>
        <entity id="DDI-MedLine.d29.s8.e1" charOffset="74-84"
            type="drug" text="cloxacillin"/>
        <pair id="DDI-MedLine.d29.s8.p0" e1="DDI-MedLine.d29.s8.e0"
            e2="DDI-MedLine.d29.s8.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d122.s0" text="Behavioral mechanisms underlying the link between smoking and drinking.&#xd;&#xa;"/>
    <sentence id="DDI-MedLine.d122.s1" text="Many people use both alcohol and nicotine (i.e., cigarettes and other tobacco products). ">
        <entity id="DDI-MedLine.d122.s1.e0" charOffset="21-27"
            type="drug" text="alcohol"/>
        <entity id="DDI-MedLine.d122.s1.e1" charOffset="33-40"
            type="drug" text="nicotine"/>
        <pair id="DDI-MedLine.d122.s1.p0" e1="DDI-MedLine.d122.s1.e0"
            e2="DDI-MedLine.d122.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d122.s2" text="The behavioral effects of these two drugs differ, and they do not act on the same target sites in the brain, although they may share, or partly share, certain properties. "/>
    <sentence id="DDI-MedLine.d122.s3" text="The initiation of alcohol or nicotine use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking. ">
        <entity id="DDI-MedLine.d122.s3.e0" charOffset="18-24"
            type="drug" text="alcohol"/>
        <entity id="DDI-MedLine.d122.s3.e1" charOffset="29-36"
            type="drug" text="nicotine"/>
        <pair id="DDI-MedLine.d122.s3.p0" e1="DDI-MedLine.d122.s3.e0"
            e2="DDI-MedLine.d122.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d122.s4" text="Moreover, the mechanisms underlying the development of dependence may be similar for alcohol and nicotine. ">
        <entity id="DDI-MedLine.d122.s4.e0" charOffset="85-91"
            type="drug" text="alcohol"/>
        <entity id="DDI-MedLine.d122.s4.e1" charOffset="97-104"
            type="drug" text="nicotine"/>
        <pair id="DDI-MedLine.d122.s4.p0" e1="DDI-MedLine.d122.s4.e0"
            e2="DDI-MedLine.d122.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d122.s5" text="Thus, certain factors, such as reinforcing drug effects, conditioning processes, automatic behavior, and stress, may influence the development of dependence on both drugs. "/>
    <sentence id="DDI-MedLine.d122.s6" text="Other factors, such as tolerance and sensitization to the drugs' actions and the development of withdrawal symptoms, may also contribute to dependence. "/>
    <sentence id="DDI-MedLine.d122.s7" text="This review discusses the actions of the two drugs on certain brain chemical (i.e., neurotransmitter) systems and the extent to which the effects of the two drugs may interact."/>
    <sentence id="DDI-MedLine.d134.s0" text="[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. ">
        <entity id="DDI-MedLine.d134.s0.e0" charOffset="50-67"
            type="drug" text="radiopertechnetate"/>
        <entity id="DDI-MedLine.d134.s0.e1" charOffset="72-89"
            type="drug_n" text="sodium perchlorate"/>
        <entity id="DDI-MedLine.d134.s0.e2" charOffset="169-186"
            type="drug_n" text="sodium perchlorate"/>
        <entity id="DDI-MedLine.d134.s0.e3" charOffset="266-283"
            type="drug" text="radiopertechnetate"/>
        <pair id="DDI-MedLine.d134.s0.p0" e1="DDI-MedLine.d134.s0.e0"
            e2="DDI-MedLine.d134.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d134.s0.p1" e1="DDI-MedLine.d134.s0.e0"
            e2="DDI-MedLine.d134.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d134.s0.p2" e1="DDI-MedLine.d134.s0.e0"
            e2="DDI-MedLine.d134.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d134.s0.p3" e1="DDI-MedLine.d134.s0.e1"
            e2="DDI-MedLine.d134.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d134.s0.p4" e1="DDI-MedLine.d134.s0.e1"
            e2="DDI-MedLine.d134.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d134.s0.p5" e1="DDI-MedLine.d134.s0.e2"
            e2="DDI-MedLine.d134.s0.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d134.s1" text="An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate. ">
        <entity id="DDI-MedLine.d134.s1.e0" charOffset="29-39"
            type="drug_n" text="perchlorate"/>
        <entity id="DDI-MedLine.d134.s1.e1" charOffset="116-128"
            type="drug" text="pertechnetate"/>
        <entity id="DDI-MedLine.d134.s1.e2" charOffset="237-254"
            type="drug" text="radiopertechnetate"/>
        <pair id="DDI-MedLine.d134.s1.p0" e1="DDI-MedLine.d134.s1.e0"
            e2="DDI-MedLine.d134.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d134.s1.p1" e1="DDI-MedLine.d134.s1.e0"
            e2="DDI-MedLine.d134.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d134.s1.p2" e1="DDI-MedLine.d134.s1.e1"
            e2="DDI-MedLine.d134.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d134.s2" text="An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels. ">
        <entity id="DDI-MedLine.d134.s2.e0" charOffset="28-38"
            type="drug_n" text="perchlorate"/>
        <entity id="DDI-MedLine.d134.s2.e1" charOffset="116-128"
            type="drug" text="pertechnetate"/>
        <pair id="DDI-MedLine.d134.s2.p0" e1="DDI-MedLine.d134.s2.e0"
            e2="DDI-MedLine.d134.s2.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d134.s3" text="20 mg result in incomplete depletion which becomes complete after a second additional dose. "/>
    <sentence id="DDI-MedLine.d134.s4" text="The intravenous application of perchlorate offers advantages in clinical use.">
        <entity id="DDI-MedLine.d134.s4.e0" charOffset="31-41"
            type="drug_n" text="perchlorate"/>
    </sentence>
    <sentence id="DDI-MedLine.d10.s0" text="Herbal remedies, nephropathies, and renal disease.&#xa;"/>
    <sentence id="DDI-MedLine.d10.s1" text="The use of herbal remedies is becoming increasingly popular in the United States. "/>
    <sentence id="DDI-MedLine.d10.s2" text="Research has shown that herbal remedy use may be associated with acute renal failure. "/>
    <sentence id="DDI-MedLine.d10.s3" text="In addition, the use of herbal remedies may be detrimental for the patient with compromised renal function. "/>
    <sentence id="DDI-MedLine.d10.s4" text="Patients with renal insufficiency or renal failure may be at risk for further kidney damage as well as complications related to interactions of herbal remedies with complex renal therapy regimens. "/>
    <sentence id="DDI-MedLine.d10.s5" text="This article will describe the escalating use of herbal therapy and the hazards of herbal remedy use among patients."/>
    <sentence id="DDI-MedLine.d118.s0" text="Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.&#xd;&#xa;">
        <entity id="DDI-MedLine.d118.s0.e0" charOffset="0-8" type="drug" text="Sirolimus"/>
        <entity id="DDI-MedLine.d118.s0.e1" charOffset="31-39"
            type="drug" text="rapamycin"/>
        <pair id="DDI-MedLine.d118.s0.p0" e1="DDI-MedLine.d118.s0.e0"
            e2="DDI-MedLine.d118.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d118.s1" text="Current immunosuppressive therapies are effective but can be associated with significant adverse reactions. "/>
    <sentence id="DDI-MedLine.d118.s2" text="Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. ">
        <entity id="DDI-MedLine.d118.s2.e0" charOffset="0-8" type="drug" text="Sirolimus"/>
        <entity id="DDI-MedLine.d118.s2.e1" charOffset="37-54"
            type="group" text="immunosuppressants"/>
        <entity id="DDI-MedLine.d118.s2.e2" charOffset="148-156"
            type="drug" text="sirolimus"/>
        <entity id="DDI-MedLine.d118.s2.e3" charOffset="231-242"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-MedLine.d118.s2.e4" charOffset="247-256"
            type="drug" text="tacrolimus"/>
        <pair id="DDI-MedLine.d118.s2.p0" e1="DDI-MedLine.d118.s2.e0"
            e2="DDI-MedLine.d118.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d118.s2.p1" e1="DDI-MedLine.d118.s2.e0"
            e2="DDI-MedLine.d118.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d118.s2.p2" e1="DDI-MedLine.d118.s2.e0"
            e2="DDI-MedLine.d118.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d118.s2.p3" e1="DDI-MedLine.d118.s2.e0"
            e2="DDI-MedLine.d118.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d118.s2.p4" e1="DDI-MedLine.d118.s2.e1"
            e2="DDI-MedLine.d118.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d118.s2.p5" e1="DDI-MedLine.d118.s2.e1"
            e2="DDI-MedLine.d118.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d118.s2.p6" e1="DDI-MedLine.d118.s2.e1"
            e2="DDI-MedLine.d118.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d118.s2.p7" e1="DDI-MedLine.d118.s2.e2"
            e2="DDI-MedLine.d118.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d118.s2.p8" e1="DDI-MedLine.d118.s2.e2"
            e2="DDI-MedLine.d118.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d118.s2.p9" e1="DDI-MedLine.d118.s2.e3"
            e2="DDI-MedLine.d118.s2.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d118.s3" text="While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).">
        <entity id="DDI-MedLine.d118.s3.e0" charOffset="97-105"
            type="drug" text="sirolimus"/>
        <entity id="DDI-MedLine.d118.s3.e1" charOffset="128-139"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-MedLine.d118.s3.e2" charOffset="144-153"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-MedLine.d118.s3.e3" charOffset="249-260"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-MedLine.d118.s3.e4" charOffset="265-274"
            type="drug" text="tacrolimus"/>
        <pair id="DDI-MedLine.d118.s3.p0" e1="DDI-MedLine.d118.s3.e0"
            e2="DDI-MedLine.d118.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d118.s3.p1" e1="DDI-MedLine.d118.s3.e0"
            e2="DDI-MedLine.d118.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d118.s3.p2" e1="DDI-MedLine.d118.s3.e0"
            e2="DDI-MedLine.d118.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d118.s3.p3" e1="DDI-MedLine.d118.s3.e0"
            e2="DDI-MedLine.d118.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d118.s3.p4" e1="DDI-MedLine.d118.s3.e1"
            e2="DDI-MedLine.d118.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d118.s3.p5" e1="DDI-MedLine.d118.s3.e1"
            e2="DDI-MedLine.d118.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d118.s3.p6" e1="DDI-MedLine.d118.s3.e1"
            e2="DDI-MedLine.d118.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d118.s3.p7" e1="DDI-MedLine.d118.s3.e2"
            e2="DDI-MedLine.d118.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d118.s3.p8" e1="DDI-MedLine.d118.s3.e2"
            e2="DDI-MedLine.d118.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d118.s3.p9" e1="DDI-MedLine.d118.s3.e3"
            e2="DDI-MedLine.d118.s3.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d88.s0" text="The effects of chlordiazepoxide, amphetamine and cocaine on bar-press behavior in normal and genetically nervous dogs.&#xd;&#xa;">
        <entity id="DDI-MedLine.d88.s0.e0" charOffset="15-30"
            type="drug" text="chlordiazepoxide"/>
        <entity id="DDI-MedLine.d88.s0.e1" charOffset="33-43"
            type="drug" text="amphetamine"/>
        <entity id="DDI-MedLine.d88.s0.e2" charOffset="49-55"
            type="drug" text="cocaine"/>
        <pair id="DDI-MedLine.d88.s0.p0" e1="DDI-MedLine.d88.s0.e0"
            e2="DDI-MedLine.d88.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d88.s0.p1" e1="DDI-MedLine.d88.s0.e0"
            e2="DDI-MedLine.d88.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d88.s0.p2" e1="DDI-MedLine.d88.s0.e1"
            e2="DDI-MedLine.d88.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d88.s1" text="Studies on two strains of pointer dogs have demonstrated that administration of a benzodiazepine (chlordiazepoxide) facilitates acquisition of goal-directed behavior in &quot;genetically nervous&quot;">
        <entity id="DDI-MedLine.d88.s1.e0" charOffset="82-95"
            type="group" text="benzodiazepine"/>
        <entity id="DDI-MedLine.d88.s1.e1" charOffset="98-113"
            type="drug" text="chlordiazepoxide"/>
        <pair id="DDI-MedLine.d88.s1.p0" e1="DDI-MedLine.d88.s1.e0"
            e2="DDI-MedLine.d88.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d88.s2" text="subjects. "/>
    <sentence id="DDI-MedLine.d88.s3" text="Continued admistration of the drug is required to maintain barpress response in this strain of dogs. "/>
    <sentence id="DDI-MedLine.d88.s4" text="The concomitant administration of either cocaine or amphetamine, compounds which inhibit neuronal reuptake of norepinephrine, disrupts the behavioral response of the genetically nervous E-strain subjects to a far greater extent than the stable A-strain subjects. ">
        <entity id="DDI-MedLine.d88.s4.e0" charOffset="41-47"
            type="drug" text="cocaine"/>
        <entity id="DDI-MedLine.d88.s4.e1" charOffset="52-62"
            type="drug" text="amphetamine"/>
        <pair id="DDI-MedLine.d88.s4.p0" e1="DDI-MedLine.d88.s4.e0"
            e2="DDI-MedLine.d88.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d88.s5" text="It is also shown that after 14 days of daily administration of chlordiazepoxide, withdrawal of the drug not only re-results in almost complete loss of bar-press response in the E-strain subjects but also results in a temporary decrease in the acquired behavioral response of the stable A-strain subjects.">
        <entity id="DDI-MedLine.d88.s5.e0" charOffset="63-78"
            type="drug" text="chlordiazepoxide"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s0" text="Development and pharmacology of fluvastatin.&#xa;">
        <entity id="DDI-MedLine.d119.s0.e0" charOffset="32-42"
            type="drug" text="fluvastatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s1" text="Fluvastatin is the first synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor to be approved for clinical use, and has been studied extensively in humans since 1986. ">
        <entity id="DDI-MedLine.d119.s1.e0" charOffset="0-10"
            type="drug" text="Fluvastatin"/>
        <entity id="DDI-MedLine.d119.s1.e1" charOffset="25-100"
            type="group" text="synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor"/>
        <pair id="DDI-MedLine.d119.s1.p0" e1="DDI-MedLine.d119.s1.e0"
            e2="DDI-MedLine.d119.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s2" text="It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. ">
        <entity id="DDI-MedLine.d119.s2.e0" charOffset="63-89"
            type="group" text="HMGCoA reductase inhibitors"/>
        <entity id="DDI-MedLine.d119.s2.e1" charOffset="92-101"
            type="drug" text="lovastatin"/>
        <entity id="DDI-MedLine.d119.s2.e2" charOffset="104-114"
            type="drug" text="simvastatin"/>
        <entity id="DDI-MedLine.d119.s2.e3" charOffset="121-131"
            type="drug" text="pravastatin"/>
        <pair id="DDI-MedLine.d119.s2.p0" e1="DDI-MedLine.d119.s2.e0"
            e2="DDI-MedLine.d119.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d119.s2.p1" e1="DDI-MedLine.d119.s2.e0"
            e2="DDI-MedLine.d119.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d119.s2.p2" e1="DDI-MedLine.d119.s2.e0"
            e2="DDI-MedLine.d119.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d119.s2.p3" e1="DDI-MedLine.d119.s2.e1"
            e2="DDI-MedLine.d119.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d119.s2.p4" e1="DDI-MedLine.d119.s2.e1"
            e2="DDI-MedLine.d119.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d119.s2.p5" e1="DDI-MedLine.d119.s2.e2"
            e2="DDI-MedLine.d119.s2.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s3" text="Absorption of fluvastatin is virtually complete across all species, including man, and is not affected by the presence of food. ">
        <entity id="DDI-MedLine.d119.s3.e0" charOffset="14-24"
            type="drug" text="fluvastatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s4" text="Systemic exposure is limited, as fluvastatin is subject to first-pass metabolism, and the plasma half-life of the drug is approximately 30 minutes. ">
        <entity id="DDI-MedLine.d119.s4.e0" charOffset="33-43"
            type="drug" text="fluvastatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s5" text="Some 95% of a single dosage of fluvastatin is excreted via the biliary route, with less than 2% of this being the parent compound. ">
        <entity id="DDI-MedLine.d119.s5.e0" charOffset="31-41"
            type="drug" text="fluvastatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s6" text="Additionally, there is no evidence of circulating active metabolites or accumulation during chronic dosing. "/>
    <sentence id="DDI-MedLine.d119.s7" text="Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; ">
        <entity id="DDI-MedLine.d119.s7.e0" charOffset="57-67"
            type="drug" text="fluvastatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s8" text="however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens. ">
        <entity id="DDI-MedLine.d119.s8.e0" charOffset="25-35"
            type="drug" text="fluvastatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s9" text="Furthermore, no significant difference in pharmacodynamic effect (reduction in low-density lipoprotein cholesterol levels) could be ascertained between mealtime dosing and bedtime dosing. "/>
    <sentence id="DDI-MedLine.d119.s10" text="The pharmacokinetics of fluvastatin have also been assessed in various demographic groups. ">
        <entity id="DDI-MedLine.d119.s10.e0" charOffset="24-34"
            type="drug" text="fluvastatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s11" text="Relative to the general population, plasma concentrations of fluvastatin do not vary as a function of either age or gender. ">
        <entity id="DDI-MedLine.d119.s11.e0" charOffset="61-71"
            type="drug" text="fluvastatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s12" text="In addition, administration to a patient population with hepatic insufficiency resulted in a 2.5-fold increase in both the rate and extent of bioavailability relative to controls. "/>
    <sentence id="DDI-MedLine.d119.s13" text="Also, although minimal alterations of fluvastatin clearance in patients with renal insufficiency are anticipated due to limited renal excretion (5%), a study in this patient group is currently underway to examine this further. ">
        <entity id="DDI-MedLine.d119.s13.e0" charOffset="38-48"
            type="drug" text="fluvastatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s14" text="Interaction studies have been performed with fluvastatin and several drugs with which it might be coadministered. ">
        <entity id="DDI-MedLine.d119.s14.e0" charOffset="45-55"
            type="drug" text="fluvastatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s15" text="Cholestyramine, an anionic-binding resin, has a considerable effect in lowering the rate and extent of fluvastatin bioavailability. ">
        <entity id="DDI-MedLine.d119.s15.e0" charOffset="0-13"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-MedLine.d119.s15.e1" charOffset="103-113"
            type="drug" text="fluvastatin"/>
        <pair id="DDI-MedLine.d119.s15.p0" e1="DDI-MedLine.d119.s15.e0"
            e2="DDI-MedLine.d119.s15.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s16" text="Although this effect was noted even when cholestyramine was given 4 hours prior to fluvastatin, this regimen did not result in diminished efficacy. ">
        <entity id="DDI-MedLine.d119.s16.e0" charOffset="41-54"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-MedLine.d119.s16.e1" charOffset="83-93"
            type="drug" text="fluvastatin"/>
        <pair id="DDI-MedLine.d119.s16.p0" e1="DDI-MedLine.d119.s16.e0"
            e2="DDI-MedLine.d119.s16.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s17" text="Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin. ">
        <entity id="DDI-MedLine.d119.s17.e0" charOffset="30-37"
            type="drug" text="warfarin"/>
        <entity id="DDI-MedLine.d119.s17.e1" charOffset="132-139"
            type="drug" text="warfarin"/>
        <entity id="DDI-MedLine.d119.s17.e2" charOffset="145-155"
            type="drug" text="fluvastatin"/>
        <pair id="DDI-MedLine.d119.s17.p0" e1="DDI-MedLine.d119.s17.e0"
            e2="DDI-MedLine.d119.s17.e1" ddi="false"/>
        <pair id="DDI-MedLine.d119.s17.p1" e1="DDI-MedLine.d119.s17.e0"
            e2="DDI-MedLine.d119.s17.e2" ddi="false"/>
        <pair id="DDI-MedLine.d119.s17.p2" e1="DDI-MedLine.d119.s17.e1"
            e2="DDI-MedLine.d119.s17.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s18" text="Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. ">
        <entity id="DDI-MedLine.d119.s18.e0" charOffset="46-51"
            type="drug" text="niacin"/>
        <entity id="DDI-MedLine.d119.s18.e1" charOffset="57-67"
            type="drug" text="propranolol"/>
        <entity id="DDI-MedLine.d119.s18.e2" charOffset="105-115"
            type="drug" text="fluvastatin"/>
        <entity id="DDI-MedLine.d119.s18.e3" charOffset="197-203"
            type="drug" text="digoxin"/>
        <entity id="DDI-MedLine.d119.s18.e4" charOffset="267-273"
            type="drug" text="digoxin"/>
        <pair id="DDI-MedLine.d119.s18.p0" e1="DDI-MedLine.d119.s18.e0"
            e2="DDI-MedLine.d119.s18.e1" ddi="false"/>
        <pair id="DDI-MedLine.d119.s18.p1" e1="DDI-MedLine.d119.s18.e0"
            e2="DDI-MedLine.d119.s18.e2" ddi="false"/>
        <pair id="DDI-MedLine.d119.s18.p2" e1="DDI-MedLine.d119.s18.e0"
            e2="DDI-MedLine.d119.s18.e3" ddi="false"/>
        <pair id="DDI-MedLine.d119.s18.p3" e1="DDI-MedLine.d119.s18.e0"
            e2="DDI-MedLine.d119.s18.e4" ddi="false"/>
        <pair id="DDI-MedLine.d119.s18.p4" e1="DDI-MedLine.d119.s18.e1"
            e2="DDI-MedLine.d119.s18.e2" ddi="false"/>
        <pair id="DDI-MedLine.d119.s18.p5" e1="DDI-MedLine.d119.s18.e1"
            e2="DDI-MedLine.d119.s18.e3" ddi="false"/>
        <pair id="DDI-MedLine.d119.s18.p6" e1="DDI-MedLine.d119.s18.e1"
            e2="DDI-MedLine.d119.s18.e4" ddi="false"/>
        <pair id="DDI-MedLine.d119.s18.p7" e1="DDI-MedLine.d119.s18.e2"
            e2="DDI-MedLine.d119.s18.e3" ddi="false"/>
        <pair id="DDI-MedLine.d119.s18.p8" e1="DDI-MedLine.d119.s18.e2"
            e2="DDI-MedLine.d119.s18.e4" ddi="false"/>
        <pair id="DDI-MedLine.d119.s18.p9" e1="DDI-MedLine.d119.s18.e3"
            e2="DDI-MedLine.d119.s18.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d119.s19" text="The results generated to date in clinical pharmacokinetic studies with fluvastatin thus support its use in a broad population of hypercholesterolaemic patients.">
        <entity id="DDI-MedLine.d119.s19.e0" charOffset="71-81"
            type="drug" text="fluvastatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d43.s0" text="Tumor phenotype and susceptibility to progression as an expression of subpopulations of initiated murine cells.&#xa;"/>
    <sentence id="DDI-MedLine.d43.s1" text="Currently, it is conceived that a number of events, or hits, are required for the induction of tumors by chemical agents. "/>
    <sentence id="DDI-MedLine.d43.s2" text="The first phase of this sequence, initiation, is considered to result from at least one event in the genetic apparatus. "/>
    <sentence id="DDI-MedLine.d43.s3" text="Analyses of this sequence, however, usually give little consideration to the nature of the target cell or to the characteristics of the resultant tumors. "/>
    <sentence id="DDI-MedLine.d43.s4" text="Vesselinovitch et al. "/>
    <sentence id="DDI-MedLine.d43.s5" text="(Cancer Res., 38: 2003-2010, 1978) have reported that a single, small pulse of carcinogen can induce early and numerous liver tumors when administered neonatally to mice with a genetic predisposition to hepatotumorigenesis. "/>
    <sentence id="DDI-MedLine.d43.s6" text="In the current study, the nonpredisposed strain C57BL/6N was also shown to be highly susceptible to diethylnitrosamine during the neonatal period. "/>
    <sentence id="DDI-MedLine.d43.s7" text="C57BL/6N demonstrated large numbers of two of the three types of liver tumors seen in livers of genetically predisposed mice, one of which required the additional stimulus of dietary phenobarbital for growth. ">
        <entity id="DDI-MedLine.d43.s7.e0" charOffset="183-195"
            type="drug" text="phenobarbital"/>
    </sentence>
    <sentence id="DDI-MedLine.d43.s8" text="Tumors of more malignant phenotype were demonstrated only in genetically predisposed mice (C57BL/6N X C3H/HeN F1) that received one dose of carcinogen. "/>
    <sentence id="DDI-MedLine.d43.s9" text="These findings suggest that the phenotype of a tumor that results from a pulse of a chemical carcinogen may depend upon the target cell. "/>
    <sentence id="DDI-MedLine.d43.s10" text="The initiated cells that result from this hit may vary from those that demonstrate very little progression in cell type and may or may not require exogenous enhancement of growth to those that can progress very rapidly to fully malignant behavior. "/>
    <sentence id="DDI-MedLine.d43.s11" text="The latter might arise from a hit in a genetically initiated cell, the result of which is a more rapid progression in tumor type."/>
    <sentence id="DDI-MedLine.d57.s0" text="Analgesic effects of antihistaminics.&#xa;">
        <entity id="DDI-MedLine.d57.s0.e0" charOffset="21-35"
            type="group" text="antihistaminics"/>
    </sentence>
    <sentence id="DDI-MedLine.d57.s1" text="The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed analgesic agents and some are analgesic adjuvants as well.">
        <entity id="DDI-MedLine.d57.s1.e0" charOffset="83-97"
            type="group" text="antihistaminics"/>
        <entity id="DDI-MedLine.d57.s1.e1" charOffset="111-126"
            type="group" text="analgesic agents"/>
        <entity id="DDI-MedLine.d57.s1.e2" charOffset="141-159"
            type="group" text="analgesic adjuvants"/>
        <pair id="DDI-MedLine.d57.s1.p0" e1="DDI-MedLine.d57.s1.e0"
            e2="DDI-MedLine.d57.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d57.s1.p1" e1="DDI-MedLine.d57.s1.e0"
            e2="DDI-MedLine.d57.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d57.s1.p2" e1="DDI-MedLine.d57.s1.e1"
            e2="DDI-MedLine.d57.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d57.s2" text="Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. ">
        <entity id="DDI-MedLine.d57.s2.e0" charOffset="51-65"
            type="drug" text="diphenhydramine"/>
        <entity id="DDI-MedLine.d57.s2.e1" charOffset="68-78"
            type="drug" text="hydroxyzine"/>
        <entity id="DDI-MedLine.d57.s2.e2" charOffset="81-92"
            type="drug" text="orphenadrine"/>
        <entity id="DDI-MedLine.d57.s2.e3" charOffset="95-104"
            type="drug" text="pyrilamine"/>
        <entity id="DDI-MedLine.d57.s2.e4" charOffset="107-122"
            type="drug_n" text="phenyltoloxamine"/>
        <entity id="DDI-MedLine.d57.s2.e5" charOffset="125-136"
            type="drug" text="promethazine"/>
        <entity id="DDI-MedLine.d57.s2.e6" charOffset="139-150"
            type="drug" text="methdilazine"/>
        <entity id="DDI-MedLine.d57.s2.e7" charOffset="157-170"
            type="drug" text="tripelennamine"/>
        <pair id="DDI-MedLine.d57.s2.p0" e1="DDI-MedLine.d57.s2.e0"
            e2="DDI-MedLine.d57.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p1" e1="DDI-MedLine.d57.s2.e0"
            e2="DDI-MedLine.d57.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p2" e1="DDI-MedLine.d57.s2.e0"
            e2="DDI-MedLine.d57.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p3" e1="DDI-MedLine.d57.s2.e0"
            e2="DDI-MedLine.d57.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p4" e1="DDI-MedLine.d57.s2.e0"
            e2="DDI-MedLine.d57.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p5" e1="DDI-MedLine.d57.s2.e0"
            e2="DDI-MedLine.d57.s2.e6" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p6" e1="DDI-MedLine.d57.s2.e0"
            e2="DDI-MedLine.d57.s2.e7" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p7" e1="DDI-MedLine.d57.s2.e1"
            e2="DDI-MedLine.d57.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p8" e1="DDI-MedLine.d57.s2.e1"
            e2="DDI-MedLine.d57.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p9" e1="DDI-MedLine.d57.s2.e1"
            e2="DDI-MedLine.d57.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p10" e1="DDI-MedLine.d57.s2.e1"
            e2="DDI-MedLine.d57.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p11" e1="DDI-MedLine.d57.s2.e1"
            e2="DDI-MedLine.d57.s2.e6" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p12" e1="DDI-MedLine.d57.s2.e1"
            e2="DDI-MedLine.d57.s2.e7" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p13" e1="DDI-MedLine.d57.s2.e2"
            e2="DDI-MedLine.d57.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p14" e1="DDI-MedLine.d57.s2.e2"
            e2="DDI-MedLine.d57.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p15" e1="DDI-MedLine.d57.s2.e2"
            e2="DDI-MedLine.d57.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p16" e1="DDI-MedLine.d57.s2.e2"
            e2="DDI-MedLine.d57.s2.e6" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p17" e1="DDI-MedLine.d57.s2.e2"
            e2="DDI-MedLine.d57.s2.e7" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p18" e1="DDI-MedLine.d57.s2.e3"
            e2="DDI-MedLine.d57.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p19" e1="DDI-MedLine.d57.s2.e3"
            e2="DDI-MedLine.d57.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p20" e1="DDI-MedLine.d57.s2.e3"
            e2="DDI-MedLine.d57.s2.e6" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p21" e1="DDI-MedLine.d57.s2.e3"
            e2="DDI-MedLine.d57.s2.e7" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p22" e1="DDI-MedLine.d57.s2.e4"
            e2="DDI-MedLine.d57.s2.e5" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p23" e1="DDI-MedLine.d57.s2.e4"
            e2="DDI-MedLine.d57.s2.e6" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p24" e1="DDI-MedLine.d57.s2.e4"
            e2="DDI-MedLine.d57.s2.e7" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p25" e1="DDI-MedLine.d57.s2.e5"
            e2="DDI-MedLine.d57.s2.e6" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p26" e1="DDI-MedLine.d57.s2.e5"
            e2="DDI-MedLine.d57.s2.e7" ddi="false"/>
        <pair id="DDI-MedLine.d57.s2.p27" e1="DDI-MedLine.d57.s2.e6"
            e2="DDI-MedLine.d57.s2.e7" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d57.s3" text="The proposed mechanisms of analgesic action of antihistaminics are reviewed and discussed. ">
        <entity id="DDI-MedLine.d57.s3.e0" charOffset="47-61"
            type="group" text="antihistaminics"/>
    </sentence>
    <sentence id="DDI-MedLine.d57.s4" text="The literature suggests that more than one mechanism of action exists for them. "/>
    <sentence id="DDI-MedLine.d57.s5" text="There is considerable evidence suggesting that histaminergic and serotoninergic central pathways are involved in nociception and that antihistaminic drugs can modulate their responses (1). ">
        <entity id="DDI-MedLine.d57.s5.e0" charOffset="134-147"
            type="group" text="antihistaminic"/>
    </sentence>
    <sentence id="DDI-MedLine.d57.s6" text="The evidence for a role for norepinephrine and dopamine and the effects of antihistaminics on them are less well established. ">
        <entity id="DDI-MedLine.d57.s6.e0" charOffset="75-89"
            type="group" text="antihistaminics"/>
    </sentence>
    <sentence id="DDI-MedLine.d57.s7" text="Still other pathways have been proposed. "/>
    <sentence id="DDI-MedLine.d57.s8" text="A greater understanding of pain mechanisms will aid in elucidating the role of antihistaminics in analgesia.">
        <entity id="DDI-MedLine.d57.s8.e0" charOffset="79-93"
            type="group" text="antihistaminics"/>
    </sentence>
    <sentence id="DDI-MedLine.d27.s0" text="[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ">
        <entity id="DDI-MedLine.d27.s0.e0" charOffset="116-125"
            type="drug_n" text="picrotoxin"/>
        <entity id="DDI-MedLine.d27.s0.e1" charOffset="173-180"
            type="drug" text="diazepam"/>
        <entity id="DDI-MedLine.d27.s0.e2" charOffset="183-192"
            type="drug_n" text="phenazepam"/>
        <entity id="DDI-MedLine.d27.s0.e3" charOffset="195-202"
            type="drug_n" text="phenibut"/>
        <entity id="DDI-MedLine.d27.s0.e4" charOffset="208-213"
            type="drug_n" text="amizyl"/>
        <entity id="DDI-MedLine.d27.s0.e5" charOffset="241-252"
            type="drug" text="phentolamine"/>
        <pair id="DDI-MedLine.d27.s0.p0" e1="DDI-MedLine.d27.s0.e0"
            e2="DDI-MedLine.d27.s0.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d27.s0.p1" e1="DDI-MedLine.d27.s0.e0"
            e2="DDI-MedLine.d27.s0.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d27.s0.p2" e1="DDI-MedLine.d27.s0.e0"
            e2="DDI-MedLine.d27.s0.e3" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d27.s0.p3" e1="DDI-MedLine.d27.s0.e0"
            e2="DDI-MedLine.d27.s0.e4" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d27.s0.p4" e1="DDI-MedLine.d27.s0.e0"
            e2="DDI-MedLine.d27.s0.e5" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d27.s0.p5" e1="DDI-MedLine.d27.s0.e1"
            e2="DDI-MedLine.d27.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d27.s0.p6" e1="DDI-MedLine.d27.s0.e1"
            e2="DDI-MedLine.d27.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d27.s0.p7" e1="DDI-MedLine.d27.s0.e1"
            e2="DDI-MedLine.d27.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d27.s0.p8" e1="DDI-MedLine.d27.s0.e1"
            e2="DDI-MedLine.d27.s0.e5" ddi="false"/>
        <pair id="DDI-MedLine.d27.s0.p9" e1="DDI-MedLine.d27.s0.e2"
            e2="DDI-MedLine.d27.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d27.s0.p10" e1="DDI-MedLine.d27.s0.e2"
            e2="DDI-MedLine.d27.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d27.s0.p11" e1="DDI-MedLine.d27.s0.e2"
            e2="DDI-MedLine.d27.s0.e5" ddi="false"/>
        <pair id="DDI-MedLine.d27.s0.p12" e1="DDI-MedLine.d27.s0.e3"
            e2="DDI-MedLine.d27.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d27.s0.p13" e1="DDI-MedLine.d27.s0.e3"
            e2="DDI-MedLine.d27.s0.e5" ddi="false"/>
        <pair id="DDI-MedLine.d27.s0.p14" e1="DDI-MedLine.d27.s0.e4"
            e2="DDI-MedLine.d27.s0.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d27.s1" text="When the dose of picrotoxin is minimized to 0.5 mg/kg such an effect is not observed. ">
        <entity id="DDI-MedLine.d27.s1.e0" charOffset="17-26"
            type="drug_n" text="picrotoxin"/>
    </sentence>
    <sentence id="DDI-MedLine.d27.s2" text="Prolonged daily administration of picrotoxin in a dose of 1 mg/kg results in the development of brain edema. ">
        <entity id="DDI-MedLine.d27.s2.e0" charOffset="34-43"
            type="drug_n" text="picrotoxin"/>
    </sentence>
    <sentence id="DDI-MedLine.d27.s3" text="It is recommended that GABA-positive drugs be included into a complex of treatment measures for edema."/>
    <sentence id="DDI-MedLine.d15.s0" text="[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. ">
        <entity id="DDI-MedLine.d15.s0.e0" charOffset="16-23"
            type="drug_n" text="cerulein"/>
        <entity id="DDI-MedLine.d15.s0.e1" charOffset="75-89"
            type="drug_n" text="3H-spiroperidol"/>
        <entity id="DDI-MedLine.d15.s0.e2" charOffset="137-148"
            type="group" text="neuroleptics"/>
        <entity id="DDI-MedLine.d15.s0.e3" charOffset="268-278"
            type="drug" text="haloperidol"/>
        <entity id="DDI-MedLine.d15.s0.e4" charOffset="297-308"
            type="drug_n" text="pyreneperone"/>
        <entity id="DDI-MedLine.d15.s0.e5" charOffset="367-381"
            type="drug_n" text="3H-spiroperidol"/>
        <entity id="DDI-MedLine.d15.s0.e6" charOffset="418-428"
            type="drug" text="apomorphine"/>
        <entity id="DDI-MedLine.d15.s0.e7" charOffset="465-479"
            type="drug_n" text="3H-spiroperidol"/>
        <entity id="DDI-MedLine.d15.s0.e8" charOffset="526-536"
            type="drug" text="apomorphine"/>
        <pair id="DDI-MedLine.d15.s0.p0" e1="DDI-MedLine.d15.s0.e0"
            e2="DDI-MedLine.d15.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p1" e1="DDI-MedLine.d15.s0.e0"
            e2="DDI-MedLine.d15.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p2" e1="DDI-MedLine.d15.s0.e0"
            e2="DDI-MedLine.d15.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p3" e1="DDI-MedLine.d15.s0.e0"
            e2="DDI-MedLine.d15.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p4" e1="DDI-MedLine.d15.s0.e0"
            e2="DDI-MedLine.d15.s0.e5" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p5" e1="DDI-MedLine.d15.s0.e0"
            e2="DDI-MedLine.d15.s0.e6" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p6" e1="DDI-MedLine.d15.s0.e0"
            e2="DDI-MedLine.d15.s0.e7" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p7" e1="DDI-MedLine.d15.s0.e0"
            e2="DDI-MedLine.d15.s0.e8" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p8" e1="DDI-MedLine.d15.s0.e1"
            e2="DDI-MedLine.d15.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p9" e1="DDI-MedLine.d15.s0.e1"
            e2="DDI-MedLine.d15.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p10" e1="DDI-MedLine.d15.s0.e1"
            e2="DDI-MedLine.d15.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p11" e1="DDI-MedLine.d15.s0.e1"
            e2="DDI-MedLine.d15.s0.e5" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p12" e1="DDI-MedLine.d15.s0.e1"
            e2="DDI-MedLine.d15.s0.e6" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p13" e1="DDI-MedLine.d15.s0.e1"
            e2="DDI-MedLine.d15.s0.e7" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p14" e1="DDI-MedLine.d15.s0.e1"
            e2="DDI-MedLine.d15.s0.e8" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p15" e1="DDI-MedLine.d15.s0.e2"
            e2="DDI-MedLine.d15.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p16" e1="DDI-MedLine.d15.s0.e2"
            e2="DDI-MedLine.d15.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p17" e1="DDI-MedLine.d15.s0.e2"
            e2="DDI-MedLine.d15.s0.e5" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p18" e1="DDI-MedLine.d15.s0.e2"
            e2="DDI-MedLine.d15.s0.e6" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p19" e1="DDI-MedLine.d15.s0.e2"
            e2="DDI-MedLine.d15.s0.e7" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p20" e1="DDI-MedLine.d15.s0.e2"
            e2="DDI-MedLine.d15.s0.e8" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p21" e1="DDI-MedLine.d15.s0.e3"
            e2="DDI-MedLine.d15.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p22" e1="DDI-MedLine.d15.s0.e3"
            e2="DDI-MedLine.d15.s0.e5" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p23" e1="DDI-MedLine.d15.s0.e3"
            e2="DDI-MedLine.d15.s0.e6" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p24" e1="DDI-MedLine.d15.s0.e3"
            e2="DDI-MedLine.d15.s0.e7" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p25" e1="DDI-MedLine.d15.s0.e3"
            e2="DDI-MedLine.d15.s0.e8" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p26" e1="DDI-MedLine.d15.s0.e4"
            e2="DDI-MedLine.d15.s0.e5" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p27" e1="DDI-MedLine.d15.s0.e4"
            e2="DDI-MedLine.d15.s0.e6" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p28" e1="DDI-MedLine.d15.s0.e4"
            e2="DDI-MedLine.d15.s0.e7" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p29" e1="DDI-MedLine.d15.s0.e4"
            e2="DDI-MedLine.d15.s0.e8" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p30" e1="DDI-MedLine.d15.s0.e5"
            e2="DDI-MedLine.d15.s0.e6" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p31" e1="DDI-MedLine.d15.s0.e5"
            e2="DDI-MedLine.d15.s0.e7" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p32" e1="DDI-MedLine.d15.s0.e5"
            e2="DDI-MedLine.d15.s0.e8" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p33" e1="DDI-MedLine.d15.s0.e6"
            e2="DDI-MedLine.d15.s0.e7" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p34" e1="DDI-MedLine.d15.s0.e6"
            e2="DDI-MedLine.d15.s0.e8" ddi="false"/>
        <pair id="DDI-MedLine.d15.s0.p35" e1="DDI-MedLine.d15.s0.e7"
            e2="DDI-MedLine.d15.s0.e8" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d15.s1" text="After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding. ">
        <entity id="DDI-MedLine.d15.s1.e0" charOffset="34-45"
            type="group" text="neuroleptics"/>
        <entity id="DDI-MedLine.d15.s1.e1" charOffset="72-79"
            type="drug_n" text="cerulein"/>
        <entity id="DDI-MedLine.d15.s1.e2" charOffset="164-178"
            type="drug_n" text="3H-spiroperidol"/>
        <pair id="DDI-MedLine.d15.s1.p0" e1="DDI-MedLine.d15.s1.e0"
            e2="DDI-MedLine.d15.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d15.s1.p1" e1="DDI-MedLine.d15.s1.e0"
            e2="DDI-MedLine.d15.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d15.s1.p2" e1="DDI-MedLine.d15.s1.e1"
            e2="DDI-MedLine.d15.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d15.s2" text="It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration. ">
        <entity id="DDI-MedLine.d15.s2.e0" charOffset="49-63"
            type="drug_n" text="3H-spiroperidol"/>
        <entity id="DDI-MedLine.d15.s2.e1" charOffset="101-111"
            type="drug" text="apomorphine"/>
        <entity id="DDI-MedLine.d15.s2.e2" charOffset="190-201"
            type="group" text="neuroleptics"/>
        <pair id="DDI-MedLine.d15.s2.p0" e1="DDI-MedLine.d15.s2.e0"
            e2="DDI-MedLine.d15.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d15.s2.p1" e1="DDI-MedLine.d15.s2.e0"
            e2="DDI-MedLine.d15.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d15.s2.p2" e1="DDI-MedLine.d15.s2.e1"
            e2="DDI-MedLine.d15.s2.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d15.s3" text="Cholecystokinin octapeptide is a necessary factor for realization of this action of neuroleptics.">
        <entity id="DDI-MedLine.d15.s3.e0" charOffset="84-95"
            type="group" text="neuroleptics"/>
    </sentence>
    <sentence id="DDI-MedLine.d56.s0" text="Dual effect of ouabain on the palytoxin-induced contraction and norepinephrine release in the guinea-pig vas deferens.">
        <entity id="DDI-MedLine.d56.s0.e0" charOffset="15-21"
            type="drug" text="ouabain"/>
        <entity id="DDI-MedLine.d56.s0.e1" charOffset="30-38"
            type="drug_n" text="palytoxin"/>
        <pair id="DDI-MedLine.d56.s0.p0" e1="DDI-MedLine.d56.s0.e0"
            e2="DDI-MedLine.d56.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d56.s1" text="Palytoxin (PTX), C129H223N3O54, isolated from marine coelenterates of Palythoa tuberculosa, caused a first rapid contraction followed by the slow phasic contraction of guinea-pig vas deferens. ">
        <entity id="DDI-MedLine.d56.s1.e0" charOffset="0-8"
            type="drug_n" text="Palytoxin"/>
        <entity id="DDI-MedLine.d56.s1.e1" charOffset="11-13"
            type="drug_n" text="PTX"/>
        <pair id="DDI-MedLine.d56.s1.p0" e1="DDI-MedLine.d56.s1.e0"
            e2="DDI-MedLine.d56.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d56.s2" text="In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction; ">
        <entity id="DDI-MedLine.d56.s2.e0" charOffset="19-25"
            type="drug" text="ouabain"/>
        <entity id="DDI-MedLine.d56.s2.e1" charOffset="39-41"
            type="drug_n" text="PTX"/>
        <pair id="DDI-MedLine.d56.s2.p0" e1="DDI-MedLine.d56.s2.e0"
            e2="DDI-MedLine.d56.s2.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d56.s3" text="however, the second contraction was potentiated. "/>
    <sentence id="DDI-MedLine.d56.s4" text="In the presence of phentolamine (10(-6) M), the second contraction was inhibited selectively. ">
        <entity id="DDI-MedLine.d56.s4.e0" charOffset="19-30"
            type="drug" text="phentolamine"/>
    </sentence>
    <sentence id="DDI-MedLine.d56.s5" text="When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. ">
        <entity id="DDI-MedLine.d56.s5.e0" charOffset="5-11" type="drug" text="ouabain"/>
        <entity id="DDI-MedLine.d56.s5.e1" charOffset="58-69"
            type="drug" text="phentolamine"/>
        <entity id="DDI-MedLine.d56.s5.e2" charOffset="119-121"
            type="drug_n" text="PTX"/>
        <pair id="DDI-MedLine.d56.s5.p0" e1="DDI-MedLine.d56.s5.e0"
            e2="DDI-MedLine.d56.s5.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d56.s5.p1" e1="DDI-MedLine.d56.s5.e0"
            e2="DDI-MedLine.d56.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d56.s5.p2" e1="DDI-MedLine.d56.s5.e1"
            e2="DDI-MedLine.d56.s5.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d56.s6" text="When the muscle was exposed to the potassium-depleted solution, the first contractile response to PTX was rather potentiated. ">
        <entity id="DDI-MedLine.d56.s6.e0" charOffset="98-100"
            type="drug_n" text="PTX"/>
    </sentence>
    <sentence id="DDI-MedLine.d56.s7" text="PTX caused the release of norepinephrine from the muscle. ">
        <entity id="DDI-MedLine.d56.s7.e0" charOffset="0-2"
            type="drug_n" text="PTX"/>
    </sentence>
    <sentence id="DDI-MedLine.d56.s8" text="Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX-induced release. ">
        <entity id="DDI-MedLine.d56.s8.e0" charOffset="26-32"
            type="drug" text="ouabain"/>
        <entity id="DDI-MedLine.d56.s8.e1" charOffset="68-70"
            type="drug_n" text="PTX"/>
        <pair id="DDI-MedLine.d56.s8.p0" e1="DDI-MedLine.d56.s8.e0"
            e2="DDI-MedLine.d56.s8.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d56.s9" text="It is indicated that the first and second contractile responses to PTX have entirely different properties. ">
        <entity id="DDI-MedLine.d56.s9.e0" charOffset="67-69"
            type="drug_n" text="PTX"/>
    </sentence>
    <sentence id="DDI-MedLine.d56.s10" text="The second response is due to a release of norepinephrine from nerves and was potentiated by ouabain through the increase in the norepinephrine release, whereas the first response was not due to the norepinephrine release but presumably to a direct action on smooth muscle cell and was inhibited by ouabain. ">
        <entity id="DDI-MedLine.d56.s10.e0" charOffset="93-99"
            type="drug" text="ouabain"/>
        <entity id="DDI-MedLine.d56.s10.e1" charOffset="299-305"
            type="drug" text="ouabain"/>
        <pair id="DDI-MedLine.d56.s10.p0" e1="DDI-MedLine.d56.s10.e0"
            e2="DDI-MedLine.d56.s10.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d56.s11" text="The mechanism of the action of PTX was discussed in the relation with Na,K-ATPase.">
        <entity id="DDI-MedLine.d56.s11.e0" charOffset="31-33"
            type="drug_n" text="PTX"/>
    </sentence>
    <sentence id="DDI-MedLine.d139.s0" text="[Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with neuroleptics are illustrated by six typical case reports. ">
        <entity id="DDI-MedLine.d139.s0.e0" charOffset="50-61"
            type="group" text="neuroleptics"/>
        <entity id="DDI-MedLine.d139.s0.e1" charOffset="173-184"
            type="group" text="neuroleptics"/>
        <pair id="DDI-MedLine.d139.s0.p0" e1="DDI-MedLine.d139.s0.e0"
            e2="DDI-MedLine.d139.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d139.s1" text="A group of patients who had had a new acute episode despite seemingly adequate treatment were selected. "/>
    <sentence id="DDI-MedLine.d139.s2" text="In these six cases it was demonstrated that the neuroleptics dosage was inappropriate, being either too high or too low as judged from the plasma concentrations. ">
        <entity id="DDI-MedLine.d139.s2.e0" charOffset="48-59"
            type="group" text="neuroleptics"/>
    </sentence>
    <sentence id="DDI-MedLine.d139.s3" text="Ways of improving the adequacy of the treatment of psychotic patients with neuroleptics are discussed.">
        <entity id="DDI-MedLine.d139.s3.e0" charOffset="75-86"
            type="group" text="neuroleptics"/>
    </sentence>
    <sentence id="DDI-MedLine.d82.s0" text="Intestinal absorption of arsenate in the chick.&#xa;">
        <entity id="DDI-MedLine.d82.s0.e0" charOffset="25-32"
            type="drug_n" text="arsenate"/>
    </sentence>
    <sentence id="DDI-MedLine.d82.s1" text="The intestinal absorption of arsenate(As(V)) has been investigated in the chick by means of the in situ ligated duodenal loop technique. ">
        <entity id="DDI-MedLine.d82.s1.e0" charOffset="29-36"
            type="drug_n" text="arsenate"/>
        <entity id="DDI-MedLine.d82.s1.e1" charOffset="38-42"
            type="drug_n" text="As(V)"/>
        <pair id="DDI-MedLine.d82.s1.p0" e1="DDI-MedLine.d82.s1.e0"
            e2="DDI-MedLine.d82.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d82.s2" text="By this procedure, it was observed that arsenate is rapidly and essentially completely absorbed (80-95%) from the lumen at As(V) concentrations up to 5 mM, declining to about 50% absorption at 50 mM. ">
        <entity id="DDI-MedLine.d82.s2.e0" charOffset="40-47"
            type="drug_n" text="arsenate"/>
        <entity id="DDI-MedLine.d82.s2.e1" charOffset="123-127"
            type="drug_n" text="As(V)"/>
        <pair id="DDI-MedLine.d82.s2.p0" e1="DDI-MedLine.d82.s2.e0"
            e2="DDI-MedLine.d82.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d82.s3" text="Transfer from the intestinal lumen to the mucosal cells at low As(V) concentration (0.1 mM) is rapid, while transfer from the mucosal cells to the body occurs more slowly. ">
        <entity id="DDI-MedLine.d82.s3.e0" charOffset="63-67"
            type="drug_n" text="As(V)"/>
    </sentence>
    <sentence id="DDI-MedLine.d82.s4" text="At stable As(V) concentrations greater than 1 mM, fractional mucosal cell accumulation of As(V) remains constant, while fractional transfer to the body declines. ">
        <entity id="DDI-MedLine.d82.s4.e0" charOffset="10-14"
            type="drug_n" text="As(V)"/>
        <entity id="DDI-MedLine.d82.s4.e1" charOffset="90-94"
            type="drug_n" text="As(V)"/>
        <pair id="DDI-MedLine.d82.s4.p0" e1="DDI-MedLine.d82.s4.e0"
            e2="DDI-MedLine.d82.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d82.s5" text="However, total mucosal accumulation of As(V) and that transferred to the body increase in a linear logarithmic fashion from 0.05 to 5 mm As(V). ">
        <entity id="DDI-MedLine.d82.s5.e0" charOffset="39-43"
            type="drug_n" text="As(V)"/>
        <entity id="DDI-MedLine.d82.s5.e1" charOffset="137-141"
            type="drug_n" text="As(V)"/>
        <pair id="DDI-MedLine.d82.s5.p0" e1="DDI-MedLine.d82.s5.e0"
            e2="DDI-MedLine.d82.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d82.s6" text="The results indicate that As(V) readily penetrates both the mucosal and serosal surfaces of the epithelial membrane. ">
        <entity id="DDI-MedLine.d82.s6.e0" charOffset="26-30"
            type="drug_n" text="As(V)"/>
    </sentence>
    <sentence id="DDI-MedLine.d82.s7" text="Furthermore, arsenate and phosphate do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level. ">
        <entity id="DDI-MedLine.d82.s7.e0" charOffset="13-20"
            type="drug_n" text="arsenate"/>
        <entity id="DDI-MedLine.d82.s7.e1" charOffset="26-34"
            type="drug" text="phosphate"/>
        <pair id="DDI-MedLine.d82.s7.p0" e1="DDI-MedLine.d82.s7.e0"
            e2="DDI-MedLine.d82.s7.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d82.s8" text="Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport.">
        <entity id="DDI-MedLine.d82.s8.e0" charOffset="0-9" type="drug" text="Vitamin D3"/>
        <entity id="DDI-MedLine.d82.s8.e1" charOffset="95-102"
            type="drug_n" text="arsenate"/>
        <pair id="DDI-MedLine.d82.s8.p0" e1="DDI-MedLine.d82.s8.e0"
            e2="DDI-MedLine.d82.s8.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d22.s0" text="Spermine promotes the translocation of phosphatidate phosphohydrolase from the cytosol to the microsomal fraction of rat liver and it enhances the effects of oleate in this respect.">
        <entity id="DDI-MedLine.d22.s0.e0" charOffset="0-7" type="drug" text="Spermine"/>
    </sentence>
    <sentence id="DDI-MedLine.d22.s1" text="Spermine (0.5-2 mM) promoted the translocation of phosphatidate phosphohydrolase from the soluble to the microsomal fraction in a cell-free system derived from rat liver. ">
        <entity id="DDI-MedLine.d22.s1.e0" charOffset="0-7" type="drug" text="Spermine"/>
    </sentence>
    <sentence id="DDI-MedLine.d22.s2" text="By contrast, spermidine (1 mM) and putrescine (1 mM) had no significant effect on the translocation when added alone. ">
        <entity id="DDI-MedLine.d22.s2.e0" charOffset="13-22"
            type="drug_n" text="spermidine"/>
        <entity id="DDI-MedLine.d22.s2.e1" charOffset="35-44"
            type="drug_n" text="putrescine"/>
        <pair id="DDI-MedLine.d22.s2.p0" e1="DDI-MedLine.d22.s2.e0"
            e2="DDI-MedLine.d22.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d22.s3" text="Spermine, and to a lesser extent, spermidine, enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction. ">
        <entity id="DDI-MedLine.d22.s3.e0" charOffset="0-7" type="drug" text="Spermine"/>
        <entity id="DDI-MedLine.d22.s3.e1" charOffset="34-43"
            type="drug_n" text="spermidine"/>
        <pair id="DDI-MedLine.d22.s3.p0" e1="DDI-MedLine.d22.s3.e0"
            e2="DDI-MedLine.d22.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d22.s4" text="It is proposed that the phosphohydrolase becomes metabolically active when it combines with membranes and that polyamines might help to regulate this interaction. "/>
    <sentence id="DDI-MedLine.d22.s5" text="This could facilitate the action of fatty acids and enable cells to increase their capacity for triacylglycerol synthesis to match an increased availability of fatty acids."/>
    <sentence id="DDI-MedLine.d100.s0" text="Influence of calcium-channel blockers on platelet function and arachidonic acid metabolism.&#xd;&#xa;">
        <entity id="DDI-MedLine.d100.s0.e0" charOffset="13-36"
            type="group" text="calcium-channel blockers"/>
    </sentence>
    <sentence id="DDI-MedLine.d100.s1" text="Available data indicate that platelet function and arachidonic acid metabolism are important factors in hemostasis and regulation of vascular tone. "/>
    <sentence id="DDI-MedLine.d100.s2" text="Plasma membrane and intracellular mobilization of calcium ions are intimately related to platelet activation and release of platelet contents. "/>
    <sentence id="DDI-MedLine.d100.s3" text="Release of arachidonic acid from membrane phospholipids as well as subsequent synthesis and release of vasoconstrictor thromboxane A2 are also regulated by movement of calcium ions. "/>
    <sentence id="DDI-MedLine.d100.s4" text="Adenosine 3':5'-cyclic phosphate in turn controls levels of free calcium ions in platelets and regulates calcium-dependent reactions. "/>
    <sentence id="DDI-MedLine.d100.s5" text="Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. ">
        <entity id="DDI-MedLine.d100.s5.e0" charOffset="0-28"
            type="group" text="Slow-channel calcium blockers"/>
        <entity id="DDI-MedLine.d100.s5.e1" charOffset="39-47"
            type="drug" text="verapamil"/>
        <entity id="DDI-MedLine.d100.s5.e2" charOffset="50-58"
            type="drug" text="diltiazem"/>
        <entity id="DDI-MedLine.d100.s5.e3" charOffset="64-73"
            type="drug" text="nifedipine"/>
        <pair id="DDI-MedLine.d100.s5.p0" e1="DDI-MedLine.d100.s5.e0"
            e2="DDI-MedLine.d100.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d100.s5.p1" e1="DDI-MedLine.d100.s5.e0"
            e2="DDI-MedLine.d100.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d100.s5.p2" e1="DDI-MedLine.d100.s5.e0"
            e2="DDI-MedLine.d100.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d100.s5.p3" e1="DDI-MedLine.d100.s5.e1"
            e2="DDI-MedLine.d100.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d100.s5.p4" e1="DDI-MedLine.d100.s5.e1"
            e2="DDI-MedLine.d100.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d100.s5.p5" e1="DDI-MedLine.d100.s5.e2"
            e2="DDI-MedLine.d100.s5.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d100.s6" text="These agents have also been shown to decrease platelet nucleotide release and thromboxane A2 generation. "/>
    <sentence id="DDI-MedLine.d100.s7" text="Some preliminary data suggest that calcium blockers also increase generation of vasodilator and platelet antiaggregant prostacyclin, which could contribute to decrease in platelet function. ">
        <entity id="DDI-MedLine.d100.s7.e0" charOffset="35-50"
            type="group" text="calcium blockers"/>
    </sentence>
    <sentence id="DDI-MedLine.d100.s8" text="These effects of calcium blockers on platelet function and arachidonic acid metabolism could contribute in part to their efficacy in patients with ischemic heart disease.">
        <entity id="DDI-MedLine.d100.s8.e0" charOffset="17-32"
            type="group" text="calcium blockers"/>
    </sentence>
    <sentence id="DDI-MedLine.d63.s0" text="Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.&#xd;&#xa;">
        <entity id="DDI-MedLine.d63.s0.e0" charOffset="36-43"
            type="drug" text="naloxone"/>
        <entity id="DDI-MedLine.d63.s0.e1" charOffset="111-124"
            type="drug_n" text="beta-endorphin"/>
        <entity id="DDI-MedLine.d63.s0.e2" charOffset="130-137"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d63.s0.p0" e1="DDI-MedLine.d63.s0.e0"
            e2="DDI-MedLine.d63.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d63.s0.p1" e1="DDI-MedLine.d63.s0.e0"
            e2="DDI-MedLine.d63.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d63.s0.p2" e1="DDI-MedLine.d63.s0.e1"
            e2="DDI-MedLine.d63.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d63.s1" text="In the present study, it is proposed that the opioids applied to supraspinal brain sites produced their analgesic effects by the activation of different descending pain inhibitory systems. ">
        <entity id="DDI-MedLine.d63.s1.e0" charOffset="46-52"
            type="group" text="opioids"/>
    </sentence>
    <sentence id="DDI-MedLine.d63.s2" text="The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. ">
        <entity id="DDI-MedLine.d63.s2.e0" charOffset="64-71"
            type="drug" text="naloxone"/>
        <entity id="DDI-MedLine.d63.s2.e1" charOffset="144-157"
            type="drug_n" text="beta-endorphin"/>
        <entity id="DDI-MedLine.d63.s2.e2" charOffset="163-170"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d63.s2.p0" e1="DDI-MedLine.d63.s2.e0"
            e2="DDI-MedLine.d63.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d63.s2.p1" e1="DDI-MedLine.d63.s2.e0"
            e2="DDI-MedLine.d63.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d63.s2.p2" e1="DDI-MedLine.d63.s2.e1"
            e2="DDI-MedLine.d63.s2.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d63.s3" text="Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats. ">
        <entity id="DDI-MedLine.d63.s3.e0" charOffset="30-43"
            type="drug_n" text="beta-endorphin"/>
        <entity id="DDI-MedLine.d63.s3.e1" charOffset="49-56"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d63.s3.p0" e1="DDI-MedLine.d63.s3.e0"
            e2="DDI-MedLine.d63.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d63.s4" text="Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). ">
        <entity id="DDI-MedLine.d63.s4.e0" charOffset="25-32"
            type="drug" text="naloxone"/>
        <entity id="DDI-MedLine.d63.s4.e1" charOffset="184-197"
            type="drug_n" text="beta-endorphin"/>
        <entity id="DDI-MedLine.d63.s4.e2" charOffset="219-226"
            type="drug" text="naloxone"/>
        <entity id="DDI-MedLine.d63.s4.e3" charOffset="317-330"
            type="drug_n" text="beta-endorphin"/>
        <pair id="DDI-MedLine.d63.s4.p0" e1="DDI-MedLine.d63.s4.e0"
            e2="DDI-MedLine.d63.s4.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d63.s4.p1" e1="DDI-MedLine.d63.s4.e0"
            e2="DDI-MedLine.d63.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d63.s4.p2" e1="DDI-MedLine.d63.s4.e0"
            e2="DDI-MedLine.d63.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d63.s4.p3" e1="DDI-MedLine.d63.s4.e1"
            e2="DDI-MedLine.d63.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d63.s4.p4" e1="DDI-MedLine.d63.s4.e1"
            e2="DDI-MedLine.d63.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d63.s4.p5" e1="DDI-MedLine.d63.s4.e2"
            e2="DDI-MedLine.d63.s4.e3" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d63.s5" text="On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). ">
        <entity id="DDI-MedLine.d63.s5.e0" charOffset="31-38"
            type="drug" text="naloxone"/>
        <entity id="DDI-MedLine.d63.s5.e1" charOffset="145-152"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d63.s5.p0" e1="DDI-MedLine.d63.s5.e0"
            e2="DDI-MedLine.d63.s5.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d63.s6" text="Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. ">
        <entity id="DDI-MedLine.d63.s6.e0" charOffset="30-37"
            type="drug" text="naloxone"/>
        <entity id="DDI-MedLine.d63.s6.e1" charOffset="173-186"
            type="drug_n" text="beta-endorphin"/>
        <entity id="DDI-MedLine.d63.s6.e2" charOffset="192-199"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d63.s6.p0" e1="DDI-MedLine.d63.s6.e0"
            e2="DDI-MedLine.d63.s6.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d63.s6.p1" e1="DDI-MedLine.d63.s6.e0"
            e2="DDI-MedLine.d63.s6.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d63.s6.p2" e1="DDI-MedLine.d63.s6.e1"
            e2="DDI-MedLine.d63.s6.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d63.s7" text="The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; ">
        <entity id="DDI-MedLine.d63.s7.e0" charOffset="35-42"
            type="drug" text="naloxone"/>
        <entity id="DDI-MedLine.d63.s7.e1" charOffset="109-122"
            type="drug_n" text="beta-endorphin"/>
        <entity id="DDI-MedLine.d63.s7.e2" charOffset="132-139"
            type="drug" text="morphine"/>
        <entity id="DDI-MedLine.d63.s7.e3" charOffset="206-219"
            type="drug_n" text="beta-endorphin"/>
        <entity id="DDI-MedLine.d63.s7.e4" charOffset="225-232"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d63.s7.p0" e1="DDI-MedLine.d63.s7.e0"
            e2="DDI-MedLine.d63.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d63.s7.p1" e1="DDI-MedLine.d63.s7.e0"
            e2="DDI-MedLine.d63.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d63.s7.p2" e1="DDI-MedLine.d63.s7.e0"
            e2="DDI-MedLine.d63.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d63.s7.p3" e1="DDI-MedLine.d63.s7.e0"
            e2="DDI-MedLine.d63.s7.e4" ddi="false"/>
        <pair id="DDI-MedLine.d63.s7.p4" e1="DDI-MedLine.d63.s7.e1"
            e2="DDI-MedLine.d63.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d63.s7.p5" e1="DDI-MedLine.d63.s7.e1"
            e2="DDI-MedLine.d63.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d63.s7.p6" e1="DDI-MedLine.d63.s7.e1"
            e2="DDI-MedLine.d63.s7.e4" ddi="false"/>
        <pair id="DDI-MedLine.d63.s7.p7" e1="DDI-MedLine.d63.s7.e2"
            e2="DDI-MedLine.d63.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d63.s7.p8" e1="DDI-MedLine.d63.s7.e2"
            e2="DDI-MedLine.d63.s7.e4" ddi="false"/>
        <pair id="DDI-MedLine.d63.s7.p9" e1="DDI-MedLine.d63.s7.e3"
            e2="DDI-MedLine.d63.s7.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d63.s8" text="descending epsilon and mu systems for beta-endorphin and morphine, respectively, are proposed.">
        <entity id="DDI-MedLine.d63.s8.e0" charOffset="38-51"
            type="drug_n" text="beta-endorphin"/>
        <entity id="DDI-MedLine.d63.s8.e1" charOffset="57-64"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d63.s8.p0" e1="DDI-MedLine.d63.s8.e0"
            e2="DDI-MedLine.d63.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d73.s0" text="Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.&#xd;&#xa;">
        <entity id="DDI-MedLine.d73.s0.e0" charOffset="52-95"
            type="drug_n" text="1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d73.s0.e1" charOffset="98-101"
            type="drug_n" text="MPTP"/>
        <entity id="DDI-MedLine.d73.s0.e2" charOffset="108-122"
            type="drug" text="methamphetamine"/>
        <pair id="DDI-MedLine.d73.s0.p0" e1="DDI-MedLine.d73.s0.e0"
            e2="DDI-MedLine.d73.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d73.s0.p1" e1="DDI-MedLine.d73.s0.e0"
            e2="DDI-MedLine.d73.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d73.s0.p2" e1="DDI-MedLine.d73.s0.e1"
            e2="DDI-MedLine.d73.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d73.s1" text="The neurochemical and functional consequences following MPTP administration to the rat were evaluated and compared to similar effects following methamphetamine administration. ">
        <entity id="DDI-MedLine.d73.s1.e0" charOffset="56-59"
            type="drug_n" text="MPTP"/>
        <entity id="DDI-MedLine.d73.s1.e1" charOffset="144-158"
            type="drug" text="methamphetamine"/>
        <pair id="DDI-MedLine.d73.s1.p0" e1="DDI-MedLine.d73.s1.e0"
            e2="DDI-MedLine.d73.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d73.s2" text="It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment. ">
        <entity id="DDI-MedLine.d73.s2.e0" charOffset="21-24"
            type="drug_n" text="MPTP"/>
        <entity id="DDI-MedLine.d73.s2.e1" charOffset="143-151"
            type="drug" text="pargyline"/>
        <pair id="DDI-MedLine.d73.s2.p0" e1="DDI-MedLine.d73.s2.e0"
            e2="DDI-MedLine.d73.s2.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d73.s3" text="The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. ">
        <entity id="DDI-MedLine.d73.s3.e0" charOffset="4-7" type="drug" text="MPTP"/>
        <entity id="DDI-MedLine.d73.s3.e1" charOffset="83-93"
            type="drug" text="amphetamine"/>
        <entity id="DDI-MedLine.d73.s3.e2" charOffset="147-157"
            type="drug" text="apomorphine"/>
        <pair id="DDI-MedLine.d73.s3.p0" e1="DDI-MedLine.d73.s3.e0"
            e2="DDI-MedLine.d73.s3.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d73.s3.p1" e1="DDI-MedLine.d73.s3.e0"
            e2="DDI-MedLine.d73.s3.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d73.s3.p2" e1="DDI-MedLine.d73.s3.e1"
            e2="DDI-MedLine.d73.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d73.s4" text="Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. ">
        <entity id="DDI-MedLine.d73.s4.e0" charOffset="0-14" type="drug" text="Methamphetamine"/>
        <entity id="DDI-MedLine.d73.s4.e1" charOffset="22-25"
            type="drug_n" text="MPTP"/>
        <entity id="DDI-MedLine.d73.s4.e2" charOffset="107-115"
            type="drug" text="pargyline"/>
        <pair id="DDI-MedLine.d73.s4.p0" e1="DDI-MedLine.d73.s4.e0"
            e2="DDI-MedLine.d73.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d73.s4.p1" e1="DDI-MedLine.d73.s4.e0"
            e2="DDI-MedLine.d73.s4.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d73.s4.p2" e1="DDI-MedLine.d73.s4.e1"
            e2="DDI-MedLine.d73.s4.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d73.s5" text="These observations are discussed in reference to possible deleterious effects following the administration of pargyline to patients with Parkinson's Disease.">
        <entity id="DDI-MedLine.d73.s5.e0" charOffset="110-118"
            type="drug" text="pargyline"/>
    </sentence>
    <sentence id="DDI-MedLine.d96.s0" text="Jacalin: an IgA-binding lectin.&#xd;&#xa;">
        <entity id="DDI-MedLine.d96.s0.e0" charOffset="0-6"
            type="drug_n" text="Jacalin"/>
    </sentence>
    <sentence id="DDI-MedLine.d96.s1" text="We previously reported that seeds of Artocarpus integrifolia (jackfruit) contain a lectin, which we call jacalin, that is both a potent T cell mitogen and an apparently T cell-independent activator of human B cells for the secretion of immunoglobulins. ">
        <entity id="DDI-MedLine.d96.s1.e0" charOffset="105-111"
            type="drug_n" text="jacalin"/>
    </sentence>
    <sentence id="DDI-MedLine.d96.s2" text="During the above experiments we noted a massive precipitation in cell cultures stimulated with greater than or equal to 100 micrograms of lectin. "/>
    <sentence id="DDI-MedLine.d96.s3" text="In this paper, we show that the precipitate is formed after the interaction of jacalin and the serum protein added to the culture medium. ">
        <entity id="DDI-MedLine.d96.s3.e0" charOffset="79-85"
            type="drug_n" text="jacalin"/>
    </sentence>
    <sentence id="DDI-MedLine.d96.s4" text="More importantly, we demonstrate that IgA is probably the major serum constituent precipitated by the lectin and that no IgG or IgM can be detected in the precipitates. "/>
    <sentence id="DDI-MedLine.d96.s5" text="In secretions such as colostrum, IgA is the only protein precipitated by jacalin. ">
        <entity id="DDI-MedLine.d96.s5.e0" charOffset="73-79"
            type="drug_n" text="jacalin"/>
    </sentence>
    <sentence id="DDI-MedLine.d96.s6" text="On the basis of this specificity we describe a simple and reliable affinity chromatography procedure for the purification of both human serum and colostrum IgA. "/>
    <sentence id="DDI-MedLine.d96.s7" text="Jacalin is a D-Gal binding lectin and should be a useful tool for studying of serum and secretory IgA.">
        <entity id="DDI-MedLine.d96.s7.e0" charOffset="0-6"
            type="drug_n" text="Jacalin"/>
    </sentence>
    <sentence id="DDI-MedLine.d31.s0" text="Cancer in the elderly: basic science and clinical aspects.&#xa;"/>
    <sentence id="DDI-MedLine.d31.s1" text="The incidence of cancer increases progressively with age. "/>
    <sentence id="DDI-MedLine.d31.s2" text="Rearrangements of genomes have been found to accompany cellular aging. "/>
    <sentence id="DDI-MedLine.d31.s3" text="These factors, in concert with age-dependent alterations in immune function and host defense, may help to explain the increased risk of malignant disease in aged persons. "/>
    <sentence id="DDI-MedLine.d31.s4" text="The clinical presentation and natural history of neoplasia are also affected by aging. "/>
    <sentence id="DDI-MedLine.d31.s5" text="This conference reviews recent developments in these areas, examines the effects of drug use in the elderly and implications for management, and discusses current information on how age may influence the response of cancer to therapy."/>
    <sentence id="DDI-MedLine.d12.s0" text="Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.">
        <entity id="DDI-MedLine.d12.s0.e0" charOffset="0-12" type="drug" text="Dexamethasone"/>
        <entity id="DDI-MedLine.d12.s0.e1" charOffset="18-32"
            type="drug" text="retinyl acetate"/>
        <entity id="DDI-MedLine.d12.s0.e2" charOffset="66-68"
            type="drug_n" text="EGF"/>
        <entity id="DDI-MedLine.d12.s0.e3" charOffset="74-80"
            type="drug" text="insulin"/>
        <pair id="DDI-MedLine.d12.s0.p0" e1="DDI-MedLine.d12.s0.e0"
            e2="DDI-MedLine.d12.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d12.s0.p1" e1="DDI-MedLine.d12.s0.e0"
            e2="DDI-MedLine.d12.s0.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s0.p2" e1="DDI-MedLine.d12.s0.e0"
            e2="DDI-MedLine.d12.s0.e3" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s0.p3" e1="DDI-MedLine.d12.s0.e1"
            e2="DDI-MedLine.d12.s0.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s0.p4" e1="DDI-MedLine.d12.s0.e1"
            e2="DDI-MedLine.d12.s0.e3" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s0.p5" e1="DDI-MedLine.d12.s0.e2"
            e2="DDI-MedLine.d12.s0.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d12.s1" text="Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml). ">
        <entity id="DDI-MedLine.d12.s1.e0" charOffset="101-111"
            type="drug_n" text="transferrin"/>
        <entity id="DDI-MedLine.d12.s1.e1" charOffset="131-133"
            type="drug_n" text="EGF"/>
        <entity id="DDI-MedLine.d12.s1.e2" charOffset="151-157"
            type="drug" text="insulin"/>
        <pair id="DDI-MedLine.d12.s1.p0" e1="DDI-MedLine.d12.s1.e0"
            e2="DDI-MedLine.d12.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d12.s1.p1" e1="DDI-MedLine.d12.s1.e0"
            e2="DDI-MedLine.d12.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d12.s1.p2" e1="DDI-MedLine.d12.s1.e1"
            e2="DDI-MedLine.d12.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d12.s2" text="Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ">
        <entity id="DDI-MedLine.d12.s2.e0" charOffset="17-29"
            type="drug" text="dexamethasone"/>
        <entity id="DDI-MedLine.d12.s2.e1" charOffset="35-49"
            type="drug" text="retinyl acetate"/>
        <entity id="DDI-MedLine.d12.s2.e2" charOffset="125-135"
            type="drug_n" text="transferrin"/>
        <entity id="DDI-MedLine.d12.s2.e3" charOffset="180-182"
            type="drug_n" text="EGF"/>
        <entity id="DDI-MedLine.d12.s2.e4" charOffset="188-194"
            type="drug" text="insulin"/>
        <pair id="DDI-MedLine.d12.s2.p0" e1="DDI-MedLine.d12.s2.e0"
            e2="DDI-MedLine.d12.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d12.s2.p1" e1="DDI-MedLine.d12.s2.e0"
            e2="DDI-MedLine.d12.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d12.s2.p2" e1="DDI-MedLine.d12.s2.e0"
            e2="DDI-MedLine.d12.s2.e3" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s2.p3" e1="DDI-MedLine.d12.s2.e0"
            e2="DDI-MedLine.d12.s2.e4" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s2.p4" e1="DDI-MedLine.d12.s2.e1"
            e2="DDI-MedLine.d12.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d12.s2.p5" e1="DDI-MedLine.d12.s2.e1"
            e2="DDI-MedLine.d12.s2.e3" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s2.p6" e1="DDI-MedLine.d12.s2.e1"
            e2="DDI-MedLine.d12.s2.e4" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s2.p7" e1="DDI-MedLine.d12.s2.e2"
            e2="DDI-MedLine.d12.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d12.s2.p8" e1="DDI-MedLine.d12.s2.e2"
            e2="DDI-MedLine.d12.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d12.s2.p9" e1="DDI-MedLine.d12.s2.e3"
            e2="DDI-MedLine.d12.s2.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d12.s3" text="Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. ">
        <entity id="DDI-MedLine.d12.s3.e0" charOffset="0-12" type="drug" text="Dexamethasone"/>
        <entity id="DDI-MedLine.d12.s3.e1" charOffset="30-44"
            type="drug" text="retinyl acetate"/>
        <entity id="DDI-MedLine.d12.s3.e2" charOffset="105-107"
            type="drug_n" text="EGF"/>
        <pair id="DDI-MedLine.d12.s3.p0" e1="DDI-MedLine.d12.s3.e0"
            e2="DDI-MedLine.d12.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d12.s3.p1" e1="DDI-MedLine.d12.s3.e0"
            e2="DDI-MedLine.d12.s3.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s3.p2" e1="DDI-MedLine.d12.s3.e1"
            e2="DDI-MedLine.d12.s3.e2" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d12.s4" text="Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. ">
        <entity id="DDI-MedLine.d12.s4.e0" charOffset="25-37"
            type="drug" text="dexamethasone"/>
        <entity id="DDI-MedLine.d12.s4.e1" charOffset="62-76"
            type="drug" text="retinyl acetate"/>
        <entity id="DDI-MedLine.d12.s4.e2" charOffset="136-138"
            type="drug_n" text="EGF"/>
        <pair id="DDI-MedLine.d12.s4.p0" e1="DDI-MedLine.d12.s4.e0"
            e2="DDI-MedLine.d12.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d12.s4.p1" e1="DDI-MedLine.d12.s4.e0"
            e2="DDI-MedLine.d12.s4.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s4.p2" e1="DDI-MedLine.d12.s4.e1"
            e2="DDI-MedLine.d12.s4.e2" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d12.s5" text="Dexamethasone had a similar effect in the presence of insulin. ">
        <entity id="DDI-MedLine.d12.s5.e0" charOffset="0-12" type="drug" text="Dexamethasone"/>
        <entity id="DDI-MedLine.d12.s5.e1" charOffset="54-60"
            type="drug" text="insulin"/>
        <pair id="DDI-MedLine.d12.s5.p0" e1="DDI-MedLine.d12.s5.e0"
            e2="DDI-MedLine.d12.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d12.s6" text="However, retinyl acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin. ">
        <entity id="DDI-MedLine.d12.s6.e0" charOffset="9-23" type="drug" text="retinyl acetate"/>
        <entity id="DDI-MedLine.d12.s6.e1" charOffset="105-111"
            type="drug" text="insulin"/>
        <pair id="DDI-MedLine.d12.s6.p0" e1="DDI-MedLine.d12.s6.e0"
            e2="DDI-MedLine.d12.s6.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d12.s7" text="These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.">
        <entity id="DDI-MedLine.d12.s7.e0" charOffset="32-44"
            type="drug" text="dexamethasone"/>
        <entity id="DDI-MedLine.d12.s7.e1" charOffset="50-64"
            type="drug" text="retinyl acetate"/>
        <entity id="DDI-MedLine.d12.s7.e2" charOffset="86-100"
            type="group" text="glucocorticoids"/>
        <entity id="DDI-MedLine.d12.s7.e3" charOffset="106-114"
            type="group" text="retinoids"/>
        <entity id="DDI-MedLine.d12.s7.e4" charOffset="223-229"
            type="drug" text="insulin"/>
        <entity id="DDI-MedLine.d12.s7.e5" charOffset="235-237"
            type="drug_n" text="EGF"/>
        <pair id="DDI-MedLine.d12.s7.p0" e1="DDI-MedLine.d12.s7.e0"
            e2="DDI-MedLine.d12.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d12.s7.p1" e1="DDI-MedLine.d12.s7.e0"
            e2="DDI-MedLine.d12.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d12.s7.p2" e1="DDI-MedLine.d12.s7.e0"
            e2="DDI-MedLine.d12.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d12.s7.p3" e1="DDI-MedLine.d12.s7.e0"
            e2="DDI-MedLine.d12.s7.e4" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s7.p4" e1="DDI-MedLine.d12.s7.e0"
            e2="DDI-MedLine.d12.s7.e5" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s7.p5" e1="DDI-MedLine.d12.s7.e1"
            e2="DDI-MedLine.d12.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d12.s7.p6" e1="DDI-MedLine.d12.s7.e1"
            e2="DDI-MedLine.d12.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d12.s7.p7" e1="DDI-MedLine.d12.s7.e1"
            e2="DDI-MedLine.d12.s7.e4" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s7.p8" e1="DDI-MedLine.d12.s7.e1"
            e2="DDI-MedLine.d12.s7.e5" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s7.p9" e1="DDI-MedLine.d12.s7.e2"
            e2="DDI-MedLine.d12.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d12.s7.p10" e1="DDI-MedLine.d12.s7.e2"
            e2="DDI-MedLine.d12.s7.e4" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s7.p11" e1="DDI-MedLine.d12.s7.e2"
            e2="DDI-MedLine.d12.s7.e5" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s7.p12" e1="DDI-MedLine.d12.s7.e3"
            e2="DDI-MedLine.d12.s7.e4" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s7.p13" e1="DDI-MedLine.d12.s7.e3"
            e2="DDI-MedLine.d12.s7.e5" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d12.s7.p14" e1="DDI-MedLine.d12.s7.e4"
            e2="DDI-MedLine.d12.s7.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d9.s0" text="Pharmacokinetics of calcium-entry blockers.&#xa;">
        <entity id="DDI-MedLine.d9.s0.e0" charOffset="20-41"
            type="group" text="calcium-entry blockers"/>
    </sentence>
    <sentence id="DDI-MedLine.d9.s1" text="Effective use of drugs in therapy depends not only on clinical acumen but also on the availability of relevant pharmacokinetic and pharmacodynamic data. "/>
    <sentence id="DDI-MedLine.d9.s2" text="Such information assists in development of safe dosing regimens, prediction of abnormal handling of drugs in states of disease and disorder and anticipation of drug interactions. "/>
    <sentence id="DDI-MedLine.d9.s3" text="For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. ">
        <entity id="DDI-MedLine.d9.s3.e0" charOffset="8-36" type="group" text="calcium-entry blocking agents"/>
        <entity id="DDI-MedLine.d9.s3.e1" charOffset="74-82" type="drug" text="verapamil"/>
        <entity id="DDI-MedLine.d9.s3.e2" charOffset="85-94" type="drug" text="nifedipine"/>
        <entity id="DDI-MedLine.d9.s3.e3" charOffset="100-108"
            type="drug" text="diltiazem"/>
        <pair id="DDI-MedLine.d9.s3.p0" e1="DDI-MedLine.d9.s3.e0"
            e2="DDI-MedLine.d9.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d9.s3.p1" e1="DDI-MedLine.d9.s3.e0"
            e2="DDI-MedLine.d9.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d9.s3.p2" e1="DDI-MedLine.d9.s3.e0"
            e2="DDI-MedLine.d9.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d9.s3.p3" e1="DDI-MedLine.d9.s3.e1"
            e2="DDI-MedLine.d9.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d9.s3.p4" e1="DDI-MedLine.d9.s3.e1"
            e2="DDI-MedLine.d9.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d9.s3.p5" e1="DDI-MedLine.d9.s3.e2"
            e2="DDI-MedLine.d9.s3.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d9.s4" text="Nonetheless, their relevance continues to be demonstrated by the dependence of each agent on intact liver blood flow and function for normal rates of elimination; "/>
    <sentence id="DDI-MedLine.d9.s5" text="by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements; ">
        <entity id="DDI-MedLine.d9.s5.e0" charOffset="45-53" type="drug" text="verapamil"/>
        <entity id="DDI-MedLine.d9.s5.e1" charOffset="59-67" type="drug" text="diltiazem"/>
        <entity id="DDI-MedLine.d9.s5.e2" charOffset="87-96" type="drug" text="nifedipine"/>
        <pair id="DDI-MedLine.d9.s5.p0" e1="DDI-MedLine.d9.s5.e0"
            e2="DDI-MedLine.d9.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d9.s5.p1" e1="DDI-MedLine.d9.s5.e0"
            e2="DDI-MedLine.d9.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d9.s5.p2" e1="DDI-MedLine.d9.s5.e1"
            e2="DDI-MedLine.d9.s5.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d9.s6" text="and by observations now appearing on the relation between plasma drug levels and drug effects, both therapeutic and toxic. "/>
    <sentence id="DDI-MedLine.d9.s7" text="Such data are discussed herein, with emphasis on those aspects that impact on the clinical use of the calcium-entry antagonists.">
        <entity id="DDI-MedLine.d9.s7.e0" charOffset="102-126"
            type="group" text="calcium-entry antagonists"/>
    </sentence>
    <sentence id="DDI-MedLine.d45.s0" text="Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts.&#xd;&#xa;">
        <entity id="DDI-MedLine.d45.s0.e0" charOffset="22-32"
            type="drug" text="pentazocine"/>
        <entity id="DDI-MedLine.d45.s0.e1" charOffset="38-51"
            type="drug" text="tripelennamine"/>
        <pair id="DDI-MedLine.d45.s0.p0" e1="DDI-MedLine.d45.s0.e0"
            e2="DDI-MedLine.d45.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d45.s1" text="The growth of Pseudomonas aeruginosa, particularly serotype O11, in pentazocine and tripelennamine ">
        <entity id="DDI-MedLine.d45.s1.e0" charOffset="68-78"
            type="drug" text="pentazocine"/>
        <entity id="DDI-MedLine.d45.s1.e1" charOffset="84-97"
            type="drug" text="tripelennamine"/>
        <pair id="DDI-MedLine.d45.s1.p0" e1="DDI-MedLine.d45.s1.e0"
            e2="DDI-MedLine.d45.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d45.s2" text="was evaluated as a possible explanation for the association of deep-seated infection with this organism and abuse of these drugs. "/>
    <sentence id="DDI-MedLine.d45.s3" text="The mean reduction of growth caused by the drugs was 1,000-fold greater for 49 Pseudomonas strains from normal subjects than for 32 strains from drug addicts (4.2 vs. 1.3 logs of reduction at 2 hr, P less than .0005). "/>
    <sentence id="DDI-MedLine.d45.s4" text="A common phenotypic subset of the serotype O11 strains from drug addicts was especially resistant to the inhibitory effects. "/>
    <sentence id="DDI-MedLine.d45.s5" text="Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. ">
        <entity id="DDI-MedLine.d45.s5.e0" charOffset="74-79"
            type="drug_n" text="heroin"/>
        <entity id="DDI-MedLine.d45.s5.e1" charOffset="93-103"
            type="drug" text="pentazocine"/>
        <entity id="DDI-MedLine.d45.s5.e2" charOffset="109-122"
            type="drug" text="tripelennamine"/>
        <pair id="DDI-MedLine.d45.s5.p0" e1="DDI-MedLine.d45.s5.e0"
            e2="DDI-MedLine.d45.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d45.s5.p1" e1="DDI-MedLine.d45.s5.e0"
            e2="DDI-MedLine.d45.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d45.s5.p2" e1="DDI-MedLine.d45.s5.e1"
            e2="DDI-MedLine.d45.s5.e2" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d45.s6" text="Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine. ">
        <entity id="DDI-MedLine.d45.s6.e0" charOffset="105-118"
            type="drug" text="tripelennamine"/>
        <entity id="DDI-MedLine.d45.s6.e1" charOffset="200-210"
            type="drug" text="pentazocine"/>
        <pair id="DDI-MedLine.d45.s6.p0" e1="DDI-MedLine.d45.s6.e0"
            e2="DDI-MedLine.d45.s6.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d45.s7" text="We conclude that an ability of some P. "/>
    <sentence id="DDI-MedLine.d45.s8" text="aeruginosa serotype O11 strains, but not S. "/>
    <sentence id="DDI-MedLine.d45.s9" text="aureus, to survive in pentazocine and tripelennamine may explain in part a shift from S. ">
        <entity id="DDI-MedLine.d45.s9.e0" charOffset="22-32"
            type="drug" text="pentazocine"/>
        <entity id="DDI-MedLine.d45.s9.e1" charOffset="38-51"
            type="drug" text="tripelennamine"/>
        <pair id="DDI-MedLine.d45.s9.p0" e1="DDI-MedLine.d45.s9.e0"
            e2="DDI-MedLine.d45.s9.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d45.s10" text="aureus to P. "/>
    <sentence id="DDI-MedLine.d45.s11" text="aeruginosa as common pathogens of drug addicts in areas where abuse of this combination of drugs has increased."/>
    <sentence id="DDI-MedLine.d61.s0" text="Pharmacokinetic evaluation of the digoxin-amiodarone interaction.&#xa;">
        <entity id="DDI-MedLine.d61.s0.e0" charOffset="34-40"
            type="drug" text="digoxin"/>
        <entity id="DDI-MedLine.d61.s0.e1" charOffset="42-51"
            type="drug" text="amiodarone"/>
        <pair id="DDI-MedLine.d61.s0.p0" e1="DDI-MedLine.d61.s0.e0"
            e2="DDI-MedLine.d61.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d61.s1" text="Amiodarone is known to raise serum digoxin levels. ">
        <entity id="DDI-MedLine.d61.s1.e0" charOffset="0-9" type="drug" text="Amiodarone"/>
        <entity id="DDI-MedLine.d61.s1.e1" charOffset="35-41"
            type="drug" text="digoxin"/>
        <pair id="DDI-MedLine.d61.s1.p0" e1="DDI-MedLine.d61.s1.e0"
            e2="DDI-MedLine.d61.s1.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d61.s2" text="This study was designed to evaluate the pharmacokinetic basis of this interaction in 10 normal subjects. "/>
    <sentence id="DDI-MedLine.d61.s3" text="The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks. ">
        <entity id="DDI-MedLine.d61.s3.e0" charOffset="34-40"
            type="drug" text="digoxin"/>
        <entity id="DDI-MedLine.d61.s3.e1" charOffset="93-99"
            type="drug" text="digoxin"/>
        <entity id="DDI-MedLine.d61.s3.e2" charOffset="140-149"
            type="drug" text="amiodarone"/>
        <pair id="DDI-MedLine.d61.s3.p0" e1="DDI-MedLine.d61.s3.e0"
            e2="DDI-MedLine.d61.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d61.s3.p1" e1="DDI-MedLine.d61.s3.e0"
            e2="DDI-MedLine.d61.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d61.s3.p2" e1="DDI-MedLine.d61.s3.e1"
            e2="DDI-MedLine.d61.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d61.s4" text="During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). ">
        <entity id="DDI-MedLine.d61.s4.e0" charOffset="7-16" type="drug" text="amiodarone"/>
        <entity id="DDI-MedLine.d61.s4.e1" charOffset="56-62"
            type="drug" text="digoxin"/>
        <pair id="DDI-MedLine.d61.s4.p0" e1="DDI-MedLine.d61.s4.e0"
            e2="DDI-MedLine.d61.s4.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d61.s5" text="This was due to reductions in both renal clearance (from 105 +/- 39 to 84 +/- 15 ml/min) (p less than 0.05) and nonrenal clearance (from 130 +/- 38 to 88 +/- 20 ml/min) (p less than 0.01). "/>
    <sentence id="DDI-MedLine.d61.s6" text="Digoxin half-life of elimination was prolonged from 34 +/- 13 to 40 +/- 16 hours (p less than 0.05). ">
        <entity id="DDI-MedLine.d61.s6.e0" charOffset="0-6" type="drug" text="Digoxin"/>
    </sentence>
    <sentence id="DDI-MedLine.d61.s7" text="Digoxin volume of distribution was not significantly changed. ">
        <entity id="DDI-MedLine.d61.s7.e0" charOffset="0-6" type="drug" text="Digoxin"/>
    </sentence>
    <sentence id="DDI-MedLine.d61.s8" text="Amiodarone caused a three- to fivefold increase in serum reverse triiodothyronine levels, but changes in thyroid function were not quantitatively related to the changes in digoxin pharmacokinetics. ">
        <entity id="DDI-MedLine.d61.s8.e0" charOffset="0-9" type="drug" text="Amiodarone"/>
        <entity id="DDI-MedLine.d61.s8.e1" charOffset="172-178"
            type="drug" text="digoxin"/>
        <pair id="DDI-MedLine.d61.s8.p0" e1="DDI-MedLine.d61.s8.e0"
            e2="DDI-MedLine.d61.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d61.s9" text="These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.">
        <entity id="DDI-MedLine.d61.s9.e0" charOffset="21-27"
            type="drug" text="digoxin"/>
        <entity id="DDI-MedLine.d61.s9.e1" charOffset="58-67"
            type="drug" text="amiodarone"/>
        <entity id="DDI-MedLine.d61.s9.e2" charOffset="99-105"
            type="drug" text="digoxin"/>
        <pair id="DDI-MedLine.d61.s9.p0" e1="DDI-MedLine.d61.s9.e0"
            e2="DDI-MedLine.d61.s9.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d61.s9.p1" e1="DDI-MedLine.d61.s9.e0"
            e2="DDI-MedLine.d61.s9.e2" ddi="false"/>
        <pair id="DDI-MedLine.d61.s9.p2" e1="DDI-MedLine.d61.s9.e1"
            e2="DDI-MedLine.d61.s9.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d85.s0" text="Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.&#xd;&#xa;">
        <entity id="DDI-MedLine.d85.s0.e0" charOffset="0-11"
            type="drug_n" text="Misonidazole"/>
        <entity id="DDI-MedLine.d85.s0.e1" charOffset="80-83"
            type="drug" text="CCNU"/>
        <pair id="DDI-MedLine.d85.s0.p0" e1="DDI-MedLine.d85.s0.e0"
            e2="DDI-MedLine.d85.s0.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d85.s1" text="Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ">
        <entity id="DDI-MedLine.d85.s1.e0" charOffset="12-22"
            type="group" text="nitrosourea"/>
        <entity id="DDI-MedLine.d85.s1.e1" charOffset="24-27"
            type="drug" text="CCNU"/>
        <entity id="DDI-MedLine.d85.s1.e2" charOffset="184-187"
            type="drug" text="CCNU"/>
        <entity id="DDI-MedLine.d85.s1.e3" charOffset="246-257"
            type="drug_n" text="misonidazole"/>
        <pair id="DDI-MedLine.d85.s1.p0" e1="DDI-MedLine.d85.s1.e0"
            e2="DDI-MedLine.d85.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d85.s1.p1" e1="DDI-MedLine.d85.s1.e0"
            e2="DDI-MedLine.d85.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d85.s1.p2" e1="DDI-MedLine.d85.s1.e0"
            e2="DDI-MedLine.d85.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d85.s1.p3" e1="DDI-MedLine.d85.s1.e1"
            e2="DDI-MedLine.d85.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d85.s1.p4" e1="DDI-MedLine.d85.s1.e1"
            e2="DDI-MedLine.d85.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d85.s1.p5" e1="DDI-MedLine.d85.s1.e2"
            e2="DDI-MedLine.d85.s1.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d85.s2" text="In both plasma and KHT tumour the peak concentration and &quot;early&quot;"/>
    <sentence id="DDI-MedLine.d85.s3" text="AUC for total nitrosoureas were about 1.4-1.5 fold greater for the oral compared to the i.p. ">
        <entity id="DDI-MedLine.d85.s3.e0" charOffset="14-25"
            type="group" text="nitrosoureas"/>
    </sentence>
    <sentence id="DDI-MedLine.d85.s4" text="route. "/>
    <sentence id="DDI-MedLine.d85.s5" text="These differences were reflected in the roughly twofold greater antitumour activity for the oral route. "/>
    <sentence id="DDI-MedLine.d85.s6" text="In contrast, acute toxicity tests showed that oral CCNU was 1.45 times less toxic to normal tissue, although the dose-limiting organ may be different for the two routes. ">
        <entity id="DDI-MedLine.d85.s6.e0" charOffset="51-54"
            type="drug" text="CCNU"/>
    </sentence>
    <sentence id="DDI-MedLine.d85.s7" text="Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71. ">
        <entity id="DDI-MedLine.d85.s7.e0" charOffset="0-11"
            type="drug_n" text="Misonidazole"/>
        <entity id="DDI-MedLine.d85.s7.e1" charOffset="53-56"
            type="drug" text="CCNU"/>
        <pair id="DDI-MedLine.d85.s7.p0" e1="DDI-MedLine.d85.s7.e0"
            e2="DDI-MedLine.d85.s7.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d85.s8" text="Similarly, the acute toxicity was also diminished by a DMF of 0.74. "/>
    <sentence id="DDI-MedLine.d85.s9" text="Misonidazole has a complex effect on oral CCNU pharmacokinetics. ">
        <entity id="DDI-MedLine.d85.s9.e0" charOffset="0-11"
            type="drug_n" text="Misonidazole"/>
        <entity id="DDI-MedLine.d85.s9.e1" charOffset="42-45"
            type="drug" text="CCNU"/>
        <pair id="DDI-MedLine.d85.s9.p0" e1="DDI-MedLine.d85.s9.e0"
            e2="DDI-MedLine.d85.s9.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d85.s10" text="The plasma and tumour total nitrosourea peak concentrations were reduced by 1.5 and 1.7 fold respectively. ">
        <entity id="DDI-MedLine.d85.s10.e0" charOffset="28-38"
            type="group" text="nitrosourea"/>
    </sentence>
    <sentence id="DDI-MedLine.d85.s11" text="Misonidazole also reduced the &quot;early&quot;">
        <entity id="DDI-MedLine.d85.s11.e0" charOffset="0-11"
            type="drug_n" text="Misonidazole"/>
    </sentence>
    <sentence id="DDI-MedLine.d85.s12" text="nitrosourea AUC, with the extent of the reduction depending on the minimum effective concentration (MEC) chosen. ">
        <entity id="DDI-MedLine.d85.s12.e0" charOffset="0-10"
            type="group" text="nitrosourea"/>
    </sentence>
    <sentence id="DDI-MedLine.d85.s13" text="For example, the plasma nitrosourea AUC was reduced by factors of 1.05 and 9.6 for MEC values of 1 and 2 micrograms ml-1 respectively. ">
        <entity id="DDI-MedLine.d85.s13.e0" charOffset="24-34"
            type="group" text="nitrosourea"/>
    </sentence>
    <sentence id="DDI-MedLine.d85.s14" text="We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole. ">
        <entity id="DDI-MedLine.d85.s14.e0" charOffset="98-101"
            type="drug" text="CCNU"/>
        <entity id="DDI-MedLine.d85.s14.e1" charOffset="119-130"
            type="drug_n" text="misonidazole"/>
        <pair id="DDI-MedLine.d85.s14.p0" e1="DDI-MedLine.d85.s14.e0"
            e2="DDI-MedLine.d85.s14.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d85.s15" text="Clinical trials of such combinations should be accompanied by detailed pharmacokinetic evaluation."/>
    <sentence id="DDI-MedLine.d7.s0" text="Enhanced theophylline clearance secondary to phenytoin therapy.&#xd;&#xa;">
        <entity id="DDI-MedLine.d7.s0.e0" charOffset="9-20" type="drug" text="theophylline"/>
        <entity id="DDI-MedLine.d7.s0.e1" charOffset="45-53" type="drug" text="phenytoin"/>
        <pair id="DDI-MedLine.d7.s0.p0" e1="DDI-MedLine.d7.s0.e0"
            e2="DDI-MedLine.d7.s0.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d7.s1" text="This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration. ">
        <entity id="DDI-MedLine.d7.s1.e0" charOffset="41-52" type="drug" text="theophylline"/>
        <entity id="DDI-MedLine.d7.s1.e1" charOffset="102-110"
            type="drug" text="phenytoin"/>
        <pair id="DDI-MedLine.d7.s1.p0" e1="DDI-MedLine.d7.s1.e0"
            e2="DDI-MedLine.d7.s1.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d7.s2" text="Maximum calculated theophylline clearance ranged from 2 1/2 to 3 1/2 times baseline. ">
        <entity id="DDI-MedLine.d7.s2.e0" charOffset="19-30" type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-MedLine.d7.s3" text="Onset of the interaction began within five days of beginning concurrent therapy. "/>
    <sentence id="DDI-MedLine.d7.s4" text="With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.">
        <entity id="DDI-MedLine.d7.s4.e0" charOffset="52-60" type="drug" text="phenytoin"/>
        <entity id="DDI-MedLine.d7.s4.e1" charOffset="157-168"
            type="drug" text="theophylline"/>
        <pair id="DDI-MedLine.d7.s4.p0" e1="DDI-MedLine.d7.s4.e0"
            e2="DDI-MedLine.d7.s4.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d30.s0" text="Stereoselective behavioral effects of N-allylnormetazocine in pigeons and squirrel monkeys.&#xd;&#xa;">
        <entity id="DDI-MedLine.d30.s0.e0" charOffset="38-57"
            type="drug_n" text="N-allylnormetazocine"/>
    </sentence>
    <sentence id="DDI-MedLine.d30.s1" text="The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. ">
        <entity id="DDI-MedLine.d30.s1.e0" charOffset="47-66"
            type="drug_n" text="N-allylnormetazocine"/>
        <entity id="DDI-MedLine.d30.s1.e1" charOffset="69-72"
            type="drug_n" text="NANM"/>
        <entity id="DDI-MedLine.d30.s1.e2" charOffset="103-115"
            type="drug_n" text="phencyclidine"/>
        <entity id="DDI-MedLine.d30.s1.e3" charOffset="118-120"
            type="drug_n" text="PCP"/>
        <pair id="DDI-MedLine.d30.s1.p0" e1="DDI-MedLine.d30.s1.e0"
            e2="DDI-MedLine.d30.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d30.s1.p1" e1="DDI-MedLine.d30.s1.e0"
            e2="DDI-MedLine.d30.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d30.s1.p2" e1="DDI-MedLine.d30.s1.e0"
            e2="DDI-MedLine.d30.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d30.s1.p3" e1="DDI-MedLine.d30.s1.e1"
            e2="DDI-MedLine.d30.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d30.s1.p4" e1="DDI-MedLine.d30.s1.e1"
            e2="DDI-MedLine.d30.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d30.s1.p5" e1="DDI-MedLine.d30.s1.e2"
            e2="DDI-MedLine.d30.s1.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d30.s2" text="Intermediate doses of (+)-NANM or PCP produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons; ">
        <entity id="DDI-MedLine.d30.s2.e0" charOffset="22-29"
            type="drug_n" text="(+)-NANM"/>
        <entity id="DDI-MedLine.d30.s2.e1" charOffset="34-36"
            type="drug_n" text="PCP"/>
        <pair id="DDI-MedLine.d30.s2.p0" e1="DDI-MedLine.d30.s2.e0"
            e2="DDI-MedLine.d30.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d30.s3" text="higher doses decreased FI and FR responding in both species. "/>
    <sentence id="DDI-MedLine.d30.s4" text="In contrast to its enantiomer, (-)-NANM failed to increase FI responding significantly in either species; ">
        <entity id="DDI-MedLine.d30.s4.e0" charOffset="31-38"
            type="drug_n" text="(-)-NANM"/>
    </sentence>
    <sentence id="DDI-MedLine.d30.s5" text="at high doses, (-)-NANM decreased FI and FR responding. ">
        <entity id="DDI-MedLine.d30.s5.e0" charOffset="15-22"
            type="drug_n" text="(-)-NANM"/>
    </sentence>
    <sentence id="DDI-MedLine.d30.s6" text="In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. ">
        <entity id="DDI-MedLine.d30.s6.e0" charOffset="12-19"
            type="drug_n" text="(-)-NANM"/>
        <entity id="DDI-MedLine.d30.s6.e1" charOffset="57-64"
            type="drug_n" text="(+)-NANM"/>
        <entity id="DDI-MedLine.d30.s6.e2" charOffset="111-118"
            type="drug_n" text="(-)-NANM"/>
        <entity id="DDI-MedLine.d30.s6.e3" charOffset="146-153"
            type="drug_n" text="(+)-NANM"/>
        <pair id="DDI-MedLine.d30.s6.p0" e1="DDI-MedLine.d30.s6.e0"
            e2="DDI-MedLine.d30.s6.e1" ddi="false"/>
        <pair id="DDI-MedLine.d30.s6.p1" e1="DDI-MedLine.d30.s6.e0"
            e2="DDI-MedLine.d30.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d30.s6.p2" e1="DDI-MedLine.d30.s6.e0"
            e2="DDI-MedLine.d30.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d30.s6.p3" e1="DDI-MedLine.d30.s6.e1"
            e2="DDI-MedLine.d30.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d30.s6.p4" e1="DDI-MedLine.d30.s6.e1"
            e2="DDI-MedLine.d30.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d30.s6.p5" e1="DDI-MedLine.d30.s6.e2"
            e2="DDI-MedLine.d30.s6.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d30.s7" text="In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding. ">
        <entity id="DDI-MedLine.d30.s7.e0" charOffset="17-24"
            type="drug_n" text="(-)-NANM"/>
        <entity id="DDI-MedLine.d30.s7.e1" charOffset="35-42"
            type="drug_n" text="(+)-NANM"/>
        <entity id="DDI-MedLine.d30.s7.e2" charOffset="88-95"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d30.s7.p0" e1="DDI-MedLine.d30.s7.e0"
            e2="DDI-MedLine.d30.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d30.s7.p1" e1="DDI-MedLine.d30.s7.e0"
            e2="DDI-MedLine.d30.s7.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d30.s7.p2" e1="DDI-MedLine.d30.s7.e1"
            e2="DDI-MedLine.d30.s7.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d30.s8" text="In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; ">
        <entity id="DDI-MedLine.d30.s8.e0" charOffset="27-34"
            type="drug_n" text="(-)-NANM"/>
        <entity id="DDI-MedLine.d30.s8.e1" charOffset="45-52"
            type="drug_n" text="(+)-NANM"/>
        <entity id="DDI-MedLine.d30.s8.e2" charOffset="57-59"
            type="drug_n" text="PCP"/>
        <entity id="DDI-MedLine.d30.s8.e3" charOffset="82-89"
            type="drug" text="naloxone"/>
        <pair id="DDI-MedLine.d30.s8.p0" e1="DDI-MedLine.d30.s8.e0"
            e2="DDI-MedLine.d30.s8.e1" ddi="false"/>
        <pair id="DDI-MedLine.d30.s8.p1" e1="DDI-MedLine.d30.s8.e0"
            e2="DDI-MedLine.d30.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d30.s8.p2" e1="DDI-MedLine.d30.s8.e0"
            e2="DDI-MedLine.d30.s8.e3" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d30.s8.p3" e1="DDI-MedLine.d30.s8.e1"
            e2="DDI-MedLine.d30.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d30.s8.p4" e1="DDI-MedLine.d30.s8.e1"
            e2="DDI-MedLine.d30.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d30.s8.p5" e1="DDI-MedLine.d30.s8.e2"
            e2="DDI-MedLine.d30.s8.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d30.s9" text="the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. ">
        <entity id="DDI-MedLine.d30.s9.e0" charOffset="13-20"
            type="drug" text="naloxone"/>
        <entity id="DDI-MedLine.d30.s9.e1" charOffset="60-67"
            type="drug_n" text="(-)-NANM"/>
        <entity id="DDI-MedLine.d30.s9.e2" charOffset="150-157"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d30.s9.p0" e1="DDI-MedLine.d30.s9.e0"
            e2="DDI-MedLine.d30.s9.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d30.s9.p1" e1="DDI-MedLine.d30.s9.e0"
            e2="DDI-MedLine.d30.s9.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d30.s9.p2" e1="DDI-MedLine.d30.s9.e1"
            e2="DDI-MedLine.d30.s9.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d30.s10" text="In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. ">
        <entity id="DDI-MedLine.d30.s10.e0" charOffset="12-19"
            type="drug" text="naloxone"/>
        <entity id="DDI-MedLine.d30.s10.e1" charOffset="65-72"
            type="drug_n" text="(-)-NANM"/>
        <entity id="DDI-MedLine.d30.s10.e2" charOffset="75-82"
            type="drug_n" text="(+)-NANM"/>
        <entity id="DDI-MedLine.d30.s10.e3" charOffset="87-89"
            type="drug_n" text="PCP"/>
        <pair id="DDI-MedLine.d30.s10.p0" e1="DDI-MedLine.d30.s10.e0"
            e2="DDI-MedLine.d30.s10.e1" ddi="false"/>
        <pair id="DDI-MedLine.d30.s10.p1" e1="DDI-MedLine.d30.s10.e0"
            e2="DDI-MedLine.d30.s10.e2" ddi="false"/>
        <pair id="DDI-MedLine.d30.s10.p2" e1="DDI-MedLine.d30.s10.e0"
            e2="DDI-MedLine.d30.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d30.s10.p3" e1="DDI-MedLine.d30.s10.e1"
            e2="DDI-MedLine.d30.s10.e2" ddi="false"/>
        <pair id="DDI-MedLine.d30.s10.p4" e1="DDI-MedLine.d30.s10.e1"
            e2="DDI-MedLine.d30.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d30.s10.p5" e1="DDI-MedLine.d30.s10.e2"
            e2="DDI-MedLine.d30.s10.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d30.s11" text="Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. ">
        <entity id="DDI-MedLine.d30.s11.e0" charOffset="0-10"
            type="drug" text="Haloperidol"/>
        <entity id="DDI-MedLine.d30.s11.e1" charOffset="106-113"
            type="drug_n" text="(+)-NANM"/>
        <entity id="DDI-MedLine.d30.s11.e2" charOffset="118-120"
            type="drug_n" text="PCP"/>
        <entity id="DDI-MedLine.d30.s11.e3" charOffset="250-253"
            type="drug_n" text="NANM"/>
        <pair id="DDI-MedLine.d30.s11.p0" e1="DDI-MedLine.d30.s11.e0"
            e2="DDI-MedLine.d30.s11.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d30.s11.p1" e1="DDI-MedLine.d30.s11.e0"
            e2="DDI-MedLine.d30.s11.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d30.s11.p2" e1="DDI-MedLine.d30.s11.e0"
            e2="DDI-MedLine.d30.s11.e3" ddi="false"/>
        <pair id="DDI-MedLine.d30.s11.p3" e1="DDI-MedLine.d30.s11.e1"
            e2="DDI-MedLine.d30.s11.e2" ddi="false"/>
        <pair id="DDI-MedLine.d30.s11.p4" e1="DDI-MedLine.d30.s11.e1"
            e2="DDI-MedLine.d30.s11.e3" ddi="false"/>
        <pair id="DDI-MedLine.d30.s11.p5" e1="DDI-MedLine.d30.s11.e2"
            e2="DDI-MedLine.d30.s11.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d30.s12" text="The results demonstrate a high degree of stereoselectivity in the behavioral effects of NANM. ">
        <entity id="DDI-MedLine.d30.s12.e0" charOffset="88-91"
            type="drug_n" text="NANM"/>
    </sentence>
    <sentence id="DDI-MedLine.d30.s13" text="The levorotatory isomer had opioid-antagonist and non-opioid agonist effects in pigeons and mixed opioid agonist-antagonist effects in monkeys. "/>
    <sentence id="DDI-MedLine.d30.s14" text="The dextrorotatory isomer, on the other hand, had effects similar to those of PCP in both species.">
        <entity id="DDI-MedLine.d30.s14.e0" charOffset="78-80"
            type="drug_n" text="PCP"/>
    </sentence>
    <sentence id="DDI-MedLine.d55.s0" text="Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.">
        <entity id="DDI-MedLine.d55.s0.e0" charOffset="28-40"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-MedLine.d55.s0.e1" charOffset="75-82"
            type="drug" text="caffeine"/>
        <pair id="DDI-MedLine.d55.s0.p0" e1="DDI-MedLine.d55.s0.e0"
            e2="DDI-MedLine.d55.s0.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d55.s1" text="Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. ">
        <entity id="DDI-MedLine.d55.s1.e0" charOffset="6-13" type="drug" text="caffeine"/>
        <entity id="DDI-MedLine.d55.s1.e1" charOffset="50-62"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-MedLine.d55.s1.e2" charOffset="115-122"
            type="drug" text="caffeine"/>
        <entity id="DDI-MedLine.d55.s1.e3" charOffset="149-161"
            type="drug" text="acetaminophen"/>
        <pair id="DDI-MedLine.d55.s1.p0" e1="DDI-MedLine.d55.s1.e0"
            e2="DDI-MedLine.d55.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d55.s1.p1" e1="DDI-MedLine.d55.s1.e0"
            e2="DDI-MedLine.d55.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d55.s1.p2" e1="DDI-MedLine.d55.s1.e0"
            e2="DDI-MedLine.d55.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d55.s1.p3" e1="DDI-MedLine.d55.s1.e1"
            e2="DDI-MedLine.d55.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d55.s1.p4" e1="DDI-MedLine.d55.s1.e1"
            e2="DDI-MedLine.d55.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d55.s1.p5" e1="DDI-MedLine.d55.s1.e2"
            e2="DDI-MedLine.d55.s1.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d55.s2" text="In male Sprague-Dawley rats fasted for 18 h, concomitant administration of caffeine (0.1 g/kg, i.p.) ">
        <entity id="DDI-MedLine.d55.s2.e0" charOffset="75-82"
            type="drug" text="caffeine"/>
    </sentence>
    <sentence id="DDI-MedLine.d55.s3" text="as judged by increased serum enzyme activities and increased incidence of hepatic necrosis. "/>
    <sentence id="DDI-MedLine.d55.s4" text="Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.">
        <entity id="DDI-MedLine.d55.s4.e0" charOffset="58-70"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-MedLine.d55.s4.e1" charOffset="91-98"
            type="drug" text="caffeine"/>
        <pair id="DDI-MedLine.d55.s4.p0" e1="DDI-MedLine.d55.s4.e0"
            e2="DDI-MedLine.d55.s4.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d130.s0" text="High-dose cisplatin with sodium thiosulfate protection.&#xd;&#xa;">
        <entity id="DDI-MedLine.d130.s0.e0" charOffset="10-18"
            type="drug" text="cisplatin"/>
        <entity id="DDI-MedLine.d130.s0.e1" charOffset="25-42"
            type="drug" text="sodium thiosulfate"/>
        <pair id="DDI-MedLine.d130.s0.p0" e1="DDI-MedLine.d130.s0.e0"
            e2="DDI-MedLine.d130.s0.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d130.s1" text="Nephrotoxicity frequently limits the dose of cisplatin to less than 120 mg/m2 per injection. ">
        <entity id="DDI-MedLine.d130.s1.e0" charOffset="45-53"
            type="drug" text="cisplatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d130.s2" text="Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage. ">
        <entity id="DDI-MedLine.d130.s2.e0" charOffset="0-17"
            type="drug" text="Sodium thiosulfate"/>
        <entity id="DDI-MedLine.d130.s2.e1" charOffset="47-55"
            type="drug" text="cisplatin"/>
        <pair id="DDI-MedLine.d130.s2.p0" e1="DDI-MedLine.d130.s2.e0"
            e2="DDI-MedLine.d130.s2.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d130.s3" text="To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. ">
        <entity id="DDI-MedLine.d130.s3.e0" charOffset="34-44"
            type="drug" text="thiosulfate"/>
        <entity id="DDI-MedLine.d130.s3.e1" charOffset="75-83"
            type="drug" text="cisplatin"/>
        <entity id="DDI-MedLine.d130.s3.e2" charOffset="130-140"
            type="drug" text="thiosulfate"/>
        <entity id="DDI-MedLine.d130.s3.e3" charOffset="221-229"
            type="drug" text="cisplatin"/>
        <pair id="DDI-MedLine.d130.s3.p0" e1="DDI-MedLine.d130.s3.e0"
            e2="DDI-MedLine.d130.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d130.s3.p1" e1="DDI-MedLine.d130.s3.e0"
            e2="DDI-MedLine.d130.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d130.s3.p2" e1="DDI-MedLine.d130.s3.e0"
            e2="DDI-MedLine.d130.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d130.s3.p3" e1="DDI-MedLine.d130.s3.e1"
            e2="DDI-MedLine.d130.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d130.s3.p4" e1="DDI-MedLine.d130.s3.e1"
            e2="DDI-MedLine.d130.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d130.s3.p5" e1="DDI-MedLine.d130.s3.e2"
            e2="DDI-MedLine.d130.s3.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d130.s4" text="Cisplatin was administered over the last two hours of the thiosulfate infusion. ">
        <entity id="DDI-MedLine.d130.s4.e0" charOffset="0-8" type="drug" text="Cisplatin"/>
        <entity id="DDI-MedLine.d130.s4.e1" charOffset="58-68"
            type="drug" text="thiosulfate"/>
        <pair id="DDI-MedLine.d130.s4.p0" e1="DDI-MedLine.d130.s4.e0"
            e2="DDI-MedLine.d130.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d130.s5" text="Using this technique, it was possible to escalate the cisplatin dose to 225 mg/m2 before dose-limiting toxicities were encountered. ">
        <entity id="DDI-MedLine.d130.s5.e0" charOffset="54-62"
            type="drug" text="cisplatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d130.s6" text="Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. ">
        <entity id="DDI-MedLine.d130.s6.e0" charOffset="14-22"
            type="drug" text="cisplatin"/>
        <entity id="DDI-MedLine.d130.s6.e1" charOffset="83-93"
            type="drug" text="thiosulfate"/>
        <entity id="DDI-MedLine.d130.s6.e2" charOffset="147-157"
            type="drug" text="thiosulfate"/>
        <entity id="DDI-MedLine.d130.s6.e3" charOffset="281-289"
            type="drug" text="cisplatin"/>
        <pair id="DDI-MedLine.d130.s6.p0" e1="DDI-MedLine.d130.s6.e0"
            e2="DDI-MedLine.d130.s6.e1" ddi="false"/>
        <pair id="DDI-MedLine.d130.s6.p1" e1="DDI-MedLine.d130.s6.e0"
            e2="DDI-MedLine.d130.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d130.s6.p2" e1="DDI-MedLine.d130.s6.e0"
            e2="DDI-MedLine.d130.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d130.s6.p3" e1="DDI-MedLine.d130.s6.e1"
            e2="DDI-MedLine.d130.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d130.s6.p4" e1="DDI-MedLine.d130.s6.e1"
            e2="DDI-MedLine.d130.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d130.s6.p5" e1="DDI-MedLine.d130.s6.e2"
            e2="DDI-MedLine.d130.s6.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d130.s7" text="The total drug exposure for the plasma was approximately twofold at the higher cisplatin dose. ">
        <entity id="DDI-MedLine.d130.s7.e0" charOffset="79-87"
            type="drug" text="cisplatin"/>
    </sentence>
    <sentence id="DDI-MedLine.d130.s8" text="This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.">
        <entity id="DDI-MedLine.d130.s8.e0" charOffset="58-68"
            type="drug" text="thiosulfate"/>
        <entity id="DDI-MedLine.d130.s8.e1" charOffset="136-144"
            type="drug" text="cisplatin"/>
        <pair id="DDI-MedLine.d130.s8.p0" e1="DDI-MedLine.d130.s8.e0"
            e2="DDI-MedLine.d130.s8.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d41.s0" text="Interferon induction: tool for establishing interactions among homopolyribonucleotides.&#xa;"/>
    <sentence id="DDI-MedLine.d41.s1" text="Hitherto unrecognized interactions between homopolyribonucleotides and complexes thereof are suggested by interferon induction data obtained in a highly sensitive assay system of primary rabbit kidney cell cultures superinduced by metabolic inhibitors."/>
    <sentence id="DDI-MedLine.d5.s0" text="Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.&#xd;&#xa;">
        <entity id="DDI-MedLine.d5.s0.e0" charOffset="32-40"
            type="drug_n" text="coumaphos"/>
        <entity id="DDI-MedLine.d5.s0.e1" charOffset="68-76"
            type="drug_n" text="coumaphos"/>
        <entity id="DDI-MedLine.d5.s0.e2" charOffset="83-100"
            type="drug" text="bishydroxycoumarin"/>
        <entity id="DDI-MedLine.d5.s0.e3" charOffset="103-113"
            type="drug_n" text="trichlorfon"/>
        <entity id="DDI-MedLine.d5.s0.e4" charOffset="120-139"
            type="drug" text="phenobarbital sodium"/>
        <pair id="DDI-MedLine.d5.s0.p0" e1="DDI-MedLine.d5.s0.e0"
            e2="DDI-MedLine.d5.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d5.s0.p1" e1="DDI-MedLine.d5.s0.e0"
            e2="DDI-MedLine.d5.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d5.s0.p2" e1="DDI-MedLine.d5.s0.e0"
            e2="DDI-MedLine.d5.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d5.s0.p3" e1="DDI-MedLine.d5.s0.e0"
            e2="DDI-MedLine.d5.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d5.s0.p4" e1="DDI-MedLine.d5.s0.e1"
            e2="DDI-MedLine.d5.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d5.s0.p5" e1="DDI-MedLine.d5.s0.e1"
            e2="DDI-MedLine.d5.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d5.s0.p6" e1="DDI-MedLine.d5.s0.e1"
            e2="DDI-MedLine.d5.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d5.s0.p7" e1="DDI-MedLine.d5.s0.e2"
            e2="DDI-MedLine.d5.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d5.s0.p8" e1="DDI-MedLine.d5.s0.e2"
            e2="DDI-MedLine.d5.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d5.s0.p9" e1="DDI-MedLine.d5.s0.e3"
            e2="DDI-MedLine.d5.s0.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d5.s1" text="Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. ">
        <entity id="DDI-MedLine.d5.s1.e0" charOffset="37-45"
            type="drug_n" text="coumaphos"/>
        <entity id="DDI-MedLine.d5.s1.e1" charOffset="48-65" type="drug" text="bishydroxycoumarin"/>
        <entity id="DDI-MedLine.d5.s1.e2" charOffset="71-83"
            type="group" text="anticoagulant"/>
        <entity id="DDI-MedLine.d5.s1.e3" charOffset="87-97"
            type="drug_n" text="trichlorfon"/>
        <entity id="DDI-MedLine.d5.s1.e4" charOffset="103-128"
            type="group" text="organophosphorous compound"/>
        <entity id="DDI-MedLine.d5.s1.e5" charOffset="136-155"
            type="drug" text="phenobarbital sodium"/>
        <pair id="DDI-MedLine.d5.s1.p0" e1="DDI-MedLine.d5.s1.e0"
            e2="DDI-MedLine.d5.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d5.s1.p1" e1="DDI-MedLine.d5.s1.e0"
            e2="DDI-MedLine.d5.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d5.s1.p2" e1="DDI-MedLine.d5.s1.e0"
            e2="DDI-MedLine.d5.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d5.s1.p3" e1="DDI-MedLine.d5.s1.e0"
            e2="DDI-MedLine.d5.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d5.s1.p4" e1="DDI-MedLine.d5.s1.e0"
            e2="DDI-MedLine.d5.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d5.s1.p5" e1="DDI-MedLine.d5.s1.e1"
            e2="DDI-MedLine.d5.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d5.s1.p6" e1="DDI-MedLine.d5.s1.e1"
            e2="DDI-MedLine.d5.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d5.s1.p7" e1="DDI-MedLine.d5.s1.e1"
            e2="DDI-MedLine.d5.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d5.s1.p8" e1="DDI-MedLine.d5.s1.e1"
            e2="DDI-MedLine.d5.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d5.s1.p9" e1="DDI-MedLine.d5.s1.e2"
            e2="DDI-MedLine.d5.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d5.s1.p10" e1="DDI-MedLine.d5.s1.e2"
            e2="DDI-MedLine.d5.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d5.s1.p11" e1="DDI-MedLine.d5.s1.e2"
            e2="DDI-MedLine.d5.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d5.s1.p12" e1="DDI-MedLine.d5.s1.e3"
            e2="DDI-MedLine.d5.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d5.s1.p13" e1="DDI-MedLine.d5.s1.e3"
            e2="DDI-MedLine.d5.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d5.s1.p14" e1="DDI-MedLine.d5.s1.e4"
            e2="DDI-MedLine.d5.s1.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d5.s2" text="A daily dose of 2 mg of coumaphos/kg of body weight for 6 days did not affect the plasma enzymes or the antiprothrombinemic effect of bishydroxy-coumarin in wethers. ">
        <entity id="DDI-MedLine.d5.s2.e0" charOffset="24-32"
            type="drug_n" text="coumaphos"/>
        <entity id="DDI-MedLine.d5.s2.e1" charOffset="134-152"
            type="drug" text="bishydroxy-coumarin"/>
        <pair id="DDI-MedLine.d5.s2.p0" e1="DDI-MedLine.d5.s2.e0"
            e2="DDI-MedLine.d5.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d5.s3" text="The treatment of ewes with an intravenous (IV) injection of trichlorfon, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of coumaphos/kg/day. ">
        <entity id="DDI-MedLine.d5.s3.e0" charOffset="60-70"
            type="drug_n" text="trichlorfon"/>
        <entity id="DDI-MedLine.d5.s3.e1" charOffset="267-275"
            type="drug_n" text="coumaphos"/>
        <pair id="DDI-MedLine.d5.s3.p0" e1="DDI-MedLine.d5.s3.e0"
            e2="DDI-MedLine.d5.s3.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d5.s4" text="In ewes given 40 mg of phenobarbital sodium/kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of coumaphos/kg was significantly reduced and signs of toxicity were not present. ">
        <entity id="DDI-MedLine.d5.s4.e0" charOffset="23-42" type="drug" text="phenobarbital sodium"/>
        <entity id="DDI-MedLine.d5.s4.e1" charOffset="123-131"
            type="drug_n" text="coumaphos"/>
        <pair id="DDI-MedLine.d5.s4.p0" e1="DDI-MedLine.d5.s4.e0"
            e2="DDI-MedLine.d5.s4.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d5.s5" text="Treatment with daily doses of 2 mg of coumaphos/kg for 6 days did not modify the anticholinesterase effect of a 2nd series of treatments given 6 weeks later.">
        <entity id="DDI-MedLine.d5.s5.e0" charOffset="38-46"
            type="drug_n" text="coumaphos"/>
    </sentence>
    <sentence id="DDI-MedLine.d91.s0" text="Diagnostic, treatment and aftercare approaches to cocaine abuse.&#xd;&#xa;">
        <entity id="DDI-MedLine.d91.s0.e0" charOffset="50-56"
            type="drug" text="cocaine"/>
    </sentence>
    <sentence id="DDI-MedLine.d91.s1" text="The general public feels that cocaine is not particularly dangerous because it does not produce a well defined physical dependency and abstinence syndrome. ">
        <entity id="DDI-MedLine.d91.s1.e0" charOffset="30-36"
            type="drug" text="cocaine"/>
    </sentence>
    <sentence id="DDI-MedLine.d91.s2" text="However, when addiction is defined as compulsion, loss of control and continued use in spite of adverse consequences, cocaine drug hunger can be seen as an agent of addictive disease. ">
        <entity id="DDI-MedLine.d91.s2.e0" charOffset="118-124"
            type="drug" text="cocaine"/>
    </sentence>
    <sentence id="DDI-MedLine.d91.s3" text="Withdrawal from cocaine dependence usually involves depression, anxiety and lethargy. ">
        <entity id="DDI-MedLine.d91.s3.e0" charOffset="16-22"
            type="drug" text="cocaine"/>
    </sentence>
    <sentence id="DDI-MedLine.d91.s4" text="These usually clear within a week, leaving only the &quot;drug hunger&quot;"/>
    <sentence id="DDI-MedLine.d91.s5" text="to contend with. "/>
    <sentence id="DDI-MedLine.d91.s6" text="Medication is rarely needed. "/>
    <sentence id="DDI-MedLine.d91.s7" text="When cocaine is the primary addiction, after withdrawal the most effective treatment is group therapy with other recovering cocaine abusers. ">
        <entity id="DDI-MedLine.d91.s7.e0" charOffset="5-11" type="drug" text="cocaine"/>
    </sentence>
    <sentence id="DDI-MedLine.d91.s8" text="We incorporate the principles of recovery and define positive and constructive alternatives in dealing with cocaine hunger. "/>
    <sentence id="DDI-MedLine.d91.s9" text="Recovery programs should be flexible and involve individual and family education on recovery and the nature of addictive disease. "/>
    <sentence id="DDI-MedLine.d91.s10" text="Exercise that produces cardiopulmonary stimulation is a helpful means of reducing drug hunger and anxiety during recovery therapy."/>
    <sentence id="DDI-MedLine.d2.s0" text="Failure of neomycin to modify ACTH induced hypertension in sheep.">
        <entity id="DDI-MedLine.d2.s0.e0" charOffset="11-18" type="drug" text="neomycin"/>
        <entity id="DDI-MedLine.d2.s0.e1" charOffset="30-33"
            type="group" text="ACTH"/>
        <pair id="DDI-MedLine.d2.s0.p0" e1="DDI-MedLine.d2.s0.e0"
            e2="DDI-MedLine.d2.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d2.s1" text="Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. ">
        <entity id="DDI-MedLine.d2.s1.e0" charOffset="32-39" type="drug" text="neomycin"/>
        <entity id="DDI-MedLine.d2.s1.e1" charOffset="84-105"
            type="group" text="adrenocortical steroid"/>
        <entity id="DDI-MedLine.d2.s1.e2" charOffset="141-144"
            type="drug" text="ACTH"/>
        <pair id="DDI-MedLine.d2.s1.p0" e1="DDI-MedLine.d2.s1.e0"
            e2="DDI-MedLine.d2.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d2.s1.p1" e1="DDI-MedLine.d2.s1.e0"
            e2="DDI-MedLine.d2.s1.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d2.s1.p2" e1="DDI-MedLine.d2.s1.e1"
            e2="DDI-MedLine.d2.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d2.s2" text="The effects of oral neomycin on ACTH induced hypertension were examined in conscious sheep. ">
        <entity id="DDI-MedLine.d2.s2.e0" charOffset="20-27" type="drug" text="neomycin"/>
        <entity id="DDI-MedLine.d2.s2.e1" charOffset="32-35"
            type="group" text="ACTH"/>
        <pair id="DDI-MedLine.d2.s2.p0" e1="DDI-MedLine.d2.s2.e0"
            e2="DDI-MedLine.d2.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d2.s3" text="Neomycin has no effect on the blood pressure or metabolic responses to ACTH in sheep.">
        <entity id="DDI-MedLine.d2.s3.e0" charOffset="0-7" type="drug" text="Neomycin"/>
        <entity id="DDI-MedLine.d2.s3.e1" charOffset="71-74"
            type="group" text="ACTH"/>
        <pair id="DDI-MedLine.d2.s3.p0" e1="DDI-MedLine.d2.s3.e0"
            e2="DDI-MedLine.d2.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d66.s0" text="Changes in urinary homocysteine following synthetic steroidal estrogen and progestogen administration to rats.">
        <entity id="DDI-MedLine.d66.s0.e0" charOffset="42-69"
            type="group" text="synthetic steroidal estrogen"/>
        <entity id="DDI-MedLine.d66.s0.e1" charOffset="42-60;75-85"
            type="group" text="synthetic steroidal progestogen"/>
        <pair id="DDI-MedLine.d66.s0.p0" e1="DDI-MedLine.d66.s0.e0"
            e2="DDI-MedLine.d66.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d66.s1" text="The present work involved the administration of both ethynyl estradiol and levonorgestrel to groups of rats, followed by determination of the homocysteine excretion rate in urine. ">
        <entity id="DDI-MedLine.d66.s1.e0" charOffset="53-69"
            type="drug" text="ethynyl estradiol"/>
        <entity id="DDI-MedLine.d66.s1.e1" charOffset="75-88"
            type="drug" text="levonorgestrel"/>
        <pair id="DDI-MedLine.d66.s1.p0" e1="DDI-MedLine.d66.s1.e0"
            e2="DDI-MedLine.d66.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d66.s2" text="The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and levonorgestrel-treated rats and the levels shown by rats treated with ethynyl estradiol. ">
        <entity id="DDI-MedLine.d66.s2.e0" charOffset="149-162"
            type="drug" text="levonorgestrel"/>
        <entity id="DDI-MedLine.d66.s2.e1" charOffset="219-235"
            type="drug" text="ethynyl estradiol"/>
        <pair id="DDI-MedLine.d66.s2.p0" e1="DDI-MedLine.d66.s2.e0"
            e2="DDI-MedLine.d66.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d66.s3" text="The implications of these results are discussed, especially with respect to observations which indicate that homocysteine may be a precipitating factor in the development of thrombosis. "/>
    <sentence id="DDI-MedLine.d66.s4" text="Also included in this paper is a study which confirms the identity of the HPLC peak as being homocysteine by forming a radioactive derivative of this particular sulphydryl-containing amino acid, and then analysing the resulting mixture by TLC."/>
    <sentence id="DDI-MedLine.d93.s0" text="Altered responsiveness to alcohol after exposure to organic lead.&#xa;">
        <entity id="DDI-MedLine.d93.s0.e0" charOffset="26-32"
            type="drug" text="alcohol"/>
    </sentence>
    <sentence id="DDI-MedLine.d93.s1" text="Ethyl alcohol is known to effect the functional integrity of the limbic system, particularly the hippocampus, and to alter behaviors which are thought to be mediated through limbic function. ">
        <entity id="DDI-MedLine.d93.s1.e0" charOffset="0-12" type="drug" text="Ethyl alcohol"/>
    </sentence>
    <sentence id="DDI-MedLine.d93.s2" text="Organometals also compromise the limbic system and result in deficits in learning and memory. "/>
    <sentence id="DDI-MedLine.d93.s3" text="Since both alcohol and organoleads are present in the environment and seem to influence limbic integration, the interaction of these two compounds was assessed in the present experiment. ">
        <entity id="DDI-MedLine.d93.s3.e0" charOffset="11-17"
            type="drug" text="alcohol"/>
    </sentence>
    <sentence id="DDI-MedLine.d93.s4" text="Thirty male rats of the Fischer-344 strain were divided into three equal groups and were given injections of trimethyl lead (TML) (8.0 or 17.0 mg/kg/ml SC) or the saline vehicle. ">
        <entity id="DDI-MedLine.d93.s4.e0" charOffset="109-122"
            type="drug_n" text="trimethyl lead"/>
        <entity id="DDI-MedLine.d93.s4.e1" charOffset="125-127"
            type="drug_n" text="TML"/>
        <pair id="DDI-MedLine.d93.s4.p0" e1="DDI-MedLine.d93.s4.e0"
            e2="DDI-MedLine.d93.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d93.s5" text="Fourteen days later, all animals were challenged with a single hypnotic dose of ethanol (3.5 g/kg IP). ">
        <entity id="DDI-MedLine.d93.s5.e0" charOffset="80-86"
            type="drug" text="ethanol"/>
    </sentence>
    <sentence id="DDI-MedLine.d93.s6" text="The 20% v/v solution of alcohol was prepared in water from a stock solution of 95% ethanol. ">
        <entity id="DDI-MedLine.d93.s6.e0" charOffset="24-30"
            type="drug" text="alcohol"/>
        <entity id="DDI-MedLine.d93.s6.e1" charOffset="83-89"
            type="drug" text="ethanol"/>
        <pair id="DDI-MedLine.d93.s6.p0" e1="DDI-MedLine.d93.s6.e0"
            e2="DDI-MedLine.d93.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d93.s7" text="The latency to loss of the righting reflex and duration of sleep time were recorded while the rats were kept in sound-attenuating chambers. "/>
    <sentence id="DDI-MedLine.d93.s8" text="The rats treated with the highest dose of TML manifested significantly longer latencies to lose the righting reflex and shorter durations of sleep than did controls. ">
        <entity id="DDI-MedLine.d93.s8.e0" charOffset="42-44"
            type="drug_n" text="TML"/>
    </sentence>
    <sentence id="DDI-MedLine.d93.s9" text="These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol.">
        <entity id="DDI-MedLine.d93.s9.e0" charOffset="53-56"
            type="drug_n" text="lead"/>
        <entity id="DDI-MedLine.d93.s9.e1" charOffset="129-135"
            type="drug" text="alcohol"/>
        <pair id="DDI-MedLine.d93.s9.p0" e1="DDI-MedLine.d93.s9.e0"
            e2="DDI-MedLine.d93.s9.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d54.s0" text="Cholinergic role in alcohol's effects on evoked potentials in visual cortex of the albino rat.&#xd;&#xa;">
        <entity id="DDI-MedLine.d54.s0.e0" charOffset="20-26"
            type="drug" text="alcohol"/>
    </sentence>
    <sentence id="DDI-MedLine.d54.s1" text="Photic evoked potentials were recorded from the visual cortex of chronically implanted albino rats. "/>
    <sentence id="DDI-MedLine.d54.s2" text="Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation, study of the effects of alcohol on these components may help to trace pathways which are affected by alcohol. ">
        <entity id="DDI-MedLine.d54.s2.e0" charOffset="151-157"
            type="drug" text="alcohol"/>
        <entity id="DDI-MedLine.d54.s2.e1" charOffset="228-234"
            type="drug" text="alcohol"/>
        <pair id="DDI-MedLine.d54.s2.p0" e1="DDI-MedLine.d54.s2.e0"
            e2="DDI-MedLine.d54.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d54.s3" text="In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), physostigmine (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days. ">
        <entity id="DDI-MedLine.d54.s3.e0" charOffset="110-116"
            type="drug" text="ethanol"/>
        <entity id="DDI-MedLine.d54.s3.e1" charOffset="130-142"
            type="drug" text="physostigmine"/>
        <entity id="DDI-MedLine.d54.s3.e2" charOffset="159-166"
            type="drug" text="atropine"/>
        <pair id="DDI-MedLine.d54.s3.p0" e1="DDI-MedLine.d54.s3.e0"
            e2="DDI-MedLine.d54.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d54.s3.p1" e1="DDI-MedLine.d54.s3.e0"
            e2="DDI-MedLine.d54.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d54.s3.p2" e1="DDI-MedLine.d54.s3.e1"
            e2="DDI-MedLine.d54.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d54.s4" text="Ethanol depressed the amplitudes of most evoked potential components in comparison to saline administration. ">
        <entity id="DDI-MedLine.d54.s4.e0" charOffset="0-6" type="drug" text="Ethanol"/>
    </sentence>
    <sentence id="DDI-MedLine.d54.s5" text="Component P2, however, was increased in amplitude. "/>
    <sentence id="DDI-MedLine.d54.s6" text="Physostigmine briefly reduced the amplitude of most components, including P2. ">
        <entity id="DDI-MedLine.d54.s6.e0" charOffset="0-12" type="drug" text="Physostigmine"/>
    </sentence>
    <sentence id="DDI-MedLine.d54.s7" text="In contrast, atropine increased the amplitudes of components P1 and P2, while decreasing components N1, N2 and N3 for varying durations of time. ">
        <entity id="DDI-MedLine.d54.s7.e0" charOffset="13-20"
            type="drug" text="atropine"/>
    </sentence>
    <sentence id="DDI-MedLine.d54.s8" text="Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. ">
        <entity id="DDI-MedLine.d54.s8.e0" charOffset="0-12" type="drug" text="Physostigmine"/>
        <entity id="DDI-MedLine.d54.s8.e1" charOffset="62-68"
            type="drug" text="alcohol"/>
        <entity id="DDI-MedLine.d54.s8.e2" charOffset="123-129"
            type="drug" text="alcohol"/>
        <pair id="DDI-MedLine.d54.s8.p0" e1="DDI-MedLine.d54.s8.e0"
            e2="DDI-MedLine.d54.s8.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d54.s8.p1" e1="DDI-MedLine.d54.s8.e0"
            e2="DDI-MedLine.d54.s8.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d54.s8.p2" e1="DDI-MedLine.d54.s8.e1"
            e2="DDI-MedLine.d54.s8.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d54.s9" text="Pretreatment with atropine likewise further reduced the amplitudes of components P1 and N1, and produced a similar effect on component N3. ">
        <entity id="DDI-MedLine.d54.s9.e0" charOffset="18-25"
            type="drug" text="atropine"/>
    </sentence>
    <sentence id="DDI-MedLine.d54.s10" text="Atropine, either alone or in combination with alcohol, produced approximately the same degree of enhancement of component P2. ">
        <entity id="DDI-MedLine.d54.s10.e0" charOffset="0-7" type="drug" text="Atropine"/>
        <entity id="DDI-MedLine.d54.s10.e1" charOffset="46-52"
            type="drug" text="alcohol"/>
        <pair id="DDI-MedLine.d54.s10.p0" e1="DDI-MedLine.d54.s10.e0"
            e2="DDI-MedLine.d54.s10.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d54.s11" text="In comparison to saline values, all three agents produced reliable increases in peak latency for most of the components, with only N3 showing no effects. "/>
    <sentence id="DDI-MedLine.d54.s12" text="The amplitude data from this study suggest that ethanol's augmentation of component P2 may result, at least in part, from alterations in cholinergic functions.">
        <entity id="DDI-MedLine.d54.s12.e0" charOffset="48-54"
            type="drug" text="ethanol"/>
    </sentence>
    <sentence id="DDI-MedLine.d81.s0" text="Hypothermia as an index of the disulfiram-ethanol reaction in the rat.&#xd;&#xa;">
        <entity id="DDI-MedLine.d81.s0.e0" charOffset="31-40"
            type="drug" text="disulfiram"/>
        <entity id="DDI-MedLine.d81.s0.e1" charOffset="42-48"
            type="drug" text="ethanol"/>
        <pair id="DDI-MedLine.d81.s0.p0" e1="DDI-MedLine.d81.s0.e0"
            e2="DDI-MedLine.d81.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d81.s1" text="Decreased core temperature in female rats was investigated as one possible index of the disulfiram-ethanol reaction (DER). ">
        <entity id="DDI-MedLine.d81.s1.e0" charOffset="88-97"
            type="drug" text="disulfiram"/>
        <entity id="DDI-MedLine.d81.s1.e1" charOffset="99-105"
            type="drug" text="ethanol"/>
        <pair id="DDI-MedLine.d81.s1.p0" e1="DDI-MedLine.d81.s1.e0"
            e2="DDI-MedLine.d81.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d81.s2" text="Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. ">
        <entity id="DDI-MedLine.d81.s2.e0" charOffset="71-77"
            type="drug" text="ethanol"/>
        <entity id="DDI-MedLine.d81.s2.e1" charOffset="117-126"
            type="drug" text="disulfiram"/>
        <entity id="DDI-MedLine.d81.s2.e2" charOffset="147-153"
            type="drug" text="ethanol"/>
        <pair id="DDI-MedLine.d81.s2.p0" e1="DDI-MedLine.d81.s2.e0"
            e2="DDI-MedLine.d81.s2.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d81.s2.p1" e1="DDI-MedLine.d81.s2.e0"
            e2="DDI-MedLine.d81.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d81.s2.p2" e1="DDI-MedLine.d81.s2.e1"
            e2="DDI-MedLine.d81.s2.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d81.s3" text="The decrease in temperature began within 20 minutes after ethanol administration, reaching a maximal decrease between 60 and 120 minutes post ethanol. ">
        <entity id="DDI-MedLine.d81.s3.e0" charOffset="58-64"
            type="drug" text="ethanol"/>
        <entity id="DDI-MedLine.d81.s3.e1" charOffset="142-148"
            type="drug" text="ethanol"/>
        <pair id="DDI-MedLine.d81.s3.p0" e1="DDI-MedLine.d81.s3.e0"
            e2="DDI-MedLine.d81.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d81.s4" text="The core temperature returned to normal 300 minutes after ethanol. ">
        <entity id="DDI-MedLine.d81.s4.e0" charOffset="58-64"
            type="drug" text="ethanol"/>
    </sentence>
    <sentence id="DDI-MedLine.d81.s5" text="The blood pressure (carotid cannulation) decreased along with the core temperature. "/>
    <sentence id="DDI-MedLine.d81.s6" text="Maximal hypotension was found 120 minutes post ethanol, and returned to normal 300 minutes after ethanol. ">
        <entity id="DDI-MedLine.d81.s6.e0" charOffset="47-53"
            type="drug" text="ethanol"/>
        <entity id="DDI-MedLine.d81.s6.e1" charOffset="97-103"
            type="drug" text="ethanol"/>
        <pair id="DDI-MedLine.d81.s6.p0" e1="DDI-MedLine.d81.s6.e0"
            e2="DDI-MedLine.d81.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d81.s7" text="Heart rate increased initially and returned to normal 40 minutes after ethanol challenge.">
        <entity id="DDI-MedLine.d81.s7.e0" charOffset="71-77"
            type="drug" text="ethanol"/>
    </sentence>
    <sentence id="DDI-MedLine.d24.s0" text="Excretion of thioethers in urine after exposure to electrophilic chemicals.&#xd;&#xa;"/>
    <sentence id="DDI-MedLine.d24.s1" text="Electrophilic agents--a class of chemicals that includes most genotoxic compounds--can be inactivated by reaction with glutathione or other SH-bearing molecules. "/>
    <sentence id="DDI-MedLine.d24.s2" text="The conjugates so formed often appear in the urine as mercapturic acids or other thioether products. "/>
    <sentence id="DDI-MedLine.d24.s3" text="This paper critically reviews the suitability of the urinary thioether assay as a method for the detection of exposure to electrophilic agents or their precursors. "/>
    <sentence id="DDI-MedLine.d24.s4" text="In practice, the greatest value of the thioether assay appears to lie in its signal function. "/>
    <sentence id="DDI-MedLine.d24.s5" text="This is demonstrated for cigarette smokers and industrial workers involved in chemical waste incineration. "/>
    <sentence id="DDI-MedLine.d24.s6" text="Whenever increased thioether excretion is observed, it is likely to be due to exposure to one or more suspect compounds. "/>
    <sentence id="DDI-MedLine.d24.s7" text="However, when the thioether concentration ranges within the limits of the normal value, one must not conclude that there is no, or negligible, exposure. "/>
    <sentence id="DDI-MedLine.d24.s8" text="More specific applications of the assay of thio compounds in urine allow development of selective methods that may be useful for biological monitoring."/>
    <sentence id="DDI-MedLine.d131.s0" text="Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.&#xd;&#xa;">
        <entity id="DDI-MedLine.d131.s0.e0" charOffset="50-60"
            type="drug_n" text="neurotensin"/>
        <entity id="DDI-MedLine.d131.s0.e1" charOffset="66-76"
            type="drug_n" text="enkephalins"/>
        <entity id="DDI-MedLine.d131.s0.e2" charOffset="81-87"
            type="drug_n" text="tuftsin"/>
        <pair id="DDI-MedLine.d131.s0.p0" e1="DDI-MedLine.d131.s0.e0"
            e2="DDI-MedLine.d131.s0.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d131.s0.p1" e1="DDI-MedLine.d131.s0.e0"
            e2="DDI-MedLine.d131.s0.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d131.s0.p2" e1="DDI-MedLine.d131.s0.e1"
            e2="DDI-MedLine.d131.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d131.s1" text="The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. ">
        <entity id="DDI-MedLine.d131.s1.e0" charOffset="59-69"
            type="drug_n" text="neurotensin"/>
        <entity id="DDI-MedLine.d131.s1.e1" charOffset="80-90"
            type="drug_n" text="enkephalins"/>
        <entity id="DDI-MedLine.d131.s1.e2" charOffset="118-142"
            type="drug_n" text="D-Ala2-metenkephalinamide"/>
        <entity id="DDI-MedLine.d131.s1.e3" charOffset="148-154"
            type="drug_n" text="tuftsin"/>
        <pair id="DDI-MedLine.d131.s1.p0" e1="DDI-MedLine.d131.s1.e0"
            e2="DDI-MedLine.d131.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d131.s1.p1" e1="DDI-MedLine.d131.s1.e0"
            e2="DDI-MedLine.d131.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d131.s1.p2" e1="DDI-MedLine.d131.s1.e0"
            e2="DDI-MedLine.d131.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d131.s1.p3" e1="DDI-MedLine.d131.s1.e1"
            e2="DDI-MedLine.d131.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d131.s1.p4" e1="DDI-MedLine.d131.s1.e1"
            e2="DDI-MedLine.d131.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d131.s1.p5" e1="DDI-MedLine.d131.s1.e2"
            e2="DDI-MedLine.d131.s1.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d131.s2" text="Antinociception was measured by the hot-plate method. "/>
    <sentence id="DDI-MedLine.d131.s3" text="It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue. ">
        <entity id="DDI-MedLine.d131.s3.e0" charOffset="18-28"
            type="drug_n" text="neurotensin"/>
        <entity id="DDI-MedLine.d131.s3.e1" charOffset="82-92"
            type="drug_n" text="enkephalins"/>
        <pair id="DDI-MedLine.d131.s3.p0" e1="DDI-MedLine.d131.s3.e0"
            e2="DDI-MedLine.d131.s3.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d131.s4" text="On the contrary, neurotensin and tuftsin were agonists in induction of analgesia. ">
        <entity id="DDI-MedLine.d131.s4.e0" charOffset="17-27"
            type="drug_n" text="neurotensin"/>
        <entity id="DDI-MedLine.d131.s4.e1" charOffset="33-39"
            type="drug_n" text="tuftsin"/>
        <pair id="DDI-MedLine.d131.s4.p0" e1="DDI-MedLine.d131.s4.e0"
            e2="DDI-MedLine.d131.s4.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d131.s5" text="It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.">
        <entity id="DDI-MedLine.d131.s5.e0" charOffset="21-31"
            type="drug_n" text="neurotensin"/>
        <entity id="DDI-MedLine.d131.s5.e1" charOffset="132-138"
            type="drug_n" text="tuftsin"/>
        <pair id="DDI-MedLine.d131.s5.p0" e1="DDI-MedLine.d131.s5.e0"
            e2="DDI-MedLine.d131.s5.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d71.s0" text="Drug-lab interactions: implications for nutrition support. "/>
    <sentence id="DDI-MedLine.d71.s1" text="Acetylcysteine interference with urine ketone test.&#xd;&#xa;">
        <entity id="DDI-MedLine.d71.s1.e0" charOffset="0-13" type="drug" text="Acetylcysteine"/>
    </sentence>
    <sentence id="DDI-MedLine.d71.s2" text="It is important that health care professionals be aware of the potential for medications to interfere with clinical laboratory tests. "/>
    <sentence id="DDI-MedLine.d71.s3" text="Medications can cause in vivo effects when the concentration or activity of the analyte is altered before the analysis and therefore the assay result is true and accurate. "/>
    <sentence id="DDI-MedLine.d71.s4" text="An in vitro effect occurs when the medication interferes with the assay, and the result is erroneous and cannot be interpreted. "/>
    <sentence id="DDI-MedLine.d71.s5" text="This report describes a recently identified case of interference of acetylcysteine with the urine test for ketones and demonstrates the importance of a thorough medication review in evaluating abnormal laboratory tests.">
        <entity id="DDI-MedLine.d71.s5.e0" charOffset="68-81"
            type="drug" text="acetylcysteine"/>
    </sentence>
    <sentence id="DDI-MedLine.d97.s0" text="[2 epidemics of arsenical encephalopathy in the treatment of trypanosomiasis, Uganda, 1992-1993] Since 1988, the french non-governmental organisation M  decins Sans Fronti  res is running a control program of human african trypanosomiasis in the district of Moyo, North-Uganda. "/>
    <sentence id="DDI-MedLine.d97.s1" text="Between 1988 and 1993, more than 7,000 patients were diagnosed and treated. "/>
    <sentence id="DDI-MedLine.d97.s2" text="Since 1988, it has been noted that incidence of melarsoprol reaction had increased systematically between June and October of each year, indicating strong seasonal variation. ">
        <entity id="DDI-MedLine.d97.s2.e0" charOffset="48-58"
            type="drug" text="melarsoprol"/>
    </sentence>
    <sentence id="DDI-MedLine.d97.s3" text="In 1992 and 1993, two outbreaks of arsenical reactive encephalopathy (ARE) occurred in the sleeping sickness center of Adjumani. "/>
    <sentence id="DDI-MedLine.d97.s4" text="The incidence of ARE suddenly exceeded 10% of the patients treated by melarsoprol during August 1992 and September 1993. ">
        <entity id="DDI-MedLine.d97.s4.e0" charOffset="70-80"
            type="drug" text="melarsoprol"/>
    </sentence>
    <sentence id="DDI-MedLine.d97.s5" text="The onset of 80% of those &quot;epidemic&quot;"/>
    <sentence id="DDI-MedLine.d97.s6" text="cases, occurred between the 5th and the 11th day of treatment. "/>
    <sentence id="DDI-MedLine.d97.s7" text="Two retrospective studies were conducted in 1992 (75 cases) and in 1993 (51 cases). "/>
    <sentence id="DDI-MedLine.d97.s8" text="Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients. ">
        <entity id="DDI-MedLine.d97.s8.e0" charOffset="92-104"
            type="drug" text="thiabendazole"/>
        <entity id="DDI-MedLine.d97.s8.e1" charOffset="143-153"
            type="drug" text="melarsoprol"/>
        <pair id="DDI-MedLine.d97.s8.p0" e1="DDI-MedLine.d97.s8.e0"
            e2="DDI-MedLine.d97.s8.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d97.s9" text="These observations suggest that exogenous co-factors could be involved in the occurrence of ARE. "/>
    <sentence id="DDI-MedLine.d97.s10" text="Recommendations were to avoid administration of diffusible anti-helminthic treatment during the cure, and to improve the general conditions of patients before the cure of melarsoprol.">
        <entity id="DDI-MedLine.d97.s10.e0" charOffset="59-73"
            type="group" text="anti-helminthic"/>
        <entity id="DDI-MedLine.d97.s10.e1" charOffset="171-181"
            type="drug" text="melarsoprol"/>
        <pair id="DDI-MedLine.d97.s10.p0" e1="DDI-MedLine.d97.s10.e0"
            e2="DDI-MedLine.d97.s10.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d34.s0" text="Interactions of cobalt and iron in absorption and retention.&#xd;&#xa;">
        <entity id="DDI-MedLine.d34.s0.e0" charOffset="16-21"
            type="drug" text="cobalt"/>
        <entity id="DDI-MedLine.d34.s0.e1" charOffset="27-30"
            type="drug" text="iron"/>
        <pair id="DDI-MedLine.d34.s0.p0" e1="DDI-MedLine.d34.s0.e0"
            e2="DDI-MedLine.d34.s0.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d34.s1" text="The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. ">
        <entity id="DDI-MedLine.d34.s1.e0" charOffset="34-39"
            type="drug" text="cobalt"/>
        <entity id="DDI-MedLine.d34.s1.e1" charOffset="45-48"
            type="drug" text="iron"/>
        <entity id="DDI-MedLine.d34.s1.e2" charOffset="271-272"
            type="drug" text="Co"/>
        <entity id="DDI-MedLine.d34.s1.e3" charOffset="297-298"
            type="drug" text="Fe"/>
        <pair id="DDI-MedLine.d34.s1.p0" e1="DDI-MedLine.d34.s1.e0"
            e2="DDI-MedLine.d34.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d34.s1.p1" e1="DDI-MedLine.d34.s1.e0"
            e2="DDI-MedLine.d34.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d34.s1.p2" e1="DDI-MedLine.d34.s1.e0"
            e2="DDI-MedLine.d34.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d34.s1.p3" e1="DDI-MedLine.d34.s1.e1"
            e2="DDI-MedLine.d34.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d34.s1.p4" e1="DDI-MedLine.d34.s1.e1"
            e2="DDI-MedLine.d34.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d34.s1.p5" e1="DDI-MedLine.d34.s1.e2"
            e2="DDI-MedLine.d34.s1.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d34.s2" text="Retention was calculated by the balance technique and by the comparative slaughter technique. "/>
    <sentence id="DDI-MedLine.d34.s3" text="After one day, fecal as well as urinary excretion of both elements had already responded to the dietary treatments, with constant values being reached after approximately three days. "/>
    <sentence id="DDI-MedLine.d34.s4" text="Cobalt excretion was enhanced by supplementary cobalt; ">
        <entity id="DDI-MedLine.d34.s4.e0" charOffset="0-5" type="drug" text="Cobalt"/>
        <entity id="DDI-MedLine.d34.s4.e1" charOffset="47-52"
            type="drug" text="cobalt"/>
        <pair id="DDI-MedLine.d34.s4.p0" e1="DDI-MedLine.d34.s4.e0"
            e2="DDI-MedLine.d34.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d34.s5" text="fecal excretion, too, was increased by supplementary iron; ">
        <entity id="DDI-MedLine.d34.s5.e0" charOffset="53-56"
            type="drug" text="iron"/>
    </sentence>
    <sentence id="DDI-MedLine.d34.s6" text="whereas urinary excretion was decreased in both cases. "/>
    <sentence id="DDI-MedLine.d34.s7" text="Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. ">
        <entity id="DDI-MedLine.d34.s7.e0" charOffset="11-14"
            type="drug" text="iron"/>
        <entity id="DDI-MedLine.d34.s7.e1" charOffset="58-63"
            type="drug" text="cobalt"/>
        <entity id="DDI-MedLine.d34.s7.e2" charOffset="81-86"
            type="drug" text="cobalt"/>
        <pair id="DDI-MedLine.d34.s7.p0" e1="DDI-MedLine.d34.s7.e0"
            e2="DDI-MedLine.d34.s7.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d34.s7.p1" e1="DDI-MedLine.d34.s7.e0"
            e2="DDI-MedLine.d34.s7.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d34.s7.p2" e1="DDI-MedLine.d34.s7.e1"
            e2="DDI-MedLine.d34.s7.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d34.s8" text="The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt. ">
        <entity id="DDI-MedLine.d34.s8.e0" charOffset="60-61"
            type="drug" text="Fe"/>
        <entity id="DDI-MedLine.d34.s8.e1" charOffset="83-84"
            type="drug" text="Fe"/>
        <entity id="DDI-MedLine.d34.s8.e2" charOffset="141-146"
            type="drug" text="cobalt"/>
        <pair id="DDI-MedLine.d34.s8.p0" e1="DDI-MedLine.d34.s8.e0"
            e2="DDI-MedLine.d34.s8.e1" ddi="false"/>
        <pair id="DDI-MedLine.d34.s8.p1" e1="DDI-MedLine.d34.s8.e0"
            e2="DDI-MedLine.d34.s8.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d34.s8.p2" e1="DDI-MedLine.d34.s8.e1"
            e2="DDI-MedLine.d34.s8.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d34.s9" text="Consequently, the effect of iron on the retention of cobalt was lower than on absorption. ">
        <entity id="DDI-MedLine.d34.s9.e0" charOffset="28-31"
            type="drug" text="iron"/>
        <entity id="DDI-MedLine.d34.s9.e1" charOffset="53-58"
            type="drug" text="cobalt"/>
        <pair id="DDI-MedLine.d34.s9.p0" e1="DDI-MedLine.d34.s9.e0"
            e2="DDI-MedLine.d34.s9.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d34.s10" text="This suggests that interactions between the two elements only take place at the site of absorption. "/>
    <sentence id="DDI-MedLine.d34.s11" text="Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. ">
        <entity id="DDI-MedLine.d34.s11.e0" charOffset="27-32"
            type="drug" text="cobalt"/>
        <entity id="DDI-MedLine.d34.s11.e1" charOffset="67-70"
            type="drug" text="iron"/>
        <entity id="DDI-MedLine.d34.s11.e2" charOffset="108-113"
            type="drug" text="cobalt"/>
        <entity id="DDI-MedLine.d34.s11.e3" charOffset="118-121"
            type="drug" text="iron"/>
        <pair id="DDI-MedLine.d34.s11.p0" e1="DDI-MedLine.d34.s11.e0"
            e2="DDI-MedLine.d34.s11.e1" ddi="false"/>
        <pair id="DDI-MedLine.d34.s11.p1" e1="DDI-MedLine.d34.s11.e0"
            e2="DDI-MedLine.d34.s11.e2" ddi="false"/>
        <pair id="DDI-MedLine.d34.s11.p2" e1="DDI-MedLine.d34.s11.e0"
            e2="DDI-MedLine.d34.s11.e3" ddi="false"/>
        <pair id="DDI-MedLine.d34.s11.p3" e1="DDI-MedLine.d34.s11.e1"
            e2="DDI-MedLine.d34.s11.e2" ddi="false"/>
        <pair id="DDI-MedLine.d34.s11.p4" e1="DDI-MedLine.d34.s11.e1"
            e2="DDI-MedLine.d34.s11.e3" ddi="false"/>
        <pair id="DDI-MedLine.d34.s11.p5" e1="DDI-MedLine.d34.s11.e2"
            e2="DDI-MedLine.d34.s11.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d34.s12" text="Differences in iron balance were only observed between both dietary concentrations, showing a higher absolute but a lower relative absorption as well as retention in the groups fed further Fe.(ABSTRACT TRUNCATED AT 250 WORDS)">
        <entity id="DDI-MedLine.d34.s12.e0" charOffset="15-18"
            type="drug" text="iron"/>
        <entity id="DDI-MedLine.d34.s12.e1" charOffset="189-190"
            type="drug" text="Fe"/>
        <pair id="DDI-MedLine.d34.s12.p0" e1="DDI-MedLine.d34.s12.e0"
            e2="DDI-MedLine.d34.s12.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d39.s0" text="Effect of estradiol on endotoxin-induced changes in steroid hormone levels and lethality in male rats.">
        <entity id="DDI-MedLine.d39.s0.e0" charOffset="10-18"
            type="drug" text="estradiol"/>
        <entity id="DDI-MedLine.d39.s0.e1" charOffset="23-31"
            type="drug_n" text="endotoxin"/>
        <pair id="DDI-MedLine.d39.s0.p0" e1="DDI-MedLine.d39.s0.e0"
            e2="DDI-MedLine.d39.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d39.s1" text="We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin. ">
        <entity id="DDI-MedLine.d39.s1.e0" charOffset="36-44"
            type="drug" text="estradiol"/>
        <entity id="DDI-MedLine.d39.s1.e1" charOffset="141-149"
            type="drug_n" text="endotoxin"/>
        <entity id="DDI-MedLine.d39.s1.e2" charOffset="216-224"
            type="drug_n" text="endotoxin"/>
        <pair id="DDI-MedLine.d39.s1.p0" e1="DDI-MedLine.d39.s1.e0"
            e2="DDI-MedLine.d39.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d39.s1.p1" e1="DDI-MedLine.d39.s1.e0"
            e2="DDI-MedLine.d39.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d39.s1.p2" e1="DDI-MedLine.d39.s1.e1"
            e2="DDI-MedLine.d39.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d39.s2" text="Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin. ">
        <entity id="DDI-MedLine.d39.s2.e0" charOffset="13-21"
            type="drug" text="estradiol"/>
        <entity id="DDI-MedLine.d39.s2.e1" charOffset="56-64"
            type="drug_n" text="endotoxin"/>
        <entity id="DDI-MedLine.d39.s2.e2" charOffset="129-137"
            type="drug_n" text="endotoxin"/>
        <pair id="DDI-MedLine.d39.s2.p0" e1="DDI-MedLine.d39.s2.e0"
            e2="DDI-MedLine.d39.s2.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d39.s2.p1" e1="DDI-MedLine.d39.s2.e0"
            e2="DDI-MedLine.d39.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d39.s2.p2" e1="DDI-MedLine.d39.s2.e1"
            e2="DDI-MedLine.d39.s2.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d39.s3" text="The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold). ">
        <entity id="DDI-MedLine.d39.s3.e0" charOffset="37-45"
            type="drug" text="estradiol"/>
        <entity id="DDI-MedLine.d39.s3.e1" charOffset="49-57"
            type="drug_n" text="endotoxin"/>
        <entity id="DDI-MedLine.d39.s3.e2" charOffset="109-117"
            type="drug_n" text="endotoxin"/>
        <pair id="DDI-MedLine.d39.s3.p0" e1="DDI-MedLine.d39.s3.e0"
            e2="DDI-MedLine.d39.s3.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d39.s3.p1" e1="DDI-MedLine.d39.s3.e0"
            e2="DDI-MedLine.d39.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d39.s3.p2" e1="DDI-MedLine.d39.s3.e1"
            e2="DDI-MedLine.d39.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d39.s4" text="The serum androgen concentrations of estradiol + endotoxin-treated rats did not change significantly, while those of endotoxin-treated rats dropped to 30-40%">
        <entity id="DDI-MedLine.d39.s4.e0" charOffset="37-45"
            type="drug" text="estradiol"/>
        <entity id="DDI-MedLine.d39.s4.e1" charOffset="49-57"
            type="drug_n" text="endotoxin"/>
        <entity id="DDI-MedLine.d39.s4.e2" charOffset="117-125"
            type="drug_n" text="endotoxin"/>
        <pair id="DDI-MedLine.d39.s4.p0" e1="DDI-MedLine.d39.s4.e0"
            e2="DDI-MedLine.d39.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d39.s4.p1" e1="DDI-MedLine.d39.s4.e0"
            e2="DDI-MedLine.d39.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d39.s4.p2" e1="DDI-MedLine.d39.s4.e1"
            e2="DDI-MedLine.d39.s4.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d39.s5" text="0.001. "/>
    <sentence id="DDI-MedLine.d39.s6" text="Exogenous estradiol also appeared to influence the percentage of endotoxin-induced deaths in a dose-dependent manner. ">
        <entity id="DDI-MedLine.d39.s6.e0" charOffset="10-18"
            type="drug" text="estradiol"/>
        <entity id="DDI-MedLine.d39.s6.e1" charOffset="65-73"
            type="drug_n" text="endotoxin"/>
        <pair id="DDI-MedLine.d39.s6.p0" e1="DDI-MedLine.d39.s6.e0"
            e2="DDI-MedLine.d39.s6.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d39.s7" text="It reduced the number of deaths induced by nonlethal (2 mg/kg) dose of endotoxin but increased the number of deaths induced by a highly lethal dose (8 mg/kg). ">
        <entity id="DDI-MedLine.d39.s7.e0" charOffset="71-79"
            type="drug_n" text="endotoxin"/>
    </sentence>
    <sentence id="DDI-MedLine.d39.s8" text="These results, together with the known relationships between estrogen and the immune response, suggest that estrogens affect the course of septic shock in a complex fashion and may have either protective or deleterious effect.">
        <entity id="DDI-MedLine.d39.s8.e0" charOffset="61-68"
            type="group" text="estrogen"/>
        <entity id="DDI-MedLine.d39.s8.e1" charOffset="108-116"
            type="group" text="estrogens"/>
        <pair id="DDI-MedLine.d39.s8.p0" e1="DDI-MedLine.d39.s8.e0"
            e2="DDI-MedLine.d39.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d128.s0" text="Analysis of 16,16-dimethylprostaglandin E2-induced diarrhea in cecectomized rats.&#xd;&#xa;">
        <entity id="DDI-MedLine.d128.s0.e0" charOffset="12-41"
            type="drug_n" text="16,16-dimethylprostaglandin E2"/>
    </sentence>
    <sentence id="DDI-MedLine.d128.s1" text="The 16,16-dimethylprostaglandin E2 (dmPGE2)-induced diarrhea was analyzed in cecectomized rats prepared by resecting the cecum and its vasculature without disturbing the ileocecal junction. ">
        <entity id="DDI-MedLine.d128.s1.e0" charOffset="4-33"
            type="drug_n" text="16,16-dimethylprostaglandin E2"/>
        <entity id="DDI-MedLine.d128.s1.e1" charOffset="36-41"
            type="drug_n" text="dmPGE2"/>
        <pair id="DDI-MedLine.d128.s1.p0" e1="DDI-MedLine.d128.s1.e0"
            e2="DDI-MedLine.d128.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d128.s2" text="dmPGE2 (0.1-1.0 mg/kg, p.o.) ">
        <entity id="DDI-MedLine.d128.s2.e0" charOffset="0-5"
            type="drug_n" text="dmPGE2"/>
    </sentence>
    <sentence id="DDI-MedLine.d128.s3" text="dose-dependently increased the number of defecation episodes and induced a soft and watery stool in cecectomized rats. "/>
    <sentence id="DDI-MedLine.d128.s4" text="At 0.3 mg/kg, the diarrhea-inducing effects of dmPGE2 were more pronounced in cecectomized than in control rats. ">
        <entity id="DDI-MedLine.d128.s4.e0" charOffset="47-52"
            type="drug_n" text="dmPGE2"/>
    </sentence>
    <sentence id="DDI-MedLine.d128.s5" text="When given i.p., dmPGE2 (0.3 mg/kg) induced a watery stool in cecectomized and control rats with the same efficacy, although these effects were short-lasting as compared to oral administration. ">
        <entity id="DDI-MedLine.d128.s5.e0" charOffset="17-22"
            type="drug_n" text="dmPGE2"/>
    </sentence>
    <sentence id="DDI-MedLine.d128.s6" text="Castor oil (4 ml/kg, p.o.) ">
        <entity id="DDI-MedLine.d128.s6.e0" charOffset="0-9" type="drug" text="Castor oil"/>
    </sentence>
    <sentence id="DDI-MedLine.d128.s7" text="also induced diarrhea, but did not produce a watery stool in cecectomized rats. "/>
    <sentence id="DDI-MedLine.d128.s8" text="There were no differences between cecectomized and control rats in basal small intestinal transits or in dmPGE2 (0.3 mg/kg, p.o.)-induced enhancements. ">
        <entity id="DDI-MedLine.d128.s8.e0" charOffset="105-110"
            type="drug_n" text="dmPGE2"/>
    </sentence>
    <sentence id="DDI-MedLine.d128.s9" text="Moreover, the basal and dmPGE2-induced jejunal net fluid transfers were the same in cecectomized and in control rats. ">
        <entity id="DDI-MedLine.d128.s9.e0" charOffset="24-29"
            type="drug_n" text="dmPGE2"/>
    </sentence>
    <sentence id="DDI-MedLine.d128.s10" text="On the other hand, the enhanced secretion of colonic fluid by dmPGE2, given intraluminally, was only half of that in control rats, whereas the colonic transit-enhancing effect of dmPGE2 in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration. ">
        <entity id="DDI-MedLine.d128.s10.e0" charOffset="62-67"
            type="drug_n" text="dmPGE2"/>
        <entity id="DDI-MedLine.d128.s10.e1" charOffset="179-184"
            type="drug_n" text="dmPGE2"/>
        <pair id="DDI-MedLine.d128.s10.p0" e1="DDI-MedLine.d128.s10.e0"
            e2="DDI-MedLine.d128.s10.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d128.s11" text="The basal colonic fluid contents and transits were the same in cecectomized and in control rats. "/>
    <sentence id="DDI-MedLine.d128.s12" text="Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) ">
        <entity id="DDI-MedLine.d128.s12.e0" charOffset="0-9"
            type="drug" text="Loperamide"/>
        <entity id="DDI-MedLine.d128.s12.e1" charOffset="15-22"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d128.s12.p0" e1="DDI-MedLine.d128.s12.e0"
            e2="DDI-MedLine.d128.s12.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d128.s13" text="Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. ">
        <entity id="DDI-MedLine.d128.s13.e0" charOffset="0-9"
            type="drug" text="Loperamide"/>
        <entity id="DDI-MedLine.d128.s13.e1" charOffset="15-22"
            type="drug" text="morphine"/>
        <entity id="DDI-MedLine.d128.s13.e2" charOffset="64-69"
            type="drug_n" text="dmPGE2"/>
        <pair id="DDI-MedLine.d128.s13.p0" e1="DDI-MedLine.d128.s13.e0"
            e2="DDI-MedLine.d128.s13.e1" ddi="false"/>
        <pair id="DDI-MedLine.d128.s13.p1" e1="DDI-MedLine.d128.s13.e0"
            e2="DDI-MedLine.d128.s13.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d128.s13.p2" e1="DDI-MedLine.d128.s13.e1"
            e2="DDI-MedLine.d128.s13.e2" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d128.s14" text="N-methyllevallorphan (5 mg/kg, s.c.) ">
        <entity id="DDI-MedLine.d128.s14.e0" charOffset="0-19"
            type="drug_n" text="N-methyllevallorphan"/>
    </sentence>
    <sentence id="DDI-MedLine.d128.s15" text="N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine. ">
        <entity id="DDI-MedLine.d128.s15.e0" charOffset="0-19"
            type="drug_n" text="N-methyllevallorphan"/>
        <entity id="DDI-MedLine.d128.s15.e1" charOffset="85-94"
            type="drug" text="loperamide"/>
        <entity id="DDI-MedLine.d128.s15.e2" charOffset="133-140"
            type="drug" text="morphine"/>
        <pair id="DDI-MedLine.d128.s15.p0" e1="DDI-MedLine.d128.s15.e0"
            e2="DDI-MedLine.d128.s15.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d128.s15.p1" e1="DDI-MedLine.d128.s15.e0"
            e2="DDI-MedLine.d128.s15.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d128.s15.p2" e1="DDI-MedLine.d128.s15.e1"
            e2="DDI-MedLine.d128.s15.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d128.s16" text="These results suggest that oral administration of dmPGE2 induces a more pronounced secretory diarrhea in cecectomized than in control rats, probably due to the lack of the reservoir function of the cecum in the operated animals. ">
        <entity id="DDI-MedLine.d128.s16.e0" charOffset="50-55"
            type="drug_n" text="dmPGE2"/>
    </sentence>
    <sentence id="DDI-MedLine.d128.s17" text="This secretory diarrhea model is suitable for evaluating the antidiarrheal activity of drugs."/>
    <sentence id="DDI-MedLine.d89.s0" text="Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.&#xd;&#xa;">
        <entity id="DDI-MedLine.d89.s0.e0" charOffset="71-99"
            type="drug" text="99mTc-methylene diphosphonate"/>
        <entity id="DDI-MedLine.d89.s0.e1" charOffset="107-116"
            type="drug" text="gentamicin"/>
        <pair id="DDI-MedLine.d89.s0.p0" e1="DDI-MedLine.d89.s0.e0"
            e2="DDI-MedLine.d89.s0.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d89.s1" text="Gentamicin is an aminoglycoside antibiotic used to treat a wide variety of infections caused by gram-negative organisms, but it is potentially toxic to the kidneys. ">
        <entity id="DDI-MedLine.d89.s1.e0" charOffset="0-9" type="drug" text="Gentamicin"/>
        <entity id="DDI-MedLine.d89.s1.e1" charOffset="17-41"
            type="group" text="aminoglycoside antibiotic"/>
        <pair id="DDI-MedLine.d89.s1.p0" e1="DDI-MedLine.d89.s1.e0"
            e2="DDI-MedLine.d89.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d89.s2" text="Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy. ">
        <entity id="DDI-MedLine.d89.s2.e0" charOffset="27-36"
            type="drug" text="gentamicin"/>
        <entity id="DDI-MedLine.d89.s2.e1" charOffset="84-92"
            type="drug" text="99mTc-MDP"/>
        <pair id="DDI-MedLine.d89.s2.p0" e1="DDI-MedLine.d89.s2.e0"
            e2="DDI-MedLine.d89.s2.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d89.s3" text="The presence of the radiopharmaceutical in the kidneys, along with an increase in renal retention, tend to produce scintigraphic results that falsely identify characteristics related to diseases such as renal vascular, or urinary tract obstruction, and even renal cancer. ">
        <entity id="DDI-MedLine.d89.s3.e0" charOffset="20-38"
            type="group" text="radiopharmaceutical"/>
    </sentence>
    <sentence id="DDI-MedLine.d89.s4" text="An altered biodistribution may provide misleading information that can either mask or mimic certain disease symptoms. "/>
    <sentence id="DDI-MedLine.d89.s5" text="A method to maximize the therapeutic benefit of gentamicin while minimizing the risk of nephrotoxicity and the appearance of a hot kidney on scintigraphy is desirable. ">
        <entity id="DDI-MedLine.d89.s5.e0" charOffset="48-57"
            type="drug" text="gentamicin"/>
    </sentence>
    <sentence id="DDI-MedLine.d89.s6" text="Serial pharmacokinetic dosing has been proposed as a method to accomplish this goal. "/>
    <sentence id="DDI-MedLine.d89.s7" text="Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients. ">
        <entity id="DDI-MedLine.d89.s7.e0" charOffset="37-46"
            type="drug" text="gentamicin"/>
        <entity id="DDI-MedLine.d89.s7.e1" charOffset="89-97"
            type="drug" text="99mTc-MDP"/>
        <entity id="DDI-MedLine.d89.s7.e2" charOffset="106-124"
            type="group" text="radiopharmaceutical"/>
        <pair id="DDI-MedLine.d89.s7.p0" e1="DDI-MedLine.d89.s7.e0"
            e2="DDI-MedLine.d89.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d89.s7.p1" e1="DDI-MedLine.d89.s7.e0"
            e2="DDI-MedLine.d89.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d89.s7.p2" e1="DDI-MedLine.d89.s7.e1"
            e2="DDI-MedLine.d89.s7.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d89.s8" text="The data presented here demonstrate that with serial pharmacokinetic dosing of gentamicin, the iatrogenic alteration caused by gentamicin therapy can be avoided.">
        <entity id="DDI-MedLine.d89.s8.e0" charOffset="79-88"
            type="drug" text="gentamicin"/>
        <entity id="DDI-MedLine.d89.s8.e1" charOffset="127-136"
            type="drug" text="gentamicin"/>
        <pair id="DDI-MedLine.d89.s8.p0" e1="DDI-MedLine.d89.s8.e0"
            e2="DDI-MedLine.d89.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d11.s0" text="Immunosuppressive drugs and their complications.&#xd;&#xa;">
        <entity id="DDI-MedLine.d11.s0.e0" charOffset="0-22"
            type="group" text="Immunosuppressive drugs"/>
    </sentence>
    <sentence id="DDI-MedLine.d11.s1" text="Drugs that suppress the immune system are widely used. "/>
    <sentence id="DDI-MedLine.d11.s2" text="They are part of the treatment of patients with organ transplants, malignancy, and increasingly those with conditions such as psoriasis, rheumatoid arthritis, and liver and bowel disease in which inflammation is an aetiological factor. "/>
    <sentence id="DDI-MedLine.d11.s3" text="Because of the broadening indications for immunosuppressive drugs, and the prolonged survival in conditions for which they are being used, many patients on immunosuppression are now cared for in the community or seen in non-specialist hospitals, usually in close collaboration with a specialist. ">
        <entity id="DDI-MedLine.d11.s3.e0" charOffset="42-64"
            type="group" text="immunosuppressive drugs"/>
    </sentence>
    <sentence id="DDI-MedLine.d11.s4" text="This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. ">
        <entity id="DDI-MedLine.d11.s4.e0" charOffset="41-63"
            type="group" text="immunosuppressive drugs"/>
        <entity id="DDI-MedLine.d11.s4.e1" charOffset="74-88"
            type="group" text="corticosteroids"/>
        <entity id="DDI-MedLine.d11.s4.e2" charOffset="91-101"
            type="drug" text="cyclosporin"/>
        <entity id="DDI-MedLine.d11.s4.e3" charOffset="104-115"
            type="drug" text="azathioprine"/>
        <entity id="DDI-MedLine.d11.s4.e4" charOffset="118-129"
            type="drug" text="methotrexate"/>
        <entity id="DDI-MedLine.d11.s4.e5" charOffset="132-147"
            type="drug" text="cyclophosphamide"/>
        <pair id="DDI-MedLine.d11.s4.p0" e1="DDI-MedLine.d11.s4.e0"
            e2="DDI-MedLine.d11.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d11.s4.p1" e1="DDI-MedLine.d11.s4.e0"
            e2="DDI-MedLine.d11.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d11.s4.p2" e1="DDI-MedLine.d11.s4.e0"
            e2="DDI-MedLine.d11.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d11.s4.p3" e1="DDI-MedLine.d11.s4.e0"
            e2="DDI-MedLine.d11.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d11.s4.p4" e1="DDI-MedLine.d11.s4.e0"
            e2="DDI-MedLine.d11.s4.e5" ddi="false"/>
        <pair id="DDI-MedLine.d11.s4.p5" e1="DDI-MedLine.d11.s4.e1"
            e2="DDI-MedLine.d11.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d11.s4.p6" e1="DDI-MedLine.d11.s4.e1"
            e2="DDI-MedLine.d11.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d11.s4.p7" e1="DDI-MedLine.d11.s4.e1"
            e2="DDI-MedLine.d11.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d11.s4.p8" e1="DDI-MedLine.d11.s4.e1"
            e2="DDI-MedLine.d11.s4.e5" ddi="false"/>
        <pair id="DDI-MedLine.d11.s4.p9" e1="DDI-MedLine.d11.s4.e2"
            e2="DDI-MedLine.d11.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d11.s4.p10" e1="DDI-MedLine.d11.s4.e2"
            e2="DDI-MedLine.d11.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d11.s4.p11" e1="DDI-MedLine.d11.s4.e2"
            e2="DDI-MedLine.d11.s4.e5" ddi="false"/>
        <pair id="DDI-MedLine.d11.s4.p12" e1="DDI-MedLine.d11.s4.e3"
            e2="DDI-MedLine.d11.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d11.s4.p13" e1="DDI-MedLine.d11.s4.e3"
            e2="DDI-MedLine.d11.s4.e5" ddi="false"/>
        <pair id="DDI-MedLine.d11.s4.p14" e1="DDI-MedLine.d11.s4.e4"
            e2="DDI-MedLine.d11.s4.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d11.s5" text="The management of infection is dealt with as a separate section."/>
    <sentence id="DDI-MedLine.d107.s0" text="Interaction of the constituents of alcoholic beverages in the promotion of liver damage.&#xd;&#xa;"/>
    <sentence id="DDI-MedLine.d107.s1" text="Little has been studied of the adverse effects of the exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde, coexisting in the contents of alcoholic beverages. ">
        <entity id="DDI-MedLine.d107.s1.e0" charOffset="98-104"
            type="drug" text="ethanol"/>
        <entity id="DDI-MedLine.d107.s1.e1" charOffset="129-140"
            type="drug_n" text="acetaldehyde"/>
        <pair id="DDI-MedLine.d107.s1.p0" e1="DDI-MedLine.d107.s1.e0"
            e2="DDI-MedLine.d107.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d107.s2" text="Twenty four male Wistar rats were divided into four groups. "/>
    <sentence id="DDI-MedLine.d107.s3" text="Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; ">
        <entity id="DDI-MedLine.d107.s3.e0" charOffset="111-117"
            type="drug" text="ethanol"/>
        <entity id="DDI-MedLine.d107.s3.e1" charOffset="120-127"
            type="drug_n" text="methanol"/>
        <entity id="DDI-MedLine.d107.s3.e2" charOffset="137-144"
            type="drug_n" text="alcohols"/>
        <entity id="DDI-MedLine.d107.s3.e3" charOffset="150-161"
            type="drug_n" text="acetaldehyde"/>
        <pair id="DDI-MedLine.d107.s3.p0" e1="DDI-MedLine.d107.s3.e0"
            e2="DDI-MedLine.d107.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d107.s3.p1" e1="DDI-MedLine.d107.s3.e0"
            e2="DDI-MedLine.d107.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d107.s3.p2" e1="DDI-MedLine.d107.s3.e0"
            e2="DDI-MedLine.d107.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d107.s3.p3" e1="DDI-MedLine.d107.s3.e1"
            e2="DDI-MedLine.d107.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d107.s3.p4" e1="DDI-MedLine.d107.s3.e1"
            e2="DDI-MedLine.d107.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d107.s3.p5" e1="DDI-MedLine.d107.s3.e2"
            e2="DDI-MedLine.d107.s3.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d107.s4" text="the third group (SH/EA) was treated with a hydroalcoholic solution of ethanol; ">
        <entity id="DDI-MedLine.d107.s4.e0" charOffset="70-76"
            type="drug" text="ethanol"/>
    </sentence>
    <sentence id="DDI-MedLine.d107.s5" text="the fourth group served as control and received an equivalent volume of an isocaloric solution of dextrose. ">
        <entity id="DDI-MedLine.d107.s5.e0" charOffset="98-105"
            type="drug" text="dextrose"/>
    </sentence>
    <sentence id="DDI-MedLine.d107.s6" text="All the animals were killed at the end of the 9th week of the experiment. "/>
    <sentence id="DDI-MedLine.d107.s7" text="The ratio between the liver weight and body weight was found to be lower in the treated animals than in the control group. "/>
    <sentence id="DDI-MedLine.d107.s8" text="The histology of the liver was altered in the three groups which were submitted to treatment with the hydroalcoholic solutions, with quantitative and qualitative differences between the groups. "/>
    <sentence id="DDI-MedLine.d107.s9" text="These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde; ">
        <entity id="DDI-MedLine.d107.s9.e0" charOffset="47-53"
            type="drug" text="ethanol"/>
        <entity id="DDI-MedLine.d107.s9.e1" charOffset="128-139"
            type="drug_n" text="acetaldehyde"/>
        <pair id="DDI-MedLine.d107.s9.p0" e1="DDI-MedLine.d107.s9.e0"
            e2="DDI-MedLine.d107.s9.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d107.s10" text="they also suggest that alcoholic beverages are not equivalent in their potential to cause liver damage."/>
    <sentence id="DDI-MedLine.d53.s0" text="Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens.&#xd;&#xa;">
        <entity id="DDI-MedLine.d53.s0.e0" charOffset="61-69"
            type="group" text="vitamin D"/>
        <entity id="DDI-MedLine.d53.s0.e1" charOffset="75-87"
            type="group" text="antiestrogens"/>
        <pair id="DDI-MedLine.d53.s0.p0" e1="DDI-MedLine.d53.s0.e0"
            e2="DDI-MedLine.d53.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d53.s1" text="1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. ">
        <entity id="DDI-MedLine.d53.s1.e0" charOffset="2-31" type="drug" text="25-Dihydroxycholecalciferol D3"/>
        <entity id="DDI-MedLine.d53.s1.e1" charOffset="34-44"
            type="drug" text="1,25(OH)2D3"/>
        <entity id="DDI-MedLine.d53.s1.e2" charOffset="73-81"
            type="group" text="vitamin D"/>
        <pair id="DDI-MedLine.d53.s1.p0" e1="DDI-MedLine.d53.s1.e0"
            e2="DDI-MedLine.d53.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d53.s1.p1" e1="DDI-MedLine.d53.s1.e0"
            e2="DDI-MedLine.d53.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d53.s1.p2" e1="DDI-MedLine.d53.s1.e1"
            e2="DDI-MedLine.d53.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d53.s2" text="We have shown that MCF-7 cells treated with 100 nM 1,25(OH)2D3 exhibit characteristic apoptotic morphology (pyknotic nuclei, chromatin and cytoplasmic condensation, nuclear matrix protein reorganization) within 48 h. ">
        <entity id="DDI-MedLine.d53.s2.e0" charOffset="51-61"
            type="drug" text="1,25(OH)2D3"/>
    </sentence>
    <sentence id="DDI-MedLine.d53.s3" text="In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. ">
        <entity id="DDI-MedLine.d53.s3.e0" charOffset="71-81"
            type="drug" text="1,25(OH)2D3"/>
        <entity id="DDI-MedLine.d53.s3.e1" charOffset="91-102"
            type="group" text="antiestrogen"/>
        <entity id="DDI-MedLine.d53.s3.e2" charOffset="104-121"
            type="drug_n" text="4-hydroxytamoxifen"/>
        <entity id="DDI-MedLine.d53.s3.e3" charOffset="124-126"
            type="drug_n" text="TAM"/>
        <pair id="DDI-MedLine.d53.s3.p0" e1="DDI-MedLine.d53.s3.e0"
            e2="DDI-MedLine.d53.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d53.s3.p1" e1="DDI-MedLine.d53.s3.e0"
            e2="DDI-MedLine.d53.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d53.s3.p2" e1="DDI-MedLine.d53.s3.e0"
            e2="DDI-MedLine.d53.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d53.s3.p3" e1="DDI-MedLine.d53.s3.e1"
            e2="DDI-MedLine.d53.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d53.s3.p4" e1="DDI-MedLine.d53.s3.e1"
            e2="DDI-MedLine.d53.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d53.s3.p5" e1="DDI-MedLine.d53.s3.e2"
            e2="DDI-MedLine.d53.s3.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d53.s4" text="Our data suggest that TAM significantly potentiates the reduction in cell number induced by 1,25(OH)2D3 alone. ">
        <entity id="DDI-MedLine.d53.s4.e0" charOffset="22-24"
            type="drug_n" text="TAM"/>
        <entity id="DDI-MedLine.d53.s4.e1" charOffset="92-102"
            type="drug" text="1,25(OH)2D3"/>
        <pair id="DDI-MedLine.d53.s4.p0" e1="DDI-MedLine.d53.s4.e0"
            e2="DDI-MedLine.d53.s4.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d53.s5" text="Combined treatment with 1,25(OH)2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation. ">
        <entity id="DDI-MedLine.d53.s5.e0" charOffset="24-34"
            type="drug" text="1,25(OH)2D3"/>
        <entity id="DDI-MedLine.d53.s5.e1" charOffset="40-42"
            type="drug_n" text="TAM"/>
        <pair id="DDI-MedLine.d53.s5.p0" e1="DDI-MedLine.d53.s5.e0"
            e2="DDI-MedLine.d53.s5.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d53.s6" text="We have selected a subclone of MCF-7 cells resistant to 1,25(OH)2D3 (MCF-7D3Res). ">
        <entity id="DDI-MedLine.d53.s6.e0" charOffset="56-66"
            type="drug" text="1,25(OH)2D3"/>
    </sentence>
    <sentence id="DDI-MedLine.d53.s7" text="These cells express the vitamin D receptor and exhibit doubling times comparable to the parental MCF-7 cells, even when grown in 100 mM 1,25(OH)2D3. ">
        <entity id="DDI-MedLine.d53.s7.e0" charOffset="136-146"
            type="drug" text="1,25(OH)2D3"/>
    </sentence>
    <sentence id="DDI-MedLine.d53.s8" text="Treatment of both parental and resistant MCF-7 cells with TAM induces apoptosis and clusterin. ">
        <entity id="DDI-MedLine.d53.s8.e0" charOffset="58-60"
            type="drug_n" text="TAM"/>
    </sentence>
    <sentence id="DDI-MedLine.d53.s9" text="These data emphasize that apoptosis can be induced in MCF-7 cells either by activation of vitamin-D-mediated signalling or disruption of estrogen-dependent signalling.">
        <entity id="DDI-MedLine.d53.s9.e0" charOffset="90-98"
            type="group" text="vitamin-D"/>
        <entity id="DDI-MedLine.d53.s9.e1" charOffset="137-144"
            type="group" text="estrogen"/>
        <pair id="DDI-MedLine.d53.s9.p0" e1="DDI-MedLine.d53.s9.e0"
            e2="DDI-MedLine.d53.s9.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d6.s0" text="Pharmacokinetic profile of etodolac in special populations.&#xa;">
        <entity id="DDI-MedLine.d6.s0.e0" charOffset="27-34" type="drug" text="etodolac"/>
    </sentence>
    <sentence id="DDI-MedLine.d6.s1" text="The pharmacokinetics of etodolac in healthy normal volunteers has been extensively studied and is well described. ">
        <entity id="DDI-MedLine.d6.s1.e0" charOffset="24-31" type="drug" text="etodolac"/>
    </sentence>
    <sentence id="DDI-MedLine.d6.s2" text="Etodolac is characterised by a high oral bioavailability, low clearance, a small volume of distribution, and a 7-hour half-life. ">
        <entity id="DDI-MedLine.d6.s2.e0" charOffset="0-7" type="drug" text="Etodolac"/>
    </sentence>
    <sentence id="DDI-MedLine.d6.s3" text="It is essentially completely metabolised, therefore little is excreted unchanged. "/>
    <sentence id="DDI-MedLine.d6.s4" text="Etodolac is highly protein bound. ">
        <entity id="DDI-MedLine.d6.s4.e0" charOffset="0-7" type="drug" text="Etodolac"/>
    </sentence>
    <sentence id="DDI-MedLine.d6.s5" text="To investigate the effect of disease states or concomitant drug administration on a patient's response to etodolac, additional pharmacokinetic studies were carried out in special populations. ">
        <entity id="DDI-MedLine.d6.s5.e0" charOffset="106-113"
            type="drug" text="etodolac"/>
    </sentence>
    <sentence id="DDI-MedLine.d6.s6" text="Since etodolac has a well-defined pharmacokinetic-pharmacodynamic relationship, measurement of pharmacokinetic parameters is clinically relevant. ">
        <entity id="DDI-MedLine.d6.s6.e0" charOffset="6-13" type="drug" text="etodolac"/>
    </sentence>
    <sentence id="DDI-MedLine.d6.s7" text="Data from studies to date show that disease states, underlying conditions, and concomitantly administered highly protein-bound drugs have essentially no effect on etodolac pharmacokinetics. ">
        <entity id="DDI-MedLine.d6.s7.e0" charOffset="163-170"
            type="drug" text="etodolac"/>
    </sentence>
    <sentence id="DDI-MedLine.d6.s8" text="Therefore, etodolac can generally be given without the need for dosage modifications in special populations such as uncompromised elderly patients, those with moderate renal impairment, and patients with stable hepatic disease.">
        <entity id="DDI-MedLine.d6.s8.e0" charOffset="11-18" type="drug" text="etodolac"/>
    </sentence>
    <sentence id="DDI-MedLine.d51.s0" text="Effects of xanthine derivatives in a light/dark test in mice and the contribution of adenosine receptors.&#xd;&#xa;">
        <entity id="DDI-MedLine.d51.s0.e0" charOffset="11-30"
            type="group" text="xanthine derivatives"/>
    </sentence>
    <sentence id="DDI-MedLine.d51.s1" text="We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. ">
        <entity id="DDI-MedLine.d51.s1.e0" charOffset="63-70"
            type="drug" text="caffeine"/>
        <entity id="DDI-MedLine.d51.s1.e1" charOffset="73-84"
            type="drug" text="theophylline"/>
        <entity id="DDI-MedLine.d51.s1.e2" charOffset="87-106"
            type="drug_n" text="8-phenyltheophylline"/>
        <entity id="DDI-MedLine.d51.s1.e3" charOffset="113-146"
            type="drug_n" text="8-cyclopentyl-1,3-dipropylxanthine"/>
        <entity id="DDI-MedLine.d51.s1.e4" charOffset="149-153"
            type="drug_n" text="DPCPX"/>
        <pair id="DDI-MedLine.d51.s1.p0" e1="DDI-MedLine.d51.s1.e0"
            e2="DDI-MedLine.d51.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d51.s1.p1" e1="DDI-MedLine.d51.s1.e0"
            e2="DDI-MedLine.d51.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d51.s1.p2" e1="DDI-MedLine.d51.s1.e0"
            e2="DDI-MedLine.d51.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d51.s1.p3" e1="DDI-MedLine.d51.s1.e0"
            e2="DDI-MedLine.d51.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d51.s1.p4" e1="DDI-MedLine.d51.s1.e1"
            e2="DDI-MedLine.d51.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d51.s1.p5" e1="DDI-MedLine.d51.s1.e1"
            e2="DDI-MedLine.d51.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d51.s1.p6" e1="DDI-MedLine.d51.s1.e1"
            e2="DDI-MedLine.d51.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d51.s1.p7" e1="DDI-MedLine.d51.s1.e2"
            e2="DDI-MedLine.d51.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d51.s1.p8" e1="DDI-MedLine.d51.s1.e2"
            e2="DDI-MedLine.d51.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d51.s1.p9" e1="DDI-MedLine.d51.s1.e3"
            e2="DDI-MedLine.d51.s1.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d51.s2" text="All antagonists decreased the time spent in the light zone in this test, which suggested that these compounds have anxiogenic effects. "/>
    <sentence id="DDI-MedLine.d51.s3" text="The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. ">
        <entity id="DDI-MedLine.d51.s3.e0" charOffset="26-37"
            type="drug" text="theophylline"/>
        <entity id="DDI-MedLine.d51.s3.e1" charOffset="73-81"
            type="drug_n" text="CGS 21680"/>
        <entity id="DDI-MedLine.d51.s3.e2" charOffset="120-142"
            type="drug_n" text="N6-cyclopentyladenosine"/>
        <entity id="DDI-MedLine.d51.s3.e3" charOffset="145-147"
            type="drug_n" text="CPA"/>
        <pair id="DDI-MedLine.d51.s3.p0" e1="DDI-MedLine.d51.s3.e0"
            e2="DDI-MedLine.d51.s3.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d51.s3.p1" e1="DDI-MedLine.d51.s3.e0"
            e2="DDI-MedLine.d51.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d51.s3.p2" e1="DDI-MedLine.d51.s3.e0"
            e2="DDI-MedLine.d51.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d51.s3.p3" e1="DDI-MedLine.d51.s3.e1"
            e2="DDI-MedLine.d51.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d51.s3.p4" e1="DDI-MedLine.d51.s3.e1"
            e2="DDI-MedLine.d51.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d51.s3.p5" e1="DDI-MedLine.d51.s3.e2"
            e2="DDI-MedLine.d51.s3.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d51.s4" text="However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. ">
        <entity id="DDI-MedLine.d51.s4.e0" charOffset="31-42"
            type="drug" text="theophylline"/>
        <entity id="DDI-MedLine.d51.s4.e1" charOffset="74-81"
            type="drug_n" text="CGS21680"/>
        <entity id="DDI-MedLine.d51.s4.e2" charOffset="142-146"
            type="drug_n" text="DPCPX"/>
        <entity id="DDI-MedLine.d51.s4.e3" charOffset="200-208"
            type="drug" text="CGS 21680"/>
        <entity id="DDI-MedLine.d51.s4.e4" charOffset="217-219"
            type="drug_n" text="CPA"/>
        <pair id="DDI-MedLine.d51.s4.p0" e1="DDI-MedLine.d51.s4.e0"
            e2="DDI-MedLine.d51.s4.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d51.s4.p1" e1="DDI-MedLine.d51.s4.e0"
            e2="DDI-MedLine.d51.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d51.s4.p2" e1="DDI-MedLine.d51.s4.e0"
            e2="DDI-MedLine.d51.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d51.s4.p3" e1="DDI-MedLine.d51.s4.e0"
            e2="DDI-MedLine.d51.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d51.s4.p4" e1="DDI-MedLine.d51.s4.e1"
            e2="DDI-MedLine.d51.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d51.s4.p5" e1="DDI-MedLine.d51.s4.e1"
            e2="DDI-MedLine.d51.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d51.s4.p6" e1="DDI-MedLine.d51.s4.e1"
            e2="DDI-MedLine.d51.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d51.s4.p7" e1="DDI-MedLine.d51.s4.e2"
            e2="DDI-MedLine.d51.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d51.s4.p8" e1="DDI-MedLine.d51.s4.e2"
            e2="DDI-MedLine.d51.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d51.s4.p9" e1="DDI-MedLine.d51.s4.e3"
            e2="DDI-MedLine.d51.s4.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d51.s5" text="Finally, it is notable that xanthine-derived adenosine antagonists tested here commonly showed anxiogenic effects in the light/dark test in mice. "/>
    <sentence id="DDI-MedLine.d51.s6" text="It is suggested that there is a minor contribution of adenosine receptors to these effects, although theophylline-induced anxiogenic effects were antagonized by an A2 receptor agonist.">
        <entity id="DDI-MedLine.d51.s6.e0" charOffset="101-112"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-MedLine.d4.s0" text="[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. ">
        <entity id="DDI-MedLine.d4.s0.e0" charOffset="15-24"
            type="brand" text="sandimmune"/>
        <entity id="DDI-MedLine.d4.s0.e1" charOffset="118-133"
            type="group" text="immunodepressant"/>
        <entity id="DDI-MedLine.d4.s0.e2" charOffset="145-154"
            type="brand" text="sandimmune"/>
        <pair id="DDI-MedLine.d4.s0.p0" e1="DDI-MedLine.d4.s0.e0"
            e2="DDI-MedLine.d4.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d4.s0.p1" e1="DDI-MedLine.d4.s0.e0"
            e2="DDI-MedLine.d4.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d4.s0.p2" e1="DDI-MedLine.d4.s0.e1"
            e2="DDI-MedLine.d4.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d4.s1" text="The agent was found to produce some inhibiting activity against hepatic microsomal 7-ethoxycoumarine deethylase in male Wistar rats in vitro and in vivo experiments. "/>
    <sentence id="DDI-MedLine.d4.s2" text="When given in a dose of 50 mg/kg, sandimmune produced no statistically significant effect on the duration of hexanal-induced sleep in mice. ">
        <entity id="DDI-MedLine.d4.s2.e0" charOffset="34-43"
            type="brand" text="sandimmune"/>
    </sentence>
    <sentence id="DDI-MedLine.d4.s3" text="The findings suggest that the agent has slight effects on the tested activities."/>
    <sentence id="DDI-MedLine.d68.s0" text="[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ">
        <entity id="DDI-MedLine.d68.s0.e0" charOffset="15-24"
            type="drug" text="cimetidine"/>
        <entity id="DDI-MedLine.d68.s0.e1" charOffset="52-61"
            type="drug" text="verografin"/>
        <entity id="DDI-MedLine.d68.s0.e2" charOffset="67-74"
            type="drug" text="iodamide"/>
        <entity id="DDI-MedLine.d68.s0.e3" charOffset="114-123"
            type="drug" text="cimetidine"/>
        <entity id="DDI-MedLine.d68.s0.e4" charOffset="156-166"
            type="drug" text="verografine"/>
        <entity id="DDI-MedLine.d68.s0.e5" charOffset="172-179"
            type="drug" text="iodamide"/>
        <pair id="DDI-MedLine.d68.s0.p0" e1="DDI-MedLine.d68.s0.e0"
            e2="DDI-MedLine.d68.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d68.s0.p1" e1="DDI-MedLine.d68.s0.e0"
            e2="DDI-MedLine.d68.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d68.s0.p2" e1="DDI-MedLine.d68.s0.e0"
            e2="DDI-MedLine.d68.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d68.s0.p3" e1="DDI-MedLine.d68.s0.e0"
            e2="DDI-MedLine.d68.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d68.s0.p4" e1="DDI-MedLine.d68.s0.e0"
            e2="DDI-MedLine.d68.s0.e5" ddi="false"/>
        <pair id="DDI-MedLine.d68.s0.p5" e1="DDI-MedLine.d68.s0.e1"
            e2="DDI-MedLine.d68.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d68.s0.p6" e1="DDI-MedLine.d68.s0.e1"
            e2="DDI-MedLine.d68.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d68.s0.p7" e1="DDI-MedLine.d68.s0.e1"
            e2="DDI-MedLine.d68.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d68.s0.p8" e1="DDI-MedLine.d68.s0.e1"
            e2="DDI-MedLine.d68.s0.e5" ddi="false"/>
        <pair id="DDI-MedLine.d68.s0.p9" e1="DDI-MedLine.d68.s0.e2"
            e2="DDI-MedLine.d68.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d68.s0.p10" e1="DDI-MedLine.d68.s0.e2"
            e2="DDI-MedLine.d68.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d68.s0.p11" e1="DDI-MedLine.d68.s0.e2"
            e2="DDI-MedLine.d68.s0.e5" ddi="false"/>
        <pair id="DDI-MedLine.d68.s0.p12" e1="DDI-MedLine.d68.s0.e3"
            e2="DDI-MedLine.d68.s0.e4" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d68.s0.p13" e1="DDI-MedLine.d68.s0.e3"
            e2="DDI-MedLine.d68.s0.e5" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d68.s0.p14" e1="DDI-MedLine.d68.s0.e4"
            e2="DDI-MedLine.d68.s0.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d68.s1" text="The higher verografine and iodamide excretion was due to their increased renal tubular secretion. ">
        <entity id="DDI-MedLine.d68.s1.e0" charOffset="11-21"
            type="drug" text="verografine"/>
        <entity id="DDI-MedLine.d68.s1.e1" charOffset="27-34"
            type="drug" text="iodamide"/>
        <pair id="DDI-MedLine.d68.s1.p0" e1="DDI-MedLine.d68.s1.e0"
            e2="DDI-MedLine.d68.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d68.s2" text="In dogs, cimetidine unchanged the secretion of cardiotrast, a test agent for anionic transport. ">
        <entity id="DDI-MedLine.d68.s2.e0" charOffset="9-18" type="drug" text="cimetidine"/>
        <entity id="DDI-MedLine.d68.s2.e1" charOffset="47-57"
            type="drug" text="cardiotrast"/>
        <pair id="DDI-MedLine.d68.s2.p0" e1="DDI-MedLine.d68.s2.e0"
            e2="DDI-MedLine.d68.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d68.s3" text="Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.">
        <entity id="DDI-MedLine.d68.s3.e0" charOffset="44-53"
            type="drug" text="cimetidine"/>
        <entity id="DDI-MedLine.d68.s3.e1" charOffset="58-68"
            type="drug" text="verografine"/>
        <entity id="DDI-MedLine.d68.s3.e2" charOffset="74-81"
            type="drug" text="iodamide"/>
        <pair id="DDI-MedLine.d68.s3.p0" e1="DDI-MedLine.d68.s3.e0"
            e2="DDI-MedLine.d68.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d68.s3.p1" e1="DDI-MedLine.d68.s3.e0"
            e2="DDI-MedLine.d68.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d68.s3.p2" e1="DDI-MedLine.d68.s3.e1"
            e2="DDI-MedLine.d68.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d121.s0" text="[Hippocampus as interaction sites between cerebral memory systems]&#xa;Most of the current theories assume that there are multiple forms of memory that are supported by separate brain systems and have different characteristics. "/>
    <sentence id="DDI-MedLine.d121.s1" text="Animals studies on the various dual-memory theories have been carried out mainly on the basis of hippocampal system function. "/>
    <sentence id="DDI-MedLine.d121.s2" text="Specifically, they have focused on aspects of learning and memory that are impaired (vs. spared) by lesions of the hippocampal formation. "/>
    <sentence id="DDI-MedLine.d121.s3" text="However, there are several instances in the animal literature showing that hippocampal lesions actually produced enhanced learning and memory function. "/>
    <sentence id="DDI-MedLine.d121.s4" text="Moreover, the acquisition of tasks that are facilitated by hippocampal lesions (or dysfunction) is nevertheless associated, in intact subjects, with specific neurobiological alterations in the hippocampus. "/>
    <sentence id="DDI-MedLine.d121.s5" text="This problem has been analysed using two different tasks in mice: a bar-press conditioning and a spatial discrimination task. "/>
    <sentence id="DDI-MedLine.d121.s6" text="Results showed that, depending on the task considered, the same pharmacological treatment produced either a facilitation or an impairment of acquisition. "/>
    <sentence id="DDI-MedLine.d121.s7" text="Moreover, each task induced significant alterations in hippocampal adenylate cyclase activity but in opposite directions. "/>
    <sentence id="DDI-MedLine.d121.s8" text="Together with previous findings, these results suggest that the hippocampus is involved in both the so-called &quot;hippocampal-dependent&quot;"/>
    <sentence id="DDI-MedLine.d121.s9" text="&quot;hippocampal-independent&quot; "/>
    <sentence id="DDI-MedLine.d121.s10" text="forms of memory. "/>
    <sentence id="DDI-MedLine.d121.s11" text="It is postulated that some of the observed training-induced neurobiological alterations might reflect the interaction between two (or more) competing memory systems at the hippocampal level. "/>
    <sentence id="DDI-MedLine.d121.s12" text="Thus, in addition to its proposed specific information processing functions (i.e., relational), the hippocampus would play a role in addressing information to the brain memory system that, in a given situation, has the best adaptive value.(ABSTRACT TRUNCATED AT 250 WORDS)"/>
    <sentence id="DDI-MedLine.d103.s0" text="Magnesium and therapeutics.&#xd;&#xa;">
        <entity id="DDI-MedLine.d103.s0.e0" charOffset="0-8" type="drug" text="Magnesium"/>
    </sentence>
    <sentence id="DDI-MedLine.d103.s1" text="Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. ">
        <entity id="DDI-MedLine.d103.s1.e0" charOffset="36-44"
            type="drug" text="magnesium"/>
        <entity id="DDI-MedLine.d103.s1.e1" charOffset="75-83"
            type="drug" text="magnesium"/>
        <entity id="DDI-MedLine.d103.s1.e2" charOffset="144-152"
            type="drug" text="magnesium"/>
        <entity id="DDI-MedLine.d103.s1.e3" charOffset="193-201"
            type="drug" text="magnesium"/>
        <entity id="DDI-MedLine.d103.s1.e4" charOffset="230-238"
            type="drug" text="magnesium"/>
        <entity id="DDI-MedLine.d103.s1.e5" charOffset="302-310"
            type="drug" text="magnesium"/>
        <pair id="DDI-MedLine.d103.s1.p0" e1="DDI-MedLine.d103.s1.e0"
            e2="DDI-MedLine.d103.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d103.s1.p1" e1="DDI-MedLine.d103.s1.e0"
            e2="DDI-MedLine.d103.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d103.s1.p2" e1="DDI-MedLine.d103.s1.e0"
            e2="DDI-MedLine.d103.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d103.s1.p3" e1="DDI-MedLine.d103.s1.e0"
            e2="DDI-MedLine.d103.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d103.s1.p4" e1="DDI-MedLine.d103.s1.e0"
            e2="DDI-MedLine.d103.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d103.s1.p5" e1="DDI-MedLine.d103.s1.e1"
            e2="DDI-MedLine.d103.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d103.s1.p6" e1="DDI-MedLine.d103.s1.e1"
            e2="DDI-MedLine.d103.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d103.s1.p7" e1="DDI-MedLine.d103.s1.e1"
            e2="DDI-MedLine.d103.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d103.s1.p8" e1="DDI-MedLine.d103.s1.e1"
            e2="DDI-MedLine.d103.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d103.s1.p9" e1="DDI-MedLine.d103.s1.e2"
            e2="DDI-MedLine.d103.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d103.s1.p10" e1="DDI-MedLine.d103.s1.e2"
            e2="DDI-MedLine.d103.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d103.s1.p11" e1="DDI-MedLine.d103.s1.e2"
            e2="DDI-MedLine.d103.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d103.s1.p12" e1="DDI-MedLine.d103.s1.e3"
            e2="DDI-MedLine.d103.s1.e4" ddi="false"/>
        <pair id="DDI-MedLine.d103.s1.p13" e1="DDI-MedLine.d103.s1.e3"
            e2="DDI-MedLine.d103.s1.e5" ddi="false"/>
        <pair id="DDI-MedLine.d103.s1.p14" e1="DDI-MedLine.d103.s1.e4"
            e2="DDI-MedLine.d103.s1.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d103.s2" text="Primary and secondary magnesium deficiencies constitute the sole indication of physiological oral magnesium therapy. ">
        <entity id="DDI-MedLine.d103.s2.e0" charOffset="22-30"
            type="drug" text="magnesium"/>
        <entity id="DDI-MedLine.d103.s2.e1" charOffset="98-106"
            type="drug" text="magnesium"/>
        <pair id="DDI-MedLine.d103.s2.p0" e1="DDI-MedLine.d103.s2.e0"
            e2="DDI-MedLine.d103.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d103.s3" text="It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. ">
        <entity id="DDI-MedLine.d103.s3.e0" charOffset="94-102"
            type="drug" text="magnesium"/>
        <entity id="DDI-MedLine.d103.s3.e1" charOffset="140-148"
            type="drug" text="magnesium"/>
        <entity id="DDI-MedLine.d103.s3.e2" charOffset="184-192"
            type="drug" text="magnesium"/>
        <entity id="DDI-MedLine.d103.s3.e3" charOffset="260-268"
            type="drug" text="magnesium"/>
        <entity id="DDI-MedLine.d103.s3.e4" charOffset="336-344"
            type="drug" text="magnesium"/>
        <pair id="DDI-MedLine.d103.s3.p0" e1="DDI-MedLine.d103.s3.e0"
            e2="DDI-MedLine.d103.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d103.s3.p1" e1="DDI-MedLine.d103.s3.e0"
            e2="DDI-MedLine.d103.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d103.s3.p2" e1="DDI-MedLine.d103.s3.e0"
            e2="DDI-MedLine.d103.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d103.s3.p3" e1="DDI-MedLine.d103.s3.e0"
            e2="DDI-MedLine.d103.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d103.s3.p4" e1="DDI-MedLine.d103.s3.e1"
            e2="DDI-MedLine.d103.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d103.s3.p5" e1="DDI-MedLine.d103.s3.e1"
            e2="DDI-MedLine.d103.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d103.s3.p6" e1="DDI-MedLine.d103.s3.e1"
            e2="DDI-MedLine.d103.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d103.s3.p7" e1="DDI-MedLine.d103.s3.e2"
            e2="DDI-MedLine.d103.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d103.s3.p8" e1="DDI-MedLine.d103.s3.e2"
            e2="DDI-MedLine.d103.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d103.s3.p9" e1="DDI-MedLine.d103.s3.e3"
            e2="DDI-MedLine.d103.s3.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d103.s4" text="Physiological oral magnesium load constitutes the best tool for diagnosis of magnesium deficiency and the first step of its treatment. ">
        <entity id="DDI-MedLine.d103.s4.e0" charOffset="19-27"
            type="drug" text="magnesium"/>
        <entity id="DDI-MedLine.d103.s4.e1" charOffset="77-85"
            type="drug" text="magnesium"/>
        <pair id="DDI-MedLine.d103.s4.p0" e1="DDI-MedLine.d103.s4.e0"
            e2="DDI-MedLine.d103.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d103.s5" text="Physiological oral magnesium supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with magnesium salts, with practically only one contra-indication: overt renal failure. ">
        <entity id="DDI-MedLine.d103.s5.e0" charOffset="19-27"
            type="drug" text="magnesium"/>
        <entity id="DDI-MedLine.d103.s5.e1" charOffset="110-123"
            type="drug" text="magnesium salt"/>
        <pair id="DDI-MedLine.d103.s5.p0" e1="DDI-MedLine.d103.s5.e0"
            e2="DDI-MedLine.d103.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d103.s6" text="Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. ">
        <entity id="DDI-MedLine.d103.s6.e0" charOffset="37-45"
            type="drug" text="magnesium"/>
        <entity id="DDI-MedLine.d103.s6.e1" charOffset="86-112"
            type="group" text="magnesium sparing diuretics"/>
        <entity id="DDI-MedLine.d103.s6.e2" charOffset="140-149"
            type="drug" text="vitamin B6"/>
        <entity id="DDI-MedLine.d103.s6.e3" charOffset="175-183"
            type="group" text="vitamin D"/>
        <entity id="DDI-MedLine.d103.s6.e4" charOffset="192-199"
            type="drug" text="selenium"/>
        <pair id="DDI-MedLine.d103.s6.p0" e1="DDI-MedLine.d103.s6.e0"
            e2="DDI-MedLine.d103.s6.e1" ddi="false"/>
        <pair id="DDI-MedLine.d103.s6.p1" e1="DDI-MedLine.d103.s6.e0"
            e2="DDI-MedLine.d103.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d103.s6.p2" e1="DDI-MedLine.d103.s6.e0"
            e2="DDI-MedLine.d103.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d103.s6.p3" e1="DDI-MedLine.d103.s6.e0"
            e2="DDI-MedLine.d103.s6.e4" ddi="false"/>
        <pair id="DDI-MedLine.d103.s6.p4" e1="DDI-MedLine.d103.s6.e1"
            e2="DDI-MedLine.d103.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d103.s6.p5" e1="DDI-MedLine.d103.s6.e1"
            e2="DDI-MedLine.d103.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d103.s6.p6" e1="DDI-MedLine.d103.s6.e1"
            e2="DDI-MedLine.d103.s6.e4" ddi="false"/>
        <pair id="DDI-MedLine.d103.s6.p7" e1="DDI-MedLine.d103.s6.e2"
            e2="DDI-MedLine.d103.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d103.s6.p8" e1="DDI-MedLine.d103.s6.e2"
            e2="DDI-MedLine.d103.s6.e4" ddi="false"/>
        <pair id="DDI-MedLine.d103.s6.p9" e1="DDI-MedLine.d103.s6.e3"
            e2="DDI-MedLine.d103.s6.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d103.s7" text="In order to use the pharmacological properties of induced therapeutic hypermagnesaemia, high oral doses of magnesium (> 10 mg/kg/day) are advisable for chronic indications and the parenteral route is suitable for acute indications. ">
        <entity id="DDI-MedLine.d103.s7.e0" charOffset="107-115"
            type="drug" text="magnesium"/>
    </sentence>
    <sentence id="DDI-MedLine.d103.s8" text="There are 3 types of indications: specific (for the treatment of some forms of magnesium deficit i.e. acute), pharmacological (i.e. without alterations of magnesium status) and mixed--pharmacological and aetiopathogenic--(for example complications of chronic alcoholism). ">
        <entity id="DDI-MedLine.d103.s8.e0" charOffset="79-87"
            type="drug" text="magnesium"/>
        <entity id="DDI-MedLine.d103.s8.e1" charOffset="155-163"
            type="drug" text="magnesium"/>
        <pair id="DDI-MedLine.d103.s8.p0" e1="DDI-MedLine.d103.s8.e0"
            e2="DDI-MedLine.d103.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d103.s9" text="Today pharmacological magnesium therapy mainly concerns the obstetrical, cardiological and anaesthesiological fields. ">
        <entity id="DDI-MedLine.d103.s9.e0" charOffset="22-30"
            type="drug" text="magnesium"/>
    </sentence>
    <sentence id="DDI-MedLine.d103.s10" text="The main indications are eclampsia, some dysrhythmias (torsades de pointe particularly) and myocardial ischaemias. "/>
    <sentence id="DDI-MedLine.d103.s11" text="But it is now difficult to situate the exact place of the pharmacological indications of magnesium. ">
        <entity id="DDI-MedLine.d103.s11.e0" charOffset="89-97"
            type="drug" text="magnesium"/>
    </sentence>
    <sentence id="DDI-MedLine.d103.s12" text="Magnesium infusions can only be envisaged in intensive care units with careful monitoring of pulse, arterial pressure, deep tendon reflexes, hourly diuresis, electrocardiogram and respiratory recordings. ">
        <entity id="DDI-MedLine.d103.s12.e0" charOffset="0-8"
            type="drug" text="Magnesium"/>
    </sentence>
    <sentence id="DDI-MedLine.d103.s13" text="High oral magnesium doses besides their laxative action may bring latent complications which may reduce lifespan. ">
        <entity id="DDI-MedLine.d103.s13.e0" charOffset="10-18"
            type="drug" text="magnesium"/>
    </sentence>
    <sentence id="DDI-MedLine.d103.s14" text="There may remain some indications of the laxative and antacid properties of non soluble magnesium, particularly during intermittent haemodialysis. ">
        <entity id="DDI-MedLine.d103.s14.e0" charOffset="88-96"
            type="drug" text="magnesium"/>
    </sentence>
    <sentence id="DDI-MedLine.d103.s15" text="Lastly local use of the mucocutaneous and cytoprotective properties of magnesium is still valid, in cardioplegic solutions and for preservation of transplants particularly.">
        <entity id="DDI-MedLine.d103.s15.e0" charOffset="71-79"
            type="drug" text="magnesium"/>
        <entity id="DDI-MedLine.d103.s15.e1" charOffset="100-121"
            type="drug" text="cardioplegic solutions"/>
        <pair id="DDI-MedLine.d103.s15.p0" e1="DDI-MedLine.d103.s15.e0"
            e2="DDI-MedLine.d103.s15.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d20.s0" text="Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.&#xa;">
        <entity id="DDI-MedLine.d20.s0.e0" charOffset="20-26"
            type="drug" text="glycine"/>
        <entity id="DDI-MedLine.d20.s0.e1" charOffset="32-40"
            type="drug" text="glutamate"/>
        <pair id="DDI-MedLine.d20.s0.p0" e1="DDI-MedLine.d20.s0.e0"
            e2="DDI-MedLine.d20.s0.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d20.s1" text="In this study we investigated whether also glycine fulfils the function as co-activator in glutamatergic activation of NMDA receptors in the neuronal apparatus of spontaneous motility in chick embryos. ">
        <entity id="DDI-MedLine.d20.s1.e0" charOffset="43-49"
            type="drug" text="glycine"/>
    </sentence>
    <sentence id="DDI-MedLine.d20.s2" text="The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) ">
        <entity id="DDI-MedLine.d20.s2.e0" charOffset="30-36"
            type="drug" text="glycine"/>
    </sentence>
    <sentence id="DDI-MedLine.d20.s3" text="and glutamate (15 mg/kg e.w.) ">
        <entity id="DDI-MedLine.d20.s3.e0" charOffset="4-12" type="drug" text="glutamate"/>
    </sentence>
    <sentence id="DDI-MedLine.d20.s4" text="The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. ">
        <entity id="DDI-MedLine.d20.s4.e0" charOffset="30-36"
            type="drug" text="glycine"/>
        <entity id="DDI-MedLine.d20.s4.e1" charOffset="75-83"
            type="drug" text="glutamate"/>
        <entity id="DDI-MedLine.d20.s4.e2" charOffset="246-254"
            type="drug" text="glutamate"/>
        <pair id="DDI-MedLine.d20.s4.p0" e1="DDI-MedLine.d20.s4.e0"
            e2="DDI-MedLine.d20.s4.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d20.s4.p1" e1="DDI-MedLine.d20.s4.e0"
            e2="DDI-MedLine.d20.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d20.s4.p2" e1="DDI-MedLine.d20.s4.e1"
            e2="DDI-MedLine.d20.s4.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d20.s5" text="This effect did not depend on the order of application of the drugs. "/>
    <sentence id="DDI-MedLine.d20.s6" text="In 13-day-old embryos, glycine was ineffective in both doses. ">
        <entity id="DDI-MedLine.d20.s6.e0" charOffset="23-29"
            type="drug" text="glycine"/>
    </sentence>
    <sentence id="DDI-MedLine.d20.s7" text="It is concluded from these results that the modulatory effect of glycine is evidently a later developmental acquisition (after day 15 of incubation) in the embryogenesis of NMDA-ergic activation of spontaneous motility in chick embryos similarly as glycinergic inhibition.">
        <entity id="DDI-MedLine.d20.s7.e0" charOffset="65-71"
            type="drug" text="glycine"/>
    </sentence>
    <sentence id="DDI-MedLine.d94.s0" text="Evidence for reduction of norepinephrine uptake sites in the failing human heart.&#xd;&#xa;">
        <entity id="DDI-MedLine.d94.s0.e0" charOffset="26-39"
            type="drug" text="norepinephrine"/>
    </sentence>
    <sentence id="DDI-MedLine.d94.s1" text="OBJECTIVES. "/>
    <sentence id="DDI-MedLine.d94.s2" text="This study investigated the role of neuronal uptake of norepinephrine (uptake-1) in human heart failure as a local factor for altering concentrations of norepinephrine at the cardiac myocyte membranes. ">
        <entity id="DDI-MedLine.d94.s2.e0" charOffset="55-68"
            type="drug" text="norepinephrine"/>
    </sentence>
    <sentence id="DDI-MedLine.d94.s3" text="BACKGROUND. "/>
    <sentence id="DDI-MedLine.d94.s4" text="Several beta-adrenergic neuroeffector defects occur in heart failure. "/>
    <sentence id="DDI-MedLine.d94.s5" text="Whether an alteration in norepinephrine uptake-1 occurs is still unresolved. ">
        <entity id="DDI-MedLine.d94.s5.e0" charOffset="25-38"
            type="drug" text="norepinephrine"/>
    </sentence>
    <sentence id="DDI-MedLine.d94.s6" text="METHODS. "/>
    <sentence id="DDI-MedLine.d94.s7" text="The role of norepinephrine uptake-1 was studied in electrically stimulated (1 Hz, 37 degrees C) human ventricular cardiac preparations and isolated myocardial membranes. ">
        <entity id="DDI-MedLine.d94.s7.e0" charOffset="12-25"
            type="drug" text="norepinephrine"/>
    </sentence>
    <sentence id="DDI-MedLine.d94.s8" text="RESULTS. "/>
    <sentence id="DDI-MedLine.d94.s9" text="The effectiveness of norepinephrine in increasing the force of contraction was decreased in relation to the degree of heart failure. ">
        <entity id="DDI-MedLine.d94.s9.e0" charOffset="21-34"
            type="drug" text="norepinephrine"/>
    </sentence>
    <sentence id="DDI-MedLine.d94.s10" text="In contrast, the potency of norepinephrine was increased in failing hearts (New York Heart Association functional class IV) in relation to the concentrations producing 50% of the maximal effect (EC50). ">
        <entity id="DDI-MedLine.d94.s10.e0" charOffset="28-41"
            type="drug" text="norepinephrine"/>
    </sentence>
    <sentence id="DDI-MedLine.d94.s11" text="The EC50 values for isoproterenol, which is not a substrate for norepinephrine uptake-1, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium. ">
        <entity id="DDI-MedLine.d94.s11.e0" charOffset="20-32"
            type="drug" text="isoproterenol"/>
        <entity id="DDI-MedLine.d94.s11.e1" charOffset="64-77"
            type="drug" text="norepinephrine"/>
        <pair id="DDI-MedLine.d94.s11.p0" e1="DDI-MedLine.d94.s11.e0"
            e2="DDI-MedLine.d94.s11.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d94.s12" text="The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p &lt; 0.05) but not in functional class IV myocardium. ">
        <entity id="DDI-MedLine.d94.s12.e0" charOffset="22-28"
            type="drug" text="cocaine"/>
        <entity id="DDI-MedLine.d94.s12.e1" charOffset="34-44"
            type="drug" text="desipramine"/>
        <entity id="DDI-MedLine.d94.s12.e2" charOffset="108-121"
            type="drug" text="norepinephrine"/>
        <pair id="DDI-MedLine.d94.s12.p0" e1="DDI-MedLine.d94.s12.e0"
            e2="DDI-MedLine.d94.s12.e1" ddi="false"/>
        <pair id="DDI-MedLine.d94.s12.p1" e1="DDI-MedLine.d94.s12.e0"
            e2="DDI-MedLine.d94.s12.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d94.s12.p2" e1="DDI-MedLine.d94.s12.e1"
            e2="DDI-MedLine.d94.s12.e2" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d94.s13" text="Radioligand binding experiments using the uptake inhibitor hydrogen-3 mazindol revealed a significant decrease by approximately 30% in norepinephrine uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p &lt; 0.05). ">
        <entity id="DDI-MedLine.d94.s13.e0" charOffset="70-77"
            type="drug" text="mazindol"/>
        <entity id="DDI-MedLine.d94.s13.e1" charOffset="135-148"
            type="drug" text="norepinephrine"/>
        <pair id="DDI-MedLine.d94.s13.p0" e1="DDI-MedLine.d94.s13.e0"
            e2="DDI-MedLine.d94.s13.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d94.s14" text="CONCLUSIONS. "/>
    <sentence id="DDI-MedLine.d94.s15" text="In human heart failure, there is a presynaptic defect in the sympathetic nervous system, leading to reduced uptake-1 activity. "/>
    <sentence id="DDI-MedLine.d94.s16" text="This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as cocaine and desipramine, in the nonfailing heart only. ">
        <entity id="DDI-MedLine.d94.s16.e0" charOffset="99-105"
            type="drug" text="cocaine"/>
        <entity id="DDI-MedLine.d94.s16.e1" charOffset="111-121"
            type="drug" text="desipramine"/>
        <pair id="DDI-MedLine.d94.s16.p0" e1="DDI-MedLine.d94.s16.e0"
            e2="DDI-MedLine.d94.s16.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d94.s17" text="Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine. ">
        <entity id="DDI-MedLine.d94.s17.e0" charOffset="12-25"
            type="drug" text="norepinephrine"/>
        <entity id="DDI-MedLine.d94.s17.e1" charOffset="90-96"
            type="drug" text="cocaine"/>
        <entity id="DDI-MedLine.d94.s17.e2" charOffset="102-112"
            type="drug" text="desipramine"/>
        <pair id="DDI-MedLine.d94.s17.p0" e1="DDI-MedLine.d94.s17.e0"
            e2="DDI-MedLine.d94.s17.e1" ddi="false"/>
        <pair id="DDI-MedLine.d94.s17.p1" e1="DDI-MedLine.d94.s17.e0"
            e2="DDI-MedLine.d94.s17.e2" ddi="false"/>
        <pair id="DDI-MedLine.d94.s17.p2" e1="DDI-MedLine.d94.s17.e1"
            e2="DDI-MedLine.d94.s17.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d94.s18" text="The pathophysiologic consequences could be an increased synaptic concentration of norepinephrine predisposing to adenylyl cyclase desensitization.">
        <entity id="DDI-MedLine.d94.s18.e0" charOffset="82-95"
            type="drug" text="norepinephrine"/>
    </sentence>
    <sentence id="DDI-MedLine.d14.s0" text="[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ">
        <entity id="DDI-MedLine.d14.s0.e0" charOffset="45-55"
            type="drug_n" text="angiotensin"/>
        <entity id="DDI-MedLine.d14.s0.e1" charOffset="183-195"
            type="drug_n" text="angiotensin 1"/>
        <entity id="DDI-MedLine.d14.s0.e2" charOffset="201-213"
            type="drug_n" text="angiotensin 2"/>
        <entity id="DDI-MedLine.d14.s0.e3" charOffset="218-229"
            type="drug" text="pentagastrin"/>
        <entity id="DDI-MedLine.d14.s0.e4" charOffset="236-244"
            type="drug" text="histamine"/>
        <pair id="DDI-MedLine.d14.s0.p0" e1="DDI-MedLine.d14.s0.e0"
            e2="DDI-MedLine.d14.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d14.s0.p1" e1="DDI-MedLine.d14.s0.e0"
            e2="DDI-MedLine.d14.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d14.s0.p2" e1="DDI-MedLine.d14.s0.e0"
            e2="DDI-MedLine.d14.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d14.s0.p3" e1="DDI-MedLine.d14.s0.e0"
            e2="DDI-MedLine.d14.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d14.s0.p4" e1="DDI-MedLine.d14.s0.e1"
            e2="DDI-MedLine.d14.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d14.s0.p5" e1="DDI-MedLine.d14.s0.e1"
            e2="DDI-MedLine.d14.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d14.s0.p6" e1="DDI-MedLine.d14.s0.e1"
            e2="DDI-MedLine.d14.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d14.s0.p7" e1="DDI-MedLine.d14.s0.e2"
            e2="DDI-MedLine.d14.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d14.s0.p8" e1="DDI-MedLine.d14.s0.e2"
            e2="DDI-MedLine.d14.s0.e4" ddi="false"/>
        <pair id="DDI-MedLine.d14.s0.p9" e1="DDI-MedLine.d14.s0.e3"
            e2="DDI-MedLine.d14.s0.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d14.s1" text="It was established that both angiotensins inhibited gastric acid secretion stimulated by pentagastrin but not by histamine. ">
        <entity id="DDI-MedLine.d14.s1.e0" charOffset="89-100"
            type="drug" text="pentagastrin"/>
        <entity id="DDI-MedLine.d14.s1.e1" charOffset="113-121"
            type="drug" text="histamine"/>
        <pair id="DDI-MedLine.d14.s1.p0" e1="DDI-MedLine.d14.s1.e0"
            e2="DDI-MedLine.d14.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d14.s2" text="Comparative analysis of the effects of stimulation and inhibition of cholino- and adrenoreceptors on this inhibitory action of angiotensins suggested the mediation of angiotensin influence through the modulation of cholinergic reactions of parietal cells in the stomach.">
        <entity id="DDI-MedLine.d14.s2.e0" charOffset="127-138"
            type="drug_n" text="angiotensins"/>
        <entity id="DDI-MedLine.d14.s2.e1" charOffset="167-177"
            type="drug_n" text="angiotensin"/>
        <pair id="DDI-MedLine.d14.s2.p0" e1="DDI-MedLine.d14.s2.e0"
            e2="DDI-MedLine.d14.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d90.s0" text="Interaction of gentamycin and atracurium in anaesthetised horses.&#xd;&#xa;">
        <entity id="DDI-MedLine.d90.s0.e0" charOffset="15-24"
            type="drug" text="gentamycin"/>
        <entity id="DDI-MedLine.d90.s0.e1" charOffset="30-39"
            type="drug" text="atracurium"/>
        <pair id="DDI-MedLine.d90.s0.p0" e1="DDI-MedLine.d90.s0.e0"
            e2="DDI-MedLine.d90.s0.e1" ddi="true" type="int"/>
    </sentence>
    <sentence id="DDI-MedLine.d90.s1" text="Evoked hind limb digital extensor tension (hoof twitch) was maintained at 40% of baseline for 1 h by atracurium infusion in 7 horses anaesthetised with halothane. ">
        <entity id="DDI-MedLine.d90.s1.e0" charOffset="101-110"
            type="drug" text="atracurium"/>
        <entity id="DDI-MedLine.d90.s1.e1" charOffset="152-160"
            type="drug" text="halothane"/>
        <pair id="DDI-MedLine.d90.s1.p0" e1="DDI-MedLine.d90.s1.e0"
            e2="DDI-MedLine.d90.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d90.s2" text="After 1 h, atracurium was discontinued and hoof twitch allowed to recover to 75%. ">
        <entity id="DDI-MedLine.d90.s2.e0" charOffset="11-20"
            type="drug" text="atracurium"/>
    </sentence>
    <sentence id="DDI-MedLine.d90.s3" text="Atracurium was again given by infusion to maintain 40% twitch for a second hour, then 2 mg gentamycin/kg bwt were given i.v. ">
        <entity id="DDI-MedLine.d90.s3.e0" charOffset="0-9" type="drug" text="Atracurium"/>
        <entity id="DDI-MedLine.d90.s3.e1" charOffset="91-100"
            type="drug" text="gentamycin"/>
        <pair id="DDI-MedLine.d90.s3.p0" e1="DDI-MedLine.d90.s3.e0"
            e2="DDI-MedLine.d90.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d90.s4" text="Atracurium infusion was continued for a third hour, and then hoof twitch was again allowed to recover spontaneously to 75%. ">
        <entity id="DDI-MedLine.d90.s4.e0" charOffset="0-9" type="drug" text="Atracurium"/>
    </sentence>
    <sentence id="DDI-MedLine.d90.s5" text="Gentamycin reduced twitch strength from 40 +/- 1% (mean +/- sem) to 29 +/- 4% within 7.0 +/- 1.5 min (P = 0.02). ">
        <entity id="DDI-MedLine.d90.s5.e0" charOffset="0-9" type="drug" text="Gentamycin"/>
    </sentence>
    <sentence id="DDI-MedLine.d90.s6" text="Twitch gradually returned to pre-gentamycin strength over the course of the next hour. ">
        <entity id="DDI-MedLine.d90.s6.e0" charOffset="33-42"
            type="drug" text="gentamycin"/>
    </sentence>
    <sentence id="DDI-MedLine.d90.s7" text="Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03). ">
        <entity id="DDI-MedLine.d90.s7.e0" charOffset="65-74"
            type="drug" text="atracurium"/>
        <entity id="DDI-MedLine.d90.s7.e1" charOffset="107-116"
            type="drug" text="atracurium"/>
        <entity id="DDI-MedLine.d90.s7.e2" charOffset="123-132"
            type="drug" text="gentamycin"/>
        <pair id="DDI-MedLine.d90.s7.p0" e1="DDI-MedLine.d90.s7.e0"
            e2="DDI-MedLine.d90.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d90.s7.p1" e1="DDI-MedLine.d90.s7.e0"
            e2="DDI-MedLine.d90.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d90.s7.p2" e1="DDI-MedLine.d90.s7.e1"
            e2="DDI-MedLine.d90.s7.e2" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d90.s8" text="Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin. ">
        <entity id="DDI-MedLine.d90.s8.e0" charOffset="72-81"
            type="drug" text="atracurium"/>
        <entity id="DDI-MedLine.d90.s8.e1" charOffset="114-123"
            type="drug" text="atracurium"/>
        <entity id="DDI-MedLine.d90.s8.e2" charOffset="130-139"
            type="drug" text="gentamycin"/>
        <pair id="DDI-MedLine.d90.s8.p0" e1="DDI-MedLine.d90.s8.e0"
            e2="DDI-MedLine.d90.s8.e1" ddi="false"/>
        <pair id="DDI-MedLine.d90.s8.p1" e1="DDI-MedLine.d90.s8.e0"
            e2="DDI-MedLine.d90.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d90.s8.p2" e1="DDI-MedLine.d90.s8.e1"
            e2="DDI-MedLine.d90.s8.e2" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d90.s9" text="At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin. ">
        <entity id="DDI-MedLine.d90.s9.e0" charOffset="55-64"
            type="drug" text="atracurium"/>
        <entity id="DDI-MedLine.d90.s9.e1" charOffset="90-99"
            type="drug" text="atracurium"/>
        <entity id="DDI-MedLine.d90.s9.e2" charOffset="106-115"
            type="drug" text="gentamycin"/>
        <pair id="DDI-MedLine.d90.s9.p0" e1="DDI-MedLine.d90.s9.e0"
            e2="DDI-MedLine.d90.s9.e1" ddi="false"/>
        <pair id="DDI-MedLine.d90.s9.p1" e1="DDI-MedLine.d90.s9.e0"
            e2="DDI-MedLine.d90.s9.e2" ddi="false"/>
        <pair id="DDI-MedLine.d90.s9.p2" e1="DDI-MedLine.d90.s9.e1"
            e2="DDI-MedLine.d90.s9.e2" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d90.s10" text="Reversal of the block with edrophonium and subsequent recovery of the horses from anaesthesia were uneventful. ">
        <entity id="DDI-MedLine.d90.s10.e0" charOffset="27-37"
            type="drug" text="edrophonium"/>
    </sentence>
    <sentence id="DDI-MedLine.d90.s11" text="It was concluded that, although gentamycin did augment the neuromuscular blockade of atracurium, the effect was minimal.">
        <entity id="DDI-MedLine.d90.s11.e0" charOffset="32-41"
            type="drug" text="gentamycin"/>
        <entity id="DDI-MedLine.d90.s11.e1" charOffset="85-94"
            type="drug" text="atracurium"/>
        <pair id="DDI-MedLine.d90.s11.p0" e1="DDI-MedLine.d90.s11.e0"
            e2="DDI-MedLine.d90.s11.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d37.s0" text="Anticoagulants.&#xa;">
        <entity id="DDI-MedLine.d37.s0.e0" charOffset="0-13"
            type="group" text="Anticoagulants"/>
    </sentence>
    <sentence id="DDI-MedLine.d37.s1" text="Treatment plans for patients taking anticoagulants can become complicated. ">
        <entity id="DDI-MedLine.d37.s1.e0" charOffset="36-49"
            type="group" text="anticoagulants"/>
    </sentence>
    <sentence id="DDI-MedLine.d37.s2" text="Anticoagulants predispose a patient to bleeding problems. ">
        <entity id="DDI-MedLine.d37.s2.e0" charOffset="0-13"
            type="group" text="Anticoagulants"/>
    </sentence>
    <sentence id="DDI-MedLine.d37.s3" text="Many drugs used in dentistry cannot be taken concomitantly with these medications."/>
    <sentence id="DDI-MedLine.d108.s0" text="Administration of lithium prophylaxis.&#xd;&#xa;">
        <entity id="DDI-MedLine.d108.s0.e0" charOffset="18-24"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-MedLine.d108.s1" text="Successful prophylaxis of manic-depressive disorder requires more than the prescription of lithium carbonate. ">
        <entity id="DDI-MedLine.d108.s1.e0" charOffset="91-107"
            type="drug" text="lithium carbonate"/>
    </sentence>
    <sentence id="DDI-MedLine.d108.s2" text="The administrative arrangements in an area of Scotland were accompanied by a 300% increase in the frequency of admissions for mania, whereas in an area of the West Midlands, a large decrease was achieved."/>
    <sentence id="DDI-MedLine.d136.s0" text="[Multiple occupational exposure to solvents]&#xd;&#xa;This article review papers published over the last 20 years on multiple occupational exposure to solvents. "/>
    <sentence id="DDI-MedLine.d136.s1" text="At low-levels of exposure the toxicokinetic interferences between solvents have generally not been observed in man and presumably a threshold limit exists. "/>
    <sentence id="DDI-MedLine.d136.s2" text="Conversely, at exposure levels close to the &quot;limit values&quot; "/>
    <sentence id="DDI-MedLine.d136.s3" text="metabolic interference has sometimes been observed and the behaviour of the biological indicators differs from what would be expected. "/>
    <sentence id="DDI-MedLine.d136.s4" text="Toxicodynamic interference between solvents can give rise to additive, potentiation, synergistic, antagonistic effects. "/>
    <sentence id="DDI-MedLine.d136.s5" text="For the identification of &quot;limit values&quot;, it has generally been suggested in the literature that the possible effects deriving from multiple exposure be considered as additive. "/>
    <sentence id="DDI-MedLine.d136.s6" text="However, numerous potentiation effects have frequently been reported for combined exposure to substances of widespread use. "/>
    <sentence id="DDI-MedLine.d136.s7" text="In this paper lists of multiple exposure in which the doses of the substances, the types of interferences and the behaviour of the biological levels have been drawn up and proposed as a tool for easy consultation."/>
    <sentence id="DDI-MedLine.d33.s0" text="Determinants of cellular sensitivity to topoisomerase-targeting antitumor drugs.">
        <entity id="DDI-MedLine.d33.s0.e0" charOffset="40-78"
            type="group" text="topoisomerase-targeting antitumor drugs"/>
    </sentence>
    <sentence id="DDI-MedLine.d33.s1" text="It is now clear that topoisomerase activity level is an important determinant of sensitivity to topo drugs. "/>
    <sentence id="DDI-MedLine.d33.s2" text="The regulation of topoisomerases is no doubt complex and multifaceted and is probably accomplished through redundancy at many control levels. "/>
    <sentence id="DDI-MedLine.d33.s3" text="The mechanism(s) of altered topo I expression in certain tumor types is unknown, but may be related to the central importance of topoisomerases in proliferating cell functions (transcription, replication, etc.), and the aberrant and chronic activation of these functions as a result of specific tumorigenic alterations. "/>
    <sentence id="DDI-MedLine.d33.s4" text="Small differences in sensitivity to chemotherapy can have a dramatic effect on cure rates, and therefore subtle cell type-specific differences may be important determinants of drug sensitivity. "/>
    <sentence id="DDI-MedLine.d33.s5" text="Whether abnormal topoisomerase quantity and specific activity are associated with resistance or sensitivity to topoisomerase-targeted chemotherapy in the clinic is now being studied. "/>
    <sentence id="DDI-MedLine.d33.s6" text="Determinants downstream of cleavable complex formation that affect the sensitivity of tumor versus normal cells to topo drugs in particular and DNA-damaging agents in general are little known. "/>
    <sentence id="DDI-MedLine.d33.s7" text="The goal of enhancing selective tumor cell killing relative to the normal cells that are dose limiting may be achieved either by overcoming tumor cell resistance or by protecting normal cells. "/>
    <sentence id="DDI-MedLine.d33.s8" text="Both of these strategies will become more feasible as specific molecular differences between tumor and normal cells are being rapidly identified and new combination therapies that take advantage of these differences are being designed and tested."/>
    <sentence id="DDI-MedLine.d113.s0" text="Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.">
        <entity id="DDI-MedLine.d113.s0.e0" charOffset="30-38"
            type="drug" text="temazepam"/>
        <entity id="DDI-MedLine.d113.s0.e1" charOffset="65-71"
            type="drug" text="ethanol"/>
        <pair id="DDI-MedLine.d113.s0.p0" e1="DDI-MedLine.d113.s0.e0"
            e2="DDI-MedLine.d113.s0.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d113.s1" text="The benzodiazepines are a family of anxiolytic and hypnotic drugs. ">
        <entity id="DDI-MedLine.d113.s1.e0" charOffset="4-18"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-MedLine.d113.s1.e1" charOffset="36-45"
            type="group" text="anxiolytic"/>
        <entity id="DDI-MedLine.d113.s1.e2" charOffset="51-64"
            type="group" text="hypnotic drugs"/>
        <pair id="DDI-MedLine.d113.s1.p0" e1="DDI-MedLine.d113.s1.e0"
            e2="DDI-MedLine.d113.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d113.s1.p1" e1="DDI-MedLine.d113.s1.e0"
            e2="DDI-MedLine.d113.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d113.s1.p2" e1="DDI-MedLine.d113.s1.e1"
            e2="DDI-MedLine.d113.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d113.s2" text="When taken concurrently with ethanol, a pharmacological interaction may occur, potentiating the central nervous system depression produced by either drug. ">
        <entity id="DDI-MedLine.d113.s2.e0" charOffset="29-35"
            type="drug" text="ethanol"/>
    </sentence>
    <sentence id="DDI-MedLine.d113.s3" text="In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. ">
        <entity id="DDI-MedLine.d113.s3.e0" charOffset="105-113"
            type="drug" text="temazepam"/>
        <entity id="DDI-MedLine.d113.s3.e1" charOffset="118-131"
            type="group" text="benzodiazepine"/>
        <entity id="DDI-MedLine.d113.s3.e2" charOffset="138-144"
            type="drug" text="ethanol"/>
        <pair id="DDI-MedLine.d113.s3.p0" e1="DDI-MedLine.d113.s3.e0"
            e2="DDI-MedLine.d113.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d113.s3.p1" e1="DDI-MedLine.d113.s3.e0"
            e2="DDI-MedLine.d113.s3.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d113.s3.p2" e1="DDI-MedLine.d113.s3.e1"
            e2="DDI-MedLine.d113.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d113.s4" text="Optimal conditions, kinetics, equilibrium, and the mechanism of this acid-catalyzed ethanolysis are reported. "/>
    <sentence id="DDI-MedLine.d113.s5" text="The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis. ">
        <entity id="DDI-MedLine.d113.s5.e0" charOffset="111-117"
            type="drug" text="alcohol"/>
        <entity id="DDI-MedLine.d113.s5.e1" charOffset="123-150"
            type="group" text="3-hydroxy-1,4-benzodiazepine"/>
        <pair id="DDI-MedLine.d113.s5.p0" e1="DDI-MedLine.d113.s5.e0"
            e2="DDI-MedLine.d113.s5.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d113.s6" text="The acid-catalyzed ethanol-drug reaction is a relatively unexplored area and may alter the pharmacological action of some drugs.">
        <entity id="DDI-MedLine.d113.s6.e0" charOffset="19-25"
            type="drug" text="ethanol"/>
    </sentence>
</document>
